id	sid	tid	token	lemma	pos
fnp-5049	1	1	serum	serum	PROPN
fnp-5049	1	2	neurofilament	neurofilament	PROPN
fnp-5049	1	3	light	light	ADJ
fnp-5049	1	4	chains	chain	NOUN
fnp-5049	1	5	in	in	ADP
fnp-5049	1	6	progressive	progressive	ADJ
fnp-5049	1	7	multiple	multiple	ADJ
fnp-5049	1	8	sclerosis	sclerosis	NOUN
fnp-5049	1	9	patients	patient	NOUN
fnp-5049	1	10	treated	treat	VERB
fnp-5049	1	11	with	with	ADP
fnp-5049	1	12	repeated	repeat	VERB
fnp-5049	1	13	cycles	cycle	NOUN
fnp-5049	1	14	of	of	ADP
fnp-5049	1	15	high	high	ADJ
fnp-5049	1	16	-	-	PUNCT
fnp-5049	1	17	dose	dose	NOUN
fnp-5049	1	18	intravenous	intravenous	ADJ
fnp-5049	1	19	steroids	steroid	NOUN
fnp-5049	1	20	feel	feel	VERB
fnp-5049	1	21	free	free	ADJ
fnp-5049	1	22	to	to	PART
fnp-5049	1	23	add	add	VERB
fnp-5049	1	24	comments	comment	NOUN
fnp-5049	1	25	by	by	ADP
fnp-5049	1	26	clicking	click	VERB
fnp-5049	1	27	these	these	DET
fnp-5049	1	28	icons	icon	NOUN
fnp-5049	1	29	on	on	ADP
fnp-5049	1	30	the	the	DET
fnp-5049	1	31	sidebar	sidebar	NOUN
fnp-5049	1	32	free	free	ADJ
fnp-5049	1	33	neuropathology	neuropathology	NOUN
fnp-5049	1	34	4:15	4:15	NUM
fnp-5049	1	35	(	(	PUNCT
fnp-5049	1	36	2023	2023	NUM
fnp-5049	1	37	)	)	PUNCT
fnp-5049	1	38	original	original	ADJ
fnp-5049	1	39	paper	paper	NOUN
fnp-5049	1	40	serum	serum	NOUN
fnp-5049	1	41	neurofilament	neurofilament	PROPN
fnp-5049	1	42	light	light	ADJ
fnp-5049	1	43	chains	chain	NOUN
fnp-5049	1	44	in	in	ADP
fnp-5049	1	45	progressive	progressive	ADJ
fnp-5049	1	46	multiple	multiple	ADJ
fnp-5049	1	47	sclerosis	sclerosis	NOUN
fnp-5049	1	48	patients	patient	NOUN
fnp-5049	1	49	treated	treat	VERB
fnp-5049	1	50	with	with	ADP
fnp-5049	1	51	repeated	repeat	VERB
fnp-5049	1	52	cycles	cycle	NOUN
fnp-5049	1	53	of	of	ADP
fnp-5049	1	54	high	high	ADJ
fnp-5049	1	55	-	-	PUNCT
fnp-5049	1	56	dose	dose	NOUN
fnp-5049	1	57	intravenous	intravenous	ADJ
fnp-5049	1	58	steroids	steroid	NOUN
fnp-5049	1	59	lidia	lidia	PROPN
fnp-5049	1	60	stork1	stork1	PROPN
fnp-5049	1	61	,	,	PUNCT
fnp-5049	1	62	michael	michael	PROPN
fnp-5049	1	63	haupts2	haupts2	PROPN
fnp-5049	1	64	,	,	PUNCT
fnp-5049	1	65	niels	niels	PROPN
fnp-5049	1	66	kruse1	kruse1	PROPN
fnp-5049	1	67	,	,	PUNCT
fnp-5049	1	68	petra	petra	PROPN
fnp-5049	1	69	spill	spill	PROPN
fnp-5049	1	70	-	-	PUNCT
fnp-5049	1	71	askeridis3	askeridis3	PROPN
fnp-5049	1	72	,	,	PUNCT
fnp-5049	1	73	adriane	adriane	PROPN
fnp-5049	1	74	kutllovci1	kutllovci1	PROPN
fnp-5049	1	75	,	,	PUNCT
fnp-5049	1	76	martin	martin	PROPN
fnp-5049	1	77	s.	s.	PROPN
fnp-5049	1	78	weber1,4,5	weber1,4,5	PROPN
fnp-5049	1	79	,	,	PUNCT
fnp-5049	1	80	wolfgang	wolfgang	PROPN
fnp-5049	1	81	brück1	brück1	PROPN
fnp-5049	1	82	,	,	PUNCT
fnp-5049	1	83	imke	imke	PROPN
fnp-5049	1	84	metz1	metz1	PROPN
fnp-5049	1	85	institute	institute	PROPN
fnp-5049	1	86	of	of	ADP
fnp-5049	1	87	neuropathology	neuropathology	NOUN
fnp-5049	1	88	,	,	PUNCT
fnp-5049	1	89	university	university	NOUN
fnp-5049	1	90	medical	medical	ADJ
fnp-5049	1	91	center	center	NOUN
fnp-5049	1	92	göttingen	göttingen	NOUN
fnp-5049	1	93	,	,	PUNCT
fnp-5049	1	94	germany	germany	PROPN
fnp-5049	1	95	department	department	PROPN
fnp-5049	1	96	of	of	ADP
fnp-5049	1	97	neurology	neurology	NOUN
fnp-5049	1	98	,	,	PUNCT
fnp-5049	1	99	university	university	NOUN
fnp-5049	1	100	hospital	hospital	NOUN
fnp-5049	1	101	düsseldorf	düsseldorf	PROPN
fnp-5049	1	102	,	,	PUNCT
fnp-5049	1	103	germany	germany	PROPN
fnp-5049	1	104	augusta	augusta	PROPN
fnp-5049	1	105	hospital	hospital	PROPN
fnp-5049	1	106	,	,	PUNCT
fnp-5049	1	107	anholt	anholt	PROPN
fnp-5049	1	108	,	,	PUNCT
fnp-5049	1	109	germany	germany	PROPN
fnp-5049	1	110	department	department	PROPN
fnp-5049	1	111	of	of	ADP
fnp-5049	1	112	neurology	neurology	NOUN
fnp-5049	1	113	,	,	PUNCT
fnp-5049	1	114	university	university	NOUN
fnp-5049	1	115	medical	medical	ADJ
fnp-5049	1	116	center	center	NOUN
fnp-5049	1	117	göttingen	göttingen	NOUN
fnp-5049	1	118	,	,	PUNCT
fnp-5049	1	119	germany	germany	PROPN
fnp-5049	1	120	department	department	PROPN
fnp-5049	1	121	of	of	ADP
fnp-5049	1	122	translational	translational	ADJ
fnp-5049	1	123	neuroinflammation	neuroinflammation	NOUN
fnp-5049	1	124	and	and	CCONJ
fnp-5049	1	125	automated	automate	VERB
fnp-5049	1	126	microscopy	microscopy	NOUN
fnp-5049	1	127	,	,	PUNCT
fnp-5049	1	128	fraunhofer	fraunhofer	PROPN
fnp-5049	1	129	institute	institute	PROPN
fnp-5049	1	130	for	for	ADP
fnp-5049	1	131	translational	translational	ADJ
fnp-5049	1	132	medicine	medicine	NOUN
fnp-5049	1	133	and	and	CCONJ
fnp-5049	1	134	pharmacology	pharmacology	NOUN
fnp-5049	1	135	,	,	PUNCT
fnp-5049	1	136	göttingen	göttingen	NOUN
fnp-5049	1	137	,	,	PUNCT
fnp-5049	1	138	germany	germany	PROPN
fnp-5049	1	139	corresponding	corresponding	ADJ
fnp-5049	1	140	author	author	NOUN
fnp-5049	1	141	:	:	PUNCT
fnp-5049	1	142	imke	imke	PROPN
fnp-5049	1	143	metz	metz	PROPN
fnp-5049	1	144	·	·	PUNCT
fnp-5049	1	145	institute	institute	PROPN
fnp-5049	1	146	of	of	ADP
fnp-5049	1	147	neuropathology	neuropathology	PROPN
fnp-5049	1	148	·	·	PUNCT
fnp-5049	1	149	university	university	NOUN
fnp-5049	1	150	medical	medical	ADJ
fnp-5049	1	151	center	center	NOUN
fnp-5049	1	152	göttingen	göttingen	NOUN
fnp-5049	1	153	·	·	PUNCT
fnp-5049	1	154	robert	robert	PROPN
fnp-5049	1	155	-	-	PUNCT
fnp-5049	1	156	koch	koch	PROPN
fnp-5049	1	157	-	-	PUNCT
fnp-5049	1	158	str	str	PROPN
fnp-5049	1	159	.	.	PUNCT
fnp-5049	2	1	40	40	NUM
fnp-5049	2	2	·	·	SYM
fnp-5049	2	3	37075	37075	NUM
fnp-5049	2	4	göttingen	göttingen	PROPN
fnp-5049	2	5	·	·	PUNCT
fnp-5049	2	6	germany	germany	PROPN
fnp-5049	2	7	imetz@gwdg.de	imetz@gwdg.de	PROPN
fnp-5049	2	8	submitted	submit	VERB
fnp-5049	2	9	:	:	PUNCT
fnp-5049	2	10	01	01	NUM
fnp-5049	2	11	august	august	PROPN
fnp-5049	2	12	2023	2023	NUM
fnp-5049	2	13	accepted	accept	VERB
fnp-5049	2	14	:	:	PUNCT
fnp-5049	2	15	24	24	NUM
fnp-5049	2	16	september	september	PROPN
fnp-5049	2	17	2023	2023	NUM
fnp-5049	2	18	copyedited	copyedit	VERB
fnp-5049	2	19	by	by	ADP
fnp-5049	2	20	:	:	PUNCT
fnp-5049	2	21	cinthya	cinthya	PROPN
fnp-5049	2	22	aguero	aguero	PROPN
fnp-5049	2	23	published	publish	VERB
fnp-5049	2	24	:	:	PUNCT
fnp-5049	2	25	05	05	NUM
fnp-5049	2	26	october	october	PROPN
fnp-5049	2	27	2023	2023	NUM
fnp-5049	2	28	https://doi.org/10.17879/freeneuropathology-2023-5049	https://doi.org/10.17879/freeneuropathology-2023-5049	NOUN
fnp-5049	2	29	keywords	keyword	NOUN
fnp-5049	2	30	:	:	PUNCT
fnp-5049	2	31	progressive	progressive	ADJ
fnp-5049	2	32	multiple	multiple	ADJ
fnp-5049	2	33	sclerosis	sclerosis	NOUN
fnp-5049	2	34	,	,	PUNCT
fnp-5049	2	35	serum	serum	NOUN
fnp-5049	2	36	neurofilament	neurofilament	ADJ
fnp-5049	2	37	light	light	ADJ
fnp-5049	2	38	chains	chain	NOUN
fnp-5049	2	39	,	,	PUNCT
fnp-5049	2	40	high	high	ADJ
fnp-5049	2	41	-	-	PUNCT
fnp-5049	2	42	dose	dose	NOUN
fnp-5049	2	43	intravenous	intravenous	ADJ
fnp-5049	2	44	steroids	steroid	NOUN
fnp-5049	2	45	abstract	abstract	ADJ
fnp-5049	2	46	background	background	NOUN
fnp-5049	2	47	and	and	CCONJ
fnp-5049	2	48	objectives	objective	NOUN
fnp-5049	2	49	:	:	PUNCT
fnp-5049	2	50	in	in	ADP
fnp-5049	2	51	progressive	progressive	ADJ
fnp-5049	2	52	multiple	multiple	ADJ
fnp-5049	2	53	sclerosis	sclerosis	NOUN
fnp-5049	2	54	(	(	PUNCT
fnp-5049	2	55	ms	ms	NOUN
fnp-5049	2	56	)	)	PUNCT
fnp-5049	2	57	patients	patient	NOUN
fnp-5049	2	58	,	,	PUNCT
fnp-5049	2	59	cns	cns	PROPN
fnp-5049	2	60	inflammation	inflammation	NOUN
fnp-5049	2	61	trapped	trap	VERB
fnp-5049	2	62	behind	behind	ADP
fnp-5049	2	63	a	a	DET
fnp-5049	2	64	closed	closed	ADJ
fnp-5049	2	65	blood	blood	NOUN
fnp-5049	2	66	brain	brain	NOUN
fnp-5049	2	67	barrier	barrier	NOUN
fnp-5049	2	68	drives	drive	VERB
fnp-5049	2	69	continuous	continuous	ADJ
fnp-5049	2	70	neuroaxonal	neuroaxonal	ADJ
fnp-5049	2	71	degeneration	degeneration	NOUN
fnp-5049	2	72	,	,	PUNCT
fnp-5049	2	73	thus	thus	ADV
fnp-5049	2	74	leading	lead	VERB
fnp-5049	2	75	to	to	ADP
fnp-5049	2	76	deterioration	deterioration	NOUN
fnp-5049	2	77	of	of	ADP
fnp-5049	2	78	neurological	neurological	ADJ
fnp-5049	2	79	function	function	NOUN
fnp-5049	2	80	.	.	PUNCT
fnp-5049	3	1	therapeutics	therapeutic	NOUN
fnp-5049	3	2	in	in	ADP
fnp-5049	3	3	progressive	progressive	ADJ
fnp-5049	3	4	ms	ms	NOUN
fnp-5049	3	5	are	be	AUX
fnp-5049	3	6	limited	limited	ADJ
fnp-5049	3	7	.	.	PUNCT
fnp-5049	4	1	high	high	ADJ
fnp-5049	4	2	-	-	PUNCT
fnp-5049	4	3	dose	dose	NOUN
fnp-5049	4	4	intravenous	intravenous	ADJ
fnp-5049	4	5	glucocorticosteroids	glucocorticosteroid	NOUN
fnp-5049	4	6	(	(	PUNCT
fnp-5049	4	7	hdcs	hdc	NOUN
fnp-5049	4	8	)	)	PUNCT
fnp-5049	4	9	can	can	AUX
fnp-5049	4	10	cross	cross	VERB
fnp-5049	4	11	the	the	DET
fnp-5049	4	12	blood	blood	NOUN
fnp-5049	4	13	-	-	PUNCT
fnp-5049	4	14	brain	brain	NOUN
fnp-5049	4	15	barrier	barrier	NOUN
fnp-5049	4	16	and	and	CCONJ
fnp-5049	4	17	may	may	AUX
fnp-5049	4	18	reduce	reduce	VERB
fnp-5049	4	19	inflammation	inflammation	NOUN
fnp-5049	4	20	within	within	ADP
fnp-5049	4	21	the	the	DET
fnp-5049	4	22	cns	cns	NOUN
fnp-5049	4	23	.	.	PUNCT
fnp-5049	5	1	however	however	ADV
fnp-5049	5	2	,	,	PUNCT
fnp-5049	5	3	the	the	DET
fnp-5049	5	4	treatment	treatment	NOUN
fnp-5049	5	5	efficacy	efficacy	NOUN
fnp-5049	5	6	of	of	ADP
fnp-5049	5	7	hdcs	hdcs	PROPN
fnp-5049	5	8	in	in	ADP
fnp-5049	5	9	progressive	progressive	ADJ
fnp-5049	5	10	ms	ms	NOUN
fnp-5049	5	11	remains	remain	VERB
fnp-5049	5	12	controversial	controversial	ADJ
fnp-5049	5	13	.	.	PUNCT
fnp-5049	6	1	serum	serum	PROPN
fnp-5049	6	2	neurofilament	neurofilament	PROPN
fnp-5049	6	3	light	light	NOUN
fnp-5049	6	4	chains	chain	NOUN
fnp-5049	6	5	(	(	PUNCT
fnp-5049	6	6	snfl	snfl	NOUN
fnp-5049	6	7	)	)	PUNCT
fnp-5049	6	8	are	be	AUX
fnp-5049	6	9	an	an	DET
fnp-5049	6	10	established	establish	VERB
fnp-5049	6	11	biomarker	biomarker	NOUN
fnp-5049	6	12	of	of	ADP
fnp-5049	6	13	neuroaxonal	neuroaxonal	ADJ
fnp-5049	6	14	degeneration	degeneration	NOUN
fnp-5049	6	15	and	and	CCONJ
fnp-5049	6	16	are	be	AUX
fnp-5049	6	17	used	use	VERB
fnp-5049	6	18	to	to	PART
fnp-5049	6	19	monitor	monitor	VERB
fnp-5049	6	20	treatment	treatment	NOUN
fnp-5049	6	21	responses	response	NOUN
fnp-5049	6	22	.	.	PUNCT
fnp-5049	7	1	we	we	PRON
fnp-5049	7	2	aimed	aim	VERB
fnp-5049	7	3	to	to	PART
fnp-5049	7	4	investigate	investigate	VERB
fnp-5049	7	5	whether	whether	SCONJ
fnp-5049	7	6	repeated	repeat	VERB
fnp-5049	7	7	cycles	cycle	NOUN
fnp-5049	7	8	of	of	ADP
fnp-5049	7	9	intravenous	intravenous	ADJ
fnp-5049	7	10	hdcs	hdc	NOUN
fnp-5049	7	11	reduce	reduce	VERB
fnp-5049	7	12	the	the	DET
fnp-5049	7	13	level	level	NOUN
fnp-5049	7	14	of	of	ADP
fnp-5049	7	15	snfl	snfl	NOUN
fnp-5049	7	16	in	in	ADP
fnp-5049	7	17	progressive	progressive	ADJ
fnp-5049	7	18	ms	ms	ADJ
fnp-5049	7	19	patients	patient	NOUN
fnp-5049	7	20	.	.	PUNCT
fnp-5049	8	1	methods	method	NOUN
fnp-5049	8	2	:	:	PUNCT
fnp-5049	8	3	we	we	PRON
fnp-5049	8	4	performed	perform	VERB
fnp-5049	8	5	a	a	DET
fnp-5049	8	6	monocentric	monocentric	ADJ
fnp-5049	8	7	observational	observational	ADJ
fnp-5049	8	8	study	study	NOUN
fnp-5049	8	9	of	of	ADP
fnp-5049	8	10	25	25	NUM
fnp-5049	8	11	patients	patient	NOUN
fnp-5049	8	12	recruited	recruit	VERB
fnp-5049	8	13	during	during	ADP
fnp-5049	8	14	ongoing	ongoing	ADJ
fnp-5049	8	15	clinical	clinical	ADJ
fnp-5049	8	16	routine	routine	ADJ
fnp-5049	8	17	care	care	NOUN
fnp-5049	8	18	who	who	PRON
fnp-5049	8	19	were	be	AUX
fnp-5049	8	20	treated	treat	VERB
fnp-5049	8	21	with	with	ADP
fnp-5049	8	22	repeated	repeat	VERB
fnp-5049	8	23	cycles	cycle	NOUN
fnp-5049	8	24	of	of	ADP
fnp-5049	8	25	intravenous	intravenous	ADJ
fnp-5049	8	26	hdcs	hdc	NOUN
fnp-5049	8	27	as	as	ADP
fnp-5049	8	28	long	long	ADJ
fnp-5049	8	29	-	-	PUNCT
fnp-5049	8	30	term	term	NOUN
fnp-5049	8	31	therapy	therapy	NOUN
fnp-5049	8	32	for	for	ADP
fnp-5049	8	33	their	their	PRON
fnp-5049	8	34	progressive	progressive	ADJ
fnp-5049	8	35	ms	ms	PROPN
fnp-5049	8	36	.	.	PROPN
fnp-5049	8	37	snfl	snfl	PROPN
fnp-5049	8	38	were	be	AUX
fnp-5049	8	39	measured	measure	VERB
fnp-5049	8	40	in	in	ADP
fnp-5049	8	41	103	103	NUM
fnp-5049	8	42	repeated	repeat	VERB
fnp-5049	8	43	blood	blood	NOUN
fnp-5049	8	44	samples	sample	NOUN
fnp-5049	8	45	(	(	PUNCT
fnp-5049	8	46	median	median	ADJ
fnp-5049	8	47	time	time	NOUN
fnp-5049	8	48	interval	interval	NOUN
fnp-5049	8	49	from	from	ADP
fnp-5049	8	50	baseline	baseline	PROPN
fnp-5049	8	51	28	28	NUM
fnp-5049	8	52	weeks	week	NOUN
fnp-5049	8	53	,	,	PUNCT
fnp-5049	8	54	range	range	NOUN
fnp-5049	8	55	2	2	NUM
fnp-5049	8	56	-	-	SYM
fnp-5049	8	57	55	55	NUM
fnp-5049	8	58	weeks	week	NOUN
fnp-5049	8	59	)	)	PUNCT
fnp-5049	8	60	with	with	ADP
fnp-5049	8	61	the	the	DET
fnp-5049	8	62	single	single	ADJ
fnp-5049	8	63	molecular	molecular	ADJ
fnp-5049	8	64	array	array	NOUN
fnp-5049	8	65	(	(	PUNCT
fnp-5049	8	66	simoa	simoa	PROPN
fnp-5049	8	67	)	)	PUNCT
fnp-5049	8	68	technology	technology	NOUN
fnp-5049	8	69	.	.	PUNCT
fnp-5049	9	1	the	the	DET
fnp-5049	9	2	expanded	expand	VERB
fnp-5049	9	3	disability	disability	NOUN
fnp-5049	9	4	status	status	NOUN
fnp-5049	9	5	score	score	NOUN
fnp-5049	9	6	(	(	PUNCT
fnp-5049	9	7	edss	edss	ADV
fnp-5049	9	8	)	)	PUNCT
fnp-5049	9	9	was	be	AUX
fnp-5049	9	10	documented	document	VERB
fnp-5049	9	11	at	at	ADP
fnp-5049	9	12	baseline	baseline	NOUN
fnp-5049	9	13	and	and	CCONJ
fnp-5049	9	14	follow	follow	VERB
fnp-5049	9	15	-	-	PUNCT
fnp-5049	9	16	up	up	NOUN
fnp-5049	9	17	.	.	PUNCT
fnp-5049	10	1	results	result	NOUN
fnp-5049	10	2	:	:	PUNCT
fnp-5049	10	3	the	the	DET
fnp-5049	10	4	median	median	ADJ
fnp-5049	10	5	age	age	NOUN
fnp-5049	10	6	of	of	ADP
fnp-5049	10	7	patients	patient	NOUN
fnp-5049	10	8	was	be	AUX
fnp-5049	10	9	55	55	NUM
fnp-5049	10	10	years	year	NOUN
fnp-5049	10	11	(	(	PUNCT
fnp-5049	10	12	range	range	NOUN
fnp-5049	10	13	46	46	NUM
fnp-5049	10	14	-	-	SYM
fnp-5049	10	15	77	77	NUM
fnp-5049	10	16	years	year	NOUN
fnp-5049	10	17	)	)	PUNCT
fnp-5049	10	18	with	with	ADP
fnp-5049	10	19	a	a	DET
fnp-5049	10	20	median	median	ADJ
fnp-5049	10	21	disease	disease	NOUN
fnp-5049	10	22	duration	duration	NOUN
fnp-5049	10	23	of	of	ADP
fnp-5049	10	24	26	26	NUM
fnp-5049	10	25	years	year	NOUN
fnp-5049	10	26	(	(	PUNCT
fnp-5049	10	27	range	range	NOUN
fnp-5049	10	28	11	11	NUM
fnp-5049	10	29	-	-	SYM
fnp-5049	10	30	42	42	NUM
fnp-5049	10	31	years	year	NOUN
fnp-5049	10	32	)	)	PUNCT
fnp-5049	10	33	.	.	PUNCT
fnp-5049	11	1	snfl	snfl	PROPN
fnp-5049	11	2	baseline	baseline	PROPN
fnp-5049	11	3	levels	level	NOUN
fnp-5049	11	4	at	at	ADP
fnp-5049	11	5	study	study	NOUN
fnp-5049	11	6	inclusion	inclusion	NOUN
fnp-5049	11	7	were	be	AUX
fnp-5049	11	8	significantly	significantly	ADV
fnp-5049	11	9	higher	high	ADJ
fnp-5049	11	10	in	in	ADP
fnp-5049	11	11	progressive	progressive	ADJ
fnp-5049	11	12	ms	ms	NOUN
fnp-5049	11	13	patients	patient	NOUN
fnp-5049	11	14	compared	compare	VERB
fnp-5049	11	15	to	to	ADP
fnp-5049	11	16	age	age	NOUN
fnp-5049	11	17	-	-	PUNCT
fnp-5049	11	18	matched	match	VERB
fnp-5049	11	19	healthy	healthy	ADJ
fnp-5049	11	20	controls	control	NOUN
fnp-5049	11	21	(	(	PUNCT
fnp-5049	11	22	median	median	NOUN
fnp-5049	11	23	16.7	16.7	NUM
fnp-5049	11	24	pg	pg	NOUN
fnp-5049	11	25	/	/	SYM
fnp-5049	11	26	ml	ml	ADP
fnp-5049	11	27	vs	vs	ADP
fnp-5049	11	28	11.5	11.5	NUM
fnp-5049	11	29	pg	pg	NOUN
fnp-5049	11	30	/	/	SYM
fnp-5049	11	31	ml	ml	NOUN
fnp-5049	11	32	,	,	PUNCT
fnp-5049	11	33	p=0.002	p=0.002	NOUN
fnp-5049	11	34	)	)	PUNCT
fnp-5049	11	35	.	.	PUNCT
fnp-5049	12	1	snfl	snfl	PROPN
fnp-5049	12	2	levels	level	NOUN
fnp-5049	12	3	showed	show	VERB
fnp-5049	12	4	a	a	DET
fnp-5049	12	5	positive	positive	ADJ
fnp-5049	12	6	correlation	correlation	NOUN
fnp-5049	12	7	with	with	ADP
fnp-5049	12	8	patient	patient	ADJ
fnp-5049	12	9	age	age	NOUN
fnp-5049	12	10	(	(	PUNCT
fnp-5049	12	11	r=0.2	r=0.2	NOUN
fnp-5049	12	12	,	,	PUNCT
fnp-5049	12	13	p=0.003	p=0.003	NOUN
fnp-5049	12	14	)	)	PUNCT
fnp-5049	12	15	.	.	PUNCT
fnp-5049	13	1	the	the	DET
fnp-5049	13	2	majority	majority	NOUN
fnp-5049	13	3	of	of	ADP
fnp-5049	13	4	patients	patient	NOUN
fnp-5049	13	5	(	(	PUNCT
fnp-5049	13	6	72	72	NUM
fnp-5049	13	7	%	%	NOUN
fnp-5049	13	8	,	,	PUNCT
fnp-5049	13	9	16/23	16/23	NUM
fnp-5049	13	10	)	)	PUNCT
fnp-5049	13	11	showed	show	VERB
fnp-5049	13	12	reduced	reduce	VERB
fnp-5049	13	13	snfl	snfl	NOUN
fnp-5049	13	14	levels	level	NOUN
fnp-5049	13	15	≥20	≥20	VERB
fnp-5049	13	16	weeks	week	NOUN
fnp-5049	13	17	after	after	ADP
fnp-5049	13	18	hdcs	hdc	NOUN
fnp-5049	13	19	compared	compare	VERB
fnp-5049	13	20	to	to	AUX
fnp-5049	13	21	baseline	baseline	VERB
fnp-5049	13	22	(	(	PUNCT
fnp-5049	13	23	median	median	NOUN
fnp-5049	13	24	13.3	13.3	NUM
fnp-5049	13	25	pg	pg	NOUN
fnp-5049	13	26	/	/	SYM
fnp-5049	13	27	ml	ml	NOUN
fnp-5049	13	28	,	,	PUNCT
fnp-5049	13	29	p=0.03	p=0.03	ADJ
fnp-5049	13	30	)	)	PUNCT
fnp-5049	13	31	.	.	PUNCT
fnp-5049	14	1	snfl	snfl	PROPN
fnp-5049	14	2	levels	level	NOUN
fnp-5049	14	3	correlated	correlate	VERB
fnp-5049	14	4	negatively	negatively	ADV
fnp-5049	14	5	with	with	ADP
fnp-5049	14	6	the	the	DET
fnp-5049	14	7	time	time	NOUN
fnp-5049	14	8	interval	interval	NOUN
fnp-5049	14	9	from	from	ADP
fnp-5049	14	10	baseline	baseline	PROPN
fnp-5049	14	11	hdcs	hdcs	PROPN
fnp-5049	14	12	therapy	therapy	NOUN
fnp-5049	14	13	(	(	PUNCT
fnp-5049	14	14	r=-0.2	r=-0.2	PROPN
fnp-5049	14	15	,	,	PUNCT
fnp-5049	14	16	p=0.03	p=0.03	ADJ
fnp-5049	14	17	)	)	PUNCT
fnp-5049	14	18	.	.	PUNCT
fnp-5049	15	1	this	this	DET
fnp-5049	15	2	association	association	NOUN
fnp-5049	15	3	was	be	AUX
fnp-5049	15	4	also	also	ADV
fnp-5049	15	5	evident	evident	ADJ
fnp-5049	15	6	after	after	ADP
fnp-5049	15	7	correction	correction	NOUN
fnp-5049	15	8	for	for	ADP
fnp-5049	15	9	treatment	treatment	NOUN
fnp-5049	15	10	with	with	ADP
fnp-5049	15	11	disease	disease	NOUN
fnp-5049	15	12	-	-	PUNCT
fnp-5049	15	13	modifying	modify	VERB
fnp-5049	15	14	drugs	drug	NOUN
fnp-5049	15	15	(	(	PUNCT
fnp-5049	15	16	adjusted	adjusted	ADJ
fnp-5049	15	17	r2=0.10	r2=0.10	NOUN
fnp-5049	15	18	,	,	PUNCT
fnp-5049	15	19	p=0.001	p=0.001	NUM
fnp-5049	15	20	)	)	PUNCT
fnp-5049	15	21	.	.	PUNCT
fnp-5049	16	1	the	the	DET
fnp-5049	16	2	edss	edss	NOUN
fnp-5049	16	3	remained	remain	VERB
fnp-5049	16	4	stable	stable	ADJ
fnp-5049	16	5	(	(	PUNCT
fnp-5049	16	6	median	median	NOUN
fnp-5049	16	7	6.5	6.5	NUM
fnp-5049	16	8	)	)	PUNCT
fnp-5049	16	9	within	within	ADP
fnp-5049	16	10	a	a	DET
fnp-5049	16	11	median	median	ADJ
fnp-5049	16	12	treatment	treatment	NOUN
fnp-5049	16	13	duration	duration	NOUN
fnp-5049	16	14	of	of	ADP
fnp-5049	16	15	26	26	NUM
fnp-5049	16	16	weeks	week	NOUN
fnp-5049	16	17	(	(	PUNCT
fnp-5049	16	18	range	range	NOUN
fnp-5049	16	19	13	13	NUM
fnp-5049	16	20	-	-	SYM
fnp-5049	16	21	51	51	NUM
fnp-5049	16	22	weeks	week	NOUN
fnp-5049	16	23	)	)	PUNCT
fnp-5049	16	24	.	.	PUNCT
fnp-5049	17	1	conclusion	conclusion	NOUN
fnp-5049	17	2	:	:	PUNCT
fnp-5049	17	3	although	although	SCONJ
fnp-5049	17	4	larger	large	ADJ
fnp-5049	17	5	studies	study	NOUN
fnp-5049	17	6	are	be	AUX
fnp-5049	17	7	needed	need	VERB
fnp-5049	17	8	to	to	PART
fnp-5049	17	9	confirm	confirm	VERB
fnp-5049	17	10	our	our	PRON
fnp-5049	17	11	findings	finding	NOUN
fnp-5049	17	12	,	,	PUNCT
fnp-5049	17	13	we	we	PRON
fnp-5049	17	14	were	be	AUX
fnp-5049	17	15	able	able	ADJ
fnp-5049	17	16	to	to	PART
fnp-5049	17	17	demonstrate	demonstrate	VERB
fnp-5049	17	18	that	that	SCONJ
fnp-5049	17	19	hdcs	hdc	VERB
fnp-5049	17	20	treatment	treatment	NOUN
fnp-5049	17	21	reduces	reduce	VERB
fnp-5049	17	22	snfl	snfl	NOUN
fnp-5049	17	23	levels	level	NOUN
fnp-5049	17	24	and	and	CCONJ
fnp-5049	17	25	therefore	therefore	ADV
fnp-5049	17	26	may	may	AUX
fnp-5049	17	27	slow	slow	VERB
fnp-5049	17	28	down	down	ADP
fnp-5049	17	29	neuroaxonal	neuroaxonal	ADJ
fnp-5049	17	30	damage	damage	NOUN
fnp-5049	17	31	in	in	ADP
fnp-5049	17	32	a	a	DET
fnp-5049	17	33	subgroup	subgroup	NOUN
fnp-5049	17	34	of	of	ADP
fnp-5049	17	35	patients	patient	NOUN
fnp-5049	17	36	with	with	ADP
fnp-5049	17	37	progressive	progressive	ADJ
fnp-5049	17	38	ms	ms	PROPN
fnp-5049	17	39	.	.	PROPN
fnp-5049	18	1	moreover	moreover	ADV
fnp-5049	18	2	,	,	PUNCT
fnp-5049	18	3	a	a	DET
fnp-5049	18	4	stable	stable	ADJ
fnp-5049	18	5	edss	edss	NOUN
fnp-5049	18	6	was	be	AUX
fnp-5049	18	7	observed	observe	VERB
fnp-5049	18	8	during	during	ADP
fnp-5049	18	9	therapy	therapy	NOUN
fnp-5049	18	10	.	.	PUNCT
fnp-5049	19	1	findings	finding	NOUN
fnp-5049	19	2	suggest	suggest	VERB
fnp-5049	19	3	that	that	SCONJ
fnp-5049	19	4	hdcs	hdc	NOUN
fnp-5049	19	5	may	may	AUX
fnp-5049	19	6	be	be	AUX
fnp-5049	19	7	beneficial	beneficial	ADJ
fnp-5049	19	8	for	for	ADP
fnp-5049	19	9	the	the	DET
fnp-5049	19	10	treatment	treatment	NOUN
fnp-5049	19	11	of	of	ADP
fnp-5049	19	12	progressive	progressive	ADJ
fnp-5049	19	13	ms	ms	PROPN
fnp-5049	19	14	.	.	PROPN
fnp-5049	19	15	introduction	introduction	NOUN
fnp-5049	19	16	neurodegeneration	neurodegeneration	NOUN
fnp-5049	19	17	and	and	CCONJ
fnp-5049	19	18	worsening	worsening	NOUN
fnp-5049	19	19	of	of	ADP
fnp-5049	19	20	clinical	clinical	ADJ
fnp-5049	19	21	disability	disability	NOUN
fnp-5049	19	22	in	in	ADP
fnp-5049	19	23	progressive	progressive	ADJ
fnp-5049	19	24	multiple	multiple	ADJ
fnp-5049	19	25	sclerosis	sclerosis	NOUN
fnp-5049	19	26	(	(	PUNCT
fnp-5049	19	27	ms	ms	NOUN
fnp-5049	19	28	)	)	PUNCT
fnp-5049	19	29	occur	occur	VERB
fnp-5049	19	30	independently	independently	ADV
fnp-5049	19	31	from	from	ADP
fnp-5049	19	32	newly	newly	ADV
fnp-5049	19	33	formed	form	VERB
fnp-5049	19	34	,	,	PUNCT
fnp-5049	19	35	acute	acute	ADJ
fnp-5049	19	36	inflammatory	inflammatory	ADJ
fnp-5049	19	37	lesions	lesion	NOUN
fnp-5049	19	38	characterized	characterize	VERB
fnp-5049	19	39	by	by	ADP
fnp-5049	19	40	mri	mri	NOUN
fnp-5049	19	41	contrast	contrast	NOUN
fnp-5049	19	42	enhancement	enhancement	NOUN
fnp-5049	19	43	[	[	X
fnp-5049	19	44	34	34	NUM
fnp-5049	19	45	]	]	PUNCT
fnp-5049	19	46	.	.	PUNCT
fnp-5049	20	1	pathological	pathological	ADJ
fnp-5049	20	2	findings	finding	NOUN
fnp-5049	20	3	in	in	ADP
fnp-5049	20	4	progressive	progressive	ADJ
fnp-5049	20	5	ms	ms	NOUN
fnp-5049	20	6	include	include	VERB
fnp-5049	20	7	so	so	ADV
fnp-5049	20	8	-	-	PUNCT
fnp-5049	20	9	called	call	VERB
fnp-5049	20	10	slowly	slowly	ADV
fnp-5049	20	11	expanding	expand	VERB
fnp-5049	20	12	lesions	lesion	NOUN
fnp-5049	20	13	,	,	PUNCT
fnp-5049	20	14	meaning	mean	VERB
fnp-5049	20	15	white	white	ADJ
fnp-5049	20	16	matter	matter	NOUN
fnp-5049	20	17	demyelinated	demyelinate	VERB
fnp-5049	20	18	lesions	lesion	NOUN
fnp-5049	20	19	with	with	ADP
fnp-5049	20	20	slow	slow	ADJ
fnp-5049	20	21	expansion	expansion	NOUN
fnp-5049	20	22	at	at	ADP
fnp-5049	20	23	their	their	PRON
fnp-5049	20	24	lesion	lesion	NOUN
fnp-5049	20	25	edge	edge	NOUN
fnp-5049	20	26	,	,	PUNCT
fnp-5049	20	27	as	as	ADV
fnp-5049	20	28	well	well	ADV
fnp-5049	20	29	as	as	ADP
fnp-5049	20	30	extensive	extensive	ADJ
fnp-5049	20	31	cortical	cortical	ADJ
fnp-5049	20	32	demyelination	demyelination	NOUN
fnp-5049	20	33	and	and	CCONJ
fnp-5049	20	34	diffuse	diffuse	VERB
fnp-5049	20	35	white	white	ADJ
fnp-5049	20	36	matter	matter	NOUN
fnp-5049	20	37	injury	injury	NOUN
fnp-5049	20	38	(	(	PUNCT
fnp-5049	20	39	figure	figure	NOUN
fnp-5049	20	40	1	1	NUM
fnp-5049	20	41	a	a	NOUN
fnp-5049	20	42	-	-	PUNCT
fnp-5049	20	43	c	c	NOUN
fnp-5049	20	44	)	)	PUNCT
fnp-5049	21	1	[	[	X
fnp-5049	21	2	21	21	NUM
fnp-5049	21	3	,	,	PUNCT
fnp-5049	21	4	39	39	NUM
fnp-5049	21	5	]	]	PUNCT
fnp-5049	21	6	.	.	PUNCT
fnp-5049	22	1	in	in	ADP
fnp-5049	22	2	contrast	contrast	NOUN
fnp-5049	22	3	to	to	ADP
fnp-5049	22	4	relapsing	relapse	VERB
fnp-5049	22	5	remitting	remit	VERB
fnp-5049	22	6	ms	ms	PROPN
fnp-5049	22	7	,	,	PUNCT
fnp-5049	22	8	the	the	DET
fnp-5049	22	9	inflammation	inflammation	NOUN
fnp-5049	22	10	in	in	ADP
fnp-5049	22	11	progressive	progressive	ADJ
fnp-5049	22	12	ms	ms	NOUN
fnp-5049	22	13	becomes	become	VERB
fnp-5049	22	14	trapped	trap	VERB
fnp-5049	22	15	or	or	CCONJ
fnp-5049	22	16	compartmentalized	compartmentalize	VERB
fnp-5049	22	17	behind	behind	ADP
fnp-5049	22	18	a	a	DET
fnp-5049	22	19	closed	closed	ADJ
fnp-5049	22	20	blood	blood	NOUN
fnp-5049	22	21	-	-	PUNCT
fnp-5049	22	22	brain	brain	NOUN
fnp-5049	22	23	barrier	barrier	NOUN
fnp-5049	22	24	,	,	PUNCT
fnp-5049	22	25	and	and	CCONJ
fnp-5049	22	26	typically	typically	ADV
fnp-5049	22	27	no	no	DET
fnp-5049	22	28	mri	mri	NOUN
fnp-5049	22	29	lesion	lesion	NOUN
fnp-5049	22	30	enhancement	enhancement	NOUN
fnp-5049	22	31	is	be	AUX
fnp-5049	22	32	observed	observe	VERB
fnp-5049	22	33	[	[	X
fnp-5049	22	34	11	11	NUM
fnp-5049	22	35	,	,	PUNCT
fnp-5049	22	36	34	34	NUM
fnp-5049	22	37	]	]	PUNCT
fnp-5049	22	38	.	.	PUNCT
fnp-5049	23	1	a	a	DET
fnp-5049	23	2	close	close	ADJ
fnp-5049	23	3	association	association	NOUN
fnp-5049	23	4	between	between	ADP
fnp-5049	23	5	inflammation	inflammation	NOUN
fnp-5049	23	6	and	and	CCONJ
fnp-5049	23	7	neurodegeneration	neurodegeneration	NOUN
fnp-5049	23	8	is	be	AUX
fnp-5049	23	9	also	also	ADV
fnp-5049	23	10	evident	evident	ADJ
fnp-5049	23	11	in	in	ADP
fnp-5049	23	12	progressive	progressive	ADJ
fnp-5049	23	13	ms	ms	NOUN
fnp-5049	24	1	[	[	X
fnp-5049	24	2	20	20	NUM
fnp-5049	24	3	]	]	PUNCT
fnp-5049	24	4	.	.	PUNCT
fnp-5049	25	1	a	a	DET
fnp-5049	25	2	profound	profound	ADJ
fnp-5049	25	3	microglial	microglial	ADJ
fnp-5049	25	4	activation	activation	NOUN
fnp-5049	25	5	and	and	CCONJ
fnp-5049	25	6	meningeal	meningeal	ADJ
fnp-5049	25	7	lymphoid	lymphoid	NOUN
fnp-5049	25	8	structures	structure	NOUN
fnp-5049	25	9	are	be	AUX
fnp-5049	25	10	associated	associate	VERB
fnp-5049	25	11	with	with	ADP
fnp-5049	25	12	tissue	tissue	NOUN
fnp-5049	25	13	injury	injury	NOUN
fnp-5049	25	14	and	and	CCONJ
fnp-5049	25	15	demyelination	demyelination	NOUN
fnp-5049	25	16	(	(	PUNCT
fnp-5049	25	17	figure	figure	NOUN
fnp-5049	25	18	1	1	NUM
fnp-5049	25	19	b	b	X
fnp-5049	25	20	-	-	PUNCT
fnp-5049	25	21	d	d	NOUN
fnp-5049	25	22	)	)	PUNCT
fnp-5049	26	1	[	[	X
fnp-5049	26	2	28	28	NUM
fnp-5049	26	3	,	,	PUNCT
fnp-5049	26	4	40	40	NUM
fnp-5049	26	5	]	]	PUNCT
fnp-5049	26	6	.	.	PUNCT
fnp-5049	27	1	the	the	DET
fnp-5049	27	2	inflammation	inflammation	NOUN
fnp-5049	27	3	causes	cause	VERB
fnp-5049	27	4	a	a	DET
fnp-5049	27	5	widespread	widespread	ADJ
fnp-5049	27	6	neuroaxonal	neuroaxonal	ADJ
fnp-5049	27	7	loss	loss	NOUN
fnp-5049	27	8	not	not	PART
fnp-5049	27	9	only	only	ADV
fnp-5049	27	10	in	in	ADP
fnp-5049	27	11	white	white	ADJ
fnp-5049	27	12	matter	matter	NOUN
fnp-5049	27	13	lesions	lesion	NOUN
fnp-5049	27	14	,	,	PUNCT
fnp-5049	27	15	but	but	CCONJ
fnp-5049	27	16	also	also	ADV
fnp-5049	27	17	in	in	ADP
fnp-5049	27	18	normal	normal	ADJ
fnp-5049	27	19	-	-	PUNCT
fnp-5049	27	20	appearing	appear	VERB
fnp-5049	27	21	white	white	ADJ
fnp-5049	27	22	matter	matter	NOUN
fnp-5049	27	23	as	as	ADV
fnp-5049	27	24	well	well	ADV
fnp-5049	27	25	as	as	ADP
fnp-5049	27	26	in	in	ADP
fnp-5049	27	27	cortical	cortical	ADJ
fnp-5049	27	28	and	and	CCONJ
fnp-5049	27	29	deep	deep	ADJ
fnp-5049	27	30	gray	gray	ADJ
fnp-5049	27	31	matter	matter	NOUN
fnp-5049	27	32	[	[	X
fnp-5049	27	33	11	11	NUM
fnp-5049	27	34	,	,	PUNCT
fnp-5049	27	35	41	41	NUM
fnp-5049	27	36	]	]	PUNCT
fnp-5049	27	37	.	.	PUNCT
fnp-5049	28	1	this	this	DET
fnp-5049	28	2	neuroaxonal	neuroaxonal	ADJ
fnp-5049	28	3	loss	loss	NOUN
fnp-5049	28	4	is	be	AUX
fnp-5049	28	5	thought	think	VERB
fnp-5049	28	6	to	to	PART
fnp-5049	28	7	be	be	AUX
fnp-5049	28	8	the	the	DET
fnp-5049	28	9	major	major	ADJ
fnp-5049	28	10	cause	cause	NOUN
fnp-5049	28	11	of	of	ADP
fnp-5049	28	12	progressive	progressive	ADJ
fnp-5049	28	13	,	,	PUNCT
fnp-5049	28	14	irreversible	irreversible	ADJ
fnp-5049	28	15	neurological	neurological	ADJ
fnp-5049	28	16	disability	disability	NOUN
fnp-5049	28	17	in	in	ADP
fnp-5049	28	18	patients	patient	NOUN
fnp-5049	28	19	with	with	ADP
fnp-5049	28	20	progressive	progressive	ADJ
fnp-5049	28	21	ms	ms	PROPN
fnp-5049	28	22	.	.	PROPN
fnp-5049	28	23	therefore	therefore	ADV
fnp-5049	28	24	,	,	PUNCT
fnp-5049	28	25	treatment	treatment	NOUN
fnp-5049	28	26	of	of	ADP
fnp-5049	28	27	progressive	progressive	ADJ
fnp-5049	28	28	ms	ms	PROPN
fnp-5049	28	29	needs	need	NOUN
fnp-5049	28	30	to	to	PART
fnp-5049	28	31	target	target	VERB
fnp-5049	28	32	the	the	DET
fnp-5049	28	33	compartmentalized	compartmentalized	ADJ
fnp-5049	28	34	cns	cns	NOUN
fnp-5049	28	35	inflammation	inflammation	NOUN
fnp-5049	28	36	in	in	ADP
fnp-5049	28	37	order	order	NOUN
fnp-5049	28	38	to	to	PART
fnp-5049	28	39	slow	slow	VERB
fnp-5049	28	40	down	down	ADP
fnp-5049	28	41	neurodegeneration	neurodegeneration	NOUN
fnp-5049	28	42	and	and	CCONJ
fnp-5049	28	43	disease	disease	NOUN
fnp-5049	28	44	progression	progression	NOUN
fnp-5049	28	45	.	.	PUNCT
fnp-5049	29	1	figure	figure	NOUN
fnp-5049	29	2	1	1	NUM
fnp-5049	29	3	:	:	PUNCT
fnp-5049	29	4	histological	histological	ADJ
fnp-5049	29	5	findings	finding	NOUN
fnp-5049	29	6	in	in	ADP
fnp-5049	29	7	progressive	progressive	ADJ
fnp-5049	29	8	multiple	multiple	ADJ
fnp-5049	29	9	sclerosis	sclerosis	NOUN
fnp-5049	29	10	typical	typical	ADJ
fnp-5049	29	11	histological	histological	ADJ
fnp-5049	29	12	findings	finding	NOUN
fnp-5049	29	13	in	in	ADP
fnp-5049	29	14	progressive	progressive	ADJ
fnp-5049	29	15	ms	ms	NOUN
fnp-5049	29	16	include	include	AUX
fnp-5049	29	17	slowly	slowly	ADV
fnp-5049	29	18	progressing	progress	VERB
fnp-5049	29	19	(	(	PUNCT
fnp-5049	29	20	smouldering	smoulder	VERB
fnp-5049	29	21	)	)	PUNCT
fnp-5049	29	22	lesions	lesion	NOUN
fnp-5049	29	23	(	(	PUNCT
fnp-5049	29	24	a	a	DET
fnp-5049	29	25	,	,	PUNCT
fnp-5049	29	26	b	b	NOUN
fnp-5049	29	27	)	)	PUNCT
fnp-5049	29	28	as	as	ADV
fnp-5049	29	29	well	well	ADV
fnp-5049	29	30	as	as	ADP
fnp-5049	29	31	meningeal	meningeal	ADJ
fnp-5049	29	32	inflammation	inflammation	NOUN
fnp-5049	29	33	and	and	CCONJ
fnp-5049	29	34	cortical	cortical	ADJ
fnp-5049	29	35	demyelination	demyelination	NOUN
fnp-5049	29	36	(	(	PUNCT
fnp-5049	29	37	c	c	X
fnp-5049	29	38	,	,	PUNCT
fnp-5049	29	39	d	d	NOUN
fnp-5049	29	40	)	)	PUNCT
fnp-5049	29	41	.	.	PUNCT
fnp-5049	30	1	a	a	DET
fnp-5049	30	2	:	:	PUNCT
fnp-5049	30	3	a	a	DET
fnp-5049	30	4	sharply	sharply	ADV
fnp-5049	30	5	demarcated	demarcate	VERB
fnp-5049	30	6	and	and	CCONJ
fnp-5049	30	7	demyelinated	demyelinate	VERB
fnp-5049	30	8	white	white	ADJ
fnp-5049	30	9	matter	matter	NOUN
fnp-5049	30	10	lesion	lesion	NOUN
fnp-5049	30	11	with	with	ADP
fnp-5049	30	12	an	an	DET
fnp-5049	30	13	increased	increase	VERB
fnp-5049	30	14	cellularity	cellularity	NOUN
fnp-5049	30	15	at	at	ADP
fnp-5049	30	16	the	the	DET
fnp-5049	30	17	border	border	NOUN
fnp-5049	30	18	of	of	ADP
fnp-5049	30	19	the	the	DET
fnp-5049	30	20	lesion	lesion	NOUN
fnp-5049	30	21	is	be	AUX
fnp-5049	30	22	shown	show	VERB
fnp-5049	30	23	(	(	PUNCT
fnp-5049	30	24	lfb	lfb	PROPN
fnp-5049	30	25	/	/	SYM
fnp-5049	30	26	pas	pas	PROPN
fnp-5049	30	27	)	)	PUNCT
fnp-5049	30	28	;	;	PUNCT
fnp-5049	31	1	b	b	X
fnp-5049	31	2	:	:	PUNCT
fnp-5049	31	3	the	the	DET
fnp-5049	31	4	lesion	lesion	NOUN
fnp-5049	31	5	edge	edge	NOUN
fnp-5049	31	6	is	be	AUX
fnp-5049	31	7	characterized	characterize	VERB
fnp-5049	31	8	by	by	ADP
fnp-5049	31	9	a	a	DET
fnp-5049	31	10	microglia	microglia	ADJ
fnp-5049	31	11	/	/	SYM
fnp-5049	31	12	macrophage	macrophage	ADJ
fnp-5049	31	13	rim	rim	NOUN
fnp-5049	31	14	(	(	PUNCT
fnp-5049	31	15	kim1p	kim1p	NOUN
fnp-5049	31	16	)	)	PUNCT
fnp-5049	31	17	;	;	PUNCT
fnp-5049	31	18	c	c	X
fnp-5049	31	19	:	:	PUNCT
fnp-5049	31	20	a	a	DET
fnp-5049	31	21	meningeal	meningeal	ADJ
fnp-5049	31	22	lymphoid	lymphoid	NOUN
fnp-5049	31	23	infiltration	infiltration	NOUN
fnp-5049	31	24	(	(	PUNCT
fnp-5049	31	25	arrows	arrow	NOUN
fnp-5049	31	26	)	)	PUNCT
fnp-5049	31	27	and	and	CCONJ
fnp-5049	31	28	underlying	underlie	VERB
fnp-5049	31	29	subpial	subpial	ADJ
fnp-5049	31	30	cortical	cortical	ADJ
fnp-5049	31	31	demyelination	demyelination	NOUN
fnp-5049	31	32	is	be	AUX
fnp-5049	31	33	found	find	VERB
fnp-5049	31	34	(	(	PUNCT
fnp-5049	31	35	anti	anti	ADJ
fnp-5049	31	36	-	-	ADJ
fnp-5049	31	37	plp	plp	ADJ
fnp-5049	31	38	)	)	PUNCT
fnp-5049	31	39	;	;	PUNCT
fnp-5049	32	1	d	d	X
fnp-5049	32	2	:	:	PUNCT
fnp-5049	32	3	the	the	DET
fnp-5049	32	4	same	same	ADJ
fnp-5049	32	5	lesion	lesion	NOUN
fnp-5049	32	6	as	as	ADP
fnp-5049	32	7	in	in	ADP
fnp-5049	32	8	panel	panel	NOUN
fnp-5049	32	9	c	c	PROPN
fnp-5049	32	10	reveals	reveal	VERB
fnp-5049	32	11	numerous	numerous	ADJ
fnp-5049	32	12	b	b	NOUN
fnp-5049	32	13	cells	cell	NOUN
fnp-5049	32	14	in	in	ADP
fnp-5049	32	15	the	the	DET
fnp-5049	32	16	lymphoid	lymphoid	ADJ
fnp-5049	32	17	meningeal	meningeal	NOUN
fnp-5049	32	18	infiltrate	infiltrate	VERB
fnp-5049	32	19	adjacent	adjacent	ADV
fnp-5049	32	20	to	to	ADP
fnp-5049	32	21	the	the	DET
fnp-5049	32	22	demyelinated	demyelinated	ADJ
fnp-5049	32	23	cortex	cortex	NOUN
fnp-5049	32	24	(	(	PUNCT
fnp-5049	32	25	anti	anti	ADJ
fnp-5049	32	26	-	-	ADJ
fnp-5049	32	27	cd20	cd20	ADJ
fnp-5049	32	28	)	)	PUNCT
fnp-5049	32	29	.	.	PUNCT
fnp-5049	33	1	scale	scale	NOUN
fnp-5049	33	2	bars	bar	NOUN
fnp-5049	33	3	:	:	PUNCT
fnp-5049	33	4	a	a	PRON
fnp-5049	33	5	and	and	CCONJ
fnp-5049	33	6	b	b	NOUN
fnp-5049	33	7	:	:	PUNCT
fnp-5049	33	8	500	500	NUM
fnp-5049	33	9	µm	µm	NOUN
fnp-5049	33	10	;	;	PUNCT
fnp-5049	33	11	c	c	X
fnp-5049	33	12	:	:	PUNCT
fnp-5049	33	13	200	200	NUM
fnp-5049	33	14	µm	µm	NOUN
fnp-5049	33	15	;	;	PUNCT
fnp-5049	33	16	d	d	NOUN
fnp-5049	33	17	:	:	PUNCT
fnp-5049	33	18	100	100	NUM
fnp-5049	33	19	µm	µm	NOUN
fnp-5049	33	20	.	.	PUNCT
fnp-5049	34	1	lfp	lfp	PROPN
fnp-5049	34	2	/	/	SYM
fnp-5049	34	3	pas	pas	PROPN
fnp-5049	34	4	=	=	PUNCT
fnp-5049	34	5	luxol	luxol	NOUN
fnp-5049	34	6	fast	fast	PROPN
fnp-5049	34	7	blue	blue	NOUN
fnp-5049	34	8	combined	combine	VERB
fnp-5049	34	9	with	with	ADP
fnp-5049	34	10	periodic	periodic	ADJ
fnp-5049	34	11	acid	acid	NOUN
fnp-5049	34	12	schiff	schiff	NOUN
fnp-5049	34	13	;	;	PUNCT
fnp-5049	34	14	plp	plp	NOUN
fnp-5049	34	15	=	=	SYM
fnp-5049	34	16	proteolipid	proteolipid	NOUN
fnp-5049	34	17	protein	protein	NOUN
fnp-5049	34	18	most	most	ADV
fnp-5049	34	19	approved	approve	VERB
fnp-5049	34	20	disease	disease	NOUN
fnp-5049	34	21	-	-	PUNCT
fnp-5049	34	22	modifying	modify	VERB
fnp-5049	34	23	therapies	therapy	NOUN
fnp-5049	34	24	(	(	PUNCT
fnp-5049	34	25	dmts	dmts	NOUN
fnp-5049	34	26	)	)	PUNCT
fnp-5049	34	27	target	target	VERB
fnp-5049	34	28	the	the	DET
fnp-5049	34	29	peripheral	peripheral	ADJ
fnp-5049	34	30	immune	immune	ADJ
fnp-5049	34	31	system	system	NOUN
fnp-5049	34	32	and	and	CCONJ
fnp-5049	34	33	reduce	reduce	VERB
fnp-5049	34	34	the	the	DET
fnp-5049	34	35	number	number	NOUN
fnp-5049	34	36	of	of	ADP
fnp-5049	34	37	new	new	ADJ
fnp-5049	34	38	acute	acute	ADJ
fnp-5049	34	39	inflammatory	inflammatory	ADJ
fnp-5049	34	40	lesions	lesion	NOUN
fnp-5049	34	41	,	,	PUNCT
fnp-5049	34	42	but	but	CCONJ
fnp-5049	34	43	they	they	PRON
fnp-5049	34	44	do	do	AUX
fnp-5049	34	45	not	not	PART
fnp-5049	34	46	significantly	significantly	ADV
fnp-5049	34	47	slow	slow	VERB
fnp-5049	34	48	disability	disability	NOUN
fnp-5049	34	49	progression	progression	NOUN
fnp-5049	34	50	in	in	ADP
fnp-5049	34	51	progressive	progressive	ADJ
fnp-5049	34	52	ms	ms	PROPN
fnp-5049	34	53	.	.	PROPN
fnp-5049	34	54	siponimod	siponimod	PROPN
fnp-5049	34	55	and	and	CCONJ
fnp-5049	34	56	ocrelizumab	ocrelizumab	NOUN
fnp-5049	34	57	were	be	AUX
fnp-5049	34	58	shown	show	VERB
fnp-5049	34	59	to	to	PART
fnp-5049	34	60	reduce	reduce	VERB
fnp-5049	34	61	confirmed	confirm	VERB
fnp-5049	34	62	disability	disability	NOUN
fnp-5049	34	63	progression	progression	NOUN
fnp-5049	34	64	in	in	ADP
fnp-5049	34	65	progressive	progressive	ADJ
fnp-5049	34	66	ms	ms	NOUN
fnp-5049	34	67	patients	patient	NOUN
fnp-5049	34	68	compared	compare	VERB
fnp-5049	34	69	to	to	ADP
fnp-5049	34	70	placebo	placebo	NOUN
fnp-5049	34	71	.	.	PUNCT
fnp-5049	35	1	however	however	ADV
fnp-5049	35	2	,	,	PUNCT
fnp-5049	35	3	their	their	PRON
fnp-5049	35	4	treatment	treatment	NOUN
fnp-5049	35	5	effects	effect	NOUN
fnp-5049	35	6	were	be	AUX
fnp-5049	35	7	mostly	mostly	ADV
fnp-5049	35	8	observed	observe	VERB
fnp-5049	35	9	in	in	ADP
fnp-5049	35	10	patients	patient	NOUN
fnp-5049	35	11	with	with	ADP
fnp-5049	35	12	so	so	ADV
fnp-5049	35	13	-	-	PUNCT
fnp-5049	35	14	called	call	VERB
fnp-5049	35	15	active	active	ADJ
fnp-5049	35	16	disease	disease	NOUN
fnp-5049	35	17	,	,	PUNCT
fnp-5049	35	18	meaning	mean	VERB
fnp-5049	35	19	in	in	ADP
fnp-5049	35	20	patients	patient	NOUN
fnp-5049	35	21	with	with	ADP
fnp-5049	35	22	relapses	relapse	NOUN
fnp-5049	35	23	or	or	CCONJ
fnp-5049	35	24	imaging	imaging	NOUN
fnp-5049	35	25	features	feature	NOUN
fnp-5049	35	26	of	of	ADP
fnp-5049	35	27	acute	acute	ADJ
fnp-5049	35	28	inflammatory	inflammatory	ADJ
fnp-5049	35	29	activity	activity	NOUN
fnp-5049	35	30	[	[	X
fnp-5049	35	31	30	30	NUM
fnp-5049	35	32	]	]	PUNCT
fnp-5049	35	33	.	.	PUNCT
fnp-5049	36	1	interferon	interferon	PROPN
fnp-5049	36	2	-	-	PUNCT
fnp-5049	36	3	β-1b	β-1b	PROPN
fnp-5049	36	4	was	be	AUX
fnp-5049	36	5	also	also	ADV
fnp-5049	36	6	approved	approve	VERB
fnp-5049	36	7	in	in	ADP
fnp-5049	36	8	europe	europe	PROPN
fnp-5049	36	9	for	for	ADP
fnp-5049	36	10	the	the	DET
fnp-5049	36	11	treatment	treatment	NOUN
fnp-5049	36	12	of	of	ADP
fnp-5049	36	13	progressive	progressive	ADJ
fnp-5049	36	14	ms	ms	NOUN
fnp-5049	36	15	with	with	ADP
fnp-5049	36	16	active	active	ADJ
fnp-5049	36	17	inflammation	inflammation	NOUN
fnp-5049	36	18	[	[	X
fnp-5049	36	19	17	17	NUM
fnp-5049	36	20	]	]	PUNCT
fnp-5049	36	21	.	.	PUNCT
fnp-5049	37	1	high	high	PROPN
fnp-5049	37	2	dose	dose	PROPN
fnp-5049	37	3	glucocorticosteroids	glucocorticosteroid	NOUN
fnp-5049	37	4	(	(	PUNCT
fnp-5049	37	5	hdcs	hdc	NOUN
fnp-5049	37	6	)	)	PUNCT
fnp-5049	37	7	as	as	ADP
fnp-5049	37	8	a	a	DET
fnp-5049	37	9	treatment	treatment	NOUN
fnp-5049	37	10	option	option	NOUN
fnp-5049	37	11	for	for	ADP
fnp-5049	37	12	progressive	progressive	ADJ
fnp-5049	37	13	ms	ms	NOUN
fnp-5049	37	14	,	,	PUNCT
fnp-5049	37	15	administered	administer	VERB
fnp-5049	37	16	either	either	CCONJ
fnp-5049	37	17	alone	alone	ADJ
fnp-5049	37	18	or	or	CCONJ
fnp-5049	37	19	in	in	ADP
fnp-5049	37	20	combination	combination	NOUN
fnp-5049	37	21	with	with	ADP
fnp-5049	37	22	other	other	ADJ
fnp-5049	37	23	immunomodulatory	immunomodulatory	ADJ
fnp-5049	37	24	/	/	SYM
fnp-5049	37	25	immunosuppressive	immunosuppressive	ADJ
fnp-5049	37	26	drugs	drug	NOUN
fnp-5049	37	27	,	,	PUNCT
fnp-5049	37	28	have	have	AUX
fnp-5049	37	29	been	be	AUX
fnp-5049	37	30	discussed	discuss	VERB
fnp-5049	37	31	for	for	ADP
fnp-5049	37	32	decades	decade	NOUN
fnp-5049	37	33	[	[	X
fnp-5049	37	34	5	5	NUM
fnp-5049	37	35	,	,	PUNCT
fnp-5049	37	36	10	10	NUM
fnp-5049	37	37	,	,	PUNCT
fnp-5049	37	38	25	25	NUM
fnp-5049	37	39	,	,	PUNCT
fnp-5049	37	40	44	44	NUM
fnp-5049	37	41	,	,	PUNCT
fnp-5049	37	42	46	46	NUM
fnp-5049	37	43	]	]	PUNCT
fnp-5049	37	44	.	.	PUNCT
fnp-5049	38	1	steroids	steroid	NOUN
fnp-5049	38	2	cross	cross	VERB
fnp-5049	38	3	the	the	DET
fnp-5049	38	4	blood	blood	NOUN
fnp-5049	38	5	brain	brain	NOUN
fnp-5049	38	6	barrier	barrier	NOUN
fnp-5049	38	7	and	and	CCONJ
fnp-5049	38	8	may	may	AUX
fnp-5049	38	9	thus	thus	ADV
fnp-5049	38	10	also	also	ADV
fnp-5049	38	11	target	target	VERB
fnp-5049	38	12	the	the	DET
fnp-5049	38	13	compartmentalized	compartmentalized	ADJ
fnp-5049	38	14	cns	cns	NOUN
fnp-5049	38	15	inflammation	inflammation	NOUN
fnp-5049	38	16	in	in	ADP
fnp-5049	38	17	progressive	progressive	ADJ
fnp-5049	38	18	ms	ms	ADJ
fnp-5049	38	19	patients	patient	NOUN
fnp-5049	38	20	.	.	PUNCT
fnp-5049	39	1	a	a	DET
fnp-5049	39	2	previous	previous	ADJ
fnp-5049	39	3	study	study	NOUN
fnp-5049	39	4	suggested	suggest	VERB
fnp-5049	39	5	that	that	SCONJ
fnp-5049	39	6	the	the	DET
fnp-5049	39	7	oral	oral	ADJ
fnp-5049	39	8	administration	administration	NOUN
fnp-5049	39	9	of	of	ADP
fnp-5049	39	10	hdcs	hdcs	PROPN
fnp-5049	39	11	is	be	AUX
fnp-5049	39	12	beneficial	beneficial	ADJ
fnp-5049	39	13	for	for	ADP
fnp-5049	39	14	the	the	DET
fnp-5049	39	15	treatment	treatment	NOUN
fnp-5049	39	16	of	of	ADP
fnp-5049	39	17	progressive	progressive	ADJ
fnp-5049	39	18	ms	ms	NOUN
fnp-5049	39	19	and	and	CCONJ
fnp-5049	39	20	showed	show	VERB
fnp-5049	39	21	a	a	DET
fnp-5049	39	22	reduction	reduction	NOUN
fnp-5049	39	23	in	in	ADP
fnp-5049	39	24	neurofilament	neurofilament	ADJ
fnp-5049	39	25	light	light	NOUN
fnp-5049	39	26	chain	chain	NOUN
fnp-5049	39	27	(	(	PUNCT
fnp-5049	39	28	nfl	nfl	PROPN
fnp-5049	39	29	)	)	PUNCT
fnp-5049	39	30	levels	level	NOUN
fnp-5049	39	31	in	in	ADP
fnp-5049	39	32	csf	csf	NOUN
fnp-5049	40	1	[	[	X
fnp-5049	40	2	45	45	NUM
fnp-5049	40	3	]	]	PUNCT
fnp-5049	40	4	.	.	PUNCT
fnp-5049	41	1	nfl	nfl	PROPN
fnp-5049	41	2	are	be	AUX
fnp-5049	41	3	structural	structural	ADJ
fnp-5049	41	4	proteins	protein	NOUN
fnp-5049	41	5	of	of	ADP
fnp-5049	41	6	axons	axon	NOUN
fnp-5049	41	7	that	that	PRON
fnp-5049	41	8	are	be	AUX
fnp-5049	41	9	released	release	VERB
fnp-5049	41	10	into	into	ADP
fnp-5049	41	11	the	the	DET
fnp-5049	41	12	csf	csf	NOUN
fnp-5049	41	13	and	and	CCONJ
fnp-5049	41	14	serum	serum	VERB
fnp-5049	41	15	upon	upon	SCONJ
fnp-5049	41	16	neuroaxonal	neuroaxonal	ADJ
fnp-5049	41	17	damage	damage	NOUN
fnp-5049	41	18	.	.	PUNCT
fnp-5049	42	1	numerous	numerous	ADJ
fnp-5049	42	2	prior	prior	ADJ
fnp-5049	42	3	studies	study	NOUN
fnp-5049	42	4	showed	show	VERB
fnp-5049	42	5	that	that	SCONJ
fnp-5049	42	6	serum	serum	NOUN
fnp-5049	42	7	neurofilament	neurofilament	ADJ
fnp-5049	42	8	light	light	ADJ
fnp-5049	42	9	chains	chain	NOUN
fnp-5049	42	10	(	(	PUNCT
fnp-5049	42	11	snfl	snfl	NOUN
fnp-5049	42	12	)	)	PUNCT
fnp-5049	42	13	are	be	AUX
fnp-5049	42	14	a	a	DET
fnp-5049	42	15	plausible	plausible	ADJ
fnp-5049	42	16	biomarker	biomarker	NOUN
fnp-5049	42	17	for	for	ADP
fnp-5049	42	18	neuroaxonal	neuroaxonal	ADJ
fnp-5049	42	19	degeneration	degeneration	NOUN
fnp-5049	42	20	.	.	PUNCT
fnp-5049	43	1	this	this	DET
fnp-5049	43	2	biomarker	biomarker	NOUN
fnp-5049	43	3	is	be	AUX
fnp-5049	43	4	widely	widely	ADV
fnp-5049	43	5	used	use	VERB
fnp-5049	43	6	for	for	ADP
fnp-5049	43	7	monitoring	monitor	VERB
fnp-5049	43	8	disease	disease	NOUN
fnp-5049	43	9	activity	activity	NOUN
fnp-5049	43	10	and	and	CCONJ
fnp-5049	43	11	treatment	treatment	NOUN
fnp-5049	43	12	responses	response	NOUN
fnp-5049	43	13	in	in	ADP
fnp-5049	43	14	ms	ms	PROPN
fnp-5049	43	15	[	[	X
fnp-5049	43	16	32	32	NUM
fnp-5049	43	17	,	,	PUNCT
fnp-5049	43	18	52	52	NUM
fnp-5049	43	19	,	,	PUNCT
fnp-5049	43	20	55	55	NUM
fnp-5049	43	21	]	]	PUNCT
fnp-5049	43	22	.	.	PUNCT
fnp-5049	44	1	in	in	ADP
fnp-5049	44	2	progressive	progressive	ADJ
fnp-5049	44	3	ms	ms	PROPN
fnp-5049	44	4	,	,	PUNCT
fnp-5049	44	5	snfl	snfl	NOUN
fnp-5049	44	6	correlate	correlate	VERB
fnp-5049	44	7	with	with	ADP
fnp-5049	44	8	brain	brain	NOUN
fnp-5049	44	9	atrophy	atrophy	NOUN
fnp-5049	44	10	and	and	CCONJ
fnp-5049	44	11	a	a	DET
fnp-5049	44	12	higher	high	ADJ
fnp-5049	44	13	likelihood	likelihood	NOUN
fnp-5049	44	14	of	of	ADP
fnp-5049	44	15	disability	disability	NOUN
fnp-5049	44	16	worsening	worsen	VERB
fnp-5049	44	17	[	[	X
fnp-5049	44	18	31	31	NUM
fnp-5049	44	19	]	]	PUNCT
fnp-5049	44	20	.	.	PUNCT
fnp-5049	45	1	treatment	treatment	NOUN
fnp-5049	45	2	of	of	ADP
fnp-5049	45	3	progressive	progressive	ADJ
fnp-5049	45	4	ms	ms	NOUN
fnp-5049	45	5	with	with	ADP
fnp-5049	45	6	fingolimod	fingolimod	PROPN
fnp-5049	45	7	,	,	PUNCT
fnp-5049	45	8	natalizumab	natalizumab	NOUN
fnp-5049	45	9	,	,	PUNCT
fnp-5049	45	10	siponimod	siponimod	PROPN
fnp-5049	45	11	,	,	PUNCT
fnp-5049	45	12	ocrelizumab	ocrelizumab	NOUN
fnp-5049	45	13	,	,	PUNCT
fnp-5049	45	14	and	and	CCONJ
fnp-5049	45	15	autologous	autologous	ADJ
fnp-5049	45	16	hematopoietic	hematopoietic	ADJ
fnp-5049	45	17	stem	stem	NOUN
fnp-5049	45	18	cell	cell	NOUN
fnp-5049	45	19	transplantation	transplantation	NOUN
fnp-5049	45	20	reduces	reduce	VERB
fnp-5049	45	21	snfl	snfl	NOUN
fnp-5049	45	22	levels	level	NOUN
fnp-5049	45	23	[	[	X
fnp-5049	45	24	3	3	NUM
fnp-5049	45	25	,	,	PUNCT
fnp-5049	45	26	29	29	NUM
fnp-5049	45	27	,	,	PUNCT
fnp-5049	45	28	36	36	NUM
fnp-5049	45	29	,	,	PUNCT
fnp-5049	45	30	53	53	NUM
fnp-5049	45	31	]	]	PUNCT
fnp-5049	45	32	.	.	PUNCT
fnp-5049	46	1	although	although	SCONJ
fnp-5049	46	2	snfl	snfl	NOUN
fnp-5049	46	3	levels	level	NOUN
fnp-5049	46	4	are	be	AUX
fnp-5049	46	5	well	well	ADV
fnp-5049	46	6	suited	suited	ADJ
fnp-5049	46	7	for	for	ADP
fnp-5049	46	8	comparing	compare	VERB
fnp-5049	46	9	patient	patient	ADJ
fnp-5049	46	10	groups	group	NOUN
fnp-5049	46	11	,	,	PUNCT
fnp-5049	46	12	natural	natural	ADJ
fnp-5049	46	13	fluctuations	fluctuation	NOUN
fnp-5049	46	14	should	should	AUX
fnp-5049	46	15	be	be	AUX
fnp-5049	46	16	taken	take	VERB
fnp-5049	46	17	into	into	ADP
fnp-5049	46	18	account	account	NOUN
fnp-5049	46	19	when	when	SCONJ
fnp-5049	46	20	evaluating	evaluate	VERB
fnp-5049	46	21	individual	individual	ADJ
fnp-5049	46	22	patients	patient	NOUN
fnp-5049	46	23	.	.	PUNCT
fnp-5049	47	1	fluctuations	fluctuation	NOUN
fnp-5049	47	2	in	in	ADP
fnp-5049	47	3	snfl	snfl	NOUN
fnp-5049	47	4	levels	level	NOUN
fnp-5049	47	5	of	of	ADP
fnp-5049	47	6	up	up	ADP
fnp-5049	47	7	to	to	PART
fnp-5049	47	8	20	20	NUM
fnp-5049	47	9	%	%	NOUN
fnp-5049	47	10	were	be	AUX
fnp-5049	47	11	observed	observe	VERB
fnp-5049	47	12	in	in	ADP
fnp-5049	47	13	the	the	DET
fnp-5049	47	14	majority	majority	NOUN
fnp-5049	47	15	of	of	ADP
fnp-5049	47	16	a	a	DET
fnp-5049	47	17	cohort	cohort	NOUN
fnp-5049	47	18	of	of	ADP
fnp-5049	47	19	progressive	progressive	ADJ
fnp-5049	47	20	ms	ms	NOUN
fnp-5049	47	21	patients	patient	NOUN
fnp-5049	47	22	[	[	X
fnp-5049	47	23	8	8	NUM
fnp-5049	47	24	]	]	PUNCT
fnp-5049	47	25	.	.	PUNCT
fnp-5049	48	1	in	in	ADP
fnp-5049	48	2	this	this	DET
fnp-5049	48	3	study	study	NOUN
fnp-5049	48	4	we	we	PRON
fnp-5049	48	5	present	present	VERB
fnp-5049	48	6	a	a	DET
fnp-5049	48	7	monocentric	monocentric	ADJ
fnp-5049	48	8	observational	observational	ADJ
fnp-5049	48	9	study	study	NOUN
fnp-5049	48	10	that	that	PRON
fnp-5049	48	11	evaluates	evaluate	VERB
fnp-5049	48	12	changes	change	NOUN
fnp-5049	48	13	in	in	ADP
fnp-5049	48	14	snfl	snfl	NOUN
fnp-5049	48	15	levels	level	NOUN
fnp-5049	48	16	in	in	ADP
fnp-5049	48	17	progressive	progressive	ADJ
fnp-5049	48	18	ms	ms	NOUN
fnp-5049	48	19	patients	patient	NOUN
fnp-5049	48	20	with	with	ADP
fnp-5049	48	21	repeated	repeat	VERB
fnp-5049	48	22	cycles	cycle	NOUN
fnp-5049	48	23	of	of	ADP
fnp-5049	48	24	parenterally	parenterally	ADV
fnp-5049	48	25	given	give	VERB
fnp-5049	48	26	hdcs	hdc	NOUN
fnp-5049	48	27	.	.	PUNCT
fnp-5049	49	1	results	result	NOUN
fnp-5049	49	2	indicate	indicate	VERB
fnp-5049	49	3	that	that	SCONJ
fnp-5049	49	4	long	long	ADJ
fnp-5049	49	5	-	-	PUNCT
fnp-5049	49	6	term	term	NOUN
fnp-5049	49	7	treatment	treatment	NOUN
fnp-5049	49	8	with	with	ADP
fnp-5049	49	9	hdcs	hdc	NOUN
fnp-5049	49	10	reduces	reduce	VERB
fnp-5049	49	11	the	the	DET
fnp-5049	49	12	neuroaxonal	neuroaxonal	ADJ
fnp-5049	49	13	damage	damage	NOUN
fnp-5049	49	14	in	in	ADP
fnp-5049	49	15	progressive	progressive	ADJ
fnp-5049	49	16	ms	ms	ADJ
fnp-5049	49	17	patients	patient	NOUN
fnp-5049	49	18	.	.	PUNCT
fnp-5049	50	1	methods	method	NOUN
fnp-5049	50	2	standard	standard	PROPN
fnp-5049	50	3	protocol	protocol	NOUN
fnp-5049	50	4	approval	approval	NOUN
fnp-5049	50	5	and	and	CCONJ
fnp-5049	50	6	patient	patient	NOUN
fnp-5049	50	7	consents	consent	NOUN
fnp-5049	50	8	the	the	DET
fnp-5049	50	9	ethics	ethic	NOUN
fnp-5049	50	10	committee	committee	PROPN
fnp-5049	50	11	of	of	ADP
fnp-5049	50	12	the	the	DET
fnp-5049	50	13	university	university	NOUN
fnp-5049	50	14	medical	medical	ADJ
fnp-5049	50	15	center	center	NOUN
fnp-5049	50	16	göttingen	göttingen	NOUN
fnp-5049	50	17	approved	approve	VERB
fnp-5049	50	18	this	this	DET
fnp-5049	50	19	study	study	NOUN
fnp-5049	50	20	(	(	PUNCT
fnp-5049	50	21	#	#	NOUN
fnp-5049	50	22	1/2/21	1/2/21	NUM
fnp-5049	50	23	)	)	PUNCT
fnp-5049	50	24	.	.	PUNCT
fnp-5049	51	1	patients	patient	NOUN
fnp-5049	51	2	gave	gave	AUX
fnp-5049	51	3	written	write	VERB
fnp-5049	51	4	informed	informed	ADJ
fnp-5049	51	5	consent	consent	NOUN
fnp-5049	51	6	for	for	ADP
fnp-5049	51	7	their	their	PRON
fnp-5049	51	8	study	study	NOUN
fnp-5049	51	9	inclusion	inclusion	NOUN
fnp-5049	51	10	.	.	PUNCT
fnp-5049	52	1	the	the	DET
fnp-5049	52	2	study	study	NOUN
fnp-5049	52	3	has	have	AUX
fnp-5049	52	4	been	be	AUX
fnp-5049	52	5	performed	perform	VERB
fnp-5049	52	6	in	in	ADP
fnp-5049	52	7	accordance	accordance	NOUN
fnp-5049	52	8	with	with	ADP
fnp-5049	52	9	the	the	DET
fnp-5049	52	10	ethical	ethical	ADJ
fnp-5049	52	11	standards	standard	NOUN
fnp-5049	52	12	laid	lay	VERB
fnp-5049	52	13	down	down	ADP
fnp-5049	52	14	in	in	ADP
fnp-5049	52	15	the	the	DET
fnp-5049	52	16	1964	1964	NUM
fnp-5049	52	17	declaration	declaration	NOUN
fnp-5049	52	18	of	of	ADP
fnp-5049	52	19	helsinki	helsinki	PROPN
fnp-5049	52	20	and	and	CCONJ
fnp-5049	52	21	its	its	PRON
fnp-5049	52	22	later	later	ADJ
fnp-5049	52	23	amendments	amendment	NOUN
fnp-5049	52	24	.	.	PUNCT
fnp-5049	53	1	study	study	NOUN
fnp-5049	53	2	cohort	cohort	VERB
fnp-5049	53	3	the	the	DET
fnp-5049	53	4	study	study	NOUN
fnp-5049	53	5	cohort	cohort	NOUN
fnp-5049	53	6	was	be	AUX
fnp-5049	53	7	recruited	recruit	VERB
fnp-5049	53	8	in	in	ADP
fnp-5049	53	9	the	the	DET
fnp-5049	53	10	tertiary	tertiary	ADJ
fnp-5049	53	11	neurological	neurological	ADJ
fnp-5049	53	12	clinic	clinic	NOUN
fnp-5049	53	13	augusta	augusta	PROPN
fnp-5049	53	14	hospital	hospital	PROPN
fnp-5049	53	15	in	in	ADP
fnp-5049	53	16	anholt	anholt	PROPN
fnp-5049	53	17	,	,	PUNCT
fnp-5049	53	18	germany	germany	PROPN
fnp-5049	53	19	.	.	PUNCT
fnp-5049	54	1	patients	patient	NOUN
fnp-5049	54	2	were	be	AUX
fnp-5049	54	3	recruited	recruit	VERB
fnp-5049	54	4	during	during	ADP
fnp-5049	54	5	ongoing	ongoing	ADJ
fnp-5049	54	6	clinical	clinical	ADJ
fnp-5049	54	7	routine	routine	ADJ
fnp-5049	54	8	care	care	NOUN
fnp-5049	54	9	from	from	ADP
fnp-5049	54	10	september	september	PROPN
fnp-5049	54	11	2018	2018	NUM
fnp-5049	54	12	to	to	ADP
fnp-5049	54	13	december	december	PROPN
fnp-5049	54	14	2019	2019	NUM
fnp-5049	54	15	.	.	PUNCT
fnp-5049	55	1	inclusion	inclusion	NOUN
fnp-5049	55	2	criteria	criterion	NOUN
fnp-5049	55	3	of	of	ADP
fnp-5049	55	4	the	the	DET
fnp-5049	55	5	study	study	NOUN
fnp-5049	55	6	were	be	AUX
fnp-5049	55	7	:	:	PUNCT
fnp-5049	55	8	1	1	X
fnp-5049	55	9	)	)	PUNCT
fnp-5049	55	10	clinically	clinically	ADV
fnp-5049	55	11	definite	definite	ADJ
fnp-5049	55	12	ms	ms	NOUN
fnp-5049	55	13	with	with	ADP
fnp-5049	55	14	a	a	DET
fnp-5049	55	15	primary	primary	ADJ
fnp-5049	55	16	or	or	CCONJ
fnp-5049	55	17	secondary	secondary	ADJ
fnp-5049	55	18	progressive	progressive	ADJ
fnp-5049	55	19	disease	disease	NOUN
fnp-5049	55	20	course	course	NOUN
fnp-5049	55	21	[	[	X
fnp-5049	55	22	54	54	NUM
fnp-5049	55	23	]	]	SYM
fnp-5049	55	24	,	,	PUNCT
fnp-5049	55	25	2	2	X
fnp-5049	55	26	)	)	PUNCT
fnp-5049	55	27	absence	absence	NOUN
fnp-5049	55	28	of	of	ADP
fnp-5049	55	29	relapse	relapse	NOUN
fnp-5049	55	30	activity	activity	NOUN
fnp-5049	55	31	at	at	ADP
fnp-5049	55	32	least	least	ADJ
fnp-5049	55	33	for	for	ADP
fnp-5049	55	34	3	3	NUM
fnp-5049	55	35	months	month	NOUN
fnp-5049	55	36	prior	prior	ADV
fnp-5049	55	37	to	to	AUX
fnp-5049	55	38	baseline	baseline	VERB
fnp-5049	55	39	blood	blood	NOUN
fnp-5049	55	40	sampling	sampling	NOUN
fnp-5049	55	41	and	and	CCONJ
fnp-5049	55	42	3	3	NUM
fnp-5049	55	43	)	)	PUNCT
fnp-5049	55	44	long	long	ADJ
fnp-5049	55	45	-	-	PUNCT
fnp-5049	55	46	term	term	NOUN
fnp-5049	55	47	hdcs	hdc	NOUN
fnp-5049	55	48	therapy	therapy	NOUN
fnp-5049	55	49	.	.	PUNCT
fnp-5049	56	1	initially	initially	ADV
fnp-5049	56	2	,	,	PUNCT
fnp-5049	56	3	27	27	NUM
fnp-5049	56	4	patients	patient	NOUN
fnp-5049	56	5	were	be	AUX
fnp-5049	56	6	included	include	VERB
fnp-5049	56	7	in	in	ADP
fnp-5049	56	8	this	this	DET
fnp-5049	56	9	longitudinal	longitudinal	ADJ
fnp-5049	56	10	study	study	NOUN
fnp-5049	56	11	.	.	PUNCT
fnp-5049	57	1	however	however	ADV
fnp-5049	57	2	,	,	PUNCT
fnp-5049	57	3	two	two	NUM
fnp-5049	57	4	patients	patient	NOUN
fnp-5049	57	5	had	have	VERB
fnp-5049	57	6	to	to	PART
fnp-5049	57	7	be	be	AUX
fnp-5049	57	8	excluded	exclude	VERB
fnp-5049	57	9	due	due	ADP
fnp-5049	57	10	to	to	ADP
fnp-5049	57	11	a	a	DET
fnp-5049	57	12	marked	mark	VERB
fnp-5049	57	13	increase	increase	NOUN
fnp-5049	57	14	in	in	ADP
fnp-5049	57	15	snfl	snfl	NOUN
fnp-5049	57	16	unrelated	unrelated	ADJ
fnp-5049	57	17	to	to	ADP
fnp-5049	57	18	ms	ms	PROPN
fnp-5049	57	19	disease	disease	NOUN
fnp-5049	57	20	activity	activity	NOUN
fnp-5049	57	21	,	,	PUNCT
fnp-5049	57	22	namely	namely	ADV
fnp-5049	57	23	due	due	ADP
fnp-5049	57	24	to	to	ADP
fnp-5049	57	25	a	a	DET
fnp-5049	57	26	traumatic	traumatic	ADJ
fnp-5049	57	27	brain	brain	NOUN
fnp-5049	57	28	injury	injury	NOUN
fnp-5049	57	29	in	in	ADP
fnp-5049	57	30	one	one	NUM
fnp-5049	57	31	patient	patient	NOUN
fnp-5049	57	32	and	and	CCONJ
fnp-5049	57	33	an	an	DET
fnp-5049	57	34	intrathecal	intrathecal	ADJ
fnp-5049	57	35	pump	pump	NOUN
fnp-5049	57	36	implantation	implantation	NOUN
fnp-5049	57	37	in	in	ADP
fnp-5049	57	38	the	the	DET
fnp-5049	57	39	other	other	ADJ
fnp-5049	57	40	.	.	PUNCT
fnp-5049	58	1	all	all	DET
fnp-5049	58	2	patients	patient	NOUN
fnp-5049	58	3	showed	show	VERB
fnp-5049	58	4	no	no	DET
fnp-5049	58	5	signs	sign	NOUN
fnp-5049	58	6	of	of	ADP
fnp-5049	58	7	clinical	clinical	ADJ
fnp-5049	58	8	activity	activity	NOUN
fnp-5049	58	9	and	and	CCONJ
fnp-5049	58	10	were	be	AUX
fnp-5049	58	11	thus	thus	ADV
fnp-5049	58	12	classified	classify	VERB
fnp-5049	58	13	as	as	ADP
fnp-5049	58	14	having	have	VERB
fnp-5049	58	15	inactive	inactive	ADJ
fnp-5049	58	16	progressive	progressive	ADJ
fnp-5049	58	17	ms	ms	PROPN
fnp-5049	58	18	.	.	PROPN
fnp-5049	58	19	clinical	clinical	ADJ
fnp-5049	58	20	assessment	assessment	NOUN
fnp-5049	58	21	clinical	clinical	ADJ
fnp-5049	58	22	information	information	NOUN
fnp-5049	58	23	was	be	AUX
fnp-5049	58	24	obtained	obtain	VERB
fnp-5049	58	25	by	by	ADP
fnp-5049	58	26	the	the	DET
fnp-5049	58	27	treating	treat	VERB
fnp-5049	58	28	physician	physician	NOUN
fnp-5049	58	29	via	via	ADP
fnp-5049	58	30	medical	medical	ADJ
fnp-5049	58	31	record	record	NOUN
fnp-5049	58	32	review	review	NOUN
fnp-5049	58	33	as	as	ADV
fnp-5049	58	34	well	well	ADV
fnp-5049	58	35	as	as	ADP
fnp-5049	58	36	personal	personal	ADJ
fnp-5049	58	37	interview	interview	NOUN
fnp-5049	58	38	and	and	CCONJ
fnp-5049	58	39	examination	examination	NOUN
fnp-5049	58	40	.	.	PUNCT
fnp-5049	59	1	baseline	baseline	PROPN
fnp-5049	59	2	was	be	AUX
fnp-5049	59	3	defined	define	VERB
fnp-5049	59	4	as	as	ADP
fnp-5049	59	5	time	time	NOUN
fnp-5049	59	6	point	point	NOUN
fnp-5049	59	7	of	of	ADP
fnp-5049	59	8	the	the	DET
fnp-5049	59	9	first	first	ADJ
fnp-5049	59	10	blood	blood	NOUN
fnp-5049	59	11	sampling	sampling	NOUN
fnp-5049	59	12	of	of	ADP
fnp-5049	59	13	the	the	DET
fnp-5049	59	14	first	first	ADJ
fnp-5049	59	15	course	course	NOUN
fnp-5049	59	16	of	of	ADP
fnp-5049	59	17	hdcs	hdc	NOUN
fnp-5049	59	18	within	within	ADP
fnp-5049	59	19	the	the	DET
fnp-5049	59	20	frame	frame	NOUN
fnp-5049	59	21	of	of	ADP
fnp-5049	59	22	the	the	DET
fnp-5049	59	23	present	present	ADJ
fnp-5049	59	24	study	study	NOUN
fnp-5049	59	25	.	.	PUNCT
fnp-5049	60	1	twenty	twenty	NUM
fnp-5049	60	2	-	-	PUNCT
fnp-5049	60	3	one	one	NUM
fnp-5049	60	4	out	out	ADP
fnp-5049	60	5	of	of	ADP
fnp-5049	60	6	our	our	PRON
fnp-5049	60	7	25	25	NUM
fnp-5049	60	8	included	include	VERB
fnp-5049	60	9	study	study	NOUN
fnp-5049	60	10	patients	patient	NOUN
fnp-5049	60	11	had	have	VERB
fnp-5049	60	12	previous	previous	ADJ
fnp-5049	60	13	cycles	cycle	NOUN
fnp-5049	60	14	of	of	ADP
fnp-5049	60	15	hdcs	hdc	NOUN
fnp-5049	60	16	before	before	SCONJ
fnp-5049	60	17	baseline	baseline	ADJ
fnp-5049	60	18	blood	blood	NOUN
fnp-5049	60	19	sampling	sampling	NOUN
fnp-5049	60	20	was	be	AUX
fnp-5049	60	21	done	do	VERB
fnp-5049	60	22	,	,	PUNCT
fnp-5049	60	23	with	with	ADP
fnp-5049	60	24	a	a	DET
fnp-5049	60	25	median	median	ADJ
fnp-5049	60	26	treatment	treatment	NOUN
fnp-5049	60	27	duration	duration	NOUN
fnp-5049	60	28	of	of	ADP
fnp-5049	60	29	26	26	NUM
fnp-5049	60	30	weeks	week	NOUN
fnp-5049	60	31	(	(	PUNCT
fnp-5049	60	32	range	range	NOUN
fnp-5049	60	33	8	8	NUM
fnp-5049	60	34	-	-	SYM
fnp-5049	60	35	120	120	NUM
fnp-5049	60	36	weeks	week	NOUN
fnp-5049	60	37	)	)	PUNCT
fnp-5049	60	38	.	.	PUNCT
fnp-5049	61	1	the	the	DET
fnp-5049	61	2	median	median	PROPN
fnp-5049	61	3	daily	daily	PROPN
fnp-5049	61	4	dose	dose	NOUN
fnp-5049	61	5	of	of	ADP
fnp-5049	61	6	previous	previous	ADJ
fnp-5049	61	7	hdcs	hdcs	PROPN
fnp-5049	61	8	cycles	cycle	NOUN
fnp-5049	61	9	was	be	AUX
fnp-5049	61	10	1500	1500	NUM
fnp-5049	61	11	mg	mg	PROPN
fnp-5049	61	12	(	(	PUNCT
fnp-5049	61	13	range	range	NOUN
fnp-5049	61	14	300	300	NUM
fnp-5049	61	15	-	-	SYM
fnp-5049	61	16	2250	2250	NUM
fnp-5049	61	17	mg	mg	NUM
fnp-5049	61	18	)	)	PUNCT
fnp-5049	61	19	.	.	PUNCT
fnp-5049	62	1	according	accord	VERB
fnp-5049	62	2	to	to	ADP
fnp-5049	62	3	the	the	DET
fnp-5049	62	4	individual	individual	ADJ
fnp-5049	62	5	clinical	clinical	ADJ
fnp-5049	62	6	situation	situation	NOUN
fnp-5049	62	7	and	and	CCONJ
fnp-5049	62	8	patient	patient	NOUN
fnp-5049	62	9	preferences	preference	NOUN
fnp-5049	62	10	,	,	PUNCT
fnp-5049	62	11	the	the	DET
fnp-5049	62	12	treating	treat	VERB
fnp-5049	62	13	physician	physician	NOUN
fnp-5049	62	14	determined	determine	VERB
fnp-5049	62	15	the	the	DET
fnp-5049	62	16	treatment	treatment	NOUN
fnp-5049	62	17	regimen	regiman	NOUN
fnp-5049	62	18	–	–	PUNCT
fnp-5049	62	19	the	the	DET
fnp-5049	62	20	dosage	dosage	NOUN
fnp-5049	62	21	of	of	ADP
fnp-5049	62	22	steroids	steroid	NOUN
fnp-5049	62	23	,	,	PUNCT
fnp-5049	62	24	duration	duration	NOUN
fnp-5049	62	25	of	of	ADP
fnp-5049	62	26	cycles	cycle	NOUN
fnp-5049	62	27	and	and	CCONJ
fnp-5049	62	28	interval	interval	NOUN
fnp-5049	62	29	between	between	ADP
fnp-5049	62	30	cycles	cycle	NOUN
fnp-5049	62	31	.	.	PUNCT
fnp-5049	63	1	patients	patient	NOUN
fnp-5049	63	2	also	also	ADV
fnp-5049	63	3	received	receive	VERB
fnp-5049	63	4	symptomatic	symptomatic	ADJ
fnp-5049	63	5	treatments	treatment	NOUN
fnp-5049	63	6	including	include	VERB
fnp-5049	63	7	physiotherapy	physiotherapy	NOUN
fnp-5049	63	8	.	.	PUNCT
fnp-5049	64	1	the	the	DET
fnp-5049	64	2	clinical	clinical	ADJ
fnp-5049	64	3	course	course	NOUN
fnp-5049	64	4	was	be	AUX
fnp-5049	64	5	determined	determine	VERB
fnp-5049	64	6	according	accord	VERB
fnp-5049	64	7	to	to	ADP
fnp-5049	64	8	published	publish	VERB
fnp-5049	64	9	criteria	criterion	NOUN
fnp-5049	64	10	[	[	X
fnp-5049	64	11	54	54	NUM
fnp-5049	64	12	]	]	PUNCT
fnp-5049	64	13	.	.	PUNCT
fnp-5049	65	1	the	the	DET
fnp-5049	65	2	expanded	expand	VERB
fnp-5049	65	3	disability	disability	NOUN
fnp-5049	65	4	status	status	NOUN
fnp-5049	65	5	scale	scale	NOUN
fnp-5049	65	6	(	(	PUNCT
fnp-5049	65	7	edss	edss	ADV
fnp-5049	65	8	)	)	PUNCT
fnp-5049	65	9	score	score	NOUN
fnp-5049	65	10	was	be	AUX
fnp-5049	65	11	assessed	assess	VERB
fnp-5049	65	12	at	at	ADP
fnp-5049	65	13	two	two	NUM
fnp-5049	65	14	time	time	NOUN
fnp-5049	65	15	points	point	NOUN
fnp-5049	65	16	:	:	PUNCT
fnp-5049	65	17	at	at	ADP
fnp-5049	65	18	baseline	baseline	NOUN
fnp-5049	65	19	and	and	CCONJ
fnp-5049	65	20	before	before	ADP
fnp-5049	65	21	the	the	DET
fnp-5049	65	22	next	next	ADJ
fnp-5049	65	23	hdcs	hdcs	PROPN
fnp-5049	65	24	cycle	cycle	NOUN
fnp-5049	65	25	.	.	PUNCT
fnp-5049	66	1	relapse	relapse	NOUN
fnp-5049	66	2	activity	activity	NOUN
fnp-5049	66	3	during	during	ADP
fnp-5049	66	4	the	the	DET
fnp-5049	66	5	study	study	NOUN
fnp-5049	66	6	period	period	NOUN
fnp-5049	66	7	as	as	ADV
fnp-5049	66	8	well	well	ADV
fnp-5049	66	9	as	as	ADP
fnp-5049	66	10	the	the	DET
fnp-5049	66	11	therapy	therapy	NOUN
fnp-5049	66	12	with	with	ADP
fnp-5049	66	13	dmts	dmts	NOUN
fnp-5049	66	14	were	be	AUX
fnp-5049	66	15	also	also	ADV
fnp-5049	66	16	registered	register	VERB
fnp-5049	66	17	.	.	PUNCT
fnp-5049	67	1	due	due	ADP
fnp-5049	67	2	to	to	ADP
fnp-5049	67	3	absence	absence	NOUN
fnp-5049	67	4	of	of	ADP
fnp-5049	67	5	clinical	clinical	ADJ
fnp-5049	67	6	disease	disease	NOUN
fnp-5049	67	7	activity	activity	NOUN
fnp-5049	67	8	,	,	PUNCT
fnp-5049	67	9	mris	mris	PROPN
fnp-5049	67	10	were	be	AUX
fnp-5049	67	11	not	not	PART
fnp-5049	67	12	indicated	indicate	VERB
fnp-5049	67	13	and	and	CCONJ
fnp-5049	67	14	not	not	PART
fnp-5049	67	15	available	available	ADJ
fnp-5049	67	16	for	for	ADP
fnp-5049	67	17	the	the	DET
fnp-5049	67	18	study	study	NOUN
fnp-5049	67	19	.	.	PUNCT
fnp-5049	68	1	in	in	ADP
fnp-5049	68	2	addition	addition	NOUN
fnp-5049	68	3	,	,	PUNCT
fnp-5049	68	4	comorbidities	comorbiditie	NOUN
fnp-5049	68	5	,	,	PUNCT
fnp-5049	68	6	the	the	DET
fnp-5049	68	7	presence	presence	NOUN
fnp-5049	68	8	of	of	ADP
fnp-5049	68	9	fatigue	fatigue	NOUN
fnp-5049	68	10	symptoms	symptom	NOUN
fnp-5049	68	11	as	as	ADV
fnp-5049	68	12	well	well	ADV
fnp-5049	68	13	as	as	ADP
fnp-5049	68	14	a	a	DET
fnp-5049	68	15	clinical	clinical	ADJ
fnp-5049	68	16	history	history	NOUN
fnp-5049	68	17	of	of	ADP
fnp-5049	68	18	smoking	smoking	NOUN
fnp-5049	68	19	and	and	CCONJ
fnp-5049	68	20	prior	prior	ADJ
fnp-5049	68	21	infections	infection	NOUN
fnp-5049	68	22	were	be	AUX
fnp-5049	68	23	noted	note	VERB
fnp-5049	68	24	.	.	PUNCT
fnp-5049	69	1	patients	patient	NOUN
fnp-5049	69	2	with	with	ADP
fnp-5049	69	3	diabetes	diabetes	NOUN
fnp-5049	69	4	,	,	PUNCT
fnp-5049	69	5	coronary	coronary	ADJ
fnp-5049	69	6	heart	heart	NOUN
fnp-5049	69	7	disease	disease	NOUN
fnp-5049	69	8	and	and	CCONJ
fnp-5049	69	9	stroke	stroke	NOUN
fnp-5049	69	10	in	in	ADP
fnp-5049	69	11	their	their	PRON
fnp-5049	69	12	clinical	clinical	ADJ
fnp-5049	69	13	history	history	NOUN
fnp-5049	69	14	were	be	AUX
fnp-5049	69	15	grouped	group	VERB
fnp-5049	69	16	as	as	ADP
fnp-5049	69	17	having	have	VERB
fnp-5049	69	18	cardiovascular	cardiovascular	ADJ
fnp-5049	69	19	risk	risk	NOUN
fnp-5049	69	20	factors	factor	NOUN
fnp-5049	69	21	.	.	PUNCT
fnp-5049	70	1	the	the	DET
fnp-5049	70	2	presence	presence	NOUN
fnp-5049	70	3	of	of	ADP
fnp-5049	70	4	cognitive	cognitive	ADJ
fnp-5049	70	5	deficits	deficit	NOUN
fnp-5049	70	6	and	and	CCONJ
fnp-5049	70	7	psychiatric	psychiatric	ADJ
fnp-5049	70	8	symptoms	symptom	NOUN
fnp-5049	70	9	were	be	AUX
fnp-5049	70	10	also	also	ADV
fnp-5049	70	11	recorded	record	VERB
fnp-5049	70	12	.	.	PUNCT
fnp-5049	71	1	blood	blood	NOUN
fnp-5049	71	2	sampling	sample	VERB
fnp-5049	71	3	blood	blood	NOUN
fnp-5049	71	4	sampling	sample	VERB
fnp-5049	71	5	at	at	ADP
fnp-5049	71	6	baseline	baseline	NOUN
fnp-5049	71	7	and	and	CCONJ
fnp-5049	71	8	within	within	ADP
fnp-5049	71	9	the	the	DET
fnp-5049	71	10	next	next	ADJ
fnp-5049	71	11	3	3	NUM
fnp-5049	71	12	weeks	week	NOUN
fnp-5049	71	13	(	(	PUNCT
fnp-5049	71	14	median	median	NOUN
fnp-5049	71	15	1.9	1.9	NUM
fnp-5049	71	16	,	,	PUNCT
fnp-5049	71	17	range	range	VERB
fnp-5049	71	18	0.9	0.9	NUM
fnp-5049	71	19	to	to	ADP
fnp-5049	71	20	2.6	2.6	NUM
fnp-5049	71	21	weeks	week	NOUN
fnp-5049	71	22	)	)	PUNCT
fnp-5049	71	23	after	after	SCONJ
fnp-5049	71	24	baseline	baseline	PROPN
fnp-5049	71	25	hdcs	hdcs	PROPN
fnp-5049	71	26	cycle	cycle	NOUN
fnp-5049	71	27	was	be	AUX
fnp-5049	71	28	done	do	VERB
fnp-5049	71	29	for	for	ADP
fnp-5049	71	30	all	all	DET
fnp-5049	71	31	patients	patient	NOUN
fnp-5049	71	32	.	.	PUNCT
fnp-5049	72	1	blood	blood	NOUN
fnp-5049	72	2	samples	sample	NOUN
fnp-5049	72	3	taken	take	VERB
fnp-5049	72	4	directly	directly	ADV
fnp-5049	72	5	before	before	ADP
fnp-5049	72	6	the	the	DET
fnp-5049	72	7	next	next	ADJ
fnp-5049	72	8	hdcs	hdcs	ADJ
fnp-5049	72	9	cycle	cycle	NOUN
fnp-5049	72	10	(	(	PUNCT
fnp-5049	72	11	median	median	NOUN
fnp-5049	72	12	26	26	NUM
fnp-5049	72	13	,	,	PUNCT
fnp-5049	72	14	range	range	VERB
fnp-5049	72	15	13	13	NUM
fnp-5049	72	16	51.3	51.3	NUM
fnp-5049	72	17	weeks	week	NOUN
fnp-5049	72	18	)	)	PUNCT
fnp-5049	72	19	were	be	AUX
fnp-5049	72	20	available	available	ADJ
fnp-5049	72	21	for	for	ADP
fnp-5049	72	22	analysis	analysis	NOUN
fnp-5049	72	23	in	in	ADP
fnp-5049	72	24	24	24	NUM
fnp-5049	72	25	patients	patient	NOUN
fnp-5049	72	26	.	.	PUNCT
fnp-5049	73	1	for	for	ADP
fnp-5049	73	2	a	a	DET
fnp-5049	73	3	subset	subset	NOUN
fnp-5049	73	4	of	of	ADP
fnp-5049	73	5	patients	patient	NOUN
fnp-5049	73	6	,	,	PUNCT
fnp-5049	73	7	further	further	ADJ
fnp-5049	73	8	blood	blood	NOUN
fnp-5049	73	9	samplings	sampling	NOUN
fnp-5049	73	10	were	be	AUX
fnp-5049	73	11	performed	perform	VERB
fnp-5049	73	12	at	at	ADP
fnp-5049	73	13	later	later	ADJ
fnp-5049	73	14	time	time	NOUN
fnp-5049	73	15	points	point	NOUN
fnp-5049	73	16	to	to	PART
fnp-5049	73	17	assess	assess	VERB
fnp-5049	73	18	the	the	DET
fnp-5049	73	19	change	change	NOUN
fnp-5049	73	20	in	in	ADP
fnp-5049	73	21	snfl	snfl	PROPN
fnp-5049	73	22	levels	level	NOUN
fnp-5049	73	23	over	over	ADP
fnp-5049	73	24	time	time	NOUN
fnp-5049	73	25	(	(	PUNCT
fnp-5049	73	26	median	median	NOUN
fnp-5049	73	27	4	4	NUM
fnp-5049	73	28	samples	sample	NOUN
fnp-5049	73	29	per	per	ADP
fnp-5049	73	30	patient	patient	NOUN
fnp-5049	73	31	)	)	PUNCT
fnp-5049	73	32	,	,	PUNCT
fnp-5049	73	33	with	with	ADP
fnp-5049	73	34	a	a	DET
fnp-5049	73	35	median	median	ADJ
fnp-5049	73	36	time	time	NOUN
fnp-5049	73	37	to	to	PART
fnp-5049	73	38	last	last	ADJ
fnp-5049	73	39	follow	follow	NOUN
fnp-5049	73	40	-	-	PUNCT
fnp-5049	73	41	up	up	NOUN
fnp-5049	73	42	of	of	ADP
fnp-5049	73	43	28	28	NUM
fnp-5049	73	44	weeks	week	NOUN
fnp-5049	73	45	(	(	PUNCT
fnp-5049	73	46	range	range	NOUN
fnp-5049	73	47	2	2	NUM
fnp-5049	73	48	-	-	SYM
fnp-5049	73	49	55	55	NUM
fnp-5049	73	50	weeks	week	NOUN
fnp-5049	73	51	)	)	PUNCT
fnp-5049	73	52	.	.	PUNCT
fnp-5049	74	1	blood	blood	NOUN
fnp-5049	74	2	was	be	AUX
fnp-5049	74	3	also	also	ADV
fnp-5049	74	4	taken	take	VERB
fnp-5049	74	5	from	from	ADP
fnp-5049	74	6	22	22	NUM
fnp-5049	74	7	healthy	healthy	ADJ
fnp-5049	74	8	age	age	NOUN
fnp-5049	74	9	-	-	PUNCT
fnp-5049	74	10	matched	match	VERB
fnp-5049	74	11	controls	control	NOUN
fnp-5049	74	12	and	and	CCONJ
fnp-5049	74	13	snfl	snfl	NOUN
fnp-5049	74	14	levels	level	NOUN
fnp-5049	74	15	measured	measure	VERB
fnp-5049	74	16	to	to	PART
fnp-5049	74	17	obtain	obtain	VERB
fnp-5049	74	18	a	a	DET
fnp-5049	74	19	range	range	NOUN
fnp-5049	74	20	for	for	ADP
fnp-5049	74	21	normal	normal	ADJ
fnp-5049	74	22	values	value	NOUN
fnp-5049	74	23	.	.	PUNCT
fnp-5049	75	1	snfl	snfl	PROPN
fnp-5049	75	2	measurement	measurement	PROPN
fnp-5049	75	3	with	with	ADP
fnp-5049	75	4	simoa	simoa	PROPN
fnp-5049	75	5	technology	technology	NOUN
fnp-5049	75	6	serum	serum	NOUN
fnp-5049	75	7	samples	sample	NOUN
fnp-5049	75	8	were	be	AUX
fnp-5049	75	9	stored	store	VERB
fnp-5049	75	10	at	at	ADP
fnp-5049	75	11	−80	−80	PROPN
fnp-5049	75	12	°	°	ADP
fnp-5049	75	13	c	c	NOUN
fnp-5049	75	14	until	until	ADP
fnp-5049	75	15	analysis	analysis	NOUN
fnp-5049	75	16	.	.	PUNCT
fnp-5049	76	1	quantification	quantification	NOUN
fnp-5049	76	2	of	of	ADP
fnp-5049	76	3	nfl	nfl	PROPN
fnp-5049	76	4	was	be	AUX
fnp-5049	76	5	done	do	VERB
fnp-5049	76	6	using	use	VERB
fnp-5049	76	7	the	the	DET
fnp-5049	76	8	simoa	simoa	NOUN
fnp-5049	76	9	nf	nf	ADJ
fnp-5049	76	10	-	-	PUNCT
fnp-5049	76	11	light	light	NOUN
fnp-5049	76	12	advantage	advantage	NOUN
fnp-5049	76	13	kit	kit	NOUN
fnp-5049	76	14	(	(	PUNCT
fnp-5049	76	15	quanterix	quanterix	ADJ
fnp-5049	76	16	,	,	PUNCT
fnp-5049	76	17	bellerica	bellerica	NOUN
fnp-5049	76	18	,	,	PUNCT
fnp-5049	76	19	ma	ma	PROPN
fnp-5049	76	20	,	,	PUNCT
fnp-5049	76	21	usa	usa	PROPN
fnp-5049	76	22	;	;	PUNCT
fnp-5049	76	23	cat	cat	NOUN
fnp-5049	76	24	.	.	PUNCT
fnp-5049	77	1	no	no	INTJ
fnp-5049	77	2	.	.	NOUN
fnp-5049	77	3	103186	103186	NUM
fnp-5049	77	4	)	)	PUNCT
fnp-5049	77	5	,	,	PUNCT
fnp-5049	77	6	as	as	SCONJ
fnp-5049	77	7	described	describe	VERB
fnp-5049	77	8	in	in	ADP
fnp-5049	77	9	detail	detail	NOUN
fnp-5049	77	10	previously	previously	ADV
fnp-5049	77	11	[	[	X
fnp-5049	77	12	14	14	NUM
fnp-5049	77	13	]	]	PUNCT
fnp-5049	77	14	.	.	PUNCT
fnp-5049	78	1	assays	assay	NOUN
fnp-5049	78	2	were	be	AUX
fnp-5049	78	3	performed	perform	VERB
fnp-5049	78	4	on	on	ADP
fnp-5049	78	5	a	a	DET
fnp-5049	78	6	simoa	simoa	NOUN
fnp-5049	78	7	hd-1	hd-1	PART
fnp-5049	78	8	analyzer	analyzer	NOUN
fnp-5049	78	9	(	(	PUNCT
fnp-5049	78	10	quanterix	quanterix	ADV
fnp-5049	78	11	)	)	PUNCT
fnp-5049	78	12	according	accord	VERB
fnp-5049	78	13	to	to	ADP
fnp-5049	78	14	a	a	DET
fnp-5049	78	15	quanterix	quanterix	ADV
fnp-5049	78	16	-	-	PUNCT
fnp-5049	78	17	developed	develop	VERB
fnp-5049	78	18	protocol	protocol	NOUN
fnp-5049	78	19	.	.	PUNCT
fnp-5049	79	1	after	after	ADP
fnp-5049	79	2	completion	completion	NOUN
fnp-5049	79	3	of	of	ADP
fnp-5049	79	4	the	the	DET
fnp-5049	79	5	assay	assay	NOUN
fnp-5049	79	6	,	,	PUNCT
fnp-5049	79	7	data	datum	NOUN
fnp-5049	79	8	were	be	AUX
fnp-5049	79	9	analyzed	analyze	VERB
fnp-5049	79	10	using	use	VERB
fnp-5049	79	11	quanterix	quanterix	ADJ
fnp-5049	79	12	software	software	NOUN
fnp-5049	79	13	.	.	PUNCT
fnp-5049	80	1	statistical	statistical	ADJ
fnp-5049	80	2	analyses	analysis	NOUN
fnp-5049	80	3	demographics	demographic	NOUN
fnp-5049	80	4	and	and	CCONJ
fnp-5049	80	5	clinical	clinical	ADJ
fnp-5049	80	6	characteristics	characteristic	NOUN
fnp-5049	80	7	were	be	AUX
fnp-5049	80	8	described	describe	VERB
fnp-5049	80	9	by	by	ADP
fnp-5049	80	10	summary	summary	NOUN
fnp-5049	80	11	statistics	statistic	NOUN
fnp-5049	80	12	appropriate	appropriate	ADJ
fnp-5049	80	13	for	for	ADP
fnp-5049	80	14	their	their	PRON
fnp-5049	80	15	scales	scale	NOUN
fnp-5049	80	16	.	.	PUNCT
fnp-5049	81	1	differences	difference	NOUN
fnp-5049	81	2	between	between	ADP
fnp-5049	81	3	two	two	NUM
fnp-5049	81	4	groups	group	NOUN
fnp-5049	81	5	in	in	ADP
fnp-5049	81	6	clinical	clinical	ADJ
fnp-5049	81	7	characteristics	characteristic	NOUN
fnp-5049	81	8	and	and	CCONJ
fnp-5049	81	9	snfl	snfl	NOUN
fnp-5049	81	10	levels	level	NOUN
fnp-5049	81	11	were	be	AUX
fnp-5049	81	12	tested	test	VERB
fnp-5049	81	13	using	use	VERB
fnp-5049	81	14	the	the	DET
fnp-5049	81	15	mann	mann	PROPN
fnp-5049	81	16	–	–	PUNCT
fnp-5049	81	17	whitney	whitney	PROPN
fnp-5049	81	18	u	u	PROPN
fnp-5049	81	19	test	test	NOUN
fnp-5049	81	20	.	.	PUNCT
fnp-5049	82	1	to	to	PART
fnp-5049	82	2	compare	compare	VERB
fnp-5049	82	3	snfl	snfl	NOUN
fnp-5049	82	4	levels	level	NOUN
fnp-5049	82	5	in	in	ADP
fnp-5049	82	6	repeated	repeat	VERB
fnp-5049	82	7	blood	blood	NOUN
fnp-5049	82	8	samples	sample	NOUN
fnp-5049	82	9	,	,	PUNCT
fnp-5049	82	10	the	the	DET
fnp-5049	82	11	wilcoxon	wilcoxon	ADJ
fnp-5049	82	12	test	test	NOUN
fnp-5049	82	13	was	be	AUX
fnp-5049	82	14	used	use	VERB
fnp-5049	82	15	.	.	PUNCT
fnp-5049	83	1	spearman	spearman	NOUN
fnp-5049	83	2	correlation	correlation	NOUN
fnp-5049	83	3	was	be	AUX
fnp-5049	83	4	performed	perform	VERB
fnp-5049	83	5	to	to	PART
fnp-5049	83	6	address	address	VERB
fnp-5049	83	7	the	the	DET
fnp-5049	83	8	question	question	NOUN
fnp-5049	83	9	of	of	ADP
fnp-5049	83	10	potential	potential	ADJ
fnp-5049	83	11	associations	association	NOUN
fnp-5049	83	12	between	between	ADP
fnp-5049	83	13	clinical	clinical	ADJ
fnp-5049	83	14	parameters	parameter	NOUN
fnp-5049	83	15	and	and	CCONJ
fnp-5049	83	16	snfl	snfl	NOUN
fnp-5049	83	17	levels	level	NOUN
fnp-5049	83	18	.	.	PUNCT
fnp-5049	84	1	to	to	PART
fnp-5049	84	2	adjust	adjust	VERB
fnp-5049	84	3	for	for	ADP
fnp-5049	84	4	relevant	relevant	ADJ
fnp-5049	84	5	covariates	covariate	NOUN
fnp-5049	84	6	,	,	PUNCT
fnp-5049	84	7	the	the	DET
fnp-5049	84	8	association	association	NOUN
fnp-5049	84	9	of	of	ADP
fnp-5049	84	10	snfl	snfl	NOUN
fnp-5049	84	11	with	with	ADP
fnp-5049	84	12	the	the	DET
fnp-5049	84	13	time	time	NOUN
fnp-5049	84	14	interval	interval	NOUN
fnp-5049	84	15	that	that	PRON
fnp-5049	84	16	passed	pass	VERB
fnp-5049	84	17	from	from	ADP
fnp-5049	84	18	baseline	baseline	PROPN
fnp-5049	84	19	was	be	AUX
fnp-5049	84	20	analyzed	analyze	VERB
fnp-5049	84	21	using	use	VERB
fnp-5049	84	22	logistic	logistic	ADJ
fnp-5049	84	23	regression	regression	NOUN
fnp-5049	84	24	models	model	NOUN
fnp-5049	84	25	.	.	PUNCT
fnp-5049	85	1	for	for	ADP
fnp-5049	85	2	multiple	multiple	ADJ
fnp-5049	85	3	linear	linear	ADJ
fnp-5049	85	4	regression	regression	NOUN
fnp-5049	85	5	analyses	analysis	NOUN
fnp-5049	85	6	,	,	PUNCT
fnp-5049	85	7	a	a	DET
fnp-5049	85	8	logarithmic	logarithmic	ADJ
fnp-5049	85	9	transformation	transformation	NOUN
fnp-5049	85	10	of	of	ADP
fnp-5049	85	11	snfl	snfl	NOUN
fnp-5049	85	12	levels	level	NOUN
fnp-5049	85	13	was	be	AUX
fnp-5049	85	14	carried	carry	VERB
fnp-5049	85	15	out	out	ADP
fnp-5049	85	16	.	.	PUNCT
fnp-5049	86	1	statistical	statistical	ADJ
fnp-5049	86	2	analyses	analysis	NOUN
fnp-5049	86	3	were	be	AUX
fnp-5049	86	4	done	do	VERB
fnp-5049	86	5	with	with	ADP
fnp-5049	86	6	graphpad	graphpad	NOUN
fnp-5049	86	7	prism	prism	NOUN
fnp-5049	86	8	6	6	NUM
fnp-5049	86	9	and	and	CCONJ
fnp-5049	86	10	ssps	ssps	VERB
fnp-5049	86	11	statistics	statistic	NOUN
fnp-5049	86	12	28	28	NUM
fnp-5049	86	13	for	for	ADP
fnp-5049	86	14	windows	window	NOUN
fnp-5049	86	15	.	.	PUNCT
fnp-5049	87	1	p	p	X
fnp-5049	87	2	-	-	PUNCT
fnp-5049	87	3	values	value	NOUN
fnp-5049	87	4	smaller	small	ADJ
fnp-5049	87	5	than	than	ADP
fnp-5049	87	6	or	or	CCONJ
fnp-5049	87	7	equal	equal	ADJ
fnp-5049	87	8	to	to	ADP
fnp-5049	87	9	0.05	0.05	NUM
fnp-5049	87	10	were	be	AUX
fnp-5049	87	11	regarded	regard	VERB
fnp-5049	87	12	as	as	ADP
fnp-5049	87	13	statistically	statistically	ADV
fnp-5049	87	14	significant	significant	ADJ
fnp-5049	87	15	.	.	PUNCT
fnp-5049	88	1	data	datum	NOUN
fnp-5049	88	2	availability	availability	NOUN
fnp-5049	88	3	the	the	DET
fnp-5049	88	4	first	first	ADJ
fnp-5049	88	5	and	and	CCONJ
fnp-5049	88	6	the	the	DET
fnp-5049	88	7	last	last	ADJ
fnp-5049	88	8	authors	author	NOUN
fnp-5049	88	9	take	take	VERB
fnp-5049	88	10	full	full	ADJ
fnp-5049	88	11	responsibility	responsibility	NOUN
fnp-5049	88	12	for	for	ADP
fnp-5049	88	13	the	the	DET
fnp-5049	88	14	data	data	NOUN
fnp-5049	88	15	analyses	analysis	NOUN
fnp-5049	88	16	,	,	PUNCT
fnp-5049	88	17	interpretation	interpretation	NOUN
fnp-5049	88	18	,	,	PUNCT
fnp-5049	88	19	and	and	CCONJ
fnp-5049	88	20	conduction	conduction	NOUN
fnp-5049	88	21	of	of	ADP
fnp-5049	88	22	the	the	DET
fnp-5049	88	23	research	research	NOUN
fnp-5049	88	24	.	.	PUNCT
fnp-5049	89	1	they	they	PRON
fnp-5049	89	2	have	have	VERB
fnp-5049	89	3	full	full	ADJ
fnp-5049	89	4	access	access	NOUN
fnp-5049	89	5	to	to	ADP
fnp-5049	89	6	all	all	PRON
fnp-5049	89	7	of	of	ADP
fnp-5049	89	8	the	the	DET
fnp-5049	89	9	data	datum	NOUN
fnp-5049	89	10	and	and	CCONJ
fnp-5049	89	11	the	the	DET
fnp-5049	89	12	right	right	NOUN
fnp-5049	89	13	to	to	PART
fnp-5049	89	14	publish	publish	VERB
fnp-5049	89	15	these	these	DET
fnp-5049	89	16	data	datum	NOUN
fnp-5049	89	17	apart	apart	ADV
fnp-5049	89	18	from	from	ADP
fnp-5049	89	19	any	any	DET
fnp-5049	89	20	sponsorship	sponsorship	NOUN
fnp-5049	89	21	.	.	PUNCT
fnp-5049	90	1	results	result	NOUN
fnp-5049	90	2	patient	patient	ADJ
fnp-5049	90	3	baseline	baseline	PROPN
fnp-5049	90	4	characteristics	characteristic	NOUN
fnp-5049	90	5	a	a	DET
fnp-5049	90	6	total	total	NOUN
fnp-5049	90	7	of	of	ADP
fnp-5049	90	8	103	103	NUM
fnp-5049	90	9	blood	blood	NOUN
fnp-5049	90	10	samples	sample	NOUN
fnp-5049	90	11	taken	take	VERB
fnp-5049	90	12	from	from	ADP
fnp-5049	90	13	25	25	NUM
fnp-5049	90	14	patients	patient	NOUN
fnp-5049	90	15	were	be	AUX
fnp-5049	90	16	included	include	VERB
fnp-5049	90	17	in	in	ADP
fnp-5049	90	18	our	our	PRON
fnp-5049	90	19	analyses	analysis	NOUN
fnp-5049	90	20	.	.	PUNCT
fnp-5049	91	1	the	the	DET
fnp-5049	91	2	patients	patient	NOUN
fnp-5049	91	3	’	’	PART
fnp-5049	91	4	demographic	demographic	ADJ
fnp-5049	91	5	and	and	CCONJ
fnp-5049	91	6	clinical	clinical	ADJ
fnp-5049	91	7	data	datum	NOUN
fnp-5049	91	8	at	at	ADP
fnp-5049	91	9	baseline	baseline	NOUN
fnp-5049	91	10	are	be	AUX
fnp-5049	91	11	shown	show	VERB
fnp-5049	91	12	in	in	ADP
fnp-5049	91	13	table	table	NOUN
fnp-5049	91	14	1	1	NUM
fnp-5049	91	15	.	.	PUNCT
fnp-5049	92	1	clinical	clinical	ADJ
fnp-5049	92	2	relapses	relapse	NOUN
fnp-5049	92	3	were	be	AUX
fnp-5049	92	4	not	not	PART
fnp-5049	92	5	observed	observe	VERB
fnp-5049	92	6	for	for	ADP
fnp-5049	92	7	3	3	NUM
fnp-5049	92	8	months	month	NOUN
fnp-5049	92	9	prior	prior	ADV
fnp-5049	92	10	to	to	AUX
fnp-5049	92	11	baseline	baseline	VERB
fnp-5049	92	12	blood	blood	NOUN
fnp-5049	92	13	sampling	sampling	NOUN
fnp-5049	92	14	(	(	PUNCT
fnp-5049	92	15	see	see	VERB
fnp-5049	92	16	inclusion	inclusion	NOUN
fnp-5049	92	17	criteria	criterion	NOUN
fnp-5049	92	18	)	)	PUNCT
fnp-5049	92	19	.	.	PUNCT
fnp-5049	93	1	no	no	DET
fnp-5049	93	2	relapses	relapse	NOUN
fnp-5049	93	3	occurred	occur	VERB
fnp-5049	93	4	during	during	ADP
fnp-5049	93	5	the	the	DET
fnp-5049	93	6	duration	duration	NOUN
fnp-5049	93	7	of	of	ADP
fnp-5049	93	8	the	the	DET
fnp-5049	93	9	study	study	NOUN
fnp-5049	93	10	.	.	PUNCT
fnp-5049	94	1	five	five	NUM
fnp-5049	94	2	patients	patient	NOUN
fnp-5049	94	3	were	be	AUX
fnp-5049	94	4	treated	treat	VERB
fnp-5049	94	5	with	with	ADP
fnp-5049	94	6	disease	disease	NOUN
fnp-5049	94	7	-	-	PUNCT
fnp-5049	94	8	modifying	modify	VERB
fnp-5049	94	9	therapies	therapy	NOUN
fnp-5049	94	10	(	(	PUNCT
fnp-5049	94	11	n=1	n=1	PROPN
fnp-5049	94	12	interferon	interferon	NOUN
fnp-5049	94	13	-	-	PUNCT
fnp-5049	94	14	ß-1a	ß-1a	NOUN
fnp-5049	94	15	;	;	PUNCT
fnp-5049	94	16	n=2	n=2	X
fnp-5049	94	17	dimethyl	dimethyl	NOUN
fnp-5049	94	18	fumarate	fumarate	NOUN
fnp-5049	94	19	and	and	CCONJ
fnp-5049	94	20	n=2	n=2	ADV
fnp-5049	94	21	glatiramer	glatiramer	ADJ
fnp-5049	94	22	acetate	acetate	NOUN
fnp-5049	94	23	)	)	PUNCT
fnp-5049	94	24	.	.	PUNCT
fnp-5049	95	1	despite	despite	SCONJ
fnp-5049	95	2	no	no	DET
fnp-5049	95	3	signs	sign	NOUN
fnp-5049	95	4	of	of	ADP
fnp-5049	95	5	clinical	clinical	ADJ
fnp-5049	95	6	activity	activity	NOUN
fnp-5049	95	7	,	,	PUNCT
fnp-5049	95	8	treatment	treatment	NOUN
fnp-5049	95	9	with	with	ADP
fnp-5049	95	10	dmts	dmts	NOUN
fnp-5049	95	11	was	be	AUX
fnp-5049	95	12	continued	continue	VERB
fnp-5049	95	13	due	due	ADP
fnp-5049	95	14	to	to	ADP
fnp-5049	95	15	patients	patient	NOUN
fnp-5049	95	16	’	'	PUNCT
fnp-5049	95	17	personal	personal	ADJ
fnp-5049	95	18	preferences	preference	NOUN
fnp-5049	95	19	and	and	CCONJ
fnp-5049	95	20	the	the	DET
fnp-5049	95	21	absence	absence	NOUN
fnp-5049	95	22	of	of	ADP
fnp-5049	95	23	clear	clear	ADJ
fnp-5049	95	24	recommendations	recommendation	NOUN
fnp-5049	95	25	for	for	ADP
fnp-5049	95	26	therapy	therapy	NOUN
fnp-5049	95	27	withdrawal	withdrawal	NOUN
fnp-5049	95	28	.	.	PUNCT
fnp-5049	96	1	table	table	NOUN
fnp-5049	96	2	1	1	NUM
fnp-5049	96	3	:	:	PUNCT
fnp-5049	96	4	demographic	demographic	ADJ
fnp-5049	96	5	and	and	CCONJ
fnp-5049	96	6	clinical	clinical	ADJ
fnp-5049	96	7	characteristics	characteristic	NOUN
fnp-5049	96	8	of	of	ADP
fnp-5049	96	9	the	the	DET
fnp-5049	96	10	study	study	NOUN
fnp-5049	96	11	cohort	cohort	NOUN
fnp-5049	96	12	baseline	baseline	PROPN
fnp-5049	96	13	characteristics	characteristic	NOUN
fnp-5049	96	14	number	number	NOUN
fnp-5049	96	15	of	of	ADP
fnp-5049	96	16	patients	patient	NOUN
fnp-5049	96	17	25	25	NUM
fnp-5049	96	18	age	age	NOUN
fnp-5049	96	19	in	in	ADP
fnp-5049	96	20	years	year	NOUN
fnp-5049	96	21	,	,	PUNCT
fnp-5049	96	22	median	median	NOUN
fnp-5049	96	23	(	(	PUNCT
fnp-5049	96	24	min	min	NOUN
fnp-5049	96	25	-	-	PUNCT
fnp-5049	96	26	max	max	NOUN
fnp-5049	96	27	)	)	PUNCT
fnp-5049	96	28	55	55	NUM
fnp-5049	96	29	(	(	PUNCT
fnp-5049	96	30	46	46	NUM
fnp-5049	96	31	-	-	SYM
fnp-5049	96	32	77	77	NUM
fnp-5049	96	33	)	)	PUNCT
fnp-5049	96	34	gender	gender	NOUN
fnp-5049	96	35	m	m	PROPN
fnp-5049	96	36	:	:	PUNCT
fnp-5049	96	37	f	f	PROPN
fnp-5049	96	38	(	(	PUNCT
fnp-5049	96	39	%	%	INTJ
fnp-5049	96	40	)	)	PUNCT
fnp-5049	96	41	6:19	6:19	NUM
fnp-5049	96	42	(	(	PUNCT
fnp-5049	96	43	24:76	24:76	NUM
fnp-5049	96	44	)	)	PUNCT
fnp-5049	96	45	disease	disease	NOUN
fnp-5049	96	46	duration	duration	NOUN
fnp-5049	96	47	in	in	ADP
fnp-5049	96	48	years	year	NOUN
fnp-5049	96	49	,	,	PUNCT
fnp-5049	96	50	median	median	NOUN
fnp-5049	96	51	(	(	PUNCT
fnp-5049	96	52	min	min	NOUN
fnp-5049	96	53	-	-	PUNCT
fnp-5049	96	54	max	max	NOUN
fnp-5049	96	55	)	)	PUNCT
fnp-5049	96	56	26	26	NUM
fnp-5049	96	57	(	(	PUNCT
fnp-5049	96	58	11	11	NUM
fnp-5049	96	59	-	-	SYM
fnp-5049	96	60	42	42	NUM
fnp-5049	96	61	)	)	PUNCT
fnp-5049	96	62	diagnosis	diagnosis	NOUN
fnp-5049	96	63	at	at	ADP
fnp-5049	96	64	baseline	baseline	NOUN
fnp-5049	96	65	spms	spm	NOUN
fnp-5049	96	66	:	:	PUNCT
fnp-5049	96	67	ppms	ppm	NOUN
fnp-5049	96	68	(	(	PUNCT
fnp-5049	96	69	%	%	INTJ
fnp-5049	96	70	)	)	PUNCT
fnp-5049	96	71	22:3	22:3	NUM
fnp-5049	96	72	(	(	PUNCT
fnp-5049	96	73	88:12	88:12	NUM
fnp-5049	96	74	)	)	PUNCT
fnp-5049	96	75	edss	edss	ADV
fnp-5049	96	76	at	at	ADP
fnp-5049	96	77	baseline	baseline	NOUN
fnp-5049	96	78	,	,	PUNCT
fnp-5049	96	79	median	median	ADJ
fnp-5049	96	80	(	(	PUNCT
fnp-5049	96	81	min	min	NOUN
fnp-5049	96	82	-	-	PUNCT
fnp-5049	96	83	max	max	NOUN
fnp-5049	96	84	)	)	PUNCT
fnp-5049	96	85	6.5	6.5	NUM
fnp-5049	96	86	(	(	PUNCT
fnp-5049	96	87	5.5	5.5	NUM
fnp-5049	96	88	-	-	SYM
fnp-5049	96	89	8.5	8.5	NUM
fnp-5049	96	90	)	)	PUNCT
fnp-5049	96	91	hdcs	hdc	VERB
fnp-5049	96	92	equivalent	equivalent	ADJ
fnp-5049	96	93	dose	dose	NOUN
fnp-5049	96	94	per	per	ADP
fnp-5049	96	95	day	day	NOUN
fnp-5049	96	96	in	in	ADP
fnp-5049	96	97	mg	mg	PROPN
fnp-5049	96	98	,	,	PUNCT
fnp-5049	96	99	median	median	NOUN
fnp-5049	96	100	(	(	PUNCT
fnp-5049	96	101	min	min	NOUN
fnp-5049	96	102	-	-	PUNCT
fnp-5049	96	103	max	max	NOUN
fnp-5049	96	104	)	)	PUNCT
fnp-5049	96	105	1500	1500	NUM
fnp-5049	96	106	(	(	PUNCT
fnp-5049	96	107	300	300	NUM
fnp-5049	96	108	-	-	NUM
fnp-5049	96	109	3000	3000	NUM
fnp-5049	96	110	)	)	PUNCT
fnp-5049	96	111	edss	edss	ADV
fnp-5049	96	112	before	before	ADP
fnp-5049	96	113	second	second	ADJ
fnp-5049	96	114	hdcs	hdcs	PROPN
fnp-5049	96	115	cycle	cycle	NOUN
fnp-5049	96	116	in	in	ADP
fnp-5049	96	117	years	year	NOUN
fnp-5049	96	118	,	,	PUNCT
fnp-5049	96	119	median	median	NOUN
fnp-5049	96	120	(	(	PUNCT
fnp-5049	96	121	min	min	NOUN
fnp-5049	96	122	-	-	PUNCT
fnp-5049	96	123	max	max	NOUN
fnp-5049	96	124	)	)	PUNCT
fnp-5049	96	125	6.5	6.5	NUM
fnp-5049	96	126	(	(	PUNCT
fnp-5049	96	127	6.0	6.0	NUM
fnp-5049	96	128	-	-	SYM
fnp-5049	96	129	8.5	8.5	NUM
fnp-5049	96	130	)	)	PUNCT
fnp-5049	96	131	mean	mean	ADJ
fnp-5049	96	132	number	number	NOUN
fnp-5049	96	133	of	of	ADP
fnp-5049	96	134	blood	blood	NOUN
fnp-5049	96	135	samples	sample	NOUN
fnp-5049	96	136	per	per	ADP
fnp-5049	96	137	patient	patient	NOUN
fnp-5049	96	138	(	(	PUNCT
fnp-5049	96	139	min	min	NOUN
fnp-5049	96	140	-	-	PUNCT
fnp-5049	96	141	max	max	NOUN
fnp-5049	96	142	)	)	PUNCT
fnp-5049	96	143	4.1	4.1	NUM
fnp-5049	96	144	(	(	PUNCT
fnp-5049	96	145	3	3	NUM
fnp-5049	96	146	-	-	SYM
fnp-5049	96	147	7	7	NUM
fnp-5049	96	148	)	)	PUNCT
fnp-5049	96	149	time	time	NOUN
fnp-5049	96	150	interval	interval	NOUN
fnp-5049	96	151	from	from	ADP
fnp-5049	96	152	baseline	baseline	NOUN
fnp-5049	96	153	to	to	ADP
fnp-5049	96	154	last	last	ADJ
fnp-5049	96	155	follow	follow	NOUN
fnp-5049	96	156	-	-	PUNCT
fnp-5049	96	157	up	up	NOUN
fnp-5049	96	158	in	in	ADP
fnp-5049	96	159	weeks	week	NOUN
fnp-5049	96	160	,	,	PUNCT
fnp-5049	96	161	median	median	NOUN
fnp-5049	96	162	(	(	PUNCT
fnp-5049	96	163	min	min	NOUN
fnp-5049	96	164	-	-	PUNCT
fnp-5049	96	165	max	max	NOUN
fnp-5049	96	166	)	)	PUNCT
fnp-5049	96	167	28	28	NUM
fnp-5049	96	168	(	(	PUNCT
fnp-5049	96	169	2	2	NUM
fnp-5049	96	170	-	-	SYM
fnp-5049	96	171	55	55	NUM
fnp-5049	96	172	)	)	PUNCT
fnp-5049	96	173	snfl	snfl	NOUN
fnp-5049	96	174	levels	level	NOUN
fnp-5049	96	175	decrease	decrease	VERB
fnp-5049	96	176	after	after	SCONJ
fnp-5049	96	177	hdcs	hdcs	PROPN
fnp-5049	96	178	therapy	therapy	PROPN
fnp-5049	96	179	snfl	snfl	PROPN
fnp-5049	96	180	baseline	baseline	PROPN
fnp-5049	96	181	levels	level	NOUN
fnp-5049	96	182	were	be	AUX
fnp-5049	96	183	significantly	significantly	ADV
fnp-5049	96	184	higher	high	ADJ
fnp-5049	96	185	in	in	ADP
fnp-5049	96	186	progressive	progressive	ADJ
fnp-5049	96	187	ms	ms	NOUN
fnp-5049	96	188	patients	patient	NOUN
fnp-5049	96	189	compared	compare	VERB
fnp-5049	96	190	to	to	ADP
fnp-5049	96	191	age	age	NOUN
fnp-5049	96	192	-	-	PUNCT
fnp-5049	96	193	matched	match	VERB
fnp-5049	96	194	healthy	healthy	ADJ
fnp-5049	96	195	controls	control	NOUN
fnp-5049	96	196	(	(	PUNCT
fnp-5049	96	197	median	median	NOUN
fnp-5049	96	198	16.7	16.7	NUM
fnp-5049	96	199	pg	pg	NOUN
fnp-5049	96	200	/	/	SYM
fnp-5049	96	201	ml	ml	ADP
fnp-5049	96	202	vs	vs	ADP
fnp-5049	96	203	11.5	11.5	NUM
fnp-5049	96	204	pg	pg	NOUN
fnp-5049	96	205	/	/	SYM
fnp-5049	96	206	ml	ml	NOUN
fnp-5049	96	207	,	,	PUNCT
fnp-5049	96	208	p=0.002	p=0.002	NOUN
fnp-5049	96	209	)	)	PUNCT
fnp-5049	96	210	.	.	PUNCT
fnp-5049	97	1	within	within	ADP
fnp-5049	97	2	the	the	DET
fnp-5049	97	3	first	first	ADJ
fnp-5049	97	4	two	two	NUM
fnp-5049	97	5	weeks	week	NOUN
fnp-5049	97	6	after	after	ADP
fnp-5049	97	7	baseline	baseline	PROPN
fnp-5049	97	8	hdcs	hdcs	PROPN
fnp-5049	97	9	therapy	therapy	NOUN
fnp-5049	97	10	,	,	PUNCT
fnp-5049	97	11	the	the	DET
fnp-5049	97	12	median	median	ADJ
fnp-5049	97	13	snfl	snfl	NOUN
fnp-5049	97	14	level	level	NOUN
fnp-5049	97	15	was	be	AUX
fnp-5049	97	16	not	not	PART
fnp-5049	97	17	significantly	significantly	ADV
fnp-5049	97	18	reduced	reduce	VERB
fnp-5049	97	19	(	(	PUNCT
fnp-5049	97	20	median	median	NOUN
fnp-5049	97	21	15.6	15.6	NUM
fnp-5049	97	22	pg	pg	NOUN
fnp-5049	97	23	/	/	SYM
fnp-5049	97	24	ml	ml	NOUN
fnp-5049	97	25	,	,	PUNCT
fnp-5049	97	26	p=0.7	p=0.7	ADJ
fnp-5049	97	27	)	)	PUNCT
fnp-5049	97	28	.	.	PUNCT
fnp-5049	98	1	however	however	ADV
fnp-5049	98	2	,	,	PUNCT
fnp-5049	98	3	≥20	≥20	VERB
fnp-5049	98	4	weeks	week	NOUN
fnp-5049	98	5	after	after	SCONJ
fnp-5049	98	6	baseline	baseline	PROPN
fnp-5049	98	7	hdcs	hdcs	PROPN
fnp-5049	98	8	therapy	therapy	PROPN
fnp-5049	98	9	the	the	DET
fnp-5049	98	10	majority	majority	NOUN
fnp-5049	98	11	of	of	ADP
fnp-5049	98	12	patients	patient	NOUN
fnp-5049	98	13	(	(	PUNCT
fnp-5049	98	14	72	72	NUM
fnp-5049	98	15	%	%	NOUN
fnp-5049	98	16	,	,	PUNCT
fnp-5049	98	17	16/23	16/23	NUM
fnp-5049	98	18	)	)	PUNCT
fnp-5049	98	19	showed	show	VERB
fnp-5049	98	20	reduced	reduce	VERB
fnp-5049	98	21	snfl	snfl	NOUN
fnp-5049	98	22	levels	level	NOUN
fnp-5049	98	23	compared	compare	VERB
fnp-5049	98	24	to	to	PART
fnp-5049	98	25	baseline	baseline	VERB
fnp-5049	98	26	(	(	PUNCT
fnp-5049	98	27	median	median	NOUN
fnp-5049	98	28	13.3	13.3	NUM
fnp-5049	98	29	pg	pg	NOUN
fnp-5049	98	30	/	/	SYM
fnp-5049	98	31	ml	ml	NOUN
fnp-5049	98	32	,	,	PUNCT
fnp-5049	98	33	p=0.03	p=0.03	ADJ
fnp-5049	98	34	)	)	PUNCT
fnp-5049	98	35	(	(	PUNCT
fnp-5049	98	36	figure	figure	NOUN
fnp-5049	98	37	2a	2a	NUM
fnp-5049	98	38	)	)	PUNCT
fnp-5049	98	39	.	.	PUNCT
fnp-5049	99	1	the	the	DET
fnp-5049	99	2	median	median	ADJ
fnp-5049	99	3	snfl	snfl	NOUN
fnp-5049	99	4	level	level	NOUN
fnp-5049	99	5	was	be	AUX
fnp-5049	99	6	still	still	ADV
fnp-5049	99	7	higher	high	ADJ
fnp-5049	99	8	compared	compare	VERB
fnp-5049	99	9	to	to	ADP
fnp-5049	99	10	the	the	DET
fnp-5049	99	11	healthy	healthy	ADJ
fnp-5049	99	12	control	control	NOUN
fnp-5049	99	13	cohort	cohort	NOUN
fnp-5049	99	14	,	,	PUNCT
fnp-5049	99	15	but	but	CCONJ
fnp-5049	99	16	these	these	DET
fnp-5049	99	17	differences	difference	NOUN
fnp-5049	99	18	no	no	ADV
fnp-5049	99	19	longer	long	ADV
fnp-5049	99	20	reached	reach	VERB
fnp-5049	99	21	statistical	statistical	ADJ
fnp-5049	99	22	significance	significance	NOUN
fnp-5049	99	23	.	.	PUNCT
fnp-5049	100	1	pairwise	pairwise	NOUN
fnp-5049	100	2	comparison	comparison	NOUN
fnp-5049	100	3	of	of	ADP
fnp-5049	100	4	snfl	snfl	NOUN
fnp-5049	100	5	levels	level	NOUN
fnp-5049	100	6	at	at	ADP
fnp-5049	100	7	baseline	baseline	NOUN
fnp-5049	100	8	,	,	PUNCT
fnp-5049	100	9	subsequent	subsequent	ADJ
fnp-5049	100	10	hdcs	hdc	NOUN
fnp-5049	100	11	cycle	cycle	NOUN
fnp-5049	100	12	(	(	PUNCT
fnp-5049	100	13	2nd	2nd	ADJ
fnp-5049	100	14	cycle	cycle	NOUN
fnp-5049	100	15	during	during	ADP
fnp-5049	100	16	the	the	DET
fnp-5049	100	17	study	study	NOUN
fnp-5049	100	18	)	)	PUNCT
fnp-5049	100	19	as	as	ADV
fnp-5049	100	20	well	well	ADV
fnp-5049	100	21	as	as	ADP
fnp-5049	100	22	at	at	ADP
fnp-5049	100	23	last	last	ADJ
fnp-5049	100	24	follow	follow	NOUN
fnp-5049	100	25	-	-	PUNCT
fnp-5049	100	26	up	up	NOUN
fnp-5049	100	27	revealed	reveal	VERB
fnp-5049	100	28	that	that	SCONJ
fnp-5049	100	29	even	even	ADV
fnp-5049	100	30	more	more	ADJ
fnp-5049	100	31	patients	patient	NOUN
fnp-5049	100	32	(	(	PUNCT
fnp-5049	100	33	76	76	NUM
fnp-5049	100	34	%	%	NOUN
fnp-5049	100	35	,	,	PUNCT
fnp-5049	100	36	19/25	19/25	NUM
fnp-5049	100	37	)	)	PUNCT
fnp-5049	100	38	had	have	AUX
fnp-5049	100	39	reduced	reduce	VERB
fnp-5049	100	40	snfl	snfl	NOUN
fnp-5049	100	41	levels	level	NOUN
fnp-5049	100	42	.	.	PUNCT
fnp-5049	101	1	snfl	snfl	PROPN
fnp-5049	101	2	levels	level	NOUN
fnp-5049	101	3	showed	show	VERB
fnp-5049	101	4	a	a	DET
fnp-5049	101	5	median	median	ADJ
fnp-5049	101	6	reduction	reduction	NOUN
fnp-5049	101	7	of	of	ADP
fnp-5049	101	8	22	22	NUM
fnp-5049	101	9	%	%	NOUN
fnp-5049	101	10	at	at	ADP
fnp-5049	101	11	last	last	ADJ
fnp-5049	101	12	follow	follow	NOUN
fnp-5049	101	13	-	-	PUNCT
fnp-5049	101	14	up	up	NOUN
fnp-5049	101	15	compared	compare	VERB
fnp-5049	101	16	to	to	PART
fnp-5049	101	17	baseline	baseline	VERB
fnp-5049	101	18	snfl	snfl	NOUN
fnp-5049	101	19	values	value	NOUN
fnp-5049	101	20	(	(	PUNCT
fnp-5049	101	21	p=0.01	p=0.01	NUM
fnp-5049	101	22	)	)	PUNCT
fnp-5049	101	23	(	(	PUNCT
fnp-5049	101	24	figure	figure	NOUN
fnp-5049	101	25	2b	2b	NOUN
fnp-5049	101	26	)	)	PUNCT
fnp-5049	101	27	.	.	PUNCT
fnp-5049	102	1	this	this	DET
fnp-5049	102	2	effect	effect	NOUN
fnp-5049	102	3	was	be	AUX
fnp-5049	102	4	also	also	ADV
fnp-5049	102	5	observed	observe	VERB
fnp-5049	102	6	when	when	SCONJ
fnp-5049	102	7	excluding	exclude	VERB
fnp-5049	102	8	the	the	DET
fnp-5049	102	9	5	5	NUM
fnp-5049	102	10	patients	patient	NOUN
fnp-5049	102	11	treated	treat	VERB
fnp-5049	102	12	with	with	ADP
fnp-5049	102	13	dmts	dmts	NOUN
fnp-5049	102	14	(	(	PUNCT
fnp-5049	102	15	p=0.001	p=0.001	NUM
fnp-5049	102	16	;	;	PUNCT
fnp-5049	102	17	data	datum	NOUN
fnp-5049	102	18	not	not	PART
fnp-5049	102	19	shown	show	VERB
fnp-5049	102	20	)	)	PUNCT
fnp-5049	102	21	,	,	PUNCT
fnp-5049	102	22	indicating	indicate	VERB
fnp-5049	102	23	that	that	SCONJ
fnp-5049	102	24	the	the	DET
fnp-5049	102	25	snfl	snfl	NOUN
fnp-5049	102	26	reduction	reduction	NOUN
fnp-5049	102	27	is	be	AUX
fnp-5049	102	28	not	not	PART
fnp-5049	102	29	due	due	ADJ
fnp-5049	102	30	to	to	ADP
fnp-5049	102	31	dmt	dmt	PROPN
fnp-5049	102	32	treatment	treatment	NOUN
fnp-5049	102	33	.	.	PUNCT
fnp-5049	103	1	although	although	SCONJ
fnp-5049	103	2	in	in	ADP
fnp-5049	103	3	individual	individual	ADJ
fnp-5049	103	4	patients	patient	NOUN
fnp-5049	103	5	a	a	DET
fnp-5049	103	6	20	20	NUM
fnp-5049	103	7	%	%	NOUN
fnp-5049	103	8	reduction	reduction	NOUN
fnp-5049	103	9	of	of	ADP
fnp-5049	103	10	snfl	snfl	NOUN
fnp-5049	103	11	levels	level	NOUN
fnp-5049	103	12	may	may	AUX
fnp-5049	103	13	be	be	AUX
fnp-5049	103	14	regarded	regard	VERB
fnp-5049	103	15	as	as	ADP
fnp-5049	103	16	natural	natural	ADJ
fnp-5049	103	17	fluctuation	fluctuation	NOUN
fnp-5049	103	18	[	[	X
fnp-5049	103	19	8	8	NUM
fnp-5049	103	20	]	]	PUNCT
fnp-5049	103	21	,	,	PUNCT
fnp-5049	103	22	on	on	ADP
fnp-5049	103	23	a	a	DET
fnp-5049	103	24	group	group	NOUN
fnp-5049	103	25	level	level	NOUN
fnp-5049	103	26	this	this	DET
fnp-5049	103	27	reduction	reduction	NOUN
fnp-5049	103	28	seems	seem	VERB
fnp-5049	103	29	relevant	relevant	ADJ
fnp-5049	103	30	.	.	PUNCT
fnp-5049	104	1	individual	individual	ADJ
fnp-5049	104	2	changes	change	NOUN
fnp-5049	104	3	in	in	ADP
fnp-5049	104	4	snfl	snfl	NOUN
fnp-5049	104	5	levels	level	NOUN
fnp-5049	104	6	are	be	AUX
fnp-5049	104	7	shown	show	VERB
fnp-5049	104	8	in	in	ADP
fnp-5049	104	9	figure	figure	NOUN
fnp-5049	104	10	2c	2c	NOUN
fnp-5049	104	11	.	.	PUNCT
fnp-5049	105	1	the	the	DET
fnp-5049	105	2	percentage	percentage	NOUN
fnp-5049	105	3	change	change	NOUN
fnp-5049	105	4	of	of	ADP
fnp-5049	105	5	snfl	snfl	NOUN
fnp-5049	105	6	levels	level	NOUN
fnp-5049	105	7	comparing	compare	VERB
fnp-5049	105	8	values	value	NOUN
fnp-5049	105	9	from	from	ADP
fnp-5049	105	10	baseline	baseline	ADJ
fnp-5049	105	11	and	and	CCONJ
fnp-5049	105	12	last	last	ADJ
fnp-5049	105	13	follow	follow	NOUN
fnp-5049	105	14	-	-	PUNCT
fnp-5049	105	15	up	up	NOUN
fnp-5049	105	16	for	for	ADP
fnp-5049	105	17	all	all	DET
fnp-5049	105	18	patients	patient	NOUN
fnp-5049	105	19	included	include	VERB
fnp-5049	105	20	in	in	ADP
fnp-5049	105	21	the	the	DET
fnp-5049	105	22	study	study	NOUN
fnp-5049	105	23	are	be	AUX
fnp-5049	105	24	given	give	VERB
fnp-5049	105	25	.	.	PUNCT
fnp-5049	106	1	fourteen	fourteen	NUM
fnp-5049	106	2	patients	patient	NOUN
fnp-5049	106	3	(	(	PUNCT
fnp-5049	106	4	56	56	NUM
fnp-5049	106	5	%	%	NOUN
fnp-5049	106	6	)	)	PUNCT
fnp-5049	106	7	had	have	VERB
fnp-5049	106	8	a	a	DET
fnp-5049	106	9	reduction	reduction	NOUN
fnp-5049	106	10	in	in	ADP
fnp-5049	106	11	snfl	snfl	NOUN
fnp-5049	106	12	levels	level	NOUN
fnp-5049	106	13	>	>	PUNCT
fnp-5049	106	14	20	20	NUM
fnp-5049	106	15	%	%	NOUN
fnp-5049	106	16	(	(	PUNCT
fnp-5049	106	17	figure	figure	NOUN
fnp-5049	106	18	2c	2c	NUM
fnp-5049	106	19	)	)	PUNCT
fnp-5049	106	20	,	,	PUNCT
fnp-5049	106	21	with	with	ADP
fnp-5049	106	22	some	some	DET
fnp-5049	106	23	patients	patient	NOUN
fnp-5049	106	24	showing	show	VERB
fnp-5049	106	25	a	a	DET
fnp-5049	106	26	decrease	decrease	NOUN
fnp-5049	106	27	of	of	ADP
fnp-5049	106	28	snfl	snfl	NOUN
fnp-5049	106	29	levels	level	NOUN
fnp-5049	106	30	up	up	ADP
fnp-5049	106	31	to	to	PART
fnp-5049	106	32	50	50	NUM
fnp-5049	106	33	%	%	NOUN
fnp-5049	106	34	from	from	ADP
fnp-5049	106	35	baseline	baseline	NOUN
fnp-5049	106	36	.	.	PUNCT
fnp-5049	107	1	in	in	ADP
fnp-5049	107	2	three	three	NUM
fnp-5049	107	3	patients	patient	NOUN
fnp-5049	107	4	,	,	PUNCT
fnp-5049	107	5	snfl	snfl	NOUN
fnp-5049	107	6	levels	level	NOUN
fnp-5049	107	7	increased	increase	VERB
fnp-5049	107	8	>	>	PUNCT
fnp-5049	107	9	20	20	NUM
fnp-5049	107	10	%	%	NOUN
fnp-5049	107	11	.	.	PUNCT
fnp-5049	108	1	clinical	clinical	ADJ
fnp-5049	108	2	history	history	NOUN
fnp-5049	108	3	could	could	AUX
fnp-5049	108	4	not	not	PART
fnp-5049	108	5	reveal	reveal	VERB
fnp-5049	108	6	any	any	DET
fnp-5049	108	7	reason	reason	NOUN
fnp-5049	108	8	for	for	ADP
fnp-5049	108	9	these	these	DET
fnp-5049	108	10	increases	increase	NOUN
fnp-5049	108	11	.	.	PUNCT
fnp-5049	109	1	figure	figure	VERB
fnp-5049	109	2	2	2	NUM
fnp-5049	109	3	:	:	PUNCT
fnp-5049	109	4	reduction	reduction	NOUN
fnp-5049	109	5	of	of	ADP
fnp-5049	109	6	snfl	snfl	NOUN
fnp-5049	109	7	levels	level	NOUN
fnp-5049	109	8	in	in	ADP
fnp-5049	109	9	progressive	progressive	ADJ
fnp-5049	109	10	ms	ms	NOUN
fnp-5049	109	11	patients	patient	NOUN
fnp-5049	109	12	treated	treat	VERB
fnp-5049	109	13	with	with	ADP
fnp-5049	109	14	hdcs	hdcs	PROPN
fnp-5049	109	15	a	a	DET
fnp-5049	109	16	:	:	PUNCT
fnp-5049	109	17	snfl	snfl	NOUN
fnp-5049	109	18	levels	level	NOUN
fnp-5049	109	19	at	at	ADP
fnp-5049	109	20	baseline	baseline	NOUN
fnp-5049	109	21	,	,	PUNCT
fnp-5049	109	22	within	within	ADP
fnp-5049	109	23	2	2	NUM
fnp-5049	109	24	weeks	week	NOUN
fnp-5049	109	25	after	after	ADP
fnp-5049	109	26	baseline	baseline	PROPN
fnp-5049	109	27	hdcs	hdc	NOUN
fnp-5049	109	28	cycle	cycle	NOUN
fnp-5049	109	29	and	and	CCONJ
fnp-5049	109	30	≥	≥	NUM
fnp-5049	109	31	20	20	NUM
fnp-5049	109	32	weeks	week	NOUN
fnp-5049	109	33	after	after	SCONJ
fnp-5049	109	34	baseline	baseline	PROPN
fnp-5049	109	35	hdcs	hdcs	PROPN
fnp-5049	109	36	cycle	cycle	NOUN
fnp-5049	109	37	are	be	AUX
fnp-5049	109	38	presented	present	VERB
fnp-5049	109	39	.	.	PUNCT
fnp-5049	110	1	the	the	DET
fnp-5049	110	2	median	median	ADJ
fnp-5049	110	3	snfl	snfl	NOUN
fnp-5049	110	4	levels	level	NOUN
fnp-5049	110	5	in	in	ADP
fnp-5049	110	6	pg	pg	PROPN
fnp-5049	110	7	/	/	SYM
fnp-5049	110	8	ml	ml	NOUN
fnp-5049	110	9	and	and	CCONJ
fnp-5049	110	10	the	the	DET
fnp-5049	110	11	interquartile	interquartile	ADJ
fnp-5049	110	12	range	range	NOUN
fnp-5049	110	13	are	be	AUX
fnp-5049	110	14	shown	show	VERB
fnp-5049	110	15	.	.	PUNCT
fnp-5049	111	1	the	the	DET
fnp-5049	111	2	dashed	dash	VERB
fnp-5049	111	3	line	line	NOUN
fnp-5049	111	4	indicates	indicate	VERB
fnp-5049	111	5	the	the	DET
fnp-5049	111	6	median	median	ADJ
fnp-5049	111	7	snfl	snfl	NOUN
fnp-5049	111	8	level	level	NOUN
fnp-5049	111	9	of	of	ADP
fnp-5049	111	10	the	the	DET
fnp-5049	111	11	age	age	NOUN
fnp-5049	111	12	-	-	PUNCT
fnp-5049	111	13	matched	match	VERB
fnp-5049	111	14	healthy	healthy	ADJ
fnp-5049	111	15	control	control	NOUN
fnp-5049	111	16	cohort	cohort	NOUN
fnp-5049	111	17	.	.	PUNCT
fnp-5049	112	1	significantly	significantly	ADV
fnp-5049	112	2	lower	low	ADJ
fnp-5049	112	3	levels	level	NOUN
fnp-5049	112	4	of	of	ADP
fnp-5049	112	5	snfl	snfl	NOUN
fnp-5049	112	6	were	be	AUX
fnp-5049	112	7	observed	observe	VERB
fnp-5049	112	8	≥	≥	NOUN
fnp-5049	112	9	20	20	NUM
fnp-5049	112	10	weeks	week	NOUN
fnp-5049	112	11	after	after	SCONJ
fnp-5049	112	12	baseline	baseline	NOUN
fnp-5049	112	13	hdcs	hdcs	PROPN
fnp-5049	112	14	treatment	treatment	NOUN
fnp-5049	112	15	(	(	PUNCT
fnp-5049	112	16	p=0.03	p=0.03	ADJ
fnp-5049	112	17	;	;	PUNCT
fnp-5049	112	18	wilcoxon	wilcoxon	NUM
fnp-5049	112	19	test	test	NOUN
fnp-5049	112	20	)	)	PUNCT
fnp-5049	112	21	,	,	PUNCT
fnp-5049	112	22	but	but	CCONJ
fnp-5049	112	23	not	not	PART
fnp-5049	112	24	at	at	ADP
fnp-5049	112	25	earlier	early	ADJ
fnp-5049	112	26	time	time	NOUN
fnp-5049	112	27	points	point	NOUN
fnp-5049	112	28	(	(	PUNCT
fnp-5049	112	29	<	<	X
fnp-5049	112	30	2	2	NUM
fnp-5049	112	31	weeks	week	NOUN
fnp-5049	112	32	,	,	PUNCT
fnp-5049	112	33	p=0.7	p=0.7	NOUN
fnp-5049	112	34	)	)	PUNCT
fnp-5049	112	35	.	.	PUNCT
fnp-5049	113	1	b	b	X
fnp-5049	113	2	:	:	PUNCT
fnp-5049	113	3	snfl	snfl	NOUN
fnp-5049	113	4	level	level	NOUN
fnp-5049	113	5	at	at	ADP
fnp-5049	113	6	baseline	baseline	NOUN
fnp-5049	113	7	,	,	PUNCT
fnp-5049	113	8	before	before	SCONJ
fnp-5049	113	9	the	the	DET
fnp-5049	113	10	second	second	ADJ
fnp-5049	113	11	cycle	cycle	NOUN
fnp-5049	113	12	of	of	ADP
fnp-5049	113	13	hdcs	hdc	NOUN
fnp-5049	113	14	and	and	CCONJ
fnp-5049	113	15	at	at	ADP
fnp-5049	113	16	last	last	ADJ
fnp-5049	113	17	follow	follow	NOUN
fnp-5049	113	18	-	-	PUNCT
fnp-5049	113	19	up	up	NOUN
fnp-5049	113	20	are	be	AUX
fnp-5049	113	21	depicted	depict	VERB
fnp-5049	113	22	.	.	PUNCT
fnp-5049	114	1	the	the	DET
fnp-5049	114	2	median	median	ADJ
fnp-5049	114	3	snfl	snfl	NOUN
fnp-5049	114	4	levels	level	NOUN
fnp-5049	114	5	in	in	ADP
fnp-5049	114	6	pg	pg	PROPN
fnp-5049	114	7	/	/	SYM
fnp-5049	114	8	ml	ml	NOUN
fnp-5049	114	9	and	and	CCONJ
fnp-5049	114	10	the	the	DET
fnp-5049	114	11	interquartile	interquartile	ADJ
fnp-5049	114	12	range	range	NOUN
fnp-5049	114	13	are	be	AUX
fnp-5049	114	14	shown	show	VERB
fnp-5049	114	15	.	.	PUNCT
fnp-5049	115	1	the	the	DET
fnp-5049	115	2	dashed	dash	VERB
fnp-5049	115	3	line	line	NOUN
fnp-5049	115	4	shows	show	VERB
fnp-5049	115	5	the	the	DET
fnp-5049	115	6	median	median	ADJ
fnp-5049	115	7	snfl	snfl	NOUN
fnp-5049	115	8	level	level	NOUN
fnp-5049	115	9	of	of	ADP
fnp-5049	115	10	the	the	DET
fnp-5049	115	11	age	age	NOUN
fnp-5049	115	12	-	-	PUNCT
fnp-5049	115	13	matched	match	VERB
fnp-5049	115	14	healthy	healthy	ADJ
fnp-5049	115	15	control	control	NOUN
fnp-5049	115	16	cohort	cohort	NOUN
fnp-5049	115	17	.	.	PUNCT
fnp-5049	116	1	a	a	DET
fnp-5049	116	2	significant	significant	ADJ
fnp-5049	116	3	reduction	reduction	NOUN
fnp-5049	116	4	in	in	ADP
fnp-5049	116	5	snfl	snfl	NOUN
fnp-5049	116	6	levels	level	NOUN
fnp-5049	116	7	compared	compare	VERB
fnp-5049	116	8	to	to	ADP
fnp-5049	116	9	baseline	baseline	NOUN
fnp-5049	116	10	was	be	AUX
fnp-5049	116	11	observed	observe	VERB
fnp-5049	116	12	before	before	ADP
fnp-5049	116	13	the	the	DET
fnp-5049	116	14	next	next	ADJ
fnp-5049	116	15	hdcs	hdcs	ADJ
fnp-5049	116	16	cycle	cycle	NOUN
fnp-5049	116	17	(	(	PUNCT
fnp-5049	116	18	p=0.02	p=0.02	NOUN
fnp-5049	116	19	)	)	PUNCT
fnp-5049	116	20	and	and	CCONJ
fnp-5049	116	21	at	at	ADP
fnp-5049	116	22	last	last	ADJ
fnp-5049	116	23	follow	follow	NOUN
fnp-5049	116	24	up	up	ADP
fnp-5049	116	25	(	(	PUNCT
fnp-5049	116	26	p=0.01	p=0.01	NUM
fnp-5049	116	27	;	;	PUNCT
fnp-5049	116	28	wilcoxon	wilcoxon	NUM
fnp-5049	116	29	test	test	NOUN
fnp-5049	116	30	)	)	PUNCT
fnp-5049	116	31	.	.	PUNCT
fnp-5049	117	1	the	the	DET
fnp-5049	117	2	median	median	ADJ
fnp-5049	117	3	interval	interval	NOUN
fnp-5049	117	4	from	from	ADP
fnp-5049	117	5	baseline	baseline	NOUN
fnp-5049	117	6	to	to	ADP
fnp-5049	117	7	the	the	DET
fnp-5049	117	8	subsequent	subsequent	ADJ
fnp-5049	117	9	hdcs	hdcs	PROPN
fnp-5049	117	10	cycle	cycle	NOUN
fnp-5049	117	11	was	be	AUX
fnp-5049	117	12	26	26	NUM
fnp-5049	117	13	weeks	week	NOUN
fnp-5049	117	14	and	and	CCONJ
fnp-5049	117	15	to	to	ADP
fnp-5049	117	16	the	the	DET
fnp-5049	117	17	last	last	ADJ
fnp-5049	117	18	follow	follow	NOUN
fnp-5049	117	19	-	-	PUNCT
fnp-5049	117	20	up	up	NOUN
fnp-5049	117	21	28	28	NUM
fnp-5049	117	22	weeks	week	NOUN
fnp-5049	117	23	.	.	PUNCT
fnp-5049	118	1	c	c	X
fnp-5049	118	2	:	:	PUNCT
fnp-5049	118	3	snfl	snfl	NOUN
fnp-5049	118	4	change	change	NOUN
fnp-5049	118	5	in	in	ADP
fnp-5049	118	6	percent	percent	NOUN
fnp-5049	118	7	from	from	ADP
fnp-5049	118	8	baseline	baseline	NOUN
fnp-5049	118	9	to	to	ADP
fnp-5049	118	10	last	last	ADJ
fnp-5049	118	11	follow	follow	NOUN
fnp-5049	118	12	-	-	PUNCT
fnp-5049	118	13	up	up	NOUN
fnp-5049	118	14	shown	show	VERB
fnp-5049	118	15	for	for	ADP
fnp-5049	118	16	individual	individual	ADJ
fnp-5049	118	17	patients	patient	NOUN
fnp-5049	118	18	.	.	PUNCT
fnp-5049	119	1	the	the	DET
fnp-5049	119	2	majority	majority	NOUN
fnp-5049	119	3	of	of	ADP
fnp-5049	119	4	patients	patient	NOUN
fnp-5049	119	5	shows	show	VERB
fnp-5049	119	6	a	a	DET
fnp-5049	119	7	decrease	decrease	NOUN
fnp-5049	119	8	in	in	ADP
fnp-5049	119	9	snfl	snfl	NOUN
fnp-5049	119	10	levels	level	NOUN
fnp-5049	119	11	.	.	PUNCT
fnp-5049	120	1	five	five	NUM
fnp-5049	120	2	patients	patient	NOUN
fnp-5049	120	3	showed	show	VERB
fnp-5049	120	4	an	an	DET
fnp-5049	120	5	increase	increase	NOUN
fnp-5049	120	6	of	of	ADP
fnp-5049	120	7	snfl	snfl	NOUN
fnp-5049	120	8	level	level	NOUN
fnp-5049	120	9	,	,	PUNCT
fnp-5049	120	10	which	which	PRON
fnp-5049	120	11	was	be	AUX
fnp-5049	120	12	not	not	PART
fnp-5049	120	13	accompanied	accompany	VERB
fnp-5049	120	14	by	by	ADP
fnp-5049	120	15	clinical	clinical	ADJ
fnp-5049	120	16	disease	disease	NOUN
fnp-5049	120	17	activity	activity	NOUN
fnp-5049	120	18	.	.	PUNCT
fnp-5049	121	1	the	the	DET
fnp-5049	121	2	dashed	dash	VERB
fnp-5049	121	3	line	line	NOUN
fnp-5049	121	4	indicates	indicate	VERB
fnp-5049	121	5	a	a	DET
fnp-5049	121	6	20	20	NUM
fnp-5049	121	7	%	%	NOUN
fnp-5049	121	8	decrease	decrease	NOUN
fnp-5049	121	9	or	or	CCONJ
fnp-5049	121	10	increase	increase	NOUN
fnp-5049	121	11	of	of	ADP
fnp-5049	121	12	snfl	snfl	NOUN
fnp-5049	121	13	levels	level	NOUN
fnp-5049	121	14	,	,	PUNCT
fnp-5049	121	15	possibly	possibly	ADV
fnp-5049	121	16	reflecting	reflect	VERB
fnp-5049	121	17	natural	natural	ADJ
fnp-5049	121	18	fluctuations	fluctuation	NOUN
fnp-5049	121	19	of	of	ADP
fnp-5049	121	20	snfl	snfl	NOUN
fnp-5049	121	21	values	value	NOUN
fnp-5049	121	22	[	[	X
fnp-5049	121	23	8	8	NUM
fnp-5049	121	24	]	]	PUNCT
fnp-5049	121	25	.	.	PUNCT
fnp-5049	122	1	snfl=	snfl=	NUM
fnp-5049	122	2	serum	serum	PROPN
fnp-5049	122	3	neurofilament	neurofilament	ADJ
fnp-5049	122	4	light	light	ADJ
fnp-5049	122	5	chains	chain	NOUN
fnp-5049	122	6	;	;	PUNCT
fnp-5049	122	7	hdcs=	hdcs=	NUM
fnp-5049	122	8	high	high	ADJ
fnp-5049	122	9	-	-	PUNCT
fnp-5049	122	10	dose	dose	NOUN
fnp-5049	122	11	corticosteroids	corticosteroid	NOUN
fnp-5049	122	12	in	in	ADP
fnp-5049	122	13	accordance	accordance	NOUN
fnp-5049	122	14	with	with	ADP
fnp-5049	122	15	these	these	DET
fnp-5049	122	16	findings	finding	NOUN
fnp-5049	122	17	,	,	PUNCT
fnp-5049	122	18	correlation	correlation	NOUN
fnp-5049	122	19	and	and	CCONJ
fnp-5049	122	20	logistic	logistic	ADJ
fnp-5049	122	21	regression	regression	NOUN
fnp-5049	122	22	model	model	NOUN
fnp-5049	122	23	analyses	analysis	NOUN
fnp-5049	122	24	showed	show	VERB
fnp-5049	122	25	a	a	DET
fnp-5049	122	26	negative	negative	ADJ
fnp-5049	122	27	correlation	correlation	NOUN
fnp-5049	122	28	between	between	ADP
fnp-5049	122	29	snfl	snfl	NOUN
fnp-5049	122	30	levels	level	NOUN
fnp-5049	122	31	and	and	CCONJ
fnp-5049	122	32	the	the	DET
fnp-5049	122	33	time	time	NOUN
fnp-5049	122	34	that	that	PRON
fnp-5049	122	35	passed	pass	VERB
fnp-5049	122	36	after	after	ADP
fnp-5049	122	37	baseline	baseline	PROPN
fnp-5049	122	38	hdcs	hdcs	PROPN
fnp-5049	122	39	therapy	therapy	NOUN
fnp-5049	122	40	(	(	PUNCT
fnp-5049	122	41	r=-0.2	r=-0.2	PROPN
fnp-5049	122	42	,	,	PUNCT
fnp-5049	122	43	p=0.03	p=0.03	ADV
fnp-5049	122	44	;	;	PUNCT
fnp-5049	122	45	median	median	ADJ
fnp-5049	122	46	time	time	NOUN
fnp-5049	122	47	interval	interval	NOUN
fnp-5049	122	48	from	from	ADP
fnp-5049	122	49	baseline	baseline	PROPN
fnp-5049	122	50	24	24	NUM
fnp-5049	122	51	weeks	week	NOUN
fnp-5049	122	52	,	,	PUNCT
fnp-5049	122	53	range	range	VERB
fnp-5049	122	54	0.9	0.9	NUM
fnp-5049	122	55	-	-	SYM
fnp-5049	122	56	55.0	55.0	NUM
fnp-5049	122	57	weeks	week	NOUN
fnp-5049	122	58	)	)	PUNCT
fnp-5049	122	59	(	(	PUNCT
fnp-5049	122	60	table	table	NOUN
fnp-5049	122	61	2	2	NUM
fnp-5049	122	62	)	)	PUNCT
fnp-5049	122	63	.	.	PUNCT
fnp-5049	123	1	table	table	NOUN
fnp-5049	123	2	2	2	NUM
fnp-5049	123	3	:	:	PUNCT
fnp-5049	123	4	correlation	correlation	NOUN
fnp-5049	123	5	of	of	ADP
fnp-5049	123	6	snfl	snfl	NOUN
fnp-5049	123	7	levels	level	NOUN
fnp-5049	123	8	with	with	ADP
fnp-5049	123	9	clinical	clinical	ADJ
fnp-5049	123	10	parameters	parameter	NOUN
fnp-5049	123	11	clinical	clinical	ADJ
fnp-5049	123	12	parameters	parameter	NOUN
fnp-5049	123	13	correlation	correlation	NOUN
fnp-5049	123	14	coefficient	coefficient	NOUN
fnp-5049	123	15	spearman	spearman	NOUN
fnp-5049	123	16	p	p	NOUN
fnp-5049	123	17	-	-	PUNCT
fnp-5049	123	18	value	value	NOUN
fnp-5049	123	19	number	number	NOUN
fnp-5049	123	20	of	of	ADP
fnp-5049	123	21	values	value	NOUN
fnp-5049	123	22	time	time	NOUN
fnp-5049	123	23	after	after	ADP
fnp-5049	123	24	hdcs	hdcs	NOUN
fnp-5049	123	25	therapy	therapy	NOUN
fnp-5049	123	26	-0.2	-0.2	PROPN
fnp-5049	123	27	0.03	0.03	NUM
fnp-5049	123	28	103	103	NUM
fnp-5049	123	29	age	age	NOUN
fnp-5049	123	30	0.3	0.3	NUM
fnp-5049	123	31	0.003	0.003	NUM
fnp-5049	123	32	103	103	NUM
fnp-5049	123	33	gender	gender	NOUN
fnp-5049	123	34	-0.2	-0.2	PROPN
fnp-5049	123	35	0.5	0.5	NUM
fnp-5049	123	36	25	25	NUM
fnp-5049	123	37	treatment	treatment	NOUN
fnp-5049	123	38	with	with	ADP
fnp-5049	123	39	dmts	dmts	NOUN
fnp-5049	123	40	-0.2	-0.2	PROPN
fnp-5049	123	41	0.4	0.4	NUM
fnp-5049	123	42	25	25	NUM
fnp-5049	123	43	edss	edss	ADV
fnp-5049	123	44	0.1	0.1	NUM
fnp-5049	123	45	0.6	0.6	NUM
fnp-5049	123	46	49	49	NUM
fnp-5049	123	47	disease	disease	NOUN
fnp-5049	123	48	course	course	NOUN
fnp-5049	123	49	0.0	0.0	NUM
fnp-5049	123	50	1.0	1.0	NUM
fnp-5049	123	51	25	25	NUM
fnp-5049	123	52	disease	disease	NOUN
fnp-5049	123	53	duration	duration	NOUN
fnp-5049	123	54	-0.1	-0.1	PROPN
fnp-5049	123	55	0.8	0.8	NUM
fnp-5049	123	56	25	25	NUM
fnp-5049	123	57	fatigue	fatigue	NOUN
fnp-5049	123	58	-0.4	-0.4	NUM
fnp-5049	123	59	0.1	0.1	NUM
fnp-5049	123	60	24	24	NUM
fnp-5049	123	61	cognitive	cognitive	ADJ
fnp-5049	123	62	deficits	deficit	NOUN
fnp-5049	123	63	0.1	0.1	NUM
fnp-5049	123	64	0.6	0.6	NUM
fnp-5049	123	65	25	25	NUM
fnp-5049	123	66	psychiatric	psychiatric	ADJ
fnp-5049	123	67	symptoms	symptom	NOUN
fnp-5049	123	68	0.3	0.3	NUM
fnp-5049	123	69	0.1	0.1	NUM
fnp-5049	123	70	25	25	NUM
fnp-5049	123	71	current	current	ADJ
fnp-5049	123	72	smoker	smoker	NOUN
fnp-5049	123	73	0.0	0.0	NUM
fnp-5049	123	74	1.0	1.0	NUM
fnp-5049	123	75	24	24	NUM
fnp-5049	123	76	former	former	ADJ
fnp-5049	123	77	smoker	smoker	NOUN
fnp-5049	123	78	0.2	0.2	NUM
fnp-5049	123	79	0.3	0.3	NUM
fnp-5049	123	80	24	24	NUM
fnp-5049	123	81	cardiovascular	cardiovascular	ADJ
fnp-5049	123	82	risk	risk	NOUN
fnp-5049	123	83	factors	factor	NOUN
fnp-5049	123	84	-0.3	-0.3	PROPN
fnp-5049	123	85	0.2	0.2	NUM
fnp-5049	123	86	25	25	NUM
fnp-5049	123	87	hdcs	hdc	NOUN
fnp-5049	123	88	equivalent	equivalent	ADJ
fnp-5049	123	89	dose	dose	NOUN
fnp-5049	123	90	per	per	ADP
fnp-5049	123	91	day	day	NOUN
fnp-5049	123	92	-0.4	-0.4	NUM
fnp-5049	123	93	0.1	0.1	NUM
fnp-5049	123	94	21	21	NUM
fnp-5049	123	95	stable	stable	ADJ
fnp-5049	123	96	edss	edss	ADV
fnp-5049	123	97	after	after	SCONJ
fnp-5049	123	98	hdcs	hdcs	PROPN
fnp-5049	123	99	therapy	therapy	NOUN
fnp-5049	123	100	the	the	DET
fnp-5049	123	101	edss	edss	ADJ
fnp-5049	123	102	score	score	NOUN
fnp-5049	123	103	remained	remain	VERB
fnp-5049	123	104	stable	stable	ADJ
fnp-5049	123	105	during	during	ADP
fnp-5049	123	106	a	a	DET
fnp-5049	123	107	median	median	ADJ
fnp-5049	123	108	follow	follow	NOUN
fnp-5049	123	109	-	-	PUNCT
fnp-5049	123	110	up	up	NOUN
fnp-5049	123	111	time	time	NOUN
fnp-5049	123	112	of	of	ADP
fnp-5049	123	113	26	26	NUM
fnp-5049	123	114	weeks	week	NOUN
fnp-5049	123	115	(	(	PUNCT
fnp-5049	123	116	range	range	NOUN
fnp-5049	123	117	13	13	NUM
fnp-5049	123	118	-	-	SYM
fnp-5049	123	119	51	51	NUM
fnp-5049	123	120	weeks	week	NOUN
fnp-5049	123	121	)	)	PUNCT
fnp-5049	123	122	after	after	ADP
fnp-5049	123	123	baseline	baseline	PROPN
fnp-5049	123	124	hdcs	hdcs	PROPN
fnp-5049	123	125	therapy	therapy	NOUN
fnp-5049	123	126	(	(	PUNCT
fnp-5049	123	127	median	median	PROPN
fnp-5049	123	128	edss	edss	ADV
fnp-5049	123	129	6.5	6.5	NUM
fnp-5049	123	130	at	at	ADP
fnp-5049	123	131	baseline	baseline	NOUN
fnp-5049	123	132	and	and	CCONJ
fnp-5049	123	133	before	before	ADP
fnp-5049	123	134	second	second	ADJ
fnp-5049	123	135	hdcs	hdcs	PROPN
fnp-5049	123	136	cycle	cycle	NOUN
fnp-5049	123	137	)	)	PUNCT
fnp-5049	123	138	.	.	PUNCT
fnp-5049	124	1	confounding	confound	VERB
fnp-5049	124	2	factors	factor	NOUN
fnp-5049	124	3	for	for	ADP
fnp-5049	124	4	snfl	snfl	NOUN
fnp-5049	124	5	levels	level	NOUN
fnp-5049	124	6	as	as	SCONJ
fnp-5049	124	7	described	describe	VERB
fnp-5049	124	8	in	in	ADP
fnp-5049	124	9	previous	previous	ADJ
fnp-5049	124	10	studies	study	NOUN
fnp-5049	124	11	,	,	PUNCT
fnp-5049	124	12	snfl	snfl	PROPN
fnp-5049	124	13	levels	level	NOUN
fnp-5049	124	14	showed	show	VERB
fnp-5049	124	15	a	a	DET
fnp-5049	124	16	positive	positive	ADJ
fnp-5049	124	17	correlation	correlation	NOUN
fnp-5049	124	18	with	with	ADP
fnp-5049	124	19	patient	patient	ADJ
fnp-5049	124	20	age	age	NOUN
fnp-5049	124	21	(	(	PUNCT
fnp-5049	124	22	r=0.3	r=0.3	NOUN
fnp-5049	124	23	,	,	PUNCT
fnp-5049	124	24	p=0.003	p=0.003	NOUN
fnp-5049	124	25	)	)	PUNCT
fnp-5049	124	26	(	(	PUNCT
fnp-5049	124	27	figure	figure	NOUN
fnp-5049	124	28	3a	3a	NUM
fnp-5049	124	29	)	)	PUNCT
fnp-5049	124	30	.	.	PUNCT
fnp-5049	125	1	the	the	DET
fnp-5049	125	2	gender	gender	NOUN
fnp-5049	125	3	had	have	VERB
fnp-5049	125	4	no	no	DET
fnp-5049	125	5	influence	influence	NOUN
fnp-5049	125	6	on	on	ADP
fnp-5049	125	7	snfl	snfl	NOUN
fnp-5049	125	8	levels	level	NOUN
fnp-5049	125	9	.	.	PUNCT
fnp-5049	126	1	other	other	ADJ
fnp-5049	126	2	factors	factor	NOUN
fnp-5049	126	3	such	such	ADJ
fnp-5049	126	4	as	as	ADP
fnp-5049	126	5	relapse	relapse	NOUN
fnp-5049	126	6	activity	activity	NOUN
fnp-5049	126	7	and	and	CCONJ
fnp-5049	126	8	disease	disease	NOUN
fnp-5049	126	9	-	-	PUNCT
fnp-5049	126	10	modifying	modify	VERB
fnp-5049	126	11	drugs	drug	NOUN
fnp-5049	126	12	are	be	AUX
fnp-5049	126	13	also	also	ADV
fnp-5049	126	14	known	know	VERB
fnp-5049	126	15	to	to	PART
fnp-5049	126	16	influence	influence	VERB
fnp-5049	126	17	snfl	snfl	NOUN
fnp-5049	126	18	levels	level	NOUN
fnp-5049	126	19	,	,	PUNCT
fnp-5049	126	20	but	but	CCONJ
fnp-5049	126	21	relapse	relapse	NOUN
fnp-5049	126	22	activity	activity	NOUN
fnp-5049	126	23	was	be	AUX
fnp-5049	126	24	not	not	PART
fnp-5049	126	25	observed	observe	VERB
fnp-5049	126	26	in	in	ADP
fnp-5049	126	27	our	our	PRON
fnp-5049	126	28	cohort	cohort	NOUN
fnp-5049	126	29	of	of	ADP
fnp-5049	126	30	progressive	progressive	ADJ
fnp-5049	126	31	ms	ms	ADJ
fnp-5049	126	32	patients	patient	NOUN
fnp-5049	126	33	.	.	PUNCT
fnp-5049	127	1	the	the	DET
fnp-5049	127	2	following	follow	VERB
fnp-5049	127	3	clinical	clinical	ADJ
fnp-5049	127	4	parameters	parameter	NOUN
fnp-5049	127	5	were	be	AUX
fnp-5049	127	6	analyzed	analyze	VERB
fnp-5049	127	7	and	and	CCONJ
fnp-5049	127	8	did	do	AUX
fnp-5049	127	9	not	not	PART
fnp-5049	127	10	significantly	significantly	ADV
fnp-5049	127	11	influence	influence	VERB
fnp-5049	127	12	snfl	snfl	NOUN
fnp-5049	127	13	levels	level	NOUN
fnp-5049	127	14	:	:	PUNCT
fnp-5049	127	15	treatment	treatment	NOUN
fnp-5049	127	16	with	with	ADP
fnp-5049	127	17	dmts	dmts	NOUN
fnp-5049	127	18	,	,	PUNCT
fnp-5049	127	19	disability	disability	NOUN
fnp-5049	127	20	level	level	NOUN
fnp-5049	127	21	measured	measure	VERB
fnp-5049	127	22	by	by	ADP
fnp-5049	127	23	edss	edss	ADV
fnp-5049	127	24	,	,	PUNCT
fnp-5049	127	25	disease	disease	NOUN
fnp-5049	127	26	course	course	NOUN
fnp-5049	127	27	and	and	CCONJ
fnp-5049	127	28	disease	disease	NOUN
fnp-5049	127	29	duration	duration	NOUN
fnp-5049	127	30	,	,	PUNCT
fnp-5049	127	31	presence	presence	NOUN
fnp-5049	127	32	of	of	ADP
fnp-5049	127	33	fatigue	fatigue	NOUN
fnp-5049	127	34	symptoms	symptom	NOUN
fnp-5049	127	35	,	,	PUNCT
fnp-5049	127	36	cognitive	cognitive	ADJ
fnp-5049	127	37	deficits	deficit	NOUN
fnp-5049	127	38	,	,	PUNCT
fnp-5049	127	39	psychiatric	psychiatric	ADJ
fnp-5049	127	40	symptoms	symptom	NOUN
fnp-5049	127	41	,	,	PUNCT
fnp-5049	127	42	past	past	ADJ
fnp-5049	127	43	or	or	CCONJ
fnp-5049	127	44	present	present	VERB
fnp-5049	127	45	regular	regular	ADJ
fnp-5049	127	46	nicotine	nicotine	NOUN
fnp-5049	127	47	use	use	NOUN
fnp-5049	127	48	and	and	CCONJ
fnp-5049	127	49	cardiovascular	cardiovascular	ADJ
fnp-5049	127	50	risk	risk	NOUN
fnp-5049	127	51	factors	factor	NOUN
fnp-5049	127	52	.	.	PUNCT
fnp-5049	128	1	no	no	DET
fnp-5049	128	2	association	association	NOUN
fnp-5049	128	3	was	be	AUX
fnp-5049	128	4	found	find	VERB
fnp-5049	128	5	between	between	ADP
fnp-5049	128	6	the	the	DET
fnp-5049	128	7	dose	dose	NOUN
fnp-5049	128	8	of	of	ADP
fnp-5049	128	9	hdcs	hdc	NOUN
fnp-5049	128	10	that	that	SCONJ
fnp-5049	128	11	patients	patient	NOUN
fnp-5049	128	12	received	receive	VERB
fnp-5049	128	13	and	and	CCONJ
fnp-5049	128	14	snfl	snfl	NOUN
fnp-5049	128	15	levels	level	NOUN
fnp-5049	128	16	(	(	PUNCT
fnp-5049	128	17	table	table	NOUN
fnp-5049	128	18	2	2	NUM
fnp-5049	128	19	)	)	PUNCT
fnp-5049	128	20	.	.	PUNCT
fnp-5049	129	1	we	we	PRON
fnp-5049	129	2	performed	perform	VERB
fnp-5049	129	3	a	a	DET
fnp-5049	129	4	multiple	multiple	ADJ
fnp-5049	129	5	regression	regression	NOUN
fnp-5049	129	6	analysis	analysis	NOUN
fnp-5049	129	7	including	include	VERB
fnp-5049	129	8	the	the	DET
fnp-5049	129	9	age	age	NOUN
fnp-5049	129	10	of	of	ADP
fnp-5049	129	11	patients	patient	NOUN
fnp-5049	129	12	,	,	PUNCT
fnp-5049	129	13	treatment	treatment	NOUN
fnp-5049	129	14	with	with	ADP
fnp-5049	129	15	dmts	dmts	NOUN
fnp-5049	129	16	and	and	CCONJ
fnp-5049	129	17	the	the	DET
fnp-5049	129	18	time	time	NOUN
fnp-5049	129	19	after	after	SCONJ
fnp-5049	129	20	baseline	baseline	PROPN
fnp-5049	129	21	hdcs	hdcs	PROPN
fnp-5049	129	22	therapy	therapy	NOUN
fnp-5049	129	23	to	to	PART
fnp-5049	129	24	analyze	analyze	VERB
fnp-5049	129	25	the	the	DET
fnp-5049	129	26	influence	influence	NOUN
fnp-5049	129	27	on	on	ADP
fnp-5049	129	28	snfl	snfl	NOUN
fnp-5049	129	29	levels	level	NOUN
fnp-5049	129	30	.	.	PUNCT
fnp-5049	130	1	the	the	DET
fnp-5049	130	2	negative	negative	ADJ
fnp-5049	130	3	correlation	correlation	NOUN
fnp-5049	130	4	of	of	ADP
fnp-5049	130	5	snfl	snfl	NOUN
fnp-5049	130	6	levels	level	NOUN
fnp-5049	130	7	with	with	ADP
fnp-5049	130	8	the	the	DET
fnp-5049	130	9	time	time	NOUN
fnp-5049	130	10	after	after	SCONJ
fnp-5049	130	11	baseline	baseline	PROPN
fnp-5049	130	12	hdcs	hdcs	PROPN
fnp-5049	130	13	therapy	therapy	NOUN
fnp-5049	130	14	was	be	AUX
fnp-5049	130	15	confirmed	confirm	VERB
fnp-5049	130	16	(	(	PUNCT
fnp-5049	130	17	adjusted	adjust	VERB
fnp-5049	130	18	r2=	r2=	PROPN
fnp-5049	130	19	10	10	NUM
fnp-5049	130	20	%	%	NOUN
fnp-5049	130	21	,	,	PUNCT
fnp-5049	130	22	p=0.01	p=0.01	PROPN
fnp-5049	130	23	)	)	PUNCT
fnp-5049	130	24	,	,	PUNCT
fnp-5049	130	25	verifying	verify	VERB
fnp-5049	130	26	a	a	DET
fnp-5049	130	27	reduction	reduction	NOUN
fnp-5049	130	28	in	in	ADP
fnp-5049	130	29	snfl	snfl	NOUN
fnp-5049	130	30	levels	level	NOUN
fnp-5049	130	31	after	after	ADP
fnp-5049	130	32	hdcs	hdcs	NOUN
fnp-5049	130	33	therapy	therapy	NOUN
fnp-5049	130	34	(	(	PUNCT
fnp-5049	130	35	figure	figure	NOUN
fnp-5049	130	36	3b	3b	NUM
fnp-5049	130	37	)	)	PUNCT
fnp-5049	130	38	.	.	PUNCT
fnp-5049	131	1	dmts	dmts	PROPN
fnp-5049	131	2	showed	show	VERB
fnp-5049	131	3	no	no	DET
fnp-5049	131	4	correlation	correlation	NOUN
fnp-5049	131	5	with	with	ADP
fnp-5049	131	6	snfl	snfl	NOUN
fnp-5049	131	7	and	and	CCONJ
fnp-5049	131	8	did	do	AUX
fnp-5049	131	9	not	not	PART
fnp-5049	131	10	influence	influence	VERB
fnp-5049	131	11	the	the	DET
fnp-5049	131	12	level	level	NOUN
fnp-5049	131	13	of	of	ADP
fnp-5049	131	14	snfl	snfl	NOUN
fnp-5049	131	15	in	in	ADP
fnp-5049	131	16	the	the	DET
fnp-5049	131	17	multiple	multiple	ADJ
fnp-5049	131	18	regression	regression	NOUN
fnp-5049	131	19	model	model	NOUN
fnp-5049	131	20	.	.	PUNCT
fnp-5049	132	1	however	however	ADV
fnp-5049	132	2	,	,	PUNCT
fnp-5049	132	3	this	this	DET
fnp-5049	132	4	analysis	analysis	NOUN
fnp-5049	132	5	was	be	AUX
fnp-5049	132	6	limited	limit	VERB
fnp-5049	132	7	due	due	ADP
fnp-5049	132	8	to	to	ADP
fnp-5049	132	9	a	a	DET
fnp-5049	132	10	small	small	ADJ
fnp-5049	132	11	number	number	NOUN
fnp-5049	132	12	of	of	ADP
fnp-5049	132	13	patients	patient	NOUN
fnp-5049	132	14	treated	treat	VERB
fnp-5049	132	15	with	with	ADP
fnp-5049	132	16	dmts	dmts	NOUN
fnp-5049	132	17	(	(	PUNCT
fnp-5049	132	18	n=5	n=5	PROPN
fnp-5049	132	19	)	)	PUNCT
fnp-5049	132	20	.	.	PUNCT
fnp-5049	133	1	the	the	DET
fnp-5049	133	2	model	model	NOUN
fnp-5049	133	3	is	be	AUX
fnp-5049	133	4	summarized	summarize	VERB
fnp-5049	133	5	in	in	ADP
fnp-5049	133	6	table	table	NOUN
fnp-5049	133	7	3	3	NUM
fnp-5049	133	8	.	.	PUNCT
fnp-5049	133	9	figure	figure	VERB
fnp-5049	133	10	3	3	NUM
fnp-5049	133	11	:	:	PUNCT
fnp-5049	133	12	partial	partial	ADJ
fnp-5049	133	13	regression	regression	NOUN
fnp-5049	133	14	plots	plot	NOUN
fnp-5049	133	15	of	of	ADP
fnp-5049	133	16	variables	variable	NOUN
fnp-5049	133	17	that	that	PRON
fnp-5049	133	18	contribute	contribute	VERB
fnp-5049	133	19	to	to	ADP
fnp-5049	133	20	snfl	snfl	NOUN
fnp-5049	133	21	levels	level	NOUN
fnp-5049	133	22	the	the	DET
fnp-5049	133	23	dependent	dependent	ADJ
fnp-5049	133	24	variable	variable	NOUN
fnp-5049	133	25	is	be	AUX
fnp-5049	133	26	the	the	DET
fnp-5049	133	27	snfl	snfl	NOUN
fnp-5049	133	28	level	level	NOUN
fnp-5049	133	29	.	.	PUNCT
fnp-5049	134	1	independent	independent	ADJ
fnp-5049	134	2	variables	variable	NOUN
fnp-5049	134	3	are	be	AUX
fnp-5049	134	4	the	the	DET
fnp-5049	134	5	age	age	NOUN
fnp-5049	134	6	of	of	ADP
fnp-5049	134	7	patients	patient	NOUN
fnp-5049	134	8	at	at	ADP
fnp-5049	134	9	the	the	DET
fnp-5049	134	10	time	time	NOUN
fnp-5049	134	11	of	of	ADP
fnp-5049	134	12	blood	blood	NOUN
fnp-5049	134	13	sampling	sampling	NOUN
fnp-5049	134	14	(	(	PUNCT
fnp-5049	134	15	a	a	NOUN
fnp-5049	134	16	)	)	PUNCT
fnp-5049	134	17	and	and	CCONJ
fnp-5049	134	18	the	the	DET
fnp-5049	134	19	time	time	NOUN
fnp-5049	134	20	that	that	PRON
fnp-5049	134	21	passed	pass	VERB
fnp-5049	134	22	after	after	ADP
fnp-5049	134	23	the	the	DET
fnp-5049	134	24	baseline	baseline	PROPN
fnp-5049	134	25	hdcs	hdcs	PROPN
fnp-5049	134	26	therapy	therapy	NOUN
fnp-5049	134	27	(	(	PUNCT
fnp-5049	134	28	b	b	NOUN
fnp-5049	134	29	)	)	PUNCT
fnp-5049	134	30	.	.	PUNCT
fnp-5049	135	1	due	due	ADP
fnp-5049	135	2	to	to	ADP
fnp-5049	135	3	calculations	calculation	NOUN
fnp-5049	135	4	with	with	ADP
fnp-5049	135	5	multiple	multiple	ADJ
fnp-5049	135	6	variables	variable	NOUN
fnp-5049	135	7	,	,	PUNCT
fnp-5049	135	8	the	the	DET
fnp-5049	135	9	scaling	scaling	NOUN
fnp-5049	135	10	of	of	ADP
fnp-5049	135	11	axes	axis	NOUN
fnp-5049	135	12	differs	differ	VERB
fnp-5049	135	13	from	from	ADP
fnp-5049	135	14	normal	normal	ADJ
fnp-5049	135	15	units	unit	NOUN
fnp-5049	135	16	and	and	CCONJ
fnp-5049	135	17	does	do	AUX
fnp-5049	135	18	not	not	PART
fnp-5049	135	19	seem	seem	VERB
fnp-5049	135	20	plausible	plausible	ADJ
fnp-5049	135	21	.	.	PUNCT
fnp-5049	136	1	snfl	snfl	PROPN
fnp-5049	136	2	levels	level	NOUN
fnp-5049	136	3	correlate	correlate	VERB
fnp-5049	136	4	positively	positively	ADV
fnp-5049	136	5	with	with	ADP
fnp-5049	136	6	the	the	DET
fnp-5049	136	7	age	age	NOUN
fnp-5049	136	8	of	of	ADP
fnp-5049	136	9	patients	patient	NOUN
fnp-5049	136	10	(	(	PUNCT
fnp-5049	136	11	a	a	PRON
fnp-5049	136	12	,	,	PUNCT
fnp-5049	136	13	p=0.003	p=0.003	NOUN
fnp-5049	136	14	)	)	PUNCT
fnp-5049	136	15	and	and	CCONJ
fnp-5049	136	16	shows	show	VERB
fnp-5049	136	17	a	a	DET
fnp-5049	136	18	negative	negative	ADJ
fnp-5049	136	19	correlation	correlation	NOUN
fnp-5049	136	20	with	with	ADP
fnp-5049	136	21	the	the	DET
fnp-5049	136	22	time	time	NOUN
fnp-5049	136	23	that	that	PRON
fnp-5049	136	24	passed	pass	VERB
fnp-5049	136	25	after	after	ADP
fnp-5049	136	26	the	the	DET
fnp-5049	136	27	baseline	baseline	PROPN
fnp-5049	136	28	hdcs	hdcs	PROPN
fnp-5049	136	29	therapy	therapy	NOUN
fnp-5049	136	30	(	(	PUNCT
fnp-5049	136	31	b	b	NOUN
fnp-5049	136	32	,	,	PUNCT
fnp-5049	136	33	p=0.03	p=0.03	ADJ
fnp-5049	136	34	)	)	PUNCT
fnp-5049	136	35	,	,	PUNCT
fnp-5049	136	36	indicating	indicate	VERB
fnp-5049	136	37	a	a	DET
fnp-5049	136	38	reduction	reduction	NOUN
fnp-5049	136	39	in	in	ADP
fnp-5049	136	40	snfl	snfl	NOUN
fnp-5049	136	41	levels	level	NOUN
fnp-5049	136	42	due	due	ADJ
fnp-5049	136	43	to	to	ADP
fnp-5049	136	44	hdcs	hdcs	ADJ
fnp-5049	136	45	treatment	treatment	NOUN
fnp-5049	136	46	.	.	PUNCT
fnp-5049	137	1	snfl=	snfl=	NUM
fnp-5049	137	2	serum	serum	PROPN
fnp-5049	137	3	neurofilament	neurofilament	ADJ
fnp-5049	137	4	light	light	ADJ
fnp-5049	137	5	chains	chain	NOUN
fnp-5049	137	6	;	;	PUNCT
fnp-5049	137	7	hdcs=	hdcs=	NUM
fnp-5049	137	8	high	high	ADJ
fnp-5049	137	9	-	-	PUNCT
fnp-5049	137	10	dose	dose	NOUN
fnp-5049	137	11	corticosteroids	corticosteroid	NOUN
fnp-5049	137	12	table	table	NOUN
fnp-5049	137	13	3	3	NUM
fnp-5049	137	14	:	:	PUNCT
fnp-5049	137	15	model	model	NOUN
fnp-5049	137	16	to	to	PART
fnp-5049	137	17	explain	explain	VERB
fnp-5049	137	18	snfl	snfl	NOUN
fnp-5049	137	19	levels	level	NOUN
fnp-5049	137	20	in	in	ADP
fnp-5049	137	21	patients	patient	NOUN
fnp-5049	137	22	after	after	ADP
fnp-5049	137	23	hdcs	hdcs	NOUN
fnp-5049	137	24	therapy	therapy	NOUN
fnp-5049	137	25	unstandardized	unstandardized	ADJ
fnp-5049	137	26	coefficient	coefficient	NOUN
fnp-5049	137	27	standardized	standardize	VERB
fnp-5049	137	28	coefficient	coefficient	NOUN
fnp-5049	137	29	significance	significance	NOUN
fnp-5049	137	30	95	95	NUM
fnp-5049	137	31	%	%	NOUN
fnp-5049	137	32	confidential	confidential	ADJ
fnp-5049	137	33	interval	interval	NOUN
fnp-5049	137	34	(	(	PUNCT
fnp-5049	137	35	lower	low	ADJ
fnp-5049	137	36	and	and	CCONJ
fnp-5049	137	37	upper	upper	ADJ
fnp-5049	137	38	bound	bind	VERB
fnp-5049	137	39	)	)	PUNCT
fnp-5049	137	40	time	time	NOUN
fnp-5049	137	41	after	after	ADP
fnp-5049	137	42	hdcs	hdcs	PROPN
fnp-5049	137	43	therapy	therapy	NOUN
fnp-5049	137	44	-0.003	-0.003	PUNCT
fnp-5049	137	45	-0.247	-0.247	PROPN
fnp-5049	137	46	0.001	0.001	NUM
fnp-5049	137	47	-0.005	-0.005	NUM
fnp-5049	137	48	-0.001	-0.001	NOUN
fnp-5049	137	49	treatment	treatment	NOUN
fnp-5049	137	50	with	with	ADP
fnp-5049	137	51	dmts	dmts	NOUN
fnp-5049	137	52	0.015	0.015	NUM
fnp-5049	137	53	0.035	0.035	NUM
fnp-5049	137	54	0.718	0.718	NUM
fnp-5049	137	55	-0.067	-0.067	NUM
fnp-5049	137	56	0.097	0.097	NUM
fnp-5049	137	57	age	age	NOUN
fnp-5049	137	58	at	at	ADP
fnp-5049	137	59	time	time	NOUN
fnp-5049	137	60	of	of	ADP
fnp-5049	137	61	blood	blood	NOUN
fnp-5049	137	62	sampling	sample	VERB
fnp-5049	137	63	0.007	0.007	NUM
fnp-5049	137	64	0.237	0.237	NUM
fnp-5049	137	65	0.015	0.015	NUM
fnp-5049	137	66	0.001	0.001	NUM
fnp-5049	137	67	0.012	0.012	NUM
fnp-5049	137	68	snfl	snfl	NOUN
fnp-5049	137	69	levels	level	NOUN
fnp-5049	137	70	were	be	AUX
fnp-5049	137	71	defined	define	VERB
fnp-5049	137	72	as	as	ADP
fnp-5049	137	73	dependent	dependent	ADJ
fnp-5049	137	74	variable	variable	NOUN
fnp-5049	137	75	.	.	PUNCT
fnp-5049	138	1	variables	variable	NOUN
fnp-5049	138	2	which	which	PRON
fnp-5049	138	3	possibly	possibly	ADV
fnp-5049	138	4	effect	effect	VERB
fnp-5049	138	5	snfl	snfl	NOUN
fnp-5049	138	6	levels	level	NOUN
fnp-5049	138	7	were	be	AUX
fnp-5049	138	8	included	include	VERB
fnp-5049	138	9	in	in	ADP
fnp-5049	138	10	the	the	DET
fnp-5049	138	11	model	model	NOUN
fnp-5049	138	12	.	.	PUNCT
fnp-5049	139	1	the	the	DET
fnp-5049	139	2	unstandardized	unstandardized	ADJ
fnp-5049	139	3	coefficient	coefficient	NOUN
fnp-5049	139	4	,	,	PUNCT
fnp-5049	139	5	the	the	DET
fnp-5049	139	6	standardized	standardized	ADJ
fnp-5049	139	7	coefficient	coefficient	NOUN
fnp-5049	139	8	,	,	PUNCT
fnp-5049	139	9	the	the	DET
fnp-5049	139	10	significance	significance	NOUN
fnp-5049	139	11	,	,	PUNCT
fnp-5049	139	12	and	and	CCONJ
fnp-5049	139	13	the	the	DET
fnp-5049	139	14	confidence	confidence	NOUN
fnp-5049	139	15	interval	interval	NOUN
fnp-5049	139	16	are	be	AUX
fnp-5049	139	17	shown	show	VERB
fnp-5049	139	18	.	.	PUNCT
fnp-5049	140	1	this	this	DET
fnp-5049	140	2	model	model	NOUN
fnp-5049	140	3	has	have	AUX
fnp-5049	140	4	been	be	AUX
fnp-5049	140	5	corrected	correct	VERB
fnp-5049	140	6	for	for	ADP
fnp-5049	140	7	r2=10	r2=10	NOUN
fnp-5049	140	8	%	%	NOUN
fnp-5049	140	9	.	.	PUNCT
fnp-5049	141	1	discussion	discussion	NOUN
fnp-5049	141	2	we	we	PRON
fnp-5049	141	3	aimed	aim	VERB
fnp-5049	141	4	to	to	PART
fnp-5049	141	5	evaluate	evaluate	VERB
fnp-5049	141	6	the	the	DET
fnp-5049	141	7	efficacy	efficacy	NOUN
fnp-5049	141	8	of	of	ADP
fnp-5049	141	9	long	long	ADJ
fnp-5049	141	10	-	-	PUNCT
fnp-5049	141	11	term	term	NOUN
fnp-5049	141	12	treatment	treatment	NOUN
fnp-5049	141	13	with	with	ADP
fnp-5049	141	14	hdcs	hdc	NOUN
fnp-5049	141	15	in	in	ADP
fnp-5049	141	16	patients	patient	NOUN
fnp-5049	141	17	with	with	ADP
fnp-5049	141	18	progressive	progressive	ADJ
fnp-5049	141	19	ms	ms	NOUN
fnp-5049	141	20	and	and	CCONJ
fnp-5049	141	21	used	use	VERB
fnp-5049	141	22	snfl	snfl	NOUN
fnp-5049	141	23	as	as	ADP
fnp-5049	141	24	an	an	DET
fnp-5049	141	25	established	establish	VERB
fnp-5049	141	26	biomarker	biomarker	NOUN
fnp-5049	141	27	for	for	ADP
fnp-5049	141	28	disease	disease	NOUN
fnp-5049	141	29	activity	activity	NOUN
fnp-5049	141	30	and	and	CCONJ
fnp-5049	141	31	treatment	treatment	NOUN
fnp-5049	141	32	response	response	NOUN
fnp-5049	141	33	.	.	PUNCT
fnp-5049	142	1	in	in	ADP
fnp-5049	142	2	our	our	PRON
fnp-5049	142	3	cohort	cohort	NOUN
fnp-5049	142	4	of	of	ADP
fnp-5049	142	5	25	25	NUM
fnp-5049	142	6	patients	patient	NOUN
fnp-5049	142	7	recruited	recruit	VERB
fnp-5049	142	8	from	from	ADP
fnp-5049	142	9	ongoing	ongoing	ADJ
fnp-5049	142	10	clinical	clinical	ADJ
fnp-5049	142	11	routine	routine	ADJ
fnp-5049	142	12	care	care	NOUN
fnp-5049	142	13	,	,	PUNCT
fnp-5049	142	14	we	we	PRON
fnp-5049	142	15	found	find	VERB
fnp-5049	142	16	that	that	SCONJ
fnp-5049	142	17	long	long	ADJ
fnp-5049	142	18	-	-	PUNCT
fnp-5049	142	19	term	term	NOUN
fnp-5049	142	20	repeated	repeat	VERB
fnp-5049	142	21	hdcs	hdc	NOUN
fnp-5049	142	22	therapy	therapy	NOUN
fnp-5049	142	23	for	for	ADP
fnp-5049	142	24	patients	patient	NOUN
fnp-5049	142	25	with	with	ADP
fnp-5049	142	26	progressive	progressive	ADJ
fnp-5049	142	27	ms	ms	PROPN
fnp-5049	142	28	reduced	reduce	VERB
fnp-5049	142	29	snfl	snfl	NOUN
fnp-5049	142	30	levels	level	NOUN
fnp-5049	142	31	by	by	ADP
fnp-5049	142	32	22	22	NUM
fnp-5049	142	33	%	%	NOUN
fnp-5049	142	34	after	after	ADP
fnp-5049	142	35	20	20	NUM
fnp-5049	142	36	weeks	week	NOUN
fnp-5049	142	37	.	.	PUNCT
fnp-5049	143	1	we	we	PRON
fnp-5049	143	2	observed	observe	VERB
fnp-5049	143	3	a	a	DET
fnp-5049	143	4	reduction	reduction	NOUN
fnp-5049	143	5	of	of	ADP
fnp-5049	143	6	snfl	snfl	NOUN
fnp-5049	143	7	levels	level	NOUN
fnp-5049	143	8	in	in	ADP
fnp-5049	143	9	the	the	DET
fnp-5049	143	10	majority	majority	NOUN
fnp-5049	143	11	of	of	ADP
fnp-5049	143	12	patients	patient	NOUN
fnp-5049	143	13	,	,	PUNCT
fnp-5049	143	14	so	so	SCONJ
fnp-5049	143	15	that	that	SCONJ
fnp-5049	143	16	these	these	DET
fnp-5049	143	17	changes	change	NOUN
fnp-5049	143	18	are	be	AUX
fnp-5049	143	19	most	most	ADV
fnp-5049	143	20	likely	likely	ADJ
fnp-5049	143	21	due	due	ADP
fnp-5049	143	22	to	to	ADP
fnp-5049	143	23	the	the	DET
fnp-5049	143	24	steroid	steroid	NOUN
fnp-5049	143	25	therapy	therapy	NOUN
fnp-5049	143	26	and	and	CCONJ
fnp-5049	143	27	not	not	PART
fnp-5049	143	28	to	to	ADP
fnp-5049	143	29	normal	normal	ADJ
fnp-5049	143	30	fluctuations	fluctuation	NOUN
fnp-5049	143	31	as	as	SCONJ
fnp-5049	143	32	described	describe	VERB
fnp-5049	143	33	by	by	ADP
fnp-5049	143	34	bridel	bridel	PROPN
fnp-5049	143	35	et	et	PROPN
fnp-5049	143	36	al	al	PROPN
fnp-5049	143	37	.	.	PUNCT
fnp-5049	144	1	[	[	X
fnp-5049	144	2	8	8	NUM
fnp-5049	144	3	]	]	PUNCT
fnp-5049	144	4	.	.	PUNCT
fnp-5049	145	1	this	this	PRON
fnp-5049	145	2	implies	imply	VERB
fnp-5049	145	3	that	that	SCONJ
fnp-5049	145	4	hdcs	hdcs	ADJ
fnp-5049	145	5	treatment	treatment	NOUN
fnp-5049	145	6	may	may	AUX
fnp-5049	145	7	reduce	reduce	VERB
fnp-5049	145	8	ongoing	ongoing	ADJ
fnp-5049	145	9	diseaseactivity	diseaseactivity	NOUN
fnp-5049	145	10	and	and	CCONJ
fnp-5049	145	11	neuroaxonal	neuroaxonal	ADJ
fnp-5049	145	12	damage	damage	NOUN
fnp-5049	145	13	in	in	ADP
fnp-5049	145	14	a	a	DET
fnp-5049	145	15	subgroup	subgroup	NOUN
fnp-5049	145	16	of	of	ADP
fnp-5049	145	17	progressive	progressive	ADJ
fnp-5049	145	18	ms	ms	ADJ
fnp-5049	145	19	patients	patient	NOUN
fnp-5049	145	20	,	,	PUNCT
fnp-5049	145	21	which	which	PRON
fnp-5049	145	22	is	be	AUX
fnp-5049	145	23	the	the	DET
fnp-5049	145	24	main	main	ADJ
fnp-5049	145	25	cause	cause	NOUN
fnp-5049	145	26	of	of	ADP
fnp-5049	145	27	accumulation	accumulation	NOUN
fnp-5049	145	28	of	of	ADP
fnp-5049	145	29	clinical	clinical	ADJ
fnp-5049	145	30	disability	disability	NOUN
fnp-5049	145	31	.	.	PUNCT
fnp-5049	146	1	in	in	ADP
fnp-5049	146	2	support	support	NOUN
fnp-5049	146	3	of	of	ADP
fnp-5049	146	4	this	this	PRON
fnp-5049	146	5	,	,	PUNCT
fnp-5049	146	6	the	the	DET
fnp-5049	146	7	edss	edss	ADJ
fnp-5049	146	8	score	score	NOUN
fnp-5049	146	9	did	do	AUX
fnp-5049	146	10	not	not	PART
fnp-5049	146	11	increase	increase	VERB
fnp-5049	146	12	during	during	ADP
fnp-5049	146	13	the	the	DET
fnp-5049	146	14	treatment	treatment	NOUN
fnp-5049	146	15	period	period	NOUN
fnp-5049	146	16	.	.	PUNCT
fnp-5049	147	1	hdcs	hdc	NOUN
fnp-5049	147	2	are	be	AUX
fnp-5049	147	3	effective	effective	ADJ
fnp-5049	147	4	not	not	PART
fnp-5049	147	5	only	only	ADV
fnp-5049	147	6	in	in	ADP
fnp-5049	147	7	relapsing	relapse	VERB
fnp-5049	147	8	-	-	PUNCT
fnp-5049	147	9	remitting	remit	VERB
fnp-5049	147	10	ms	ms	NOUN
fnp-5049	147	11	but	but	CCONJ
fnp-5049	147	12	also	also	ADV
fnp-5049	147	13	in	in	ADP
fnp-5049	147	14	progressive	progressive	ADJ
fnp-5049	147	15	ms	ms	PROPN
fnp-5049	147	16	hdcs	hdcs	PROPN
fnp-5049	147	17	are	be	AUX
fnp-5049	147	18	the	the	DET
fnp-5049	147	19	first	first	ADJ
fnp-5049	147	20	-	-	PUNCT
fnp-5049	147	21	line	line	NOUN
fnp-5049	147	22	treatment	treatment	NOUN
fnp-5049	147	23	for	for	ADP
fnp-5049	147	24	ms	ms	PROPN
fnp-5049	147	25	relapses	relapse	NOUN
fnp-5049	147	26	[	[	X
fnp-5049	147	27	6	6	NUM
fnp-5049	147	28	,	,	PUNCT
fnp-5049	147	29	35	35	NUM
fnp-5049	147	30	,	,	PUNCT
fnp-5049	147	31	44	44	NUM
fnp-5049	147	32	]	]	PUNCT
fnp-5049	147	33	.	.	PUNCT
fnp-5049	148	1	this	this	DET
fnp-5049	148	2	treatment	treatment	NOUN
fnp-5049	148	3	typically	typically	ADV
fnp-5049	148	4	provides	provide	VERB
fnp-5049	148	5	a	a	DET
fnp-5049	148	6	rapid	rapid	ADJ
fnp-5049	148	7	clinical	clinical	ADJ
fnp-5049	148	8	benefit	benefit	NOUN
fnp-5049	148	9	,	,	PUNCT
fnp-5049	148	10	decreasing	decrease	VERB
fnp-5049	148	11	the	the	DET
fnp-5049	148	12	severity	severity	NOUN
fnp-5049	148	13	of	of	ADP
fnp-5049	148	14	clinical	clinical	ADJ
fnp-5049	148	15	symptoms	symptom	NOUN
fnp-5049	148	16	and	and	CCONJ
fnp-5049	148	17	duration	duration	NOUN
fnp-5049	148	18	of	of	ADP
fnp-5049	148	19	the	the	DET
fnp-5049	148	20	attack	attack	NOUN
fnp-5049	148	21	[	[	X
fnp-5049	148	22	18	18	NUM
fnp-5049	148	23	]	]	PUNCT
fnp-5049	148	24	.	.	PUNCT
fnp-5049	149	1	intravenous	intravenous	PROPN
fnp-5049	149	2	hdcs	hdcs	PROPN
fnp-5049	149	3	treatment	treatment	NOUN
fnp-5049	149	4	of	of	ADP
fnp-5049	149	5	relapses	relapse	NOUN
fnp-5049	149	6	was	be	AUX
fnp-5049	149	7	also	also	ADV
fnp-5049	149	8	associated	associate	VERB
fnp-5049	149	9	with	with	ADP
fnp-5049	149	10	a	a	DET
fnp-5049	149	11	lower	low	ADJ
fnp-5049	149	12	risk	risk	NOUN
fnp-5049	149	13	of	of	ADP
fnp-5049	149	14	contrast	contrast	NOUN
fnp-5049	149	15	-	-	PUNCT
fnp-5049	149	16	enhancing	enhance	VERB
fnp-5049	149	17	lesions	lesion	NOUN
fnp-5049	149	18	to	to	PART
fnp-5049	149	19	turn	turn	VERB
fnp-5049	149	20	into	into	ADP
fnp-5049	149	21	black	black	ADJ
fnp-5049	149	22	holes	hole	NOUN
fnp-5049	149	23	,	,	PUNCT
fnp-5049	149	24	indicating	indicate	VERB
fnp-5049	149	25	a	a	DET
fnp-5049	149	26	reduction	reduction	NOUN
fnp-5049	149	27	in	in	ADP
fnp-5049	149	28	destructive	destructive	ADJ
fnp-5049	149	29	lesions	lesion	NOUN
fnp-5049	149	30	[	[	X
fnp-5049	149	31	13	13	NUM
fnp-5049	149	32	]	]	PUNCT
fnp-5049	149	33	.	.	PUNCT
fnp-5049	150	1	here	here	ADV
fnp-5049	150	2	,	,	PUNCT
fnp-5049	150	3	we	we	PRON
fnp-5049	150	4	have	have	AUX
fnp-5049	150	5	shown	show	VERB
fnp-5049	150	6	that	that	SCONJ
fnp-5049	150	7	repeated	repeat	VERB
fnp-5049	150	8	hdcs	hdcs	NOUN
fnp-5049	150	9	cycles	cycle	NOUN
fnp-5049	150	10	reduce	reduce	VERB
fnp-5049	150	11	snfl	snfl	NOUN
fnp-5049	150	12	levels	level	NOUN
fnp-5049	150	13	in	in	ADP
fnp-5049	150	14	a	a	DET
fnp-5049	150	15	subgroup	subgroup	NOUN
fnp-5049	150	16	of	of	ADP
fnp-5049	150	17	patients	patient	NOUN
fnp-5049	150	18	with	with	ADP
fnp-5049	150	19	progressive	progressive	ADJ
fnp-5049	150	20	ms	ms	NOUN
fnp-5049	150	21	without	without	ADP
fnp-5049	150	22	signs	sign	NOUN
fnp-5049	150	23	of	of	ADP
fnp-5049	150	24	active	active	ADJ
fnp-5049	150	25	inflammation	inflammation	NOUN
fnp-5049	150	26	.	.	PUNCT
fnp-5049	151	1	early	early	ADJ
fnp-5049	151	2	publications	publication	NOUN
fnp-5049	151	3	support	support	VERB
fnp-5049	151	4	our	our	PRON
fnp-5049	151	5	findings	finding	NOUN
fnp-5049	151	6	and	and	CCONJ
fnp-5049	151	7	describe	describe	VERB
fnp-5049	151	8	an	an	DET
fnp-5049	151	9	improvement	improvement	NOUN
fnp-5049	151	10	in	in	ADP
fnp-5049	151	11	the	the	DET
fnp-5049	151	12	edss	edss	ADJ
fnp-5049	151	13	score	score	NOUN
fnp-5049	151	14	as	as	ADV
fnp-5049	151	15	well	well	ADV
fnp-5049	151	16	as	as	ADP
fnp-5049	151	17	a	a	DET
fnp-5049	151	18	functional	functional	ADJ
fnp-5049	151	19	benefit	benefit	NOUN
fnp-5049	151	20	from	from	ADP
fnp-5049	151	21	repeated	repeat	VERB
fnp-5049	151	22	hdcs	hdc	NOUN
fnp-5049	151	23	cycles	cycle	NOUN
fnp-5049	151	24	in	in	ADP
fnp-5049	151	25	progressive	progressive	ADJ
fnp-5049	151	26	ms	ms	NOUN
fnp-5049	152	1	[	[	X
fnp-5049	152	2	5	5	NUM
fnp-5049	152	3	,	,	PUNCT
fnp-5049	152	4	10	10	NUM
fnp-5049	152	5	,	,	PUNCT
fnp-5049	152	6	25	25	NUM
fnp-5049	152	7	,	,	PUNCT
fnp-5049	152	8	44	44	NUM
fnp-5049	152	9	]	]	PUNCT
fnp-5049	152	10	.	.	PUNCT
fnp-5049	153	1	even	even	ADV
fnp-5049	153	2	oral	oral	ADJ
fnp-5049	153	3	monthly	monthly	ADJ
fnp-5049	153	4	administration	administration	NOUN
fnp-5049	153	5	of	of	ADP
fnp-5049	153	6	hdcs	hdcs	PROPN
fnp-5049	153	7	showed	show	VERB
fnp-5049	153	8	a	a	DET
fnp-5049	153	9	benefit	benefit	NOUN
fnp-5049	153	10	in	in	ADP
fnp-5049	153	11	progressive	progressive	ADJ
fnp-5049	153	12	ms	ms	NOUN
fnp-5049	153	13	:	:	PUNCT
fnp-5049	153	14	the	the	DET
fnp-5049	153	15	edss	edss	ADV
fnp-5049	153	16	,	,	PUNCT
fnp-5049	153	17	ms	ms	PROPN
fnp-5049	153	18	functional	functional	ADJ
fnp-5049	153	19	composite	composite	ADJ
fnp-5049	153	20	test	test	NOUN
fnp-5049	153	21	and	and	CCONJ
fnp-5049	153	22	t2	t2	NOUN
fnp-5049	153	23	lesion	lesion	NOUN
fnp-5049	153	24	volume	volume	NOUN
fnp-5049	153	25	showed	show	VERB
fnp-5049	153	26	a	a	DET
fnp-5049	153	27	significant	significant	ADJ
fnp-5049	153	28	improvement	improvement	NOUN
fnp-5049	153	29	after	after	ADP
fnp-5049	153	30	oral	oral	ADJ
fnp-5049	153	31	hdcs	hdc	NOUN
fnp-5049	153	32	therapy	therapy	NOUN
fnp-5049	153	33	[	[	X
fnp-5049	153	34	45	45	NUM
fnp-5049	153	35	]	]	PUNCT
fnp-5049	153	36	.	.	PUNCT
fnp-5049	154	1	however	however	ADV
fnp-5049	154	2	,	,	PUNCT
fnp-5049	154	3	a	a	DET
fnp-5049	154	4	reduction	reduction	NOUN
fnp-5049	154	5	in	in	ADP
fnp-5049	154	6	csf	csf	ADJ
fnp-5049	154	7	biomarkers	biomarker	NOUN
fnp-5049	154	8	of	of	ADP
fnp-5049	154	9	inflammation	inflammation	NOUN
fnp-5049	154	10	and	and	CCONJ
fnp-5049	154	11	neurodegeneration	neurodegeneration	NOUN
fnp-5049	154	12	including	include	VERB
fnp-5049	154	13	nfl	nfl	PROPN
fnp-5049	154	14	was	be	AUX
fnp-5049	154	15	not	not	PART
fnp-5049	154	16	observed	observe	VERB
fnp-5049	154	17	[	[	PUNCT
fnp-5049	154	18	45	45	NUM
fnp-5049	154	19	]	]	PUNCT
fnp-5049	154	20	.	.	PUNCT
fnp-5049	155	1	in	in	ADP
fnp-5049	155	2	our	our	PRON
fnp-5049	155	3	study	study	NOUN
fnp-5049	155	4	,	,	PUNCT
fnp-5049	155	5	we	we	PRON
fnp-5049	155	6	assessed	assess	VERB
fnp-5049	155	7	the	the	DET
fnp-5049	155	8	treatment	treatment	NOUN
fnp-5049	155	9	effect	effect	NOUN
fnp-5049	155	10	with	with	ADP
fnp-5049	155	11	the	the	DET
fnp-5049	155	12	serum	serum	NOUN
fnp-5049	155	13	biomarker	biomarker	PROPN
fnp-5049	155	14	nfl	nfl	PROPN
fnp-5049	155	15	and	and	CCONJ
fnp-5049	155	16	observed	observe	VERB
fnp-5049	155	17	a	a	DET
fnp-5049	155	18	reduction	reduction	NOUN
fnp-5049	155	19	in	in	ADP
fnp-5049	155	20	the	the	DET
fnp-5049	155	21	majority	majority	NOUN
fnp-5049	155	22	of	of	ADP
fnp-5049	155	23	patients	patient	NOUN
fnp-5049	155	24	(	(	PUNCT
fnp-5049	155	25	76	76	NUM
fnp-5049	155	26	%	%	NOUN
fnp-5049	155	27	)	)	PUNCT
fnp-5049	155	28	after	after	ADP
fnp-5049	155	29	repeated	repeat	VERB
fnp-5049	155	30	intravenous	intravenous	ADJ
fnp-5049	155	31	cycles	cycle	NOUN
fnp-5049	155	32	of	of	ADP
fnp-5049	155	33	hdcs	hdc	NOUN
fnp-5049	155	34	.	.	PUNCT
fnp-5049	156	1	importantly	importantly	ADV
fnp-5049	156	2	,	,	PUNCT
fnp-5049	156	3	all	all	PRON
fnp-5049	156	4	of	of	ADP
fnp-5049	156	5	our	our	PRON
fnp-5049	156	6	patients	patient	NOUN
fnp-5049	156	7	except	except	SCONJ
fnp-5049	156	8	for	for	ADP
fnp-5049	156	9	one	one	NUM
fnp-5049	156	10	had	have	AUX
fnp-5049	156	11	received	receive	VERB
fnp-5049	156	12	hdcs	hdcs	ADJ
fnp-5049	156	13	treatments	treatment	NOUN
fnp-5049	156	14	before	before	ADP
fnp-5049	156	15	baseline	baseline	ADJ
fnp-5049	156	16	blood	blood	NOUN
fnp-5049	156	17	sampling	sampling	NOUN
fnp-5049	156	18	,	,	PUNCT
fnp-5049	156	19	so	so	SCONJ
fnp-5049	156	20	that	that	SCONJ
fnp-5049	156	21	a	a	DET
fnp-5049	156	22	reduction	reduction	NOUN
fnp-5049	156	23	of	of	ADP
fnp-5049	156	24	snfl	snfl	NOUN
fnp-5049	156	25	might	might	AUX
fnp-5049	156	26	already	already	ADV
fnp-5049	156	27	have	have	AUX
fnp-5049	156	28	occurred	occur	VERB
fnp-5049	156	29	before	before	ADP
fnp-5049	156	30	baseline	baseline	ADJ
fnp-5049	156	31	blood	blood	NOUN
fnp-5049	156	32	sampling	sampling	NOUN
fnp-5049	156	33	.	.	PUNCT
fnp-5049	157	1	thus	thus	ADV
fnp-5049	157	2	,	,	PUNCT
fnp-5049	157	3	the	the	DET
fnp-5049	157	4	effect	effect	NOUN
fnp-5049	157	5	of	of	ADP
fnp-5049	157	6	hdcs	hdcs	PROPN
fnp-5049	157	7	therapy	therapy	NOUN
fnp-5049	157	8	on	on	ADP
fnp-5049	157	9	snfl	snfl	PROPN
fnp-5049	157	10	levels	level	NOUN
fnp-5049	157	11	might	might	AUX
fnp-5049	157	12	even	even	ADV
fnp-5049	157	13	be	be	AUX
fnp-5049	157	14	stronger	strong	ADJ
fnp-5049	157	15	than	than	SCONJ
fnp-5049	157	16	described	describe	VERB
fnp-5049	157	17	here	here	ADV
fnp-5049	157	18	.	.	PUNCT
fnp-5049	158	1	functional	functional	ADJ
fnp-5049	158	2	improvement	improvement	NOUN
fnp-5049	158	3	of	of	ADP
fnp-5049	158	4	neurological	neurological	ADJ
fnp-5049	158	5	systems	system	NOUN
fnp-5049	158	6	and	and	CCONJ
fnp-5049	158	7	mri	mri	NOUN
fnp-5049	158	8	parameters	parameter	NOUN
fnp-5049	158	9	were	be	AUX
fnp-5049	158	10	not	not	PART
fnp-5049	158	11	addressed	address	VERB
fnp-5049	158	12	in	in	ADP
fnp-5049	158	13	our	our	PRON
fnp-5049	158	14	study	study	NOUN
fnp-5049	158	15	.	.	PUNCT
fnp-5049	159	1	snfl	snfl	PROPN
fnp-5049	159	2	levels	level	NOUN
fnp-5049	159	3	for	for	ADP
fnp-5049	159	4	hdcs	hdc	NOUN
fnp-5049	159	5	therapy	therapy	NOUN
fnp-5049	159	6	monitoring	monitoring	NOUN
fnp-5049	159	7	and	and	CCONJ
fnp-5049	159	8	long	long	ADJ
fnp-5049	159	9	-	-	PUNCT
fnp-5049	159	10	term	term	NOUN
fnp-5049	159	11	treatment	treatment	NOUN
fnp-5049	159	12	effects	effect	NOUN
fnp-5049	159	13	snfl	snfl	NOUN
fnp-5049	159	14	levels	level	NOUN
fnp-5049	159	15	serve	serve	VERB
fnp-5049	159	16	as	as	ADP
fnp-5049	159	17	a	a	DET
fnp-5049	159	18	highly	highly	ADV
fnp-5049	159	19	sensitive	sensitive	ADJ
fnp-5049	159	20	marker	marker	NOUN
fnp-5049	159	21	for	for	ADP
fnp-5049	159	22	neuroaxonal	neuroaxonal	ADJ
fnp-5049	159	23	injury	injury	NOUN
fnp-5049	159	24	in	in	ADP
fnp-5049	159	25	different	different	ADJ
fnp-5049	159	26	conditions	condition	NOUN
fnp-5049	159	27	such	such	ADJ
fnp-5049	159	28	as	as	ADP
fnp-5049	159	29	alzheimer	alzheimer	NOUN
fnp-5049	159	30	,	,	PUNCT
fnp-5049	159	31	parkinson	parkinson	NOUN
fnp-5049	159	32	’s	’s	PART
fnp-5049	159	33	,	,	PUNCT
fnp-5049	159	34	traumatic	traumatic	ADJ
fnp-5049	159	35	brain	brain	NOUN
fnp-5049	159	36	injury	injury	NOUN
fnp-5049	159	37	or	or	CCONJ
fnp-5049	159	38	amyotrophic	amyotrophic	ADJ
fnp-5049	159	39	lateral	lateral	ADJ
fnp-5049	159	40	sclerosis	sclerosis	NOUN
fnp-5049	159	41	[	[	X
fnp-5049	159	42	1	1	NUM
fnp-5049	159	43	,	,	PUNCT
fnp-5049	159	44	22	22	NUM
fnp-5049	159	45	,	,	PUNCT
fnp-5049	159	46	27	27	NUM
fnp-5049	159	47	,	,	PUNCT
fnp-5049	159	48	48	48	NUM
fnp-5049	159	49	]	]	PUNCT
fnp-5049	159	50	.	.	PUNCT
fnp-5049	160	1	their	their	PRON
fnp-5049	160	2	concentration	concentration	NOUN
fnp-5049	160	3	increases	increase	NOUN
fnp-5049	160	4	with	with	ADP
fnp-5049	160	5	age	age	NOUN
fnp-5049	160	6	by	by	ADP
fnp-5049	160	7	an	an	DET
fnp-5049	160	8	average	average	NOUN
fnp-5049	160	9	of	of	ADP
fnp-5049	160	10	2.2	2.2	NUM
fnp-5049	160	11	%	%	NOUN
fnp-5049	160	12	per	per	ADP
fnp-5049	160	13	year	year	NOUN
fnp-5049	160	14	in	in	ADP
fnp-5049	160	15	healthy	healthy	ADJ
fnp-5049	160	16	controls	control	NOUN
fnp-5049	160	17	[	[	X
fnp-5049	160	18	15	15	NUM
fnp-5049	160	19	]	]	PUNCT
fnp-5049	160	20	.	.	PUNCT
fnp-5049	161	1	an	an	DET
fnp-5049	161	2	age	age	NOUN
fnp-5049	161	3	-	-	PUNCT
fnp-5049	161	4	dependent	dependent	ADJ
fnp-5049	161	5	increase	increase	NOUN
fnp-5049	161	6	in	in	ADP
fnp-5049	161	7	snfl	snfl	NOUN
fnp-5049	161	8	levels	level	NOUN
fnp-5049	161	9	could	could	AUX
fnp-5049	161	10	also	also	ADV
fnp-5049	161	11	be	be	AUX
fnp-5049	161	12	confirmed	confirm	VERB
fnp-5049	161	13	in	in	ADP
fnp-5049	161	14	our	our	PRON
fnp-5049	161	15	study	study	NOUN
fnp-5049	161	16	.	.	PUNCT
fnp-5049	162	1	increased	increase	VERB
fnp-5049	162	2	snfl	snfl	NOUN
fnp-5049	162	3	levels	level	NOUN
fnp-5049	162	4	reflect	reflect	VERB
fnp-5049	162	5	recent	recent	ADJ
fnp-5049	162	6	or	or	CCONJ
fnp-5049	162	7	ongoing	ongoing	ADJ
fnp-5049	162	8	neuroaxonal	neuroaxonal	ADJ
fnp-5049	162	9	damage	damage	NOUN
fnp-5049	162	10	related	relate	VERB
fnp-5049	162	11	to	to	ADP
fnp-5049	162	12	ongoing	ongoing	ADJ
fnp-5049	162	13	inflammatory	inflammatory	ADJ
fnp-5049	162	14	activity	activity	NOUN
fnp-5049	162	15	in	in	ADP
fnp-5049	162	16	late	late	ADJ
fnp-5049	162	17	-	-	PUNCT
fnp-5049	162	18	stage	stage	NOUN
fnp-5049	162	19	ms	ms	NOUN
fnp-5049	163	1	[	[	X
fnp-5049	163	2	7	7	NUM
fnp-5049	163	3	,	,	PUNCT
fnp-5049	163	4	14	14	NUM
fnp-5049	163	5	]	]	PUNCT
fnp-5049	163	6	.	.	PUNCT
fnp-5049	164	1	a	a	DET
fnp-5049	164	2	reduction	reduction	NOUN
fnp-5049	164	3	in	in	ADP
fnp-5049	164	4	snfl	snfl	NOUN
fnp-5049	164	5	levels	level	NOUN
fnp-5049	164	6	indicates	indicate	VERB
fnp-5049	164	7	less	less	ADJ
fnp-5049	164	8	neuroaxonal	neuroaxonal	ADJ
fnp-5049	164	9	loss	loss	NOUN
fnp-5049	164	10	and	and	CCONJ
fnp-5049	164	11	thus	thus	ADV
fnp-5049	164	12	beneficial	beneficial	ADJ
fnp-5049	164	13	treatment	treatment	NOUN
fnp-5049	164	14	effects	effect	NOUN
fnp-5049	164	15	.	.	PUNCT
fnp-5049	165	1	in	in	ADP
fnp-5049	165	2	progressive	progressive	ADJ
fnp-5049	165	3	ms	ms	ADJ
fnp-5049	165	4	patients	patient	NOUN
fnp-5049	165	5	,	,	PUNCT
fnp-5049	165	6	a	a	DET
fnp-5049	165	7	reduction	reduction	NOUN
fnp-5049	165	8	in	in	ADP
fnp-5049	165	9	snfl	snfl	NOUN
fnp-5049	165	10	was	be	AUX
fnp-5049	165	11	observed	observe	VERB
fnp-5049	165	12	after	after	ADP
fnp-5049	165	13	treatment	treatment	NOUN
fnp-5049	165	14	with	with	ADP
fnp-5049	165	15	dmts	dmts	NOUN
fnp-5049	165	16	as	as	ADV
fnp-5049	165	17	well	well	ADV
fnp-5049	165	18	as	as	ADP
fnp-5049	165	19	after	after	ADP
fnp-5049	165	20	autologous	autologous	ADJ
fnp-5049	165	21	hematopoietic	hematopoietic	ADJ
fnp-5049	165	22	stem	stem	NOUN
fnp-5049	165	23	cell	cell	NOUN
fnp-5049	165	24	transplantation	transplantation	NOUN
fnp-5049	165	25	[	[	X
fnp-5049	165	26	3	3	NUM
fnp-5049	165	27	,	,	PUNCT
fnp-5049	165	28	29	29	NUM
fnp-5049	165	29	,	,	PUNCT
fnp-5049	165	30	33	33	NUM
fnp-5049	165	31	,	,	PUNCT
fnp-5049	165	32	36	36	NUM
fnp-5049	165	33	,	,	PUNCT
fnp-5049	165	34	53	53	NUM
fnp-5049	165	35	]	]	PUNCT
fnp-5049	165	36	.	.	PUNCT
fnp-5049	166	1	snfl	snfl	PROPN
fnp-5049	166	2	levels	level	NOUN
fnp-5049	166	3	typically	typically	ADV
fnp-5049	166	4	decrease	decrease	VERB
fnp-5049	166	5	within	within	ADP
fnp-5049	166	6	3	3	NUM
fnp-5049	166	7	-	-	SYM
fnp-5049	166	8	6	6	NUM
fnp-5049	166	9	months	month	NOUN
fnp-5049	166	10	after	after	ADP
fnp-5049	166	11	initiation	initiation	NOUN
fnp-5049	166	12	of	of	ADP
fnp-5049	166	13	anti	anti	ADJ
fnp-5049	166	14	-	-	ADJ
fnp-5049	166	15	inflammatory	inflammatory	ADJ
fnp-5049	166	16	therapies	therapy	NOUN
fnp-5049	166	17	in	in	ADP
fnp-5049	166	18	relapsing	relapse	VERB
fnp-5049	166	19	-	-	PUNCT
fnp-5049	166	20	remitting	remit	VERB
fnp-5049	166	21	ms	ms	NOUN
fnp-5049	166	22	[	[	X
fnp-5049	166	23	32	32	NUM
fnp-5049	166	24	]	]	PUNCT
fnp-5049	166	25	.	.	PUNCT
fnp-5049	167	1	similar	similar	ADJ
fnp-5049	167	2	snfl	snfl	NOUN
fnp-5049	167	3	dynamics	dynamic	NOUN
fnp-5049	167	4	were	be	AUX
fnp-5049	167	5	found	find	VERB
fnp-5049	167	6	in	in	ADP
fnp-5049	167	7	our	our	PRON
fnp-5049	167	8	study	study	NOUN
fnp-5049	167	9	.	.	PUNCT
fnp-5049	168	1	a	a	DET
fnp-5049	168	2	significant	significant	ADJ
fnp-5049	168	3	reduction	reduction	NOUN
fnp-5049	168	4	in	in	ADP
fnp-5049	168	5	snfl	snfl	NOUN
fnp-5049	168	6	levels	level	NOUN
fnp-5049	168	7	was	be	AUX
fnp-5049	168	8	evident	evident	ADJ
fnp-5049	168	9	for	for	ADP
fnp-5049	168	10	the	the	DET
fnp-5049	168	11	first	first	ADJ
fnp-5049	168	12	time	time	NOUN
fnp-5049	168	13	≥20	≥20	NOUN
fnp-5049	168	14	weeks	week	NOUN
fnp-5049	168	15	after	after	SCONJ
fnp-5049	168	16	baseline	baseline	PROPN
fnp-5049	168	17	hdcs	hdcs	PROPN
fnp-5049	168	18	treatment	treatment	NOUN
fnp-5049	168	19	,	,	PUNCT
fnp-5049	168	20	but	but	CCONJ
fnp-5049	168	21	not	not	PART
fnp-5049	168	22	at	at	ADP
fnp-5049	168	23	earlier	early	ADJ
fnp-5049	168	24	time	time	NOUN
fnp-5049	168	25	points	point	NOUN
fnp-5049	168	26	,	,	PUNCT
fnp-5049	168	27	and	and	CCONJ
fnp-5049	168	28	showed	show	VERB
fnp-5049	168	29	a	a	DET
fnp-5049	168	30	positive	positive	ADJ
fnp-5049	168	31	correlation	correlation	NOUN
fnp-5049	168	32	with	with	ADP
fnp-5049	168	33	the	the	DET
fnp-5049	168	34	time	time	NOUN
fnp-5049	168	35	that	that	PRON
fnp-5049	168	36	passed	pass	VERB
fnp-5049	168	37	after	after	ADP
fnp-5049	168	38	hdcs	hdcs	PROPN
fnp-5049	168	39	treatment	treatment	NOUN
fnp-5049	168	40	.	.	PUNCT
fnp-5049	169	1	long	long	ADJ
fnp-5049	169	2	-	-	PUNCT
fnp-5049	169	3	term	term	NOUN
fnp-5049	169	4	immunomodulatory	immunomodulatory	ADJ
fnp-5049	169	5	effects	effect	NOUN
fnp-5049	169	6	of	of	ADP
fnp-5049	169	7	hdcs	hdc	NOUN
fnp-5049	169	8	have	have	AUX
fnp-5049	169	9	already	already	ADV
fnp-5049	169	10	been	be	AUX
fnp-5049	169	11	described	describe	VERB
fnp-5049	169	12	in	in	ADP
fnp-5049	169	13	previous	previous	ADJ
fnp-5049	169	14	studies	study	NOUN
fnp-5049	169	15	.	.	PUNCT
fnp-5049	170	1	for	for	ADP
fnp-5049	170	2	example	example	NOUN
fnp-5049	170	3	,	,	PUNCT
fnp-5049	170	4	treatment	treatment	NOUN
fnp-5049	170	5	of	of	ADP
fnp-5049	170	6	the	the	DET
fnp-5049	170	7	first	first	ADJ
fnp-5049	170	8	optic	optic	ADJ
fnp-5049	170	9	neuritis	neuritis	NOUN
fnp-5049	170	10	episode	episode	NOUN
fnp-5049	170	11	with	with	ADP
fnp-5049	170	12	intravenous	intravenous	ADJ
fnp-5049	170	13	hdcs	hdc	NOUN
fnp-5049	170	14	was	be	AUX
fnp-5049	170	15	found	find	VERB
fnp-5049	170	16	to	to	PART
fnp-5049	170	17	reduce	reduce	VERB
fnp-5049	170	18	the	the	DET
fnp-5049	170	19	development	development	NOUN
fnp-5049	170	20	of	of	ADP
fnp-5049	170	21	clinical	clinical	ADJ
fnp-5049	170	22	ms	ms	NOUN
fnp-5049	170	23	within	within	ADP
fnp-5049	170	24	two	two	NUM
fnp-5049	170	25	years	year	NOUN
fnp-5049	171	1	[	[	X
fnp-5049	171	2	4	4	NUM
fnp-5049	171	3	]	]	PUNCT
fnp-5049	171	4	.	.	PUNCT
fnp-5049	172	1	brain	brain	NOUN
fnp-5049	172	2	atrophy	atrophy	NOUN
fnp-5049	172	3	and	and	CCONJ
fnp-5049	172	4	the	the	DET
fnp-5049	172	5	development	development	NOUN
fnp-5049	172	6	of	of	ADP
fnp-5049	172	7	t1	t1	NOUN
fnp-5049	172	8	black	black	ADJ
fnp-5049	172	9	holes	hole	NOUN
fnp-5049	172	10	in	in	ADP
fnp-5049	172	11	ms	ms	ADJ
fnp-5049	172	12	patients	patient	NOUN
fnp-5049	172	13	were	be	AUX
fnp-5049	172	14	reduced	reduce	VERB
fnp-5049	172	15	with	with	ADP
fnp-5049	172	16	prolonged	prolonged	ADJ
fnp-5049	172	17	treatment	treatment	NOUN
fnp-5049	172	18	with	with	ADP
fnp-5049	172	19	intravenous	intravenous	ADJ
fnp-5049	172	20	hdcs	hdc	NOUN
fnp-5049	172	21	[	[	X
fnp-5049	172	22	56	56	NUM
fnp-5049	172	23	]	]	PUNCT
fnp-5049	172	24	.	.	PUNCT
fnp-5049	173	1	a	a	DET
fnp-5049	173	2	positive	positive	ADJ
fnp-5049	173	3	effect	effect	NOUN
fnp-5049	173	4	on	on	ADP
fnp-5049	173	5	the	the	DET
fnp-5049	173	6	sustained	sustained	ADJ
fnp-5049	173	7	progression	progression	NOUN
fnp-5049	173	8	of	of	ADP
fnp-5049	173	9	disability	disability	NOUN
fnp-5049	173	10	after	after	ADP
fnp-5049	173	11	hdcs	hdcs	ADJ
fnp-5049	173	12	treatment	treatment	NOUN
fnp-5049	173	13	in	in	ADP
fnp-5049	173	14	progressive	progressive	ADJ
fnp-5049	173	15	ms	ms	NOUN
fnp-5049	173	16	patients	patient	NOUN
fnp-5049	173	17	was	be	AUX
fnp-5049	173	18	also	also	ADV
fnp-5049	173	19	observed	observe	VERB
fnp-5049	173	20	[	[	X
fnp-5049	173	21	25	25	NUM
fnp-5049	173	22	]	]	PUNCT
fnp-5049	173	23	.	.	PUNCT
fnp-5049	174	1	mode	mode	NOUN
fnp-5049	174	2	of	of	ADP
fnp-5049	174	3	action	action	NOUN
fnp-5049	174	4	of	of	ADP
fnp-5049	174	5	hdcs	hdc	NOUN
fnp-5049	174	6	in	in	ADP
fnp-5049	174	7	progressive	progressive	ADJ
fnp-5049	174	8	ms	ms	NOUN
fnp-5049	174	9	corticosteroids	corticosteroid	NOUN
fnp-5049	174	10	are	be	AUX
fnp-5049	174	11	used	use	VERB
fnp-5049	174	12	in	in	ADP
fnp-5049	174	13	ms	ms	ADJ
fnp-5049	174	14	treatment	treatment	NOUN
fnp-5049	174	15	due	due	ADP
fnp-5049	174	16	to	to	ADP
fnp-5049	174	17	their	their	PRON
fnp-5049	174	18	anti	anti	ADJ
fnp-5049	174	19	-	-	ADJ
fnp-5049	174	20	inflammatory	inflammatory	ADJ
fnp-5049	174	21	effect	effect	NOUN
fnp-5049	174	22	by	by	ADP
fnp-5049	174	23	inhibiting	inhibit	VERB
fnp-5049	174	24	lymphocyte	lymphocyte	ADJ
fnp-5049	174	25	proliferation	proliferation	NOUN
fnp-5049	174	26	and	and	CCONJ
fnp-5049	174	27	the	the	DET
fnp-5049	174	28	secretion	secretion	NOUN
fnp-5049	174	29	of	of	ADP
fnp-5049	174	30	pro	pro	ADJ
fnp-5049	174	31	-	-	ADJ
fnp-5049	174	32	inflammatory	inflammatory	ADJ
fnp-5049	174	33	cytokines	cytokine	NOUN
fnp-5049	174	34	,	,	PUNCT
fnp-5049	174	35	mediated	mediate	VERB
fnp-5049	174	36	through	through	ADP
fnp-5049	174	37	specific	specific	ADJ
fnp-5049	174	38	corticoid	corticoid	NOUN
fnp-5049	174	39	receptors	receptor	NOUN
fnp-5049	174	40	.	.	PUNCT
fnp-5049	175	1	however	however	ADV
fnp-5049	175	2	,	,	PUNCT
fnp-5049	175	3	the	the	DET
fnp-5049	175	4	immediate	immediate	ADJ
fnp-5049	175	5	and	and	CCONJ
fnp-5049	175	6	long	long	ADJ
fnp-5049	175	7	-	-	PUNCT
fnp-5049	175	8	term	term	NOUN
fnp-5049	175	9	mechanisms	mechanism	NOUN
fnp-5049	175	10	of	of	ADP
fnp-5049	175	11	steroid	steroid	NOUN
fnp-5049	175	12	actions	action	NOUN
fnp-5049	175	13	are	be	AUX
fnp-5049	175	14	complex	complex	ADJ
fnp-5049	175	15	and	and	CCONJ
fnp-5049	175	16	involve	involve	VERB
fnp-5049	175	17	both	both	DET
fnp-5049	175	18	non	non	ADJ
fnp-5049	175	19	-	-	ADJ
fnp-5049	175	20	genomic	genomic	ADJ
fnp-5049	175	21	and	and	CCONJ
fnp-5049	175	22	genomic	genomic	ADJ
fnp-5049	175	23	pathways	pathway	NOUN
fnp-5049	176	1	[	[	X
fnp-5049	176	2	24	24	NUM
fnp-5049	176	3	]	]	PUNCT
fnp-5049	176	4	.	.	PUNCT
fnp-5049	177	1	interaction	interaction	NOUN
fnp-5049	177	2	of	of	ADP
fnp-5049	177	3	steroids	steroid	NOUN
fnp-5049	177	4	with	with	ADP
fnp-5049	177	5	the	the	DET
fnp-5049	177	6	cellular	cellular	ADJ
fnp-5049	177	7	membrane	membrane	NOUN
fnp-5049	177	8	and	and	CCONJ
fnp-5049	177	9	membrane	membrane	NOUN
fnp-5049	177	10	receptors	receptor	NOUN
fnp-5049	177	11	is	be	AUX
fnp-5049	177	12	responsible	responsible	ADJ
fnp-5049	177	13	for	for	ADP
fnp-5049	177	14	the	the	DET
fnp-5049	177	15	rapid	rapid	ADJ
fnp-5049	177	16	non	non	ADJ
fnp-5049	177	17	-	-	ADJ
fnp-5049	177	18	genomic	genomic	ADJ
fnp-5049	177	19	mechanism	mechanism	NOUN
fnp-5049	177	20	of	of	ADP
fnp-5049	177	21	action	action	NOUN
fnp-5049	177	22	,	,	PUNCT
fnp-5049	177	23	whereas	whereas	SCONJ
fnp-5049	177	24	binding	bind	VERB
fnp-5049	177	25	of	of	ADP
fnp-5049	177	26	specific	specific	ADJ
fnp-5049	177	27	cytosolic	cytosolic	ADJ
fnp-5049	177	28	receptors	receptor	NOUN
fnp-5049	177	29	mediates	mediate	NOUN
fnp-5049	177	30	delayed	delay	VERB
fnp-5049	177	31	genomic	genomic	ADJ
fnp-5049	177	32	effects	effect	NOUN
fnp-5049	177	33	[	[	X
fnp-5049	177	34	9	9	NUM
fnp-5049	177	35	,	,	PUNCT
fnp-5049	177	36	24	24	NUM
fnp-5049	177	37	]	]	PUNCT
fnp-5049	177	38	.	.	PUNCT
fnp-5049	178	1	in	in	ADP
fnp-5049	178	2	progressive	progressive	ADJ
fnp-5049	178	3	ms	ms	PROPN
fnp-5049	178	4	,	,	PUNCT
fnp-5049	178	5	the	the	DET
fnp-5049	178	6	degree	degree	NOUN
fnp-5049	178	7	of	of	ADP
fnp-5049	178	8	inflammation	inflammation	NOUN
fnp-5049	178	9	declines	decline	NOUN
fnp-5049	178	10	with	with	ADP
fnp-5049	178	11	age	age	NOUN
fnp-5049	178	12	and	and	CCONJ
fnp-5049	178	13	disease	disease	NOUN
fnp-5049	178	14	duration	duration	NOUN
fnp-5049	178	15	,	,	PUNCT
fnp-5049	178	16	but	but	CCONJ
fnp-5049	178	17	still	still	ADV
fnp-5049	178	18	drives	drive	VERB
fnp-5049	178	19	neuroaxonal	neuroaxonal	ADJ
fnp-5049	178	20	loss	loss	NOUN
fnp-5049	178	21	and	and	CCONJ
fnp-5049	178	22	thus	thus	ADV
fnp-5049	178	23	the	the	DET
fnp-5049	178	24	accrual	accrual	ADJ
fnp-5049	178	25	of	of	ADP
fnp-5049	178	26	disability	disability	NOUN
fnp-5049	178	27	[	[	X
fnp-5049	178	28	20	20	NUM
fnp-5049	178	29	]	]	PUNCT
fnp-5049	178	30	.	.	PUNCT
fnp-5049	179	1	so	so	ADV
fnp-5049	179	2	-	-	PUNCT
fnp-5049	179	3	called	call	VERB
fnp-5049	179	4	smouldering	smoulder	VERB
fnp-5049	179	5	lesions	lesion	NOUN
fnp-5049	179	6	with	with	ADP
fnp-5049	179	7	slowly	slowly	ADV
fnp-5049	179	8	progressing	progress	VERB
fnp-5049	179	9	demyelination	demyelination	NOUN
fnp-5049	179	10	and	and	CCONJ
fnp-5049	179	11	axonal	axonal	ADJ
fnp-5049	179	12	damage	damage	NOUN
fnp-5049	179	13	at	at	ADP
fnp-5049	179	14	the	the	DET
fnp-5049	179	15	edge	edge	NOUN
fnp-5049	179	16	of	of	ADP
fnp-5049	179	17	white	white	ADJ
fnp-5049	179	18	matter	matter	NOUN
fnp-5049	179	19	lesions	lesion	NOUN
fnp-5049	179	20	are	be	AUX
fnp-5049	179	21	a	a	DET
fnp-5049	179	22	hallmark	hallmark	NOUN
fnp-5049	179	23	of	of	ADP
fnp-5049	179	24	progressive	progressive	ADJ
fnp-5049	179	25	ms	ms	PROPN
fnp-5049	179	26	.	.	PROPN
fnp-5049	180	1	these	these	DET
fnp-5049	180	2	lesions	lesion	NOUN
fnp-5049	180	3	are	be	AUX
fnp-5049	180	4	driven	drive	VERB
fnp-5049	180	5	by	by	ADP
fnp-5049	180	6	pro	pro	ADJ
fnp-5049	180	7	-	-	ADJ
fnp-5049	180	8	inflammatory	inflammatory	ADJ
fnp-5049	180	9	microglial	microglial	ADJ
fnp-5049	180	10	cells	cell	NOUN
fnp-5049	180	11	as	as	ADV
fnp-5049	180	12	well	well	ADV
fnp-5049	180	13	as	as	ADP
fnp-5049	180	14	by	by	ADP
fnp-5049	180	15	astrocytes	astrocyte	NOUN
fnp-5049	180	16	with	with	ADP
fnp-5049	180	17	a	a	DET
fnp-5049	180	18	characteristic	characteristic	ADJ
fnp-5049	180	19	and	and	CCONJ
fnp-5049	180	20	partially	partially	ADV
fnp-5049	180	21	pro	pro	ADJ
fnp-5049	180	22	-	-	ADJ
fnp-5049	180	23	inflammatory	inflammatory	ADJ
fnp-5049	180	24	signature	signature	NOUN
fnp-5049	180	25	[	[	X
fnp-5049	180	26	2	2	NUM
fnp-5049	180	27	,	,	PUNCT
fnp-5049	180	28	28	28	NUM
fnp-5049	180	29	]	]	PUNCT
fnp-5049	180	30	.	.	PUNCT
fnp-5049	181	1	next	next	ADJ
fnp-5049	181	2	to	to	ADP
fnp-5049	181	3	white	white	ADJ
fnp-5049	181	4	matter	matter	NOUN
fnp-5049	181	5	pathology	pathology	NOUN
fnp-5049	181	6	,	,	PUNCT
fnp-5049	181	7	lymphoid	lymphoid	ADJ
fnp-5049	181	8	structures	structure	NOUN
fnp-5049	181	9	in	in	ADP
fnp-5049	181	10	meninges	meninge	NOUN
fnp-5049	181	11	orchestrate	orchestrate	ADJ
fnp-5049	181	12	inflammation	inflammation	NOUN
fnp-5049	181	13	,	,	PUNCT
fnp-5049	181	14	demyelination	demyelination	NOUN
fnp-5049	181	15	,	,	PUNCT
fnp-5049	181	16	and	and	CCONJ
fnp-5049	181	17	neurodegeneration	neurodegeneration	NOUN
fnp-5049	181	18	in	in	ADP
fnp-5049	181	19	underlying	underlie	VERB
fnp-5049	181	20	cortical	cortical	ADJ
fnp-5049	181	21	tissue	tissue	NOUN
fnp-5049	181	22	[	[	X
fnp-5049	181	23	40	40	NUM
fnp-5049	181	24	]	]	PUNCT
fnp-5049	181	25	.	.	PUNCT
fnp-5049	182	1	steroids	steroid	NOUN
fnp-5049	182	2	can	can	AUX
fnp-5049	182	3	restore	restore	VERB
fnp-5049	182	4	the	the	DET
fnp-5049	182	5	blood	blood	NOUN
fnp-5049	182	6	brain	brain	NOUN
fnp-5049	182	7	-	-	PUNCT
fnp-5049	182	8	barrier	barrier	NOUN
fnp-5049	182	9	(	(	PUNCT
fnp-5049	182	10	bbb	bbb	NOUN
fnp-5049	182	11	)	)	PUNCT
fnp-5049	182	12	and	and	CCONJ
fnp-5049	182	13	reduce	reduce	VERB
fnp-5049	182	14	the	the	DET
fnp-5049	182	15	contrast	contrast	NOUN
fnp-5049	182	16	enhancement	enhancement	NOUN
fnp-5049	182	17	of	of	ADP
fnp-5049	182	18	ms	ms	NOUN
fnp-5049	182	19	lesions	lesion	NOUN
fnp-5049	182	20	.	.	PUNCT
fnp-5049	183	1	they	they	PRON
fnp-5049	183	2	downregulate	downregulate	VERB
fnp-5049	183	3	the	the	DET
fnp-5049	183	4	expression	expression	NOUN
fnp-5049	183	5	of	of	ADP
fnp-5049	183	6	adhesion	adhesion	NOUN
fnp-5049	183	7	molecules	molecule	NOUN
fnp-5049	183	8	reducing	reduce	VERB
fnp-5049	183	9	the	the	DET
fnp-5049	183	10	extravasation	extravasation	NOUN
fnp-5049	183	11	of	of	ADP
fnp-5049	183	12	immune	immune	ADJ
fnp-5049	183	13	cells	cell	NOUN
fnp-5049	183	14	into	into	ADP
fnp-5049	183	15	the	the	DET
fnp-5049	183	16	cns	cns	NOUN
fnp-5049	183	17	and	and	CCONJ
fnp-5049	183	18	improve	improve	VERB
fnp-5049	183	19	the	the	DET
fnp-5049	183	20	integrity	integrity	NOUN
fnp-5049	183	21	of	of	ADP
fnp-5049	183	22	the	the	DET
fnp-5049	183	23	tight	tight	ADJ
fnp-5049	183	24	junctions	junction	NOUN
fnp-5049	183	25	between	between	ADP
fnp-5049	183	26	endothelial	endothelial	ADJ
fnp-5049	183	27	cells	cell	NOUN
fnp-5049	183	28	[	[	X
fnp-5049	183	29	16	16	NUM
fnp-5049	183	30	,	,	PUNCT
fnp-5049	183	31	23	23	NUM
fnp-5049	183	32	,	,	PUNCT
fnp-5049	183	33	47	47	NUM
fnp-5049	183	34	]	]	PUNCT
fnp-5049	183	35	.	.	PUNCT
fnp-5049	184	1	however	however	ADV
fnp-5049	184	2	,	,	PUNCT
fnp-5049	184	3	this	this	DET
fnp-5049	184	4	effect	effect	NOUN
fnp-5049	184	5	is	be	AUX
fnp-5049	184	6	short	short	ADJ
fnp-5049	184	7	-	-	PUNCT
fnp-5049	184	8	term	term	NOUN
fnp-5049	184	9	,	,	PUNCT
fnp-5049	184	10	as	as	SCONJ
fnp-5049	184	11	new	new	ADJ
fnp-5049	184	12	contrast	contrast	NOUN
fnp-5049	184	13	enhancing	enhance	VERB
fnp-5049	184	14	lesions	lesion	NOUN
fnp-5049	184	15	can	can	AUX
fnp-5049	184	16	already	already	ADV
fnp-5049	184	17	be	be	AUX
fnp-5049	184	18	observed	observe	VERB
fnp-5049	184	19	4	4	NUM
fnp-5049	184	20	weeks	week	NOUN
fnp-5049	184	21	after	after	ADP
fnp-5049	184	22	treatment	treatment	NOUN
fnp-5049	184	23	[	[	X
fnp-5049	184	24	19	19	NUM
fnp-5049	184	25	,	,	PUNCT
fnp-5049	184	26	43	43	NUM
fnp-5049	184	27	]	]	PUNCT
fnp-5049	184	28	.	.	PUNCT
fnp-5049	185	1	in	in	ADP
fnp-5049	185	2	our	our	PRON
fnp-5049	185	3	cohort	cohort	NOUN
fnp-5049	185	4	of	of	ADP
fnp-5049	185	5	inactive	inactive	ADJ
fnp-5049	185	6	,	,	PUNCT
fnp-5049	185	7	progressive	progressive	ADJ
fnp-5049	185	8	ms	ms	ADJ
fnp-5049	185	9	patients	patient	NOUN
fnp-5049	185	10	,	,	PUNCT
fnp-5049	185	11	we	we	PRON
fnp-5049	185	12	found	find	VERB
fnp-5049	185	13	no	no	DET
fnp-5049	185	14	indication	indication	NOUN
fnp-5049	185	15	of	of	ADP
fnp-5049	185	16	a	a	DET
fnp-5049	185	17	bbb	bbb	NOUN
fnp-5049	185	18	impairment	impairment	NOUN
fnp-5049	185	19	,	,	PUNCT
fnp-5049	185	20	and	and	CCONJ
fnp-5049	185	21	treatment	treatment	NOUN
fnp-5049	185	22	effects	effect	NOUN
fnp-5049	185	23	were	be	AUX
fnp-5049	185	24	evident	evident	ADJ
fnp-5049	185	25	20	20	NUM
fnp-5049	185	26	weeks	week	NOUN
fnp-5049	185	27	after	after	ADP
fnp-5049	185	28	hdcs	hdcs	PROPN
fnp-5049	185	29	treatment	treatment	NOUN
fnp-5049	185	30	.	.	PUNCT
fnp-5049	186	1	we	we	PRON
fnp-5049	186	2	thus	thus	ADV
fnp-5049	186	3	assume	assume	VERB
fnp-5049	186	4	that	that	SCONJ
fnp-5049	186	5	the	the	DET
fnp-5049	186	6	reduced	reduce	VERB
fnp-5049	186	7	snfl	snfl	NOUN
fnp-5049	186	8	levels	level	NOUN
fnp-5049	186	9	can	can	AUX
fnp-5049	186	10	not	not	PART
fnp-5049	186	11	be	be	AUX
fnp-5049	186	12	explained	explain	VERB
fnp-5049	186	13	by	by	ADP
fnp-5049	186	14	steroid	steroid	NOUN
fnp-5049	186	15	effects	effect	NOUN
fnp-5049	186	16	on	on	ADP
fnp-5049	186	17	the	the	DET
fnp-5049	186	18	bbb	bbb	NOUN
fnp-5049	186	19	,	,	PUNCT
fnp-5049	186	20	but	but	CCONJ
fnp-5049	186	21	indeed	indeed	ADV
fnp-5049	186	22	indicate	indicate	VERB
fnp-5049	186	23	a	a	DET
fnp-5049	186	24	reduction	reduction	NOUN
fnp-5049	186	25	in	in	ADP
fnp-5049	186	26	cns	cns	NOUN
fnp-5049	186	27	axonal	axonal	ADJ
fnp-5049	186	28	damage	damage	NOUN
fnp-5049	186	29	.	.	PUNCT
fnp-5049	187	1	hdcs	hdcs	PROPN
fnp-5049	187	2	treatment	treatment	NOUN
fnp-5049	187	3	reduces	reduce	VERB
fnp-5049	187	4	the	the	DET
fnp-5049	187	5	level	level	NOUN
fnp-5049	187	6	of	of	ADP
fnp-5049	187	7	the	the	DET
fnp-5049	187	8	pro	pro	ADJ
fnp-5049	187	9	-	-	ADJ
fnp-5049	187	10	inflammatory	inflammatory	ADJ
fnp-5049	187	11	cytokines	cytokine	VERB
fnp-5049	187	12	ifn	ifn	PROPN
fnp-5049	187	13	-	-	PUNCT
fnp-5049	187	14	γ	γ	X
fnp-5049	187	15	,	,	PUNCT
fnp-5049	187	16	tnf	tnf	PROPN
fnp-5049	187	17	-	-	PUNCT
fnp-5049	187	18	α	α	PROPN
fnp-5049	187	19	and	and	CCONJ
fnp-5049	187	20	il-12	il-12	NOUN
fnp-5049	187	21	,	,	PUNCT
fnp-5049	187	22	and	and	CCONJ
fnp-5049	187	23	the	the	DET
fnp-5049	187	24	effect	effect	NOUN
fnp-5049	187	25	on	on	ADP
fnp-5049	187	26	tnf	tnf	PROPN
fnp-5049	187	27	-	-	PUNCT
fnp-5049	187	28	α	α	PROPN
fnp-5049	187	29	may	may	AUX
fnp-5049	187	30	last	last	VERB
fnp-5049	187	31	up	up	ADP
fnp-5049	187	32	to	to	ADP
fnp-5049	187	33	several	several	ADJ
fnp-5049	187	34	months	month	NOUN
fnp-5049	187	35	after	after	ADP
fnp-5049	187	36	the	the	DET
fnp-5049	187	37	therapy	therapy	NOUN
fnp-5049	187	38	[	[	X
fnp-5049	187	39	12	12	NUM
fnp-5049	187	40	,	,	PUNCT
fnp-5049	187	41	50	50	NUM
fnp-5049	187	42	]	]	PUNCT
fnp-5049	187	43	.	.	PUNCT
fnp-5049	188	1	the	the	DET
fnp-5049	188	2	anti	anti	ADJ
fnp-5049	188	3	-	-	ADJ
fnp-5049	188	4	inflammatory	inflammatory	ADJ
fnp-5049	188	5	cytokine	cytokine	NOUN
fnp-5049	188	6	il-10	il-10	PRON
fnp-5049	188	7	is	be	AUX
fnp-5049	188	8	also	also	ADV
fnp-5049	188	9	upregulated	upregulate	VERB
fnp-5049	188	10	[	[	X
fnp-5049	188	11	26	26	NUM
fnp-5049	188	12	]	]	PUNCT
fnp-5049	188	13	.	.	PUNCT
fnp-5049	189	1	steroid	steroid	NOUN
fnp-5049	189	2	treatment	treatment	NOUN
fnp-5049	189	3	induces	induce	VERB
fnp-5049	189	4	apoptosis	apoptosis	NOUN
fnp-5049	189	5	of	of	ADP
fnp-5049	189	6	t	t	PROPN
fnp-5049	189	7	and	and	CCONJ
fnp-5049	189	8	b	b	PROPN
fnp-5049	189	9	cells	cell	NOUN
fnp-5049	189	10	[	[	X
fnp-5049	189	11	37	37	NUM
fnp-5049	189	12	,	,	PUNCT
fnp-5049	189	13	49	49	NUM
fnp-5049	189	14	]	]	PUNCT
fnp-5049	189	15	and	and	CCONJ
fnp-5049	189	16	shifts	shift	NOUN
fnp-5049	189	17	the	the	DET
fnp-5049	189	18	population	population	NOUN
fnp-5049	189	19	of	of	ADP
fnp-5049	189	20	cd4	cd4	PROPN
fnp-5049	189	21	+	+	PROPN
fnp-5049	189	22	t	t	NOUN
fnp-5049	189	23	lymphocytes	lymphocyte	VERB
fnp-5049	189	24	to	to	ADP
fnp-5049	189	25	the	the	DET
fnp-5049	189	26	memory	memory	NOUN
fnp-5049	189	27	subpopulation	subpopulation	NOUN
fnp-5049	189	28	[	[	X
fnp-5049	189	29	42	42	NUM
fnp-5049	189	30	]	]	PUNCT
fnp-5049	189	31	.	.	PUNCT
fnp-5049	190	1	chronic	chronic	ADJ
fnp-5049	190	2	activation	activation	NOUN
fnp-5049	190	3	of	of	ADP
fnp-5049	190	4	microglial	microglial	ADJ
fnp-5049	190	5	cells	cell	NOUN
fnp-5049	190	6	and	and	CCONJ
fnp-5049	190	7	astrocytes	astrocyte	NOUN
fnp-5049	190	8	may	may	AUX
fnp-5049	190	9	also	also	ADV
fnp-5049	190	10	be	be	AUX
fnp-5049	190	11	influenced	influence	VERB
fnp-5049	190	12	by	by	ADP
fnp-5049	190	13	hdcs	hdc	NOUN
fnp-5049	190	14	:	:	PUNCT
fnp-5049	190	15	in	in	ADP
fnp-5049	190	16	an	an	DET
fnp-5049	190	17	animal	animal	NOUN
fnp-5049	190	18	model	model	NOUN
fnp-5049	190	19	of	of	ADP
fnp-5049	190	20	spinal	spinal	PROPN
fnp-5049	190	21	cord	cord	NOUN
fnp-5049	190	22	injury	injury	NOUN
fnp-5049	190	23	,	,	PUNCT
fnp-5049	190	24	steroids	steroid	NOUN
fnp-5049	190	25	could	could	AUX
fnp-5049	190	26	inhibit	inhibit	VERB
fnp-5049	190	27	microglial	microglial	ADJ
fnp-5049	190	28	activation	activation	NOUN
fnp-5049	190	29	and	and	CCONJ
fnp-5049	190	30	support	support	VERB
fnp-5049	190	31	the	the	DET
fnp-5049	190	32	normal	normal	ADJ
fnp-5049	190	33	function	function	NOUN
fnp-5049	190	34	of	of	ADP
fnp-5049	190	35	astrocytes	astrocyte	NOUN
fnp-5049	190	36	[	[	X
fnp-5049	190	37	57	57	NUM
fnp-5049	190	38	]	]	PUNCT
fnp-5049	190	39	.	.	PUNCT
fnp-5049	191	1	hdcs	hdcs	PROPN
fnp-5049	191	2	treatment	treatment	NOUN
fnp-5049	191	3	also	also	ADV
fnp-5049	191	4	inhibits	inhibit	VERB
fnp-5049	191	5	proliferation	proliferation	NOUN
fnp-5049	191	6	of	of	ADP
fnp-5049	191	7	microglia	microglia	ADJ
fnp-5049	191	8	/	/	SYM
fnp-5049	191	9	macrophages	macrophage	NOUN
fnp-5049	191	10	and	and	CCONJ
fnp-5049	191	11	reduces	reduce	VERB
fnp-5049	191	12	the	the	DET
fnp-5049	191	13	production	production	NOUN
fnp-5049	191	14	of	of	ADP
fnp-5049	191	15	nitric	nitric	ADJ
fnp-5049	191	16	oxide	oxide	NOUN
fnp-5049	191	17	,	,	PUNCT
fnp-5049	191	18	which	which	PRON
fnp-5049	191	19	is	be	AUX
fnp-5049	191	20	a	a	DET
fnp-5049	191	21	main	main	ADJ
fnp-5049	191	22	effector	effector	NOUN
fnp-5049	191	23	molecule	molecule	NOUN
fnp-5049	191	24	of	of	ADP
fnp-5049	191	25	these	these	DET
fnp-5049	191	26	cells	cell	NOUN
fnp-5049	192	1	[	[	X
fnp-5049	192	2	38	38	NUM
fnp-5049	192	3	,	,	PUNCT
fnp-5049	192	4	51	51	NUM
fnp-5049	192	5	]	]	PUNCT
fnp-5049	192	6	.	.	PUNCT
fnp-5049	193	1	in	in	ADP
fnp-5049	193	2	conclusion	conclusion	NOUN
fnp-5049	193	3	,	,	PUNCT
fnp-5049	193	4	hdcs	hdcs	X
fnp-5049	193	5	treatment	treatment	NOUN
fnp-5049	193	6	may	may	AUX
fnp-5049	193	7	reduce	reduce	VERB
fnp-5049	193	8	inflammatory	inflammatory	ADJ
fnp-5049	193	9	processes	process	NOUN
fnp-5049	193	10	that	that	PRON
fnp-5049	193	11	characterize	characterize	VERB
fnp-5049	193	12	progressive	progressive	ADJ
fnp-5049	193	13	ms	ms	NOUN
fnp-5049	193	14	pathology	pathology	NOUN
fnp-5049	193	15	.	.	PUNCT
fnp-5049	194	1	limitations	limitation	NOUN
fnp-5049	194	2	of	of	ADP
fnp-5049	194	3	the	the	DET
fnp-5049	194	4	study	study	NOUN
fnp-5049	194	5	although	although	SCONJ
fnp-5049	194	6	the	the	DET
fnp-5049	194	7	present	present	ADJ
fnp-5049	194	8	study	study	NOUN
fnp-5049	194	9	is	be	AUX
fnp-5049	194	10	limited	limit	VERB
fnp-5049	194	11	due	due	ADP
fnp-5049	194	12	to	to	ADP
fnp-5049	194	13	the	the	DET
fnp-5049	194	14	small	small	ADJ
fnp-5049	194	15	patient	patient	ADJ
fnp-5049	194	16	number	number	NOUN
fnp-5049	194	17	,	,	PUNCT
fnp-5049	194	18	we	we	PRON
fnp-5049	194	19	were	be	AUX
fnp-5049	194	20	able	able	ADJ
fnp-5049	194	21	to	to	PART
fnp-5049	194	22	show	show	VERB
fnp-5049	194	23	a	a	DET
fnp-5049	194	24	reduction	reduction	NOUN
fnp-5049	194	25	in	in	ADP
fnp-5049	194	26	snfl	snfl	NOUN
fnp-5049	194	27	levels	level	NOUN
fnp-5049	194	28	with	with	ADP
fnp-5049	194	29	long	long	ADJ
fnp-5049	194	30	-	-	PUNCT
fnp-5049	194	31	term	term	NOUN
fnp-5049	194	32	hdcs	hdc	NOUN
fnp-5049	194	33	treatment	treatment	NOUN
fnp-5049	194	34	.	.	PUNCT
fnp-5049	195	1	the	the	DET
fnp-5049	195	2	observational	observational	ADJ
fnp-5049	195	3	design	design	NOUN
fnp-5049	195	4	of	of	ADP
fnp-5049	195	5	the	the	DET
fnp-5049	195	6	study	study	NOUN
fnp-5049	195	7	implies	imply	VERB
fnp-5049	195	8	that	that	SCONJ
fnp-5049	195	9	patients	patient	NOUN
fnp-5049	195	10	were	be	AUX
fnp-5049	195	11	not	not	PART
fnp-5049	195	12	randomized	randomize	VERB
fnp-5049	195	13	to	to	ADP
fnp-5049	195	14	treatment	treatment	NOUN
fnp-5049	195	15	,	,	PUNCT
fnp-5049	195	16	and	and	CCONJ
fnp-5049	195	17	a	a	DET
fnp-5049	195	18	non	non	ADJ
fnp-5049	195	19	-	-	ADJ
fnp-5049	195	20	treated	treat	VERB
fnp-5049	195	21	control	control	NOUN
fnp-5049	195	22	cohort	cohort	NOUN
fnp-5049	195	23	could	could	AUX
fnp-5049	195	24	not	not	PART
fnp-5049	195	25	be	be	AUX
fnp-5049	195	26	studied	study	VERB
fnp-5049	195	27	.	.	PUNCT
fnp-5049	196	1	the	the	DET
fnp-5049	196	2	hdcs	hdcs	PROPN
fnp-5049	196	3	therapy	therapy	NOUN
fnp-5049	196	4	was	be	AUX
fnp-5049	196	5	also	also	ADV
fnp-5049	196	6	not	not	PART
fnp-5049	196	7	standardized	standardize	VERB
fnp-5049	196	8	,	,	PUNCT
fnp-5049	196	9	and	and	CCONJ
fnp-5049	196	10	dosage	dosage	NOUN
fnp-5049	196	11	of	of	ADP
fnp-5049	196	12	steroids	steroid	NOUN
fnp-5049	196	13	ranged	range	VERB
fnp-5049	196	14	from	from	ADP
fnp-5049	196	15	300	300	NUM
fnp-5049	196	16	-	-	SYM
fnp-5049	196	17	2250	2250	NUM
fnp-5049	196	18	mg	mg	NOUN
fnp-5049	196	19	per	per	ADP
fnp-5049	196	20	day	day	NOUN
fnp-5049	196	21	,	,	PUNCT
fnp-5049	196	22	depending	depend	VERB
fnp-5049	196	23	on	on	ADP
fnp-5049	196	24	the	the	DET
fnp-5049	196	25	individual	individual	ADJ
fnp-5049	196	26	clinical	clinical	ADJ
fnp-5049	196	27	situation	situation	NOUN
fnp-5049	196	28	and	and	CCONJ
fnp-5049	196	29	patient	patient	ADJ
fnp-5049	196	30	preferences	preference	NOUN
fnp-5049	196	31	.	.	PUNCT
fnp-5049	197	1	however	however	ADV
fnp-5049	197	2	,	,	PUNCT
fnp-5049	197	3	statistical	statistical	ADJ
fnp-5049	197	4	analyses	analysis	NOUN
fnp-5049	197	5	did	do	AUX
fnp-5049	197	6	not	not	PART
fnp-5049	197	7	show	show	VERB
fnp-5049	197	8	any	any	DET
fnp-5049	197	9	steroid	steroid	NOUN
fnp-5049	197	10	dosage	dosage	NOUN
fnp-5049	197	11	effect	effect	NOUN
fnp-5049	197	12	.	.	PUNCT
fnp-5049	198	1	patients	patient	NOUN
fnp-5049	198	2	included	include	VERB
fnp-5049	198	3	in	in	ADP
fnp-5049	198	4	the	the	DET
fnp-5049	198	5	study	study	NOUN
fnp-5049	198	6	did	do	AUX
fnp-5049	198	7	not	not	PART
fnp-5049	198	8	experience	experience	VERB
fnp-5049	198	9	any	any	DET
fnp-5049	198	10	relapse	relapse	NOUN
fnp-5049	198	11	activity	activity	NOUN
fnp-5049	198	12	3	3	NUM
fnp-5049	198	13	months	month	NOUN
fnp-5049	198	14	prior	prior	ADV
fnp-5049	198	15	to	to	ADP
fnp-5049	198	16	the	the	DET
fnp-5049	198	17	study	study	NOUN
fnp-5049	198	18	.	.	PUNCT
fnp-5049	199	1	we	we	PRON
fnp-5049	199	2	can	can	AUX
fnp-5049	199	3	thus	thus	ADV
fnp-5049	199	4	assume	assume	VERB
fnp-5049	199	5	that	that	SCONJ
fnp-5049	199	6	the	the	DET
fnp-5049	199	7	observed	observed	ADJ
fnp-5049	199	8	reduction	reduction	NOUN
fnp-5049	199	9	in	in	ADP
fnp-5049	199	10	snfl	snfl	NOUN
fnp-5049	199	11	was	be	AUX
fnp-5049	199	12	indeed	indeed	ADV
fnp-5049	199	13	associated	associate	VERB
fnp-5049	199	14	with	with	ADP
fnp-5049	199	15	hdcs	hdc	NOUN
fnp-5049	199	16	therapy	therapy	NOUN
fnp-5049	199	17	and	and	CCONJ
fnp-5049	199	18	was	be	AUX
fnp-5049	199	19	not	not	PART
fnp-5049	199	20	a	a	DET
fnp-5049	199	21	consequence	consequence	NOUN
fnp-5049	199	22	of	of	ADP
fnp-5049	199	23	a	a	DET
fnp-5049	199	24	typical	typical	ADJ
fnp-5049	199	25	snfl	snfl	NOUN
fnp-5049	199	26	reduction	reduction	NOUN
fnp-5049	199	27	observed	observe	VERB
fnp-5049	199	28	within	within	ADP
fnp-5049	199	29	the	the	DET
fnp-5049	199	30	months	month	NOUN
fnp-5049	199	31	after	after	SCONJ
fnp-5049	199	32	a	a	DET
fnp-5049	199	33	relapse	relapse	NOUN
fnp-5049	199	34	had	have	AUX
fnp-5049	199	35	occurred	occur	VERB
fnp-5049	199	36	.	.	PUNCT
fnp-5049	200	1	edss	edss	ADV
fnp-5049	200	2	score	score	NOUN
fnp-5049	200	3	and	and	CCONJ
fnp-5049	200	4	clinical	clinical	ADJ
fnp-5049	200	5	disease	disease	NOUN
fnp-5049	200	6	activity	activity	NOUN
fnp-5049	200	7	were	be	AUX
fnp-5049	200	8	outcome	outcome	NOUN
fnp-5049	200	9	parameters	parameter	NOUN
fnp-5049	200	10	in	in	ADP
fnp-5049	200	11	the	the	DET
fnp-5049	200	12	study	study	NOUN
fnp-5049	200	13	.	.	PUNCT
fnp-5049	201	1	due	due	ADP
fnp-5049	201	2	to	to	ADP
fnp-5049	201	3	the	the	DET
fnp-5049	201	4	absence	absence	NOUN
fnp-5049	201	5	of	of	ADP
fnp-5049	201	6	clinical	clinical	ADJ
fnp-5049	201	7	symptoms	symptom	NOUN
fnp-5049	201	8	,	,	PUNCT
fnp-5049	201	9	mris	mris	PROPN
fnp-5049	201	10	were	be	AUX
fnp-5049	201	11	not	not	PART
fnp-5049	201	12	indicated	indicate	VERB
fnp-5049	201	13	for	for	ADP
fnp-5049	201	14	routine	routine	ADJ
fnp-5049	201	15	hospital	hospital	NOUN
fnp-5049	201	16	evaluation	evaluation	NOUN
fnp-5049	201	17	and	and	CCONJ
fnp-5049	201	18	thus	thus	ADV
fnp-5049	201	19	not	not	PART
fnp-5049	201	20	available	available	ADJ
fnp-5049	201	21	for	for	ADP
fnp-5049	201	22	analysis	analysis	NOUN
fnp-5049	201	23	.	.	PUNCT
fnp-5049	202	1	hence	hence	ADV
fnp-5049	202	2	,	,	PUNCT
fnp-5049	202	3	“	"	PUNCT
fnp-5049	202	4	silent	silent	ADJ
fnp-5049	202	5	”	"	PUNCT
fnp-5049	202	6	mri	mri	NOUN
fnp-5049	202	7	activity	activity	NOUN
fnp-5049	202	8	can	can	AUX
fnp-5049	202	9	not	not	PART
fnp-5049	202	10	be	be	AUX
fnp-5049	202	11	completely	completely	ADV
fnp-5049	202	12	excluded	exclude	VERB
fnp-5049	202	13	.	.	PUNCT
fnp-5049	203	1	although	although	SCONJ
fnp-5049	203	2	we	we	PRON
fnp-5049	203	3	did	do	AUX
fnp-5049	203	4	not	not	PART
fnp-5049	203	5	document	document	VERB
fnp-5049	203	6	steroid	steroid	NOUN
fnp-5049	203	7	side	side	NOUN
fnp-5049	203	8	effects	effect	NOUN
fnp-5049	203	9	in	in	ADP
fnp-5049	203	10	a	a	DET
fnp-5049	203	11	standardized	standardized	ADJ
fnp-5049	203	12	manner	manner	NOUN
fnp-5049	203	13	,	,	PUNCT
fnp-5049	203	14	no	no	DET
fnp-5049	203	15	severe	severe	ADJ
fnp-5049	203	16	side	side	NOUN
fnp-5049	203	17	effects	effect	NOUN
fnp-5049	203	18	were	be	AUX
fnp-5049	203	19	observed	observe	VERB
fnp-5049	203	20	during	during	ADP
fnp-5049	203	21	the	the	DET
fnp-5049	203	22	observational	observational	ADJ
fnp-5049	203	23	period	period	NOUN
fnp-5049	203	24	.	.	PUNCT
fnp-5049	204	1	conclusion	conclusion	NOUN
fnp-5049	204	2	in	in	ADP
fnp-5049	204	3	conclusion	conclusion	NOUN
fnp-5049	204	4	,	,	PUNCT
fnp-5049	204	5	we	we	PRON
fnp-5049	204	6	have	have	AUX
fnp-5049	204	7	shown	show	VERB
fnp-5049	204	8	that	that	DET
fnp-5049	204	9	treatment	treatment	NOUN
fnp-5049	204	10	with	with	ADP
fnp-5049	204	11	repeated	repeat	VERB
fnp-5049	204	12	cycles	cycle	NOUN
fnp-5049	204	13	of	of	ADP
fnp-5049	204	14	hdcs	hdc	NOUN
fnp-5049	204	15	reduces	reduce	VERB
fnp-5049	204	16	the	the	DET
fnp-5049	204	17	level	level	NOUN
fnp-5049	204	18	of	of	ADP
fnp-5049	204	19	snfl	snfl	NOUN
fnp-5049	204	20	and	and	CCONJ
fnp-5049	204	21	thus	thus	ADV
fnp-5049	204	22	suggests	suggest	VERB
fnp-5049	204	23	a	a	DET
fnp-5049	204	24	reduction	reduction	NOUN
fnp-5049	204	25	of	of	ADP
fnp-5049	204	26	ongoing	ongoing	ADJ
fnp-5049	204	27	neuroaxonal	neuroaxonal	ADJ
fnp-5049	204	28	damage	damage	NOUN
fnp-5049	204	29	in	in	ADP
fnp-5049	204	30	a	a	DET
fnp-5049	204	31	subgroup	subgroup	NOUN
fnp-5049	204	32	of	of	ADP
fnp-5049	204	33	patients	patient	NOUN
fnp-5049	204	34	with	with	ADP
fnp-5049	204	35	progressive	progressive	ADJ
fnp-5049	204	36	ms	ms	PROPN
fnp-5049	204	37	.	.	PROPN
fnp-5049	205	1	although	although	SCONJ
fnp-5049	205	2	larger	large	ADJ
fnp-5049	205	3	studies	study	NOUN
fnp-5049	205	4	are	be	AUX
fnp-5049	205	5	needed	need	VERB
fnp-5049	205	6	to	to	PART
fnp-5049	205	7	confirm	confirm	VERB
fnp-5049	205	8	these	these	DET
fnp-5049	205	9	findings	finding	NOUN
fnp-5049	205	10	,	,	PUNCT
fnp-5049	205	11	long	long	ADJ
fnp-5049	205	12	-	-	PUNCT
fnp-5049	205	13	term	term	NOUN
fnp-5049	205	14	treatment	treatment	NOUN
fnp-5049	205	15	with	with	ADP
fnp-5049	205	16	hdcs	hdc	NOUN
fnp-5049	205	17	should	should	AUX
fnp-5049	205	18	be	be	AUX
fnp-5049	205	19	considered	consider	VERB
fnp-5049	205	20	for	for	ADP
fnp-5049	205	21	the	the	DET
fnp-5049	205	22	treatment	treatment	NOUN
fnp-5049	205	23	of	of	ADP
fnp-5049	205	24	progressive	progressive	ADJ
fnp-5049	205	25	ms	ms	ADJ
fnp-5049	205	26	patients	patient	NOUN
fnp-5049	205	27	.	.	PUNCT
fnp-5049	206	1	references	reference	NOUN
fnp-5049	206	2	1	1	NUM
fnp-5049	206	3	.	.	PUNCT
fnp-5049	206	4	aamodt	aamodt	PROPN
fnp-5049	206	5	ww	ww	PROPN
fnp-5049	206	6	,	,	PUNCT
fnp-5049	206	7	waligorska	waligorska	PROPN
fnp-5049	206	8	t	t	PROPN
fnp-5049	206	9	,	,	PUNCT
fnp-5049	206	10	shen	shen	PROPN
fnp-5049	206	11	j	j	PROPN
fnp-5049	206	12	,	,	PUNCT
fnp-5049	206	13	tropea	tropea	PROPN
fnp-5049	206	14	tf	tf	PROPN
fnp-5049	206	15	,	,	PUNCT
fnp-5049	206	16	siderowf	siderowf	NOUN
fnp-5049	206	17	a	a	PRON
fnp-5049	206	18	,	,	PUNCT
fnp-5049	206	19	weintraub	weintraub	PROPN
fnp-5049	206	20	d	d	PROPN
fnp-5049	206	21	,	,	PUNCT
fnp-5049	206	22	grossman	grossman	PROPN
fnp-5049	206	23	m	m	PROPN
fnp-5049	206	24	,	,	PUNCT
fnp-5049	206	25	irwin	irwin	PROPN
fnp-5049	206	26	d	d	PROPN
fnp-5049	206	27	,	,	PUNCT
fnp-5049	206	28	wolk	wolk	NOUN
fnp-5049	206	29	da	da	PROPN
fnp-5049	206	30	,	,	PUNCT
fnp-5049	206	31	xie	xie	PROPN
fnp-5049	206	32	sx	sx	PROPN
fnp-5049	206	33	et	et	PROPN
fnp-5049	206	34	al	al	PROPN
fnp-5049	206	35	(	(	PUNCT
fnp-5049	206	36	2021	2021	NUM
fnp-5049	206	37	)	)	PUNCT
fnp-5049	206	38	neurofilament	neurofilament	ADJ
fnp-5049	206	39	light	light	NOUN
fnp-5049	206	40	chain	chain	NOUN
fnp-5049	206	41	as	as	ADP
fnp-5049	206	42	a	a	DET
fnp-5049	206	43	biomarker	biomarker	NOUN
fnp-5049	206	44	for	for	ADP
fnp-5049	206	45	cognitive	cognitive	ADJ
fnp-5049	206	46	decline	decline	NOUN
fnp-5049	206	47	in	in	ADP
fnp-5049	206	48	parkinson	parkinson	NOUN
fnp-5049	206	49	disease	disease	NOUN
fnp-5049	206	50	.	.	PUNCT
fnp-5049	207	1	movement	movement	NOUN
fnp-5049	207	2	disorders	disorder	NOUN
fnp-5049	207	3	:	:	PUNCT
fnp-5049	207	4	official	official	ADJ
fnp-5049	207	5	journal	journal	NOUN
fnp-5049	207	6	of	of	ADP
fnp-5049	207	7	the	the	DET
fnp-5049	207	8	movement	movement	NOUN
fnp-5049	207	9	disorder	disorder	NOUN
fnp-5049	207	10	society	society	NOUN
fnp-5049	207	11	36	36	NUM
fnp-5049	207	12	:	:	PUNCT
fnp-5049	207	13	2945	2945	NUM
fnp-5049	207	14	-	-	SYM
fnp-5049	207	15	2950	2950	NUM
fnp-5049	207	16	.	.	PUNCT
fnp-5049	208	1	https://doi.org/10.1002/mds.28779	https://doi.org/10.1002/mds.28779	PROPN
fnp-5049	208	2	2	2	PROPN
fnp-5049	208	3	.	.	PUNCT
fnp-5049	208	4	absinta	absinta	PROPN
fnp-5049	208	5	m	m	PROPN
fnp-5049	208	6	,	,	PUNCT
fnp-5049	208	7	maric	maric	PROPN
fnp-5049	208	8	d	d	PROPN
fnp-5049	208	9	,	,	PUNCT
fnp-5049	208	10	gharagozloo	gharagozloo	PROPN
fnp-5049	208	11	m	m	PROPN
fnp-5049	208	12	,	,	PUNCT
fnp-5049	208	13	garton	garton	PROPN
fnp-5049	208	14	t	t	PROPN
fnp-5049	208	15	,	,	PUNCT
fnp-5049	208	16	smith	smith	PROPN
fnp-5049	208	17	md	md	PROPN
fnp-5049	208	18	,	,	PUNCT
fnp-5049	208	19	jin	jin	PROPN
fnp-5049	208	20	j	j	PROPN
fnp-5049	208	21	,	,	PUNCT
fnp-5049	208	22	fitzgerald	fitzgerald	PROPN
fnp-5049	208	23	kc	kc	PROPN
fnp-5049	208	24	,	,	PUNCT
fnp-5049	208	25	song	song	NOUN
fnp-5049	208	26	a	a	PRON
fnp-5049	208	27	,	,	PUNCT
fnp-5049	208	28	liu	liu	PROPN
fnp-5049	208	29	p	p	PROPN
fnp-5049	208	30	,	,	PUNCT
fnp-5049	208	31	lin	lin	PROPN
fnp-5049	208	32	jp	jp	INTJ
fnp-5049	208	33	et	et	PROPN
fnp-5049	208	34	al	al	PROPN
fnp-5049	208	35	(	(	PUNCT
fnp-5049	208	36	2021	2021	NUM
fnp-5049	208	37	)	)	PUNCT
fnp-5049	208	38	a	a	DET
fnp-5049	208	39	lymphocyte	lymphocyte	ADJ
fnp-5049	208	40	-	-	PUNCT
fnp-5049	208	41	microglia	microglia	ADJ
fnp-5049	208	42	-	-	PUNCT
fnp-5049	208	43	astrocyte	astrocyte	NOUN
fnp-5049	208	44	axis	axis	NOUN
fnp-5049	208	45	in	in	ADP
fnp-5049	208	46	chronic	chronic	ADJ
fnp-5049	208	47	active	active	ADJ
fnp-5049	208	48	multiple	multiple	ADJ
fnp-5049	208	49	sclerosis	sclerosis	NOUN
fnp-5049	208	50	.	.	PUNCT
fnp-5049	208	51	nature	nature	NOUN
fnp-5049	208	52	597	597	NUM
fnp-5049	208	53	:	:	PUNCT
fnp-5049	208	54	709	709	NUM
fnp-5049	208	55	-	-	SYM
fnp-5049	208	56	714	714	NUM
fnp-5049	208	57	.	.	PUNCT
fnp-5049	209	1	https://doi.org/10.1038/s41586-021-03892-7	https://doi.org/10.1038/s41586-021-03892-7	NUM
fnp-5049	209	2	3	3	NUM
fnp-5049	209	3	.	.	PUNCT
fnp-5049	209	4	bar	bar	NOUN
fnp-5049	209	5	-	-	PUNCT
fnp-5049	209	6	or	or	CCONJ
fnp-5049	209	7	a	a	PRON
fnp-5049	209	8	,	,	PUNCT
fnp-5049	209	9	thanei	thanei	VERB
fnp-5049	209	10	g	g	NOUN
fnp-5049	209	11	,	,	PUNCT
fnp-5049	209	12	harp	harp	PROPN
fnp-5049	209	13	c	c	NOUN
fnp-5049	209	14	,	,	PUNCT
fnp-5049	209	15	cross	cross	VERB
fnp-5049	209	16	a	a	PRON
fnp-5049	209	17	,	,	PUNCT
fnp-5049	209	18	hauser	hauser	PROPN
fnp-5049	209	19	s	s	PROPN
fnp-5049	209	20	,	,	PUNCT
fnp-5049	209	21	kuhle	kuhle	PROPN
fnp-5049	209	22	j	j	PROPN
fnp-5049	209	23	,	,	PUNCT
fnp-5049	209	24	leppert	leppert	PROPN
fnp-5049	209	25	d	d	PROPN
fnp-5049	209	26	,	,	PUNCT
fnp-5049	209	27	oksenberg	oksenberg	PROPN
fnp-5049	209	28	j	j	PROPN
fnp-5049	209	29	,	,	PUNCT
fnp-5049	209	30	model	model	NOUN
fnp-5049	209	31	f	f	PROPN
fnp-5049	209	32	,	,	PUNCT
fnp-5049	209	33	fiore	fiore	NOUN
fnp-5049	209	34	djeol	djeol	NOUN
fnp-5049	209	35	(	(	PUNCT
fnp-5049	209	36	2019	2019	NUM
fnp-5049	209	37	)	)	PUNCT
fnp-5049	209	38	blood	blood	NOUN
fnp-5049	209	39	neurofilament	neurofilament	VERB
fnp-5049	209	40	light	light	NOUN
fnp-5049	209	41	levels	level	NOUN
fnp-5049	209	42	are	be	AUX
fnp-5049	209	43	lowered	lower	VERB
fnp-5049	209	44	to	to	ADP
fnp-5049	209	45	a	a	DET
fnp-5049	209	46	healthy	healthy	ADJ
fnp-5049	209	47	donor	donor	NOUN
fnp-5049	209	48	range	range	NOUN
fnp-5049	209	49	in	in	ADP
fnp-5049	209	50	patients	patient	NOUN
fnp-5049	209	51	with	with	ADP
fnp-5049	209	52	rms	rm	NOUN
fnp-5049	209	53	and	and	CCONJ
fnp-5049	209	54	ppms	ppm	NOUN
fnp-5049	209	55	following	follow	VERB
fnp-5049	209	56	ocrelizumab	ocrelizumab	ADJ
fnp-5049	209	57	treatment	treatment	NOUN
fnp-5049	209	58	.	.	PUNCT
fnp-5049	210	1	multiple	multiple	ADJ
fnp-5049	210	2	sclerosis	sclerosis	NOUN
fnp-5049	210	3	journal	journal	PROPN
fnp-5049	210	4	25	25	NUM
fnp-5049	210	5	:	:	SYM
fnp-5049	210	6	52	52	NUM
fnp-5049	210	7	.	.	PUNCT
fnp-5049	210	8	https://doi.org/10.1177/1352458519868070	https://doi.org/10.1177/1352458519868070	PROPN
fnp-5049	210	9	4	4	NUM
fnp-5049	210	10	.	.	PROPN
fnp-5049	210	11	beck	beck	PROPN
fnp-5049	210	12	rw	rw	PROPN
fnp-5049	210	13	,	,	PUNCT
fnp-5049	210	14	cleary	cleary	PROPN
fnp-5049	210	15	pa	pa	PROPN
fnp-5049	210	16	,	,	PUNCT
fnp-5049	210	17	trobe	trobe	PROPN
fnp-5049	210	18	jd	jd	PROPN
fnp-5049	210	19	,	,	PUNCT
fnp-5049	210	20	kaufman	kaufman	PROPN
fnp-5049	210	21	di	di	PROPN
fnp-5049	210	22	,	,	PUNCT
fnp-5049	210	23	kupersmith	kupersmith	PROPN
fnp-5049	210	24	mj	mj	PROPN
fnp-5049	210	25	,	,	PUNCT
fnp-5049	210	26	paty	paty	PROPN
fnp-5049	210	27	dw	dw	PROPN
fnp-5049	210	28	,	,	PUNCT
fnp-5049	210	29	brown	brown	ADJ
fnp-5049	210	30	ch	ch	NOUN
fnp-5049	210	31	(	(	PUNCT
fnp-5049	210	32	1993	1993	NUM
fnp-5049	210	33	)	)	PUNCT
fnp-5049	210	34	the	the	DET
fnp-5049	210	35	effect	effect	NOUN
fnp-5049	210	36	of	of	ADP
fnp-5049	210	37	corticosteroids	corticosteroid	NOUN
fnp-5049	210	38	for	for	ADP
fnp-5049	210	39	acute	acute	ADJ
fnp-5049	210	40	optic	optic	ADJ
fnp-5049	210	41	neuritis	neuritis	NOUN
fnp-5049	210	42	on	on	ADP
fnp-5049	210	43	the	the	DET
fnp-5049	210	44	subsequent	subsequent	ADJ
fnp-5049	210	45	development	development	NOUN
fnp-5049	210	46	of	of	ADP
fnp-5049	210	47	multiple	multiple	ADJ
fnp-5049	210	48	sclerosis	sclerosis	NOUN
fnp-5049	210	49	.	.	PUNCT
fnp-5049	211	1	the	the	DET
fnp-5049	211	2	optic	optic	ADJ
fnp-5049	211	3	neuritis	neuritis	NOUN
fnp-5049	211	4	study	study	NOUN
fnp-5049	211	5	group	group	NOUN
fnp-5049	211	6	.	.	PUNCT
fnp-5049	212	1	n	n	PROPN
fnp-5049	212	2	engl	engl	PROPN
fnp-5049	212	3	j	j	PROPN
fnp-5049	212	4	med	med	PROPN
fnp-5049	212	5	329	329	NUM
fnp-5049	212	6	:	:	PUNCT
fnp-5049	212	7	1764	1764	NUM
fnp-5049	212	8	-	-	SYM
fnp-5049	212	9	1769	1769	NUM
fnp-5049	212	10	.	.	PUNCT
fnp-5049	213	1	https://doi.org/10.1056/nejm199312093292403	https://doi.org/10.1056/nejm199312093292403	NOUN
fnp-5049	213	2	5	5	NUM
fnp-5049	213	3	.	.	PUNCT
fnp-5049	213	4	bergamaschi	bergamaschi	PROPN
fnp-5049	213	5	r	r	PROPN
fnp-5049	213	6	,	,	PUNCT
fnp-5049	213	7	versino	versino	NOUN
fnp-5049	213	8	m	m	PROPN
fnp-5049	213	9	,	,	PUNCT
fnp-5049	213	10	raiola	raiola	PROPN
fnp-5049	213	11	e	e	NOUN
fnp-5049	213	12	,	,	PUNCT
fnp-5049	213	13	citterio	citterio	NOUN
fnp-5049	213	14	a	a	NOUN
fnp-5049	213	15	,	,	PUNCT
fnp-5049	213	16	cosi	cosi	PROPN
fnp-5049	213	17	v	v	X
fnp-5049	213	18	(	(	PUNCT
fnp-5049	213	19	1993	1993	NUM
fnp-5049	213	20	)	)	PUNCT
fnp-5049	213	21	high	high	ADJ
fnp-5049	213	22	-	-	PUNCT
fnp-5049	213	23	dose	dose	NOUN
fnp-5049	213	24	methylprednisolone	methylprednisolone	NOUN
fnp-5049	213	25	infusions	infusion	NOUN
fnp-5049	213	26	in	in	ADP
fnp-5049	213	27	relapsing	relapse	VERB
fnp-5049	213	28	and	and	CCONJ
fnp-5049	213	29	in	in	ADP
fnp-5049	213	30	chronic	chronic	ADJ
fnp-5049	213	31	progressive	progressive	ADJ
fnp-5049	213	32	multiple	multiple	ADJ
fnp-5049	213	33	sclerosis	sclerosis	NOUN
fnp-5049	213	34	patients	patient	NOUN
fnp-5049	213	35	.	.	PUNCT
fnp-5049	214	1	one	one	NUM
fnp-5049	214	2	year	year	NOUN
fnp-5049	214	3	follow	follow	NOUN
fnp-5049	214	4	-	-	PUNCT
fnp-5049	214	5	up	up	NOUN
fnp-5049	214	6	.	.	PUNCT
fnp-5049	215	1	acta	acta	PROPN
fnp-5049	215	2	neurologica	neurologica	PROPN
fnp-5049	215	3	15	15	NUM
fnp-5049	215	4	:	:	PUNCT
fnp-5049	215	5	33	33	NUM
fnp-5049	215	6	-	-	SYM
fnp-5049	215	7	43	43	NUM
fnp-5049	215	8	6	6	NUM
fnp-5049	215	9	.	.	PUNCT
fnp-5049	216	1	berkovich	berkovich	PROPN
fnp-5049	216	2	rr	rr	PROPN
fnp-5049	216	3	(	(	PUNCT
fnp-5049	216	4	2016	2016	NUM
fnp-5049	216	5	)	)	PUNCT
fnp-5049	216	6	acute	acute	ADJ
fnp-5049	216	7	multiple	multiple	ADJ
fnp-5049	216	8	sclerosis	sclerosis	NOUN
fnp-5049	216	9	relapse	relapse	NOUN
fnp-5049	216	10	.	.	PUNCT
fnp-5049	217	1	continuum	continuum	PROPN
fnp-5049	217	2	(	(	PUNCT
fnp-5049	217	3	minneapolis	minneapolis	PROPN
fnp-5049	217	4	,	,	PUNCT
fnp-5049	217	5	minn	minn	PROPN
fnp-5049	217	6	)	)	PUNCT
fnp-5049	217	7	22	22	NUM
fnp-5049	217	8	:	:	PUNCT
fnp-5049	217	9	799	799	NUM
fnp-5049	217	10	-	-	SYM
fnp-5049	217	11	814	814	NUM
fnp-5049	217	12	.	.	PUNCT
fnp-5049	218	1	https://doi.org/10.1212/con.0000000000000330	https://doi.org/10.1212/con.0000000000000330	PROPN
fnp-5049	218	2	7	7	NUM
fnp-5049	218	3	.	.	PUNCT
fnp-5049	218	4	bosch	bosch	PROPN
fnp-5049	218	5	van	van	PROPN
fnp-5049	218	6	den	den	PROPN
fnp-5049	218	7	a	a	PRON
fnp-5049	218	8	,	,	PUNCT
fnp-5049	218	9	fransen	fransen	ADJ
fnp-5049	218	10	n	n	CCONJ
fnp-5049	218	11	,	,	PUNCT
fnp-5049	218	12	mason	mason	PROPN
fnp-5049	218	13	m	m	PROPN
fnp-5049	218	14	,	,	PUNCT
fnp-5049	218	15	rozemuller	rozemuller	PROPN
fnp-5049	218	16	aj	aj	PROPN
fnp-5049	218	17	,	,	PUNCT
fnp-5049	218	18	teunissen	teunissen	NOUN
fnp-5049	218	19	c	c	PROPN
fnp-5049	218	20	,	,	PUNCT
fnp-5049	218	21	smolders	smolder	VERB
fnp-5049	218	22	j	j	PROPN
fnp-5049	218	23	,	,	PUNCT
fnp-5049	218	24	huitinga	huitinga	VERB
fnp-5049	218	25	i	i	PRON
fnp-5049	218	26	(	(	PUNCT
fnp-5049	218	27	2022	2022	NUM
fnp-5049	218	28	)	)	PUNCT
fnp-5049	218	29	neurofilament	neurofilament	ADJ
fnp-5049	218	30	light	light	ADJ
fnp-5049	218	31	chain	chain	NOUN
fnp-5049	218	32	levels	level	NOUN
fnp-5049	218	33	in	in	ADP
fnp-5049	218	34	multiple	multiple	ADJ
fnp-5049	218	35	sclerosis	sclerosis	NOUN
fnp-5049	218	36	correlate	correlate	VERB
fnp-5049	218	37	with	with	ADP
fnp-5049	218	38	lesions	lesion	NOUN
fnp-5049	218	39	containing	contain	VERB
fnp-5049	218	40	foamy	foamy	ADJ
fnp-5049	218	41	macrophages	macrophage	NOUN
fnp-5049	218	42	and	and	CCONJ
fnp-5049	218	43	with	with	ADP
fnp-5049	218	44	acute	acute	ADJ
fnp-5049	218	45	axonal	axonal	ADJ
fnp-5049	218	46	damage	damage	NOUN
fnp-5049	218	47	.	.	PUNCT
fnp-5049	219	1	neurol	neurol	NOUN
fnp-5049	219	2	-	-	PUNCT
fnp-5049	219	3	neuroimmunol	neuroimmunol	PROPN
fnp-5049	219	4	neuroinflammation	neuroinflammation	NOUN
fnp-5049	219	5	9	9	NUM
fnp-5049	219	6	.	.	PUNCT
fnp-5049	219	7	https://doi.org/10.1212/nxi.0000000000001154	https://doi.org/10.1212/nxi.0000000000001154	PROPN
fnp-5049	219	8	8	8	NUM
fnp-5049	219	9	.	.	PUNCT
fnp-5049	220	1	bridel	bridel	PROPN
fnp-5049	220	2	c	c	PROPN
fnp-5049	220	3	,	,	PUNCT
fnp-5049	220	4	verberk	verberk	NOUN
fnp-5049	220	5	imw	imw	NOUN
fnp-5049	220	6	,	,	PUNCT
fnp-5049	220	7	heijst	heijst	ADJ
fnp-5049	220	8	jja	jja	PROPN
fnp-5049	220	9	,	,	PUNCT
fnp-5049	220	10	killestein	killestein	PROPN
fnp-5049	220	11	j	j	PROPN
fnp-5049	220	12	,	,	PUNCT
fnp-5049	220	13	teunissen	teunissen	PROPN
fnp-5049	220	14	ce	ce	PROPN
fnp-5049	220	15	(	(	PUNCT
fnp-5049	220	16	2021	2021	NUM
fnp-5049	220	17	)	)	PUNCT
fnp-5049	220	18	variations	variation	NOUN
fnp-5049	220	19	in	in	ADP
fnp-5049	220	20	consecutive	consecutive	ADJ
fnp-5049	220	21	serum	serum	NOUN
fnp-5049	220	22	neurofilament	neurofilament	ADJ
fnp-5049	220	23	light	light	ADJ
fnp-5049	220	24	levels	level	NOUN
fnp-5049	220	25	in	in	ADP
fnp-5049	220	26	healthy	healthy	ADJ
fnp-5049	220	27	controls	control	NOUN
fnp-5049	220	28	and	and	CCONJ
fnp-5049	220	29	multiple	multiple	ADJ
fnp-5049	220	30	sclerosis	sclerosis	NOUN
fnp-5049	220	31	patients	patient	NOUN
fnp-5049	220	32	.	.	PUNCT
fnp-5049	221	1	mult	mult	PROPN
fnp-5049	221	2	scler	scler	PROPN
fnp-5049	221	3	relat	relat	PROPN
fnp-5049	221	4	disord	disord	PROPN
fnp-5049	221	5	47	47	NUM
fnp-5049	221	6	:	:	SYM
fnp-5049	221	7	102666	102666	NUM
fnp-5049	221	8	.	.	PUNCT
fnp-5049	222	1	https://doi.org/10.1016/j.msard.2020.102666	https://doi.org/10.1016/j.msard.2020.102666	ADJ
fnp-5049	222	2	9	9	NUM
fnp-5049	222	3	.	.	PUNCT
fnp-5049	223	1	buttgereit	buttgereit	PROPN
fnp-5049	223	2	f	f	PROPN
fnp-5049	223	3	,	,	PUNCT
fnp-5049	223	4	wehling	wehle	VERB
fnp-5049	223	5	m	m	PROPN
fnp-5049	223	6	,	,	PUNCT
fnp-5049	223	7	burmester	burmester	NOUN
fnp-5049	223	8	gr	gr	PROPN
fnp-5049	223	9	(	(	PUNCT
fnp-5049	223	10	1998	1998	NUM
fnp-5049	223	11	)	)	PUNCT
fnp-5049	223	12	a	a	DET
fnp-5049	223	13	new	new	ADJ
fnp-5049	223	14	hypothesis	hypothesis	NOUN
fnp-5049	223	15	of	of	ADP
fnp-5049	223	16	modular	modular	ADJ
fnp-5049	223	17	glucocorticoid	glucocorticoid	ADJ
fnp-5049	223	18	actions	action	NOUN
fnp-5049	223	19	:	:	PUNCT
fnp-5049	223	20	steroid	steroid	NOUN
fnp-5049	223	21	treatment	treatment	NOUN
fnp-5049	223	22	of	of	ADP
fnp-5049	223	23	rheumatic	rheumatic	ADJ
fnp-5049	223	24	diseases	disease	NOUN
fnp-5049	223	25	revisited	revisit	VERB
fnp-5049	223	26	.	.	PUNCT
fnp-5049	224	1	arthritis	arthritis	NOUN
fnp-5049	224	2	rheum	rheum	NOUN
fnp-5049	224	3	41	41	NUM
fnp-5049	224	4	:	:	PUNCT
fnp-5049	224	5	761	761	NUM
fnp-5049	224	6	-	-	SYM
fnp-5049	224	7	767	767	NUM
fnp-5049	224	8	.	.	PUNCT
fnp-5049	225	1	https://doi.org/10.1002/1529-0131(199805)41:53.0.co;2-m	https://doi.org/10.1002/1529-0131(199805)41:53.0.co;2-m	NOUN
fnp-5049	225	2	10	10	NUM
fnp-5049	225	3	.	.	PUNCT
fnp-5049	226	1	cazzato	cazzato	VERB
fnp-5049	226	2	g	g	PROPN
fnp-5049	226	3	,	,	PUNCT
fnp-5049	226	4	mesiano	mesiano	NOUN
fnp-5049	226	5	t	t	PROPN
fnp-5049	226	6	,	,	PUNCT
fnp-5049	226	7	antonello	antonello	PROPN
fnp-5049	226	8	r	r	PROPN
fnp-5049	226	9	,	,	PUNCT
fnp-5049	226	10	monti	monti	PROPN
fnp-5049	226	11	f	f	PROPN
fnp-5049	226	12	,	,	PUNCT
fnp-5049	226	13	carraro	carraro	NOUN
fnp-5049	226	14	n	n	CCONJ
fnp-5049	226	15	,	,	PUNCT
fnp-5049	226	16	torre	torre	PROPN
fnp-5049	226	17	p	p	PROPN
fnp-5049	226	18	,	,	PUNCT
fnp-5049	226	19	bosco	bosco	PROPN
fnp-5049	226	20	a	a	PROPN
fnp-5049	226	21	,	,	PUNCT
fnp-5049	226	22	cargnelutti	cargnelutti	PROPN
fnp-5049	226	23	d	d	NOUN
fnp-5049	226	24	(	(	PUNCT
fnp-5049	226	25	1995	1995	NUM
fnp-5049	226	26	)	)	PUNCT
fnp-5049	226	27	double	double	ADJ
fnp-5049	226	28	-	-	PUNCT
fnp-5049	226	29	blind	blind	ADJ
fnp-5049	226	30	,	,	PUNCT
fnp-5049	226	31	placebo	placebo	NOUN
fnp-5049	226	32	-	-	PUNCT
fnp-5049	226	33	controlled	control	VERB
fnp-5049	226	34	,	,	PUNCT
fnp-5049	226	35	randomized	randomize	VERB
fnp-5049	226	36	,	,	PUNCT
fnp-5049	226	37	crossover	crossover	ADP
fnp-5049	226	38	trial	trial	NOUN
fnp-5049	226	39	of	of	ADP
fnp-5049	226	40	high	high	ADJ
fnp-5049	226	41	-	-	PUNCT
fnp-5049	226	42	dose	dose	NOUN
fnp-5049	226	43	methylprednisolone	methylprednisolone	NOUN
fnp-5049	226	44	in	in	ADP
fnp-5049	226	45	patients	patient	NOUN
fnp-5049	226	46	with	with	ADP
fnp-5049	226	47	chronic	chronic	ADJ
fnp-5049	226	48	progressive	progressive	ADJ
fnp-5049	226	49	form	form	NOUN
fnp-5049	226	50	of	of	ADP
fnp-5049	226	51	multiple	multiple	ADJ
fnp-5049	226	52	sclerosis	sclerosis	NOUN
fnp-5049	226	53	.	.	PUNCT
fnp-5049	227	1	eur	eur	PROPN
fnp-5049	227	2	neurol	neurol	PROPN
fnp-5049	227	3	35	35	NUM
fnp-5049	227	4	:	:	SYM
fnp-5049	227	5	193	193	NUM
fnp-5049	227	6	-	-	SYM
fnp-5049	227	7	198	198	NUM
fnp-5049	227	8	.	.	PUNCT
fnp-5049	228	1	https://doi.org/10.1159/000117127	https://doi.org/10.1159/000117127	NOUN
fnp-5049	228	2	11	11	NUM
fnp-5049	228	3	.	.	PUNCT
fnp-5049	229	1	cree	cree	PROPN
fnp-5049	229	2	bac	bac	PROPN
fnp-5049	229	3	,	,	PUNCT
fnp-5049	229	4	arnold	arnold	PROPN
fnp-5049	229	5	dl	dl	PROPN
fnp-5049	229	6	,	,	PUNCT
fnp-5049	229	7	chataway	chataway	PROPN
fnp-5049	229	8	j	j	PROPN
fnp-5049	229	9	,	,	PUNCT
fnp-5049	229	10	chitnis	chitnis	PROPN
fnp-5049	229	11	t	t	PROPN
fnp-5049	229	12	,	,	PUNCT
fnp-5049	229	13	fox	fox	PROPN
fnp-5049	229	14	rj	rj	PROPN
fnp-5049	229	15	,	,	PUNCT
fnp-5049	229	16	pozo	pozo	PROPN
fnp-5049	229	17	ramajo	ramajo	PROPN
fnp-5049	229	18	a	a	X
fnp-5049	229	19	,	,	PUNCT
fnp-5049	229	20	murphy	murphy	PROPN
fnp-5049	229	21	n	n	CCONJ
fnp-5049	229	22	,	,	PUNCT
fnp-5049	229	23	lassmann	lassmann	PROPN
fnp-5049	229	24	h	h	NOUN
fnp-5049	229	25	(	(	PUNCT
fnp-5049	229	26	2021	2021	NUM
fnp-5049	229	27	)	)	PUNCT
fnp-5049	229	28	secondary	secondary	ADJ
fnp-5049	229	29	progressive	progressive	ADJ
fnp-5049	229	30	multiple	multiple	ADJ
fnp-5049	229	31	sclerosis	sclerosis	NOUN
fnp-5049	229	32	:	:	PUNCT
fnp-5049	229	33	new	new	ADJ
fnp-5049	229	34	insights	insight	NOUN
fnp-5049	229	35	.	.	PUNCT
fnp-5049	230	1	neurology	neurology	NOUN
fnp-5049	230	2	97	97	NUM
fnp-5049	230	3	:	:	PUNCT
fnp-5049	230	4	378	378	NUM
fnp-5049	230	5	-	-	SYM
fnp-5049	230	6	388	388	NUM
fnp-5049	230	7	.	.	PUNCT
fnp-5049	231	1	https://doi.org/10.1212/wnl.0000000000012323	https://doi.org/10.1212/wnl.0000000000012323	PROPN
fnp-5049	231	2	12	12	NUM
fnp-5049	231	3	.	.	PUNCT
fnp-5049	232	1	crockard	crockard	NOUN
fnp-5049	232	2	ad	ad	NOUN
fnp-5049	232	3	,	,	PUNCT
fnp-5049	232	4	treacy	treacy	PROPN
fnp-5049	232	5	mt	mt	PROPN
fnp-5049	232	6	,	,	PUNCT
fnp-5049	232	7	droogan	droogan	PROPN
fnp-5049	232	8	ag	ag	PROPN
fnp-5049	232	9	,	,	PUNCT
fnp-5049	232	10	mcneill	mcneill	PROPN
fnp-5049	232	11	ta	ta	PROPN
fnp-5049	232	12	,	,	PUNCT
fnp-5049	232	13	hawkins	hawkins	PROPN
fnp-5049	232	14	sa	sa	PROPN
fnp-5049	232	15	(	(	PUNCT
fnp-5049	232	16	1995	1995	NUM
fnp-5049	232	17	)	)	PUNCT
fnp-5049	232	18	transient	transient	NOUN
fnp-5049	232	19	immunomodulation	immunomodulation	NOUN
fnp-5049	232	20	by	by	ADP
fnp-5049	232	21	intravenous	intravenous	ADJ
fnp-5049	232	22	methylprednisolone	methylprednisolone	ADJ
fnp-5049	232	23	treatment	treatment	NOUN
fnp-5049	232	24	of	of	ADP
fnp-5049	232	25	multiple	multiple	ADJ
fnp-5049	232	26	sclerosis	sclerosis	NOUN
fnp-5049	232	27	.	.	PUNCT
fnp-5049	233	1	mult	mult	PROPN
fnp-5049	233	2	scler	scler	PROPN
fnp-5049	233	3	1	1	NUM
fnp-5049	233	4	:	:	SYM
fnp-5049	233	5	20	20	NUM
fnp-5049	233	6	-	-	SYM
fnp-5049	233	7	24	24	NUM
fnp-5049	233	8	.	.	PUNCT
fnp-5049	234	1	https://doi.org/10.1177/135245859500100104	https://doi.org/10.1177/135245859500100104	PRON
fnp-5049	234	2	13	13	NUM
fnp-5049	234	3	.	.	PUNCT
fnp-5049	234	4	di	di	PROPN
fnp-5049	234	5	gregorio	gregorio	PROPN
fnp-5049	234	6	m	m	PROPN
fnp-5049	234	7	,	,	PUNCT
fnp-5049	234	8	gaetani	gaetani	PROPN
fnp-5049	234	9	l	l	PROPN
fnp-5049	234	10	,	,	PUNCT
fnp-5049	234	11	eusebi	eusebi	VERB
fnp-5049	234	12	p	p	NOUN
fnp-5049	234	13	,	,	PUNCT
fnp-5049	234	14	floridi	floridi	ADJ
fnp-5049	234	15	p	p	NOUN
fnp-5049	234	16	,	,	PUNCT
fnp-5049	234	17	picchioni	picchioni	NOUN
fnp-5049	234	18	a	a	NOUN
fnp-5049	234	19	,	,	PUNCT
fnp-5049	234	20	rosi	rosi	PROPN
fnp-5049	234	21	g	g	PROPN
fnp-5049	234	22	,	,	PUNCT
fnp-5049	234	23	mancini	mancini	PROPN
fnp-5049	234	24	a	a	NOUN
fnp-5049	234	25	,	,	PUNCT
fnp-5049	234	26	floridi	floridi	ADJ
fnp-5049	234	27	c	c	NOUN
fnp-5049	234	28	,	,	PUNCT
fnp-5049	234	29	baschieri	baschieri	PROPN
fnp-5049	234	30	f	f	PROPN
fnp-5049	234	31	,	,	PUNCT
fnp-5049	234	32	gentili	gentili	PROPN
fnp-5049	234	33	l	l	PROPN
fnp-5049	234	34	et	et	PROPN
fnp-5049	234	35	al	al	PROPN
fnp-5049	234	36	(	(	PUNCT
fnp-5049	234	37	2018	2018	NUM
fnp-5049	234	38	)	)	PUNCT
fnp-5049	234	39	treatment	treatment	NOUN
fnp-5049	234	40	of	of	ADP
fnp-5049	234	41	multiple	multiple	ADJ
fnp-5049	234	42	sclerosis	sclerosis	NOUN
fnp-5049	234	43	relapses	relapse	NOUN
fnp-5049	234	44	with	with	ADP
fnp-5049	234	45	high	high	ADJ
fnp-5049	234	46	-	-	PUNCT
fnp-5049	234	47	dose	dose	NOUN
fnp-5049	234	48	methylprednisolone	methylprednisolone	NOUN
fnp-5049	234	49	reduces	reduce	VERB
fnp-5049	234	50	the	the	DET
fnp-5049	234	51	evolution	evolution	NOUN
fnp-5049	234	52	of	of	ADP
fnp-5049	234	53	contrast	contrast	NOUN
fnp-5049	234	54	-	-	PUNCT
fnp-5049	234	55	enhancing	enhance	VERB
fnp-5049	234	56	lesions	lesion	NOUN
fnp-5049	234	57	into	into	ADP
fnp-5049	234	58	persistent	persistent	ADJ
fnp-5049	234	59	black	black	ADJ
fnp-5049	234	60	holes	hole	NOUN
fnp-5049	234	61	.	.	PUNCT
fnp-5049	235	1	journal	journal	NOUN
fnp-5049	235	2	of	of	ADP
fnp-5049	235	3	neurology	neurology	NOUN
fnp-5049	235	4	265	265	NUM
fnp-5049	235	5	:	:	PUNCT
fnp-5049	235	6	522	522	NUM
fnp-5049	235	7	-	-	SYM
fnp-5049	235	8	529	529	NUM
fnp-5049	235	9	.	.	PUNCT
fnp-5049	235	10	https://doi.org/10.1007/s00415-017-8726-2	https://doi.org/10.1007/s00415-017-8726-2	PROPN
fnp-5049	236	1	14	14	NUM
fnp-5049	236	2	.	.	PUNCT
fnp-5049	237	1	dietmann	dietmann	PROPN
fnp-5049	237	2	as	as	ADP
fnp-5049	237	3	,	,	PUNCT
fnp-5049	237	4	kruse	kruse	PROPN
fnp-5049	237	5	n	n	CCONJ
fnp-5049	237	6	,	,	PUNCT
fnp-5049	237	7	stork	stork	NOUN
fnp-5049	237	8	l	l	NOUN
fnp-5049	237	9	,	,	PUNCT
fnp-5049	237	10	gloth	gloth	NOUN
fnp-5049	237	11	m	m	PROPN
fnp-5049	237	12	,	,	PUNCT
fnp-5049	237	13	brück	brück	PROPN
fnp-5049	237	14	w	w	PROPN
fnp-5049	237	15	,	,	PUNCT
fnp-5049	237	16	metz	metz	PROPN
fnp-5049	237	17	i	i	PRON
fnp-5049	237	18	(	(	PUNCT
fnp-5049	237	19	2023	2023	NUM
fnp-5049	237	20	)	)	PUNCT
fnp-5049	237	21	neurofilament	neurofilament	ADJ
fnp-5049	237	22	light	light	ADJ
fnp-5049	237	23	chains	chain	NOUN
fnp-5049	237	24	in	in	ADP
fnp-5049	237	25	serum	serum	NOUN
fnp-5049	237	26	as	as	ADP
fnp-5049	237	27	biomarkers	biomarker	NOUN
fnp-5049	237	28	of	of	ADP
fnp-5049	237	29	axonal	axonal	ADJ
fnp-5049	237	30	damage	damage	NOUN
fnp-5049	237	31	in	in	ADP
fnp-5049	237	32	early	early	ADJ
fnp-5049	237	33	ms	ms	ADJ
fnp-5049	237	34	lesions	lesion	NOUN
fnp-5049	237	35	:	:	PUNCT
fnp-5049	237	36	a	a	DET
fnp-5049	237	37	histological	histological	ADJ
fnp-5049	237	38	-	-	PUNCT
fnp-5049	237	39	serological	serological	ADJ
fnp-5049	237	40	correlative	correlative	ADJ
fnp-5049	237	41	study	study	NOUN
fnp-5049	237	42	.	.	PUNCT
fnp-5049	238	1	j	j	PROPN
fnp-5049	238	2	neurol	neurol	NOUN
fnp-5049	238	3	270	270	NUM
fnp-5049	238	4	:	:	PUNCT
fnp-5049	238	5	1416	1416	NUM
fnp-5049	238	6	-	-	SYM
fnp-5049	238	7	1429	1429	NUM
fnp-5049	238	8	.	.	PUNCT
fnp-5049	239	1	https://doi.org/10.1007/s00415-022-11468-2	https://doi.org/10.1007/s00415-022-11468-2	NUM
fnp-5049	239	2	15	15	NUM
fnp-5049	239	3	.	.	PUNCT
fnp-5049	240	1	disanto	disanto	VERB
fnp-5049	240	2	g	g	PROPN
fnp-5049	240	3	,	,	PUNCT
fnp-5049	240	4	barro	barro	PROPN
fnp-5049	240	5	c	c	PROPN
fnp-5049	240	6	,	,	PUNCT
fnp-5049	240	7	benkert	benkert	NOUN
fnp-5049	240	8	p	p	NOUN
fnp-5049	240	9	,	,	PUNCT
fnp-5049	240	10	naegelin	naegelin	NOUN
fnp-5049	240	11	y	y	PROPN
fnp-5049	240	12	,	,	PUNCT
fnp-5049	240	13	schadelin	schadelin	PROPN
fnp-5049	240	14	s	s	PROPN
fnp-5049	240	15	,	,	PUNCT
fnp-5049	240	16	giardiello	giardiello	PROPN
fnp-5049	240	17	a	a	PRON
fnp-5049	240	18	,	,	PUNCT
fnp-5049	240	19	zecca	zecca	NOUN
fnp-5049	240	20	c	c	NOUN
fnp-5049	240	21	,	,	PUNCT
fnp-5049	240	22	blennow	blennow	ADV
fnp-5049	240	23	k	k	PROPN
fnp-5049	240	24	,	,	PUNCT
fnp-5049	240	25	zetterberg	zetterberg	PROPN
fnp-5049	240	26	h	h	PROPN
fnp-5049	240	27	,	,	PUNCT
fnp-5049	240	28	leppert	leppert	PROPN
fnp-5049	240	29	d	d	X
fnp-5049	240	30	et	et	PROPN
fnp-5049	240	31	al	al	PROPN
fnp-5049	240	32	(	(	PUNCT
fnp-5049	240	33	2017	2017	NUM
fnp-5049	240	34	)	)	PUNCT
fnp-5049	240	35	serum	serum	NOUN
fnp-5049	240	36	neurofilament	neurofilament	PROPN
fnp-5049	240	37	light	light	NOUN
fnp-5049	240	38	:	:	PUNCT
fnp-5049	240	39	a	a	DET
fnp-5049	240	40	biomarker	biomarker	NOUN
fnp-5049	240	41	of	of	ADP
fnp-5049	240	42	neuronal	neuronal	ADJ
fnp-5049	240	43	damage	damage	NOUN
fnp-5049	240	44	in	in	ADP
fnp-5049	240	45	multiple	multiple	ADJ
fnp-5049	240	46	sclerosis	sclerosis	NOUN
fnp-5049	240	47	.	.	PUNCT
fnp-5049	241	1	annals	annal	NOUN
fnp-5049	241	2	of	of	ADP
fnp-5049	241	3	neurology	neurology	NOUN
fnp-5049	241	4	81	81	NUM
fnp-5049	241	5	:	:	PUNCT
fnp-5049	241	6	857	857	NUM
fnp-5049	241	7	-	-	SYM
fnp-5049	241	8	870	870	NUM
fnp-5049	241	9	.	.	PUNCT
fnp-5049	242	1	https://doi.org/10.1002/ana.24954	https://doi.org/10.1002/ana.24954	VERB
fnp-5049	242	2	16	16	NUM
fnp-5049	242	3	.	.	PUNCT
fnp-5049	243	1	dufour	dufour	PROPN
fnp-5049	243	2	a	a	PROPN
fnp-5049	243	3	,	,	PUNCT
fnp-5049	243	4	corsini	corsini	PROPN
fnp-5049	243	5	e	e	PROPN
fnp-5049	243	6	,	,	PUNCT
fnp-5049	243	7	gelati	gelati	PROPN
fnp-5049	243	8	m	m	PROPN
fnp-5049	243	9	,	,	PUNCT
fnp-5049	243	10	ciusani	ciusani	PROPN
fnp-5049	243	11	e	e	NOUN
fnp-5049	243	12	,	,	PUNCT
fnp-5049	243	13	zaffaroni	zaffaroni	PROPN
fnp-5049	243	14	m	m	PROPN
fnp-5049	243	15	,	,	PUNCT
fnp-5049	243	16	giombini	giombini	NOUN
fnp-5049	243	17	s	s	PROPN
fnp-5049	243	18	,	,	PUNCT
fnp-5049	243	19	massa	massa	PROPN
fnp-5049	243	20	g	g	NOUN
fnp-5049	243	21	,	,	PUNCT
fnp-5049	243	22	salmaggi	salmaggi	VERB
fnp-5049	243	23	a	a	DET
fnp-5049	243	24	(	(	PUNCT
fnp-5049	243	25	1998	1998	NUM
fnp-5049	243	26	)	)	PUNCT
fnp-5049	243	27	modulation	modulation	NOUN
fnp-5049	243	28	of	of	ADP
fnp-5049	243	29	icam-1	icam-1	PROPN
fnp-5049	243	30	,	,	PUNCT
fnp-5049	243	31	vcam-1	vcam-1	NOUN
fnp-5049	243	32	and	and	CCONJ
fnp-5049	243	33	hla	hla	PROPN
fnp-5049	243	34	-	-	PUNCT
fnp-5049	243	35	dr	dr	PROPN
fnp-5049	243	36	by	by	ADP
fnp-5049	243	37	cytokines	cytokine	NOUN
fnp-5049	243	38	and	and	CCONJ
fnp-5049	243	39	steroids	steroid	NOUN
fnp-5049	243	40	on	on	ADP
fnp-5049	243	41	huvecs	huvec	NOUN
fnp-5049	243	42	and	and	CCONJ
fnp-5049	243	43	human	human	ADJ
fnp-5049	243	44	brain	brain	NOUN
fnp-5049	243	45	endothelial	endothelial	ADJ
fnp-5049	243	46	cells	cell	NOUN
fnp-5049	243	47	.	.	PUNCT
fnp-5049	244	1	journal	journal	NOUN
fnp-5049	244	2	of	of	ADP
fnp-5049	244	3	the	the	DET
fnp-5049	244	4	neurological	neurological	ADJ
fnp-5049	244	5	sciences	science	NOUN
fnp-5049	244	6	157	157	NUM
fnp-5049	244	7	:	:	SYM
fnp-5049	244	8	117	117	NUM
fnp-5049	244	9	-	-	SYM
fnp-5049	244	10	121	121	NUM
fnp-5049	244	11	.	.	PUNCT
fnp-5049	245	1	https://doi.org/10.1016/s0022-510x(98)00059-8	https://doi.org/10.1016/s0022-510x(98)00059-8	NOUN
fnp-5049	245	2	17	17	NUM
fnp-5049	245	3	.	.	PUNCT
fnp-5049	245	4	european	european	ADJ
fnp-5049	245	5	medicine	medicine	PROPN
fnp-5049	245	6	agency	agency	PROPN
fnp-5049	245	7	.	.	PUNCT
fnp-5049	246	1	https://www.emaeuropaeu/en/medicines/human/epar/betaferon	https://www.emaeuropaeu/en/medicines/human/epar/betaferon	PROPN
fnp-5049	246	2	update	update	NOUN
fnp-5049	246	3	2019	2019	NUM
fnp-5049	246	4	18	18	NUM
fnp-5049	246	5	.	.	PUNCT
fnp-5049	247	1	filippini	filippini	PROPN
fnp-5049	247	2	g	g	PROPN
fnp-5049	247	3	,	,	PUNCT
fnp-5049	247	4	brusaferri	brusaferri	PROPN
fnp-5049	247	5	f	f	PROPN
fnp-5049	247	6	,	,	PUNCT
fnp-5049	247	7	sibley	sibley	PROPN
fnp-5049	247	8	wa	wa	PROPN
fnp-5049	247	9	,	,	PUNCT
fnp-5049	247	10	citterio	citterio	NOUN
fnp-5049	247	11	a	a	PROPN
fnp-5049	247	12	,	,	PUNCT
fnp-5049	247	13	ciucci	ciucci	NOUN
fnp-5049	247	14	g	g	PROPN
fnp-5049	247	15	,	,	PUNCT
fnp-5049	247	16	midgard	midgard	NOUN
fnp-5049	247	17	r	r	NOUN
fnp-5049	247	18	,	,	PUNCT
fnp-5049	247	19	candelise	candelise	NOUN
fnp-5049	247	20	l	l	PROPN
fnp-5049	247	21	(	(	PUNCT
fnp-5049	247	22	2000	2000	NUM
fnp-5049	247	23	)	)	PUNCT
fnp-5049	247	24	corticosteroids	corticosteroid	NOUN
fnp-5049	247	25	or	or	CCONJ
fnp-5049	247	26	acth	acth	NOUN
fnp-5049	247	27	for	for	ADP
fnp-5049	247	28	acute	acute	ADJ
fnp-5049	247	29	exacerbations	exacerbation	NOUN
fnp-5049	247	30	in	in	ADP
fnp-5049	247	31	multiple	multiple	ADJ
fnp-5049	247	32	sclerosis	sclerosis	NOUN
fnp-5049	247	33	.	.	PUNCT
fnp-5049	248	1	cochrane	cochrane	PROPN
fnp-5049	248	2	database	database	PROPN
fnp-5049	248	3	syst	syst	PROPN
fnp-5049	248	4	rev	rev	PROPN
fnp-5049	248	5	:	:	PUNCT
fnp-5049	248	6	cd001331	cd001331	PROPN
fnp-5049	248	7	.	.	PUNCT
fnp-5049	249	1	https://doi.org/10.1002/14651858.cd001331	https://doi.org/10.1002/14651858.cd001331	PROPN
fnp-5049	249	2	19	19	NUM
fnp-5049	249	3	.	.	PUNCT
fnp-5049	249	4	frequin	frequin	PROPN
fnp-5049	249	5	st	st	PROPN
fnp-5049	249	6	,	,	PUNCT
fnp-5049	249	7	barkhof	barkhof	PROPN
fnp-5049	249	8	f	f	PROPN
fnp-5049	249	9	,	,	PUNCT
fnp-5049	249	10	lamers	lamers	PROPN
fnp-5049	249	11	kj	kj	PROPN
fnp-5049	249	12	,	,	PUNCT
fnp-5049	249	13	hommes	homme	NOUN
fnp-5049	249	14	or	or	CCONJ
fnp-5049	249	15	(	(	PUNCT
fnp-5049	249	16	1992	1992	NUM
fnp-5049	249	17	)	)	PUNCT
fnp-5049	249	18	the	the	DET
fnp-5049	249	19	effects	effect	NOUN
fnp-5049	249	20	of	of	ADP
fnp-5049	249	21	high	high	ADJ
fnp-5049	249	22	-	-	PUNCT
fnp-5049	249	23	dose	dose	NOUN
fnp-5049	249	24	methylprednisolone	methylprednisolone	NOUN
fnp-5049	249	25	on	on	ADP
fnp-5049	249	26	gadolinium	gadolinium	NOUN
fnp-5049	249	27	-	-	PUNCT
fnp-5049	249	28	enhanced	enhance	VERB
fnp-5049	249	29	magnetic	magnetic	ADJ
fnp-5049	249	30	resonance	resonance	NOUN
fnp-5049	249	31	imaging	imaging	NOUN
fnp-5049	249	32	and	and	CCONJ
fnp-5049	249	33	cerebrospinal	cerebrospinal	ADJ
fnp-5049	249	34	fluid	fluid	ADJ
fnp-5049	249	35	measurements	measurement	NOUN
fnp-5049	249	36	in	in	ADP
fnp-5049	249	37	multiple	multiple	ADJ
fnp-5049	249	38	sclerosis	sclerosis	NOUN
fnp-5049	249	39	.	.	PUNCT
fnp-5049	250	1	j	j	PROPN
fnp-5049	250	2	neuroimmunol	neuroimmunol	NOUN
fnp-5049	250	3	40	40	NUM
fnp-5049	250	4	:	:	PUNCT
fnp-5049	250	5	265	265	NUM
fnp-5049	250	6	-	-	SYM
fnp-5049	250	7	272	272	NUM
fnp-5049	250	8	.	.	PUNCT
fnp-5049	251	1	https://doi.org/10.1016/0165-5728(92)90142-8	https://doi.org/10.1016/0165-5728(92)90142-8	PROPN
fnp-5049	251	2	20	20	NUM
fnp-5049	251	3	.	.	PUNCT
fnp-5049	252	1	frischer	frischer	PROPN
fnp-5049	252	2	jm	jm	PROPN
fnp-5049	252	3	,	,	PUNCT
fnp-5049	252	4	bramow	bramow	PROPN
fnp-5049	252	5	s	s	PROPN
fnp-5049	252	6	,	,	PUNCT
fnp-5049	252	7	dal	dal	NOUN
fnp-5049	252	8	-	-	PUNCT
fnp-5049	252	9	bianco	bianco	PROPN
fnp-5049	252	10	a	a	PROPN
fnp-5049	252	11	,	,	PUNCT
fnp-5049	252	12	lucchinetti	lucchinetti	PROPN
fnp-5049	252	13	cf	cf	NOUN
fnp-5049	252	14	,	,	PUNCT
fnp-5049	252	15	rauschka	rauschka	PROPN
fnp-5049	252	16	h	h	NOUN
fnp-5049	252	17	,	,	PUNCT
fnp-5049	252	18	schmidbauer	schmidbauer	PROPN
fnp-5049	252	19	m	m	PROPN
fnp-5049	252	20	,	,	PUNCT
fnp-5049	252	21	laursen	laursen	PROPN
fnp-5049	252	22	h	h	NOUN
fnp-5049	252	23	,	,	PUNCT
fnp-5049	252	24	sorensen	sorensen	PROPN
fnp-5049	252	25	ps	ps	PROPN
fnp-5049	252	26	,	,	PUNCT
fnp-5049	252	27	lassmann	lassmann	PROPN
fnp-5049	252	28	h	h	PROPN
fnp-5049	252	29	(	(	PUNCT
fnp-5049	252	30	2009	2009	NUM
fnp-5049	252	31	)	)	PUNCT
fnp-5049	252	32	the	the	DET
fnp-5049	252	33	relation	relation	NOUN
fnp-5049	252	34	between	between	ADP
fnp-5049	252	35	inflammation	inflammation	NOUN
fnp-5049	252	36	and	and	CCONJ
fnp-5049	252	37	neurodegeneration	neurodegeneration	NOUN
fnp-5049	252	38	in	in	ADP
fnp-5049	252	39	multiple	multiple	ADJ
fnp-5049	252	40	sclerosis	sclerosis	NOUN
fnp-5049	252	41	brains	brain	NOUN
fnp-5049	252	42	.	.	PUNCT
fnp-5049	253	1	brain	brain	NOUN
fnp-5049	253	2	132	132	NUM
fnp-5049	253	3	:	:	PUNCT
fnp-5049	253	4	1175	1175	NUM
fnp-5049	253	5	-	-	SYM
fnp-5049	253	6	1189	1189	NUM
fnp-5049	253	7	.	.	PUNCT
fnp-5049	254	1	https://doi.org/10.1093/brain/awp070	https://doi.org/10.1093/brain/awp070	NOUN
fnp-5049	254	2	21	21	NUM
fnp-5049	254	3	.	.	PUNCT
fnp-5049	255	1	frischer	frischer	PROPN
fnp-5049	255	2	jm	jm	PROPN
fnp-5049	255	3	,	,	PUNCT
fnp-5049	255	4	weigand	weigand	PROPN
fnp-5049	255	5	sd	sd	PROPN
fnp-5049	255	6	,	,	PUNCT
fnp-5049	255	7	guo	guo	PROPN
fnp-5049	255	8	y	y	PROPN
fnp-5049	255	9	,	,	PUNCT
fnp-5049	255	10	kale	kale	PROPN
fnp-5049	255	11	n	n	CCONJ
fnp-5049	255	12	,	,	PUNCT
fnp-5049	255	13	parisi	parisi	PROPN
fnp-5049	255	14	je	je	PROPN
fnp-5049	255	15	,	,	PUNCT
fnp-5049	255	16	pirko	pirko	PROPN
fnp-5049	255	17	i	i	PRON
fnp-5049	255	18	,	,	PUNCT
fnp-5049	255	19	mandrekar	mandrekar	PROPN
fnp-5049	255	20	j	j	PROPN
fnp-5049	255	21	,	,	PUNCT
fnp-5049	255	22	bramow	bramow	PROPN
fnp-5049	255	23	s	s	PART
fnp-5049	255	24	,	,	PUNCT
fnp-5049	255	25	metz	metz	PROPN
fnp-5049	255	26	i	i	PROPN
fnp-5049	255	27	,	,	PUNCT
fnp-5049	255	28	bruck	bruck	PROPN
fnp-5049	255	29	w	w	PROPN
fnp-5049	255	30	et	et	PROPN
fnp-5049	255	31	al	al	PROPN
fnp-5049	255	32	(	(	PUNCT
fnp-5049	255	33	2015	2015	NUM
fnp-5049	255	34	)	)	PUNCT
fnp-5049	255	35	clinical	clinical	ADJ
fnp-5049	255	36	and	and	CCONJ
fnp-5049	255	37	pathological	pathological	ADJ
fnp-5049	255	38	insights	insight	NOUN
fnp-5049	255	39	into	into	ADP
fnp-5049	255	40	the	the	DET
fnp-5049	255	41	dynamic	dynamic	ADJ
fnp-5049	255	42	nature	nature	NOUN
fnp-5049	255	43	of	of	ADP
fnp-5049	255	44	the	the	DET
fnp-5049	255	45	white	white	ADJ
fnp-5049	255	46	matter	matter	NOUN
fnp-5049	255	47	multiple	multiple	ADJ
fnp-5049	255	48	sclerosis	sclerosis	NOUN
fnp-5049	255	49	plaque	plaque	NOUN
fnp-5049	255	50	.	.	PUNCT
fnp-5049	256	1	annals	annal	NOUN
fnp-5049	256	2	of	of	ADP
fnp-5049	256	3	neurology	neurology	NOUN
fnp-5049	256	4	78	78	NUM
fnp-5049	256	5	:	:	PUNCT
fnp-5049	256	6	710	710	NUM
fnp-5049	256	7	-	-	SYM
fnp-5049	256	8	721	721	NUM
fnp-5049	256	9	.	.	PUNCT
fnp-5049	257	1	https://doi.org/10.1002/ana.24497	https://doi.org/10.1002/ana.24497	NOUN
fnp-5049	257	2	22	22	NUM
fnp-5049	257	3	.	.	PUNCT
fnp-5049	258	1	gaetani	gaetani	PROPN
fnp-5049	258	2	l	l	PROPN
fnp-5049	258	3	,	,	PUNCT
fnp-5049	258	4	blennow	blennow	ADV
fnp-5049	258	5	k	k	PROPN
fnp-5049	258	6	,	,	PUNCT
fnp-5049	258	7	calabresi	calabresi	NOUN
fnp-5049	258	8	p	p	X
fnp-5049	258	9	,	,	PUNCT
fnp-5049	258	10	di	di	X
fnp-5049	258	11	filippo	filippo	PROPN
fnp-5049	258	12	m	m	PROPN
fnp-5049	258	13	,	,	PUNCT
fnp-5049	258	14	parnetti	parnetti	ADJ
fnp-5049	258	15	l	l	PROPN
fnp-5049	258	16	,	,	PUNCT
fnp-5049	258	17	zetterberg	zetterberg	PROPN
fnp-5049	258	18	h	h	PROPN
fnp-5049	258	19	(	(	PUNCT
fnp-5049	258	20	2019	2019	NUM
fnp-5049	258	21	)	)	PUNCT
fnp-5049	258	22	neurofilament	neurofilament	ADJ
fnp-5049	258	23	light	light	NOUN
fnp-5049	258	24	chain	chain	NOUN
fnp-5049	258	25	as	as	ADP
fnp-5049	258	26	a	a	DET
fnp-5049	258	27	biomarker	biomarker	NOUN
fnp-5049	258	28	in	in	ADP
fnp-5049	258	29	neurological	neurological	ADJ
fnp-5049	258	30	disorders	disorder	NOUN
fnp-5049	258	31	.	.	PUNCT
fnp-5049	259	1	j	j	PROPN
fnp-5049	259	2	neurol	neurol	PROPN
fnp-5049	259	3	neurosurg	neurosurg	PROPN
fnp-5049	259	4	psychiatry	psychiatry	NOUN
fnp-5049	259	5	90	90	NUM
fnp-5049	259	6	:	:	SYM
fnp-5049	259	7	870	870	NUM
fnp-5049	259	8	-	-	SYM
fnp-5049	259	9	881	881	NUM
fnp-5049	259	10	.	.	PUNCT
fnp-5049	260	1	https://doi.org/10.1136/jnnp-2018-320106	https://doi.org/10.1136/jnnp-2018-320106	NOUN
fnp-5049	260	2	23	23	NUM
fnp-5049	260	3	.	.	PUNCT
fnp-5049	261	1	gelati	gelati	PROPN
fnp-5049	261	2	m	m	PROPN
fnp-5049	261	3	,	,	PUNCT
fnp-5049	261	4	corsini	corsini	PROPN
fnp-5049	261	5	e	e	PROPN
fnp-5049	261	6	,	,	PUNCT
fnp-5049	261	7	dufour	dufour	PROPN
fnp-5049	261	8	a	a	PROPN
fnp-5049	261	9	,	,	PUNCT
fnp-5049	261	10	massa	massa	PROPN
fnp-5049	261	11	g	g	NOUN
fnp-5049	261	12	,	,	PUNCT
fnp-5049	261	13	giombini	giombini	NOUN
fnp-5049	261	14	s	s	PROPN
fnp-5049	261	15	,	,	PUNCT
fnp-5049	261	16	solero	solero	NOUN
fnp-5049	261	17	cl	cl	NOUN
fnp-5049	261	18	,	,	PUNCT
fnp-5049	261	19	salmaggi	salmaggi	VERB
fnp-5049	261	20	a	a	DET
fnp-5049	261	21	(	(	PUNCT
fnp-5049	261	22	2000	2000	NUM
fnp-5049	261	23	)	)	PUNCT
fnp-5049	261	24	high	high	ADJ
fnp-5049	261	25	-	-	PUNCT
fnp-5049	261	26	dose	dose	NOUN
fnp-5049	261	27	methylprednisolone	methylprednisolone	NOUN
fnp-5049	261	28	reduces	reduce	VERB
fnp-5049	261	29	cytokine	cytokine	NOUN
fnp-5049	261	30	-	-	PUNCT
fnp-5049	261	31	induced	induce	VERB
fnp-5049	261	32	adhesion	adhesion	NOUN
fnp-5049	261	33	molecules	molecule	NOUN
fnp-5049	261	34	on	on	ADP
fnp-5049	261	35	human	human	ADJ
fnp-5049	261	36	brain	brain	NOUN
fnp-5049	261	37	endothelium	endothelium	NOUN
fnp-5049	261	38	.	.	PUNCT
fnp-5049	262	1	the	the	DET
fnp-5049	262	2	canadian	canadian	ADJ
fnp-5049	262	3	journal	journal	NOUN
fnp-5049	262	4	of	of	ADP
fnp-5049	262	5	neurological	neurological	ADJ
fnp-5049	262	6	sciences	sciences	PROPN
fnp-5049	262	7	le	le	X
fnp-5049	262	8	journal	journal	PROPN
fnp-5049	262	9	canadien	canadien	PROPN
fnp-5049	262	10	des	des	PROPN
fnp-5049	262	11	sciences	sciences	PROPN
fnp-5049	262	12	neurologiques	neurologique	VERB
fnp-5049	262	13	27	27	NUM
fnp-5049	262	14	:	:	PUNCT
fnp-5049	262	15	241	241	NUM
fnp-5049	262	16	-	-	SYM
fnp-5049	262	17	244	244	NUM
fnp-5049	262	18	.	.	PUNCT
fnp-5049	263	1	https://doi.org/10.1017/s0317167100000883	https://doi.org/10.1017/s0317167100000883	NUM
fnp-5049	263	2	24	24	NUM
fnp-5049	263	3	.	.	PUNCT
fnp-5049	264	1	gold	gold	NOUN
fnp-5049	264	2	r	r	NOUN
fnp-5049	264	3	,	,	PUNCT
fnp-5049	264	4	buttgereit	buttgereit	ADJ
fnp-5049	264	5	f	f	X
fnp-5049	264	6	,	,	PUNCT
fnp-5049	264	7	toyka	toyka	PROPN
fnp-5049	264	8	kv	kv	PROPN
fnp-5049	264	9	(	(	PUNCT
fnp-5049	264	10	2001	2001	NUM
fnp-5049	264	11	)	)	PUNCT
fnp-5049	264	12	mechanism	mechanism	NOUN
fnp-5049	264	13	of	of	ADP
fnp-5049	264	14	action	action	NOUN
fnp-5049	264	15	of	of	ADP
fnp-5049	264	16	glucocorticosteroid	glucocorticosteroid	NOUN
fnp-5049	264	17	hormones	hormone	NOUN
fnp-5049	264	18	:	:	PUNCT
fnp-5049	264	19	possible	possible	ADJ
fnp-5049	264	20	implications	implication	NOUN
fnp-5049	264	21	for	for	ADP
fnp-5049	264	22	therapy	therapy	NOUN
fnp-5049	264	23	of	of	ADP
fnp-5049	264	24	neuroimmunological	neuroimmunological	ADJ
fnp-5049	264	25	disorders	disorder	NOUN
fnp-5049	264	26	.	.	PUNCT
fnp-5049	265	1	j	j	PROPN
fnp-5049	265	2	neuroimmunol	neuroimmunol	NOUN
fnp-5049	265	3	117	117	NUM
fnp-5049	265	4	:	:	SYM
fnp-5049	265	5	1	1	NUM
fnp-5049	265	6	-	-	SYM
fnp-5049	265	7	8	8	NUM
fnp-5049	265	8	.	.	PUNCT
fnp-5049	265	9	https://doi.org/10.1016/s0165-5728(01)00330-7	https://doi.org/10.1016/s0165-5728(01)00330-7	NOUN
fnp-5049	265	10	25	25	NUM
fnp-5049	265	11	.	.	PUNCT
fnp-5049	266	1	goodkin	goodkin	PROPN
fnp-5049	266	2	de	de	PROPN
fnp-5049	266	3	,	,	PUNCT
fnp-5049	266	4	kinkel	kinkel	PROPN
fnp-5049	266	5	rp	rp	NOUN
fnp-5049	266	6	,	,	PUNCT
fnp-5049	266	7	weinstock	weinstock	NOUN
fnp-5049	266	8	-	-	PUNCT
fnp-5049	266	9	guttman	guttman	NOUN
fnp-5049	266	10	b	b	PROPN
fnp-5049	266	11	,	,	PUNCT
fnp-5049	266	12	medendorp	medendorp	PROPN
fnp-5049	266	13	sv	sv	PROPN
fnp-5049	266	14	,	,	PUNCT
fnp-5049	266	15	secic	secic	NOUN
fnp-5049	266	16	m	m	PRON
fnp-5049	266	17	,	,	PUNCT
fnp-5049	266	18	gogol	gogol	PROPN
fnp-5049	266	19	d	d	PROPN
fnp-5049	266	20	,	,	PUNCT
fnp-5049	266	21	perryman	perryman	PROPN
fnp-5049	266	22	je	je	PROPN
fnp-5049	266	23	,	,	PUNCT
fnp-5049	266	24	uccelli	uccelli	PROPN
fnp-5049	266	25	mm	mm	PROPN
fnp-5049	266	26	,	,	PUNCT
fnp-5049	266	27	neilley	neilley	PROPN
fnp-5049	266	28	l	l	PROPN
fnp-5049	266	29	(	(	PUNCT
fnp-5049	266	30	1998	1998	NUM
fnp-5049	266	31	)	)	PUNCT
fnp-5049	266	32	a	a	DET
fnp-5049	266	33	phase	phase	NOUN
fnp-5049	266	34	ii	ii	NOUN
fnp-5049	266	35	study	study	NOUN
fnp-5049	266	36	of	of	ADP
fnp-5049	266	37	iv	iv	NOUN
fnp-5049	266	38	methylprednisolone	methylprednisolone	NOUN
fnp-5049	266	39	in	in	ADP
fnp-5049	266	40	secondary	secondary	ADJ
fnp-5049	266	41	-	-	PUNCT
fnp-5049	266	42	progressive	progressive	ADJ
fnp-5049	266	43	multiple	multiple	ADJ
fnp-5049	266	44	sclerosis	sclerosis	NOUN
fnp-5049	266	45	.	.	PUNCT
fnp-5049	267	1	neurology	neurology	NOUN
fnp-5049	267	2	51	51	NUM
fnp-5049	267	3	:	:	SYM
fnp-5049	267	4	239	239	NUM
fnp-5049	267	5	-	-	SYM
fnp-5049	267	6	245	245	NUM
fnp-5049	267	7	.	.	PUNCT
fnp-5049	268	1	https://doi.org/10.1212/wnl.51.1.239	https://doi.org/10.1212/wnl.51.1.239	PROPN
fnp-5049	268	2	26	26	NUM
fnp-5049	268	3	.	.	PUNCT
fnp-5049	269	1	hodge	hodge	PROPN
fnp-5049	269	2	s	s	PROPN
fnp-5049	269	3	,	,	PUNCT
fnp-5049	269	4	hodge	hodge	PROPN
fnp-5049	269	5	g	g	PROPN
fnp-5049	269	6	,	,	PUNCT
fnp-5049	269	7	flower	flower	NOUN
fnp-5049	269	8	r	r	NOUN
fnp-5049	269	9	,	,	PUNCT
fnp-5049	269	10	han	han	PROPN
fnp-5049	269	11	p	p	PROPN
fnp-5049	269	12	(	(	PUNCT
fnp-5049	269	13	1999	1999	NUM
fnp-5049	269	14	)	)	PUNCT
fnp-5049	269	15	methyl	methyl	NOUN
fnp-5049	269	16	-	-	PUNCT
fnp-5049	269	17	prednisolone	prednisolone	NOUN
fnp-5049	269	18	up	up	ADJ
fnp-5049	269	19	-	-	PUNCT
fnp-5049	269	20	regulates	regulate	VERB
fnp-5049	269	21	monocyte	monocyte	NOUN
fnp-5049	269	22	interleukin-10	interleukin-10	PROPN
fnp-5049	269	23	production	production	NOUN
fnp-5049	269	24	in	in	ADP
fnp-5049	269	25	stimulated	stimulate	VERB
fnp-5049	269	26	whole	whole	ADJ
fnp-5049	269	27	blood	blood	NOUN
fnp-5049	269	28	.	.	PUNCT
fnp-5049	270	1	scandinavian	scandinavian	ADJ
fnp-5049	270	2	journal	journal	NOUN
fnp-5049	270	3	of	of	ADP
fnp-5049	270	4	immunology	immunology	NOUN
fnp-5049	270	5	49	49	NUM
fnp-5049	270	6	:	:	PUNCT
fnp-5049	270	7	548	548	NUM
fnp-5049	270	8	-	-	SYM
fnp-5049	270	9	553	553	NUM
fnp-5049	270	10	.	.	PUNCT
fnp-5049	271	1	https://doi.org/10.1046/j.1365-3083.1999.00538.x	https://doi.org/10.1046/j.1365-3083.1999.00538.x	NOUN
fnp-5049	271	2	27	27	NUM
fnp-5049	271	3	.	.	PUNCT
fnp-5049	272	1	illán	illán	ADJ
fnp-5049	272	2	-	-	PUNCT
fnp-5049	272	3	gala	gala	NOUN
fnp-5049	272	4	i	i	PRON
fnp-5049	272	5	,	,	PUNCT
fnp-5049	272	6	lleo	lleo	PROPN
fnp-5049	272	7	a	a	PRON
fnp-5049	272	8	,	,	PUNCT
fnp-5049	272	9	karydas	karydas	PROPN
fnp-5049	272	10	a	a	PRON
fnp-5049	272	11	,	,	PUNCT
fnp-5049	272	12	staffaroni	staffaroni	PROPN
fnp-5049	272	13	am	am	NOUN
fnp-5049	272	14	,	,	PUNCT
fnp-5049	272	15	zetterberg	zetterberg	PROPN
fnp-5049	272	16	h	h	PROPN
fnp-5049	272	17	,	,	PUNCT
fnp-5049	272	18	sivasankaran	sivasankaran	PROPN
fnp-5049	272	19	r	r	PROPN
fnp-5049	272	20	,	,	PUNCT
fnp-5049	272	21	grinberg	grinberg	PROPN
fnp-5049	272	22	lt	lt	PROPN
fnp-5049	272	23	,	,	PUNCT
fnp-5049	272	24	spina	spina	NOUN
fnp-5049	272	25	s	s	PROPN
fnp-5049	272	26	,	,	PUNCT
fnp-5049	272	27	kramer	kramer	PROPN
fnp-5049	272	28	jh	jh	PROPN
fnp-5049	272	29	,	,	PUNCT
fnp-5049	272	30	ramos	ramo	VERB
fnp-5049	272	31	em	em	PRON
fnp-5049	272	32	et	et	PROPN
fnp-5049	272	33	al	al	PROPN
fnp-5049	272	34	(	(	PUNCT
fnp-5049	272	35	2021	2021	NUM
fnp-5049	272	36	)	)	PUNCT
fnp-5049	272	37	plasma	plasma	NOUN
fnp-5049	272	38	tau	tau	PROPN
fnp-5049	272	39	and	and	CCONJ
fnp-5049	272	40	neurofilament	neurofilament	ADJ
fnp-5049	272	41	light	light	NOUN
fnp-5049	272	42	in	in	ADP
fnp-5049	272	43	frontotemporal	frontotemporal	ADJ
fnp-5049	272	44	lobar	lobar	ADJ
fnp-5049	272	45	degeneration	degeneration	NOUN
fnp-5049	272	46	and	and	CCONJ
fnp-5049	272	47	alzheimer	alzheimer	PROPN
fnp-5049	272	48	disease	disease	PROPN
fnp-5049	272	49	.	.	PUNCT
fnp-5049	273	1	neurology	neurology	NOUN
fnp-5049	273	2	96	96	NUM
fnp-5049	273	3	:	:	PUNCT
fnp-5049	273	4	e671	e671	PROPN
fnp-5049	273	5	-	-	PUNCT
fnp-5049	273	6	e683	e683	PROPN
fnp-5049	273	7	.	.	PUNCT
fnp-5049	274	1	https://doi.org/10.1212/wnl.0000000000011226	https://doi.org/10.1212/wnl.0000000000011226	PROPN
fnp-5049	274	2	28	28	NUM
fnp-5049	274	3	.	.	PUNCT
fnp-5049	275	1	jäckle	jäckle	PROPN
fnp-5049	275	2	k	k	PROPN
fnp-5049	275	3	,	,	PUNCT
fnp-5049	275	4	zeis	zeis	PROPN
fnp-5049	275	5	t	t	PROPN
fnp-5049	275	6	,	,	PUNCT
fnp-5049	275	7	schaeren	schaeren	NOUN
fnp-5049	275	8	-	-	PUNCT
fnp-5049	275	9	wiemers	wiemer	NOUN
fnp-5049	275	10	n	n	CCONJ
fnp-5049	275	11	,	,	PUNCT
fnp-5049	275	12	junker	junker	PROPN
fnp-5049	275	13	a	a	NOUN
fnp-5049	275	14	,	,	PUNCT
fnp-5049	275	15	van	van	PROPN
fnp-5049	275	16	der	der	PROPN
fnp-5049	275	17	meer	meer	PROPN
fnp-5049	275	18	f	f	PROPN
fnp-5049	275	19	,	,	PUNCT
fnp-5049	275	20	kramann	kramann	PROPN
fnp-5049	275	21	n	n	CCONJ
fnp-5049	275	22	,	,	PUNCT
fnp-5049	275	23	stadelmann	stadelmann	PROPN
fnp-5049	275	24	c	c	NOUN
fnp-5049	275	25	,	,	PUNCT
fnp-5049	275	26	brück	brück	ADJ
fnp-5049	275	27	w	w	PROPN
fnp-5049	275	28	(	(	PUNCT
fnp-5049	275	29	2020	2020	NUM
fnp-5049	275	30	)	)	PUNCT
fnp-5049	275	31	molecular	molecular	ADJ
fnp-5049	275	32	signature	signature	NOUN
fnp-5049	275	33	of	of	ADP
fnp-5049	275	34	slowly	slowly	ADV
fnp-5049	275	35	expanding	expand	VERB
fnp-5049	275	36	lesions	lesion	NOUN
fnp-5049	275	37	in	in	ADP
fnp-5049	275	38	progressive	progressive	ADJ
fnp-5049	275	39	multiple	multiple	ADJ
fnp-5049	275	40	sclerosis	sclerosis	NOUN
fnp-5049	275	41	.	.	PUNCT
fnp-5049	276	1	brain	brain	NOUN
fnp-5049	276	2	143	143	NUM
fnp-5049	276	3	:	:	PUNCT
fnp-5049	276	4	2073	2073	NUM
fnp-5049	276	5	-	-	SYM
fnp-5049	276	6	2088	2088	NUM
fnp-5049	276	7	.	.	PUNCT
fnp-5049	277	1	https://doi.org/10.1093/brain/awaa158	https://doi.org/10.1093/brain/awaa158	NOUN
fnp-5049	277	2	29	29	NUM
fnp-5049	277	3	.	.	PUNCT
fnp-5049	278	1	kapoor	kapoor	PROPN
fnp-5049	278	2	r	r	PROPN
fnp-5049	278	3	,	,	PUNCT
fnp-5049	278	4	sellebjerg	sellebjerg	NOUN
fnp-5049	278	5	f	f	PROPN
fnp-5049	278	6	,	,	PUNCT
fnp-5049	278	7	hartung	hartung	PROPN
fnp-5049	278	8	h	h	PROPN
fnp-5049	278	9	-	-	PUNCT
fnp-5049	278	10	p	p	X
fnp-5049	278	11	,	,	PUNCT
fnp-5049	278	12	arnold	arnold	PROPN
fnp-5049	278	13	d	d	PROPN
fnp-5049	278	14	,	,	PUNCT
fnp-5049	278	15	freedman	freedman	PROPN
fnp-5049	278	16	ms	ms	PROPN
fnp-5049	278	17	,	,	PUNCT
fnp-5049	278	18	jeffery	jeffery	PROPN
fnp-5049	278	19	d	d	PROPN
fnp-5049	278	20	,	,	PUNCT
fnp-5049	278	21	miller	miller	PROPN
fnp-5049	278	22	a	a	PROPN
fnp-5049	278	23	,	,	PUNCT
fnp-5049	278	24	edwards	edwards	PROPN
fnp-5049	278	25	kr	kr	PROPN
fnp-5049	278	26	,	,	PUNCT
fnp-5049	278	27	singh	singh	PROPN
fnp-5049	278	28	cm	cm	PROPN
fnp-5049	278	29	,	,	PUNCT
fnp-5049	278	30	chang	chang	PROPN
fnp-5049	278	31	i	i	PROPN
fnp-5049	278	32	(	(	PUNCT
fnp-5049	278	33	2019	2019	NUM
fnp-5049	278	34	)	)	PUNCT
fnp-5049	278	35	natalizumab	natalizumab	NOUN
fnp-5049	278	36	reduces	reduce	VERB
fnp-5049	278	37	serum	serum	NOUN
fnp-5049	278	38	concentrations	concentration	NOUN
fnp-5049	278	39	of	of	ADP
fnp-5049	278	40	neurofilament	neurofilament	ADJ
fnp-5049	278	41	light	light	NOUN
fnp-5049	278	42	chain	chain	NOUN
fnp-5049	278	43	in	in	ADP
fnp-5049	278	44	secondary	secondary	ADJ
fnp-5049	278	45	progressive	progressive	ADJ
fnp-5049	278	46	multiple	multiple	ADJ
fnp-5049	278	47	sclerosis	sclerosis	NOUN
fnp-5049	278	48	patients	patient	NOUN
fnp-5049	278	49	from	from	ADP
fnp-5049	278	50	the	the	DET
fnp-5049	278	51	phase	phase	NOUN
fnp-5049	278	52	3	3	NUM
fnp-5049	278	53	ascend	ascend	NOUN
fnp-5049	278	54	study	study	NOUN
fnp-5049	278	55	(	(	PUNCT
fnp-5049	278	56	s12	s12	PROPN
fnp-5049	278	57	.	.	PROPN
fnp-5049	278	58	008	008	NUM
fnp-5049	278	59	)	)	PUNCT
fnp-5049	278	60	.	.	PUNCT
fnp-5049	279	1	aan	aan	PROPN
fnp-5049	279	2	enterprises	enterprise	NOUN
fnp-5049	279	3	,	,	PUNCT
fnp-5049	279	4	city	city	NOUN
fnp-5049	279	5	30	30	NUM
fnp-5049	279	6	.	.	PUNCT
fnp-5049	280	1	kappos	kappos	PROPN
fnp-5049	280	2	l	l	PROPN
fnp-5049	280	3	,	,	PUNCT
fnp-5049	280	4	bar	bar	NOUN
fnp-5049	280	5	-	-	PUNCT
fnp-5049	280	6	or	or	CCONJ
fnp-5049	280	7	a	a	DET
fnp-5049	280	8	,	,	PUNCT
fnp-5049	280	9	cree	cree	ADJ
fnp-5049	280	10	bac	bac	PROPN
fnp-5049	280	11	,	,	PUNCT
fnp-5049	280	12	fox	fox	PROPN
fnp-5049	280	13	rj	rj	PROPN
fnp-5049	280	14	,	,	PUNCT
fnp-5049	280	15	giovannoni	giovannoni	NOUN
fnp-5049	280	16	g	g	NOUN
fnp-5049	280	17	,	,	PUNCT
fnp-5049	280	18	gold	gold	NOUN
fnp-5049	280	19	r	r	NOUN
fnp-5049	280	20	,	,	PUNCT
fnp-5049	280	21	vermersch	vermersch	NOUN
fnp-5049	280	22	p	p	X
fnp-5049	280	23	,	,	PUNCT
fnp-5049	280	24	arnold	arnold	PROPN
fnp-5049	280	25	dl	dl	PROPN
fnp-5049	280	26	,	,	PUNCT
fnp-5049	280	27	arnould	arnould	PROPN
fnp-5049	280	28	s	s	PROPN
fnp-5049	280	29	,	,	PUNCT
fnp-5049	280	30	scherz	scherz	PROPN
fnp-5049	280	31	t	t	PROPN
fnp-5049	280	32	et	et	PROPN
fnp-5049	280	33	al	al	PROPN
fnp-5049	280	34	(	(	PUNCT
fnp-5049	280	35	2018	2018	NUM
fnp-5049	280	36	)	)	PUNCT
fnp-5049	280	37	siponimod	siponimod	PROPN
fnp-5049	280	38	versus	versus	ADP
fnp-5049	280	39	placebo	placebo	NOUN
fnp-5049	280	40	in	in	ADP
fnp-5049	280	41	secondary	secondary	ADJ
fnp-5049	280	42	progressive	progressive	ADJ
fnp-5049	280	43	multiple	multiple	ADJ
fnp-5049	280	44	sclerosis	sclerosis	NOUN
fnp-5049	280	45	(	(	PUNCT
fnp-5049	280	46	expand	expand	VERB
fnp-5049	280	47	):	):	PUNCT
fnp-5049	280	48	a	a	DET
fnp-5049	280	49	double	double	ADJ
fnp-5049	280	50	-	-	PUNCT
fnp-5049	280	51	blind	blind	ADJ
fnp-5049	280	52	,	,	PUNCT
fnp-5049	280	53	randomised	randomise	VERB
fnp-5049	280	54	,	,	PUNCT
fnp-5049	280	55	phase	phase	NOUN
fnp-5049	280	56	3	3	NUM
fnp-5049	280	57	study	study	NOUN
fnp-5049	280	58	.	.	PUNCT
fnp-5049	281	1	lancet	lancet	NOUN
fnp-5049	281	2	391	391	NUM
fnp-5049	281	3	:	:	PUNCT
fnp-5049	281	4	1263	1263	NUM
fnp-5049	281	5	-	-	SYM
fnp-5049	281	6	1273	1273	NUM
fnp-5049	281	7	.	.	PUNCT
fnp-5049	282	1	https://doi.org/10.1016/s0140-6736(18)30475-6	https://doi.org/10.1016/s0140-6736(18)30475-6	PROPN
fnp-5049	282	2	31	31	NUM
fnp-5049	282	3	.	.	PUNCT
fnp-5049	283	1	kuhle	kuhle	PROPN
fnp-5049	283	2	j	j	PROPN
fnp-5049	283	3	,	,	PUNCT
fnp-5049	283	4	kropshofer	kropshofer	VERB
fnp-5049	283	5	h	h	PROPN
fnp-5049	283	6	,	,	PUNCT
fnp-5049	283	7	barro	barro	PROPN
fnp-5049	283	8	c	c	X
fnp-5049	283	9	,	,	PUNCT
fnp-5049	283	10	meinert	meinert	PROPN
fnp-5049	283	11	r	r	NOUN
fnp-5049	283	12	,	,	PUNCT
fnp-5049	283	13	häring	häre	VERB
fnp-5049	283	14	da	da	NOUN
fnp-5049	283	15	,	,	PUNCT
fnp-5049	283	16	leppert	leppert	PROPN
fnp-5049	283	17	d	d	PROPN
fnp-5049	283	18	,	,	PUNCT
fnp-5049	283	19	tomic	tomic	PROPN
fnp-5049	283	20	d	d	PROPN
fnp-5049	283	21	,	,	PUNCT
fnp-5049	283	22	dahlke	dahlke	PROPN
fnp-5049	283	23	f	f	PROPN
fnp-5049	283	24	,	,	PUNCT
fnp-5049	283	25	kappos	kappos	PROPN
fnp-5049	283	26	l	l	PROPN
fnp-5049	283	27	(	(	PUNCT
fnp-5049	283	28	2018	2018	NUM
fnp-5049	283	29	)	)	PUNCT
fnp-5049	283	30	siponimod	siponimod	NOUN
fnp-5049	283	31	reduces	reduce	VERB
fnp-5049	283	32	neurofilament	neurofilament	ADJ
fnp-5049	283	33	light	light	ADJ
fnp-5049	283	34	chain	chain	NOUN
fnp-5049	283	35	blood	blood	NOUN
fnp-5049	283	36	levels	level	NOUN
fnp-5049	283	37	in	in	ADP
fnp-5049	283	38	secondary	secondary	ADJ
fnp-5049	283	39	progressive	progressive	ADJ
fnp-5049	283	40	multiple	multiple	ADJ
fnp-5049	283	41	sclerosis	sclerosis	NOUN
fnp-5049	283	42	patients	patient	NOUN
fnp-5049	283	43	(	(	PUNCT
fnp-5049	283	44	s8.006	s8.006	NOUN
fnp-5049	283	45	)	)	PUNCT
fnp-5049	283	46	.	.	PUNCT
fnp-5049	284	1	90	90	NUM
fnp-5049	284	2	:	:	PUNCT
fnp-5049	284	3	s8.006	s8.006	NOUN
fnp-5049	284	4	32	32	NUM
fnp-5049	284	5	.	.	PUNCT
fnp-5049	285	1	kuhle	kuhle	PROPN
fnp-5049	285	2	j	j	PROPN
fnp-5049	285	3	,	,	PUNCT
fnp-5049	285	4	kropshofer	kropshofer	VERB
fnp-5049	285	5	h	h	NOUN
fnp-5049	285	6	,	,	PUNCT
fnp-5049	285	7	haering	haere	VERB
fnp-5049	285	8	da	da	NOUN
fnp-5049	285	9	,	,	PUNCT
fnp-5049	285	10	kundu	kundu	NOUN
fnp-5049	285	11	u	u	NOUN
fnp-5049	285	12	,	,	PUNCT
fnp-5049	285	13	meinert	meinert	PROPN
fnp-5049	285	14	r	r	PROPN
fnp-5049	285	15	,	,	PUNCT
fnp-5049	285	16	barro	barro	PROPN
fnp-5049	285	17	c	c	NOUN
fnp-5049	285	18	,	,	PUNCT
fnp-5049	285	19	dahlke	dahlke	PROPN
fnp-5049	285	20	f	f	NUM
fnp-5049	285	21	,	,	PUNCT
fnp-5049	285	22	tomic	tomic	PROPN
fnp-5049	285	23	d	d	PROPN
fnp-5049	285	24	,	,	PUNCT
fnp-5049	285	25	leppert	leppert	PROPN
fnp-5049	285	26	d	d	PROPN
fnp-5049	285	27	,	,	PUNCT
fnp-5049	285	28	kappos	kappos	PROPN
fnp-5049	285	29	l	l	PROPN
fnp-5049	285	30	(	(	PUNCT
fnp-5049	285	31	2019	2019	NUM
fnp-5049	285	32	)	)	PUNCT
fnp-5049	285	33	blood	blood	NOUN
fnp-5049	285	34	neurofilament	neurofilament	NOUN
fnp-5049	285	35	light	light	NOUN
fnp-5049	285	36	chain	chain	NOUN
fnp-5049	285	37	as	as	ADP
fnp-5049	285	38	a	a	DET
fnp-5049	285	39	biomarker	biomarker	NOUN
fnp-5049	285	40	of	of	ADP
fnp-5049	285	41	ms	ms	NOUN
fnp-5049	285	42	disease	disease	NOUN
fnp-5049	285	43	activity	activity	NOUN
fnp-5049	285	44	and	and	CCONJ
fnp-5049	285	45	treatment	treatment	NOUN
fnp-5049	285	46	response	response	NOUN
fnp-5049	285	47	.	.	PUNCT
fnp-5049	286	1	neurology	neurology	NOUN
fnp-5049	286	2	92	92	NUM
fnp-5049	286	3	:	:	PUNCT
fnp-5049	286	4	e1007	e1007	PROPN
fnp-5049	286	5	-	-	PUNCT
fnp-5049	286	6	e1015	e1015	PROPN
fnp-5049	286	7	.	.	PUNCT
fnp-5049	287	1	https://doi.org/10.1212/wnl.0000000000007032	https://doi.org/10.1212/wnl.0000000000007032	PROPN
fnp-5049	287	2	33	33	NUM
fnp-5049	287	3	.	.	PUNCT
fnp-5049	288	1	kuhle	kuhle	PROPN
fnp-5049	288	2	j	j	PROPN
fnp-5049	288	3	,	,	PUNCT
fnp-5049	288	4	kropshofer	kropshofer	VERB
fnp-5049	288	5	h	h	NOUN
fnp-5049	288	6	,	,	PUNCT
fnp-5049	288	7	haring	haring	ADJ
fnp-5049	288	8	d	d	NOUN
fnp-5049	288	9	,	,	PUNCT
fnp-5049	288	10	barro	barro	PROPN
fnp-5049	288	11	c	c	NOUN
fnp-5049	288	12	,	,	PUNCT
fnp-5049	288	13	dahlke	dahlke	PROPN
fnp-5049	288	14	f	f	PROPN
fnp-5049	288	15	,	,	PUNCT
fnp-5049	288	16	leppert	leppert	PROPN
fnp-5049	288	17	d	d	PROPN
fnp-5049	288	18	,	,	PUNCT
fnp-5049	288	19	tomic	tomic	PROPN
fnp-5049	288	20	d	d	PROPN
fnp-5049	288	21	,	,	PUNCT
fnp-5049	288	22	kappos	kappos	PROPN
fnp-5049	288	23	l	l	PROPN
fnp-5049	288	24	(	(	PUNCT
fnp-5049	288	25	2018	2018	NUM
fnp-5049	288	26	)	)	PUNCT
fnp-5049	288	27	neurofilament	neurofilament	ADJ
fnp-5049	288	28	light	light	ADJ
fnp-5049	288	29	levels	level	NOUN
fnp-5049	288	30	in	in	ADP
fnp-5049	288	31	the	the	DET
fnp-5049	288	32	blood	blood	NOUN
fnp-5049	288	33	of	of	ADP
fnp-5049	288	34	patients	patient	NOUN
fnp-5049	288	35	with	with	ADP
fnp-5049	288	36	secondary	secondary	ADJ
fnp-5049	288	37	progressive	progressive	ADJ
fnp-5049	288	38	ms	ms	NOUN
fnp-5049	288	39	are	be	AUX
fnp-5049	288	40	higher	high	ADJ
fnp-5049	288	41	than	than	ADP
fnp-5049	288	42	in	in	ADP
fnp-5049	288	43	primary	primary	ADJ
fnp-5049	288	44	progressive	progressive	ADJ
fnp-5049	288	45	ms	ms	NOUN
fnp-5049	288	46	and	and	CCONJ
fnp-5049	288	47	may	may	AUX
fnp-5049	288	48	predict	predict	VERB
fnp-5049	288	49	brain	brain	NOUN
fnp-5049	288	50	atrophy	atrophy	NOUN
fnp-5049	288	51	in	in	ADP
fnp-5049	288	52	both	both	CCONJ
fnp-5049	288	53	ms	ms	ADJ
fnp-5049	288	54	subtypes	subtype	NOUN
fnp-5049	288	55	.	.	PUNCT
fnp-5049	289	1	multiple	multiple	ADJ
fnp-5049	289	2	sclerosis	sclerosis	NOUN
fnp-5049	289	3	journal	journal	NOUN
fnp-5049	289	4	.	.	PUNCT
fnp-5049	290	1	sage	sage	NOUN
fnp-5049	290	2	publications	publication	NOUN
fnp-5049	290	3	ltd	ltd	ADJ
fnp-5049	290	4	1	1	NUM
fnp-5049	290	5	olivers	oliver	NOUN
fnp-5049	290	6	yard	yard	NOUN
fnp-5049	290	7	,	,	PUNCT
fnp-5049	290	8	55	55	NUM
fnp-5049	290	9	city	city	NOUN
fnp-5049	290	10	road	road	NOUN
fnp-5049	290	11	,	,	PUNCT
fnp-5049	290	12	london	london	PROPN
fnp-5049	290	13	ec1y	ec1y	PROPN
fnp-5049	290	14	1sp	1sp	PROPN
fnp-5049	290	15	,	,	PUNCT
fnp-5049	290	16	england	england	PROPN
fnp-5049	290	17	,	,	PUNCT
fnp-5049	290	18	city	city	NOUN
fnp-5049	290	19	,	,	PUNCT
fnp-5049	290	20	pp	pp	ADV
fnp-5049	290	21	111	111	NUM
fnp-5049	290	22	-	-	SYM
fnp-5049	290	23	111	111	NUM
fnp-5049	290	24	34	34	NUM
fnp-5049	290	25	.	.	PUNCT
fnp-5049	291	1	lassmann	lassmann	PROPN
fnp-5049	291	2	h	h	PROPN
fnp-5049	291	3	,	,	PUNCT
fnp-5049	291	4	van	van	PROPN
fnp-5049	291	5	horssen	horssen	PROPN
fnp-5049	291	6	j	j	PROPN
fnp-5049	291	7	,	,	PUNCT
fnp-5049	291	8	mahad	mahad	PROPN
fnp-5049	291	9	d	d	X
fnp-5049	291	10	(	(	PUNCT
fnp-5049	291	11	2012	2012	NUM
fnp-5049	291	12	)	)	PUNCT
fnp-5049	291	13	progressive	progressive	ADJ
fnp-5049	291	14	multiple	multiple	ADJ
fnp-5049	291	15	sclerosis	sclerosis	NOUN
fnp-5049	291	16	:	:	PUNCT
fnp-5049	291	17	pathology	pathology	NOUN
fnp-5049	291	18	and	and	CCONJ
fnp-5049	291	19	pathogenesis	pathogenesis	NOUN
fnp-5049	291	20	.	.	PUNCT
fnp-5049	292	1	nat	nat	PROPN
fnp-5049	292	2	rev	rev	VERB
fnp-5049	292	3	neurol	neurol	PROPN
fnp-5049	292	4	8	8	NUM
fnp-5049	292	5	:	:	PUNCT
fnp-5049	292	6	647	647	NUM
fnp-5049	292	7	-	-	SYM
fnp-5049	292	8	656	656	NUM
fnp-5049	292	9	.	.	PUNCT
fnp-5049	293	1	https://doi.org/10.1038/nrneurol.2012.168	https://doi.org/10.1038/nrneurol.2012.168	NOUN
fnp-5049	293	2	35	35	NUM
fnp-5049	293	3	.	.	PUNCT
fnp-5049	293	4	le	le	PROPN
fnp-5049	293	5	page	page	PROPN
fnp-5049	293	6	e	e	PROPN
fnp-5049	293	7	,	,	PUNCT
fnp-5049	293	8	veillard	veillard	PROPN
fnp-5049	293	9	d	d	PROPN
fnp-5049	293	10	,	,	PUNCT
fnp-5049	293	11	laplaud	laplaud	ADJ
fnp-5049	293	12	da	da	NOUN
fnp-5049	293	13	,	,	PUNCT
fnp-5049	293	14	hamonic	hamonic	PROPN
fnp-5049	293	15	s	s	PART
fnp-5049	293	16	,	,	PUNCT
fnp-5049	293	17	wardi	wardi	PROPN
fnp-5049	293	18	r	r	PROPN
fnp-5049	293	19	,	,	PUNCT
fnp-5049	293	20	lebrun	lebrun	NOUN
fnp-5049	293	21	c	c	NOUN
fnp-5049	293	22	,	,	PUNCT
fnp-5049	293	23	zagnoli	zagnoli	PROPN
fnp-5049	293	24	f	f	PROPN
fnp-5049	293	25	,	,	PUNCT
fnp-5049	293	26	wiertlewski	wiertlewski	PROPN
fnp-5049	293	27	s	s	PART
fnp-5049	293	28	,	,	PUNCT
fnp-5049	293	29	deburghgraeve	deburghgraeve	VERB
fnp-5049	293	30	v	v	ADP
fnp-5049	293	31	,	,	PUNCT
fnp-5049	293	32	coustans	coustan	VERB
fnp-5049	293	33	m	m	VERB
fnp-5049	293	34	et	et	NOUN
fnp-5049	293	35	al	al	PROPN
fnp-5049	293	36	(	(	PUNCT
fnp-5049	293	37	2015	2015	NUM
fnp-5049	293	38	)	)	PUNCT
fnp-5049	293	39	oral	oral	ADJ
fnp-5049	293	40	versus	versus	ADP
fnp-5049	293	41	intravenous	intravenous	ADJ
fnp-5049	293	42	high	high	ADJ
fnp-5049	293	43	-	-	PUNCT
fnp-5049	293	44	dose	dose	NOUN
fnp-5049	293	45	methylprednisolone	methylprednisolone	NOUN
fnp-5049	293	46	for	for	ADP
fnp-5049	293	47	treatment	treatment	NOUN
fnp-5049	293	48	of	of	ADP
fnp-5049	293	49	relapses	relapse	NOUN
fnp-5049	293	50	in	in	ADP
fnp-5049	293	51	patients	patient	NOUN
fnp-5049	293	52	with	with	ADP
fnp-5049	293	53	multiple	multiple	ADJ
fnp-5049	293	54	sclerosis	sclerosis	NOUN
fnp-5049	293	55	(	(	PUNCT
fnp-5049	293	56	copousep	copousep	NOUN
fnp-5049	293	57	):	):	PUNCT
fnp-5049	293	58	a	a	DET
fnp-5049	293	59	randomised	randomise	VERB
fnp-5049	293	60	,	,	PUNCT
fnp-5049	293	61	controlled	control	VERB
fnp-5049	293	62	,	,	PUNCT
fnp-5049	293	63	double	double	ADJ
fnp-5049	293	64	-	-	PUNCT
fnp-5049	293	65	blind	blind	ADJ
fnp-5049	293	66	,	,	PUNCT
fnp-5049	293	67	non	non	ADJ
fnp-5049	293	68	-	-	ADJ
fnp-5049	293	69	inferiority	inferiority	ADJ
fnp-5049	293	70	trial	trial	NOUN
fnp-5049	293	71	.	.	PUNCT
fnp-5049	294	1	lancet	lancet	NOUN
fnp-5049	294	2	386	386	NUM
fnp-5049	294	3	:	:	PUNCT
fnp-5049	294	4	974	974	NUM
fnp-5049	294	5	-	-	SYM
fnp-5049	294	6	981	981	NUM
fnp-5049	294	7	.	.	PUNCT
fnp-5049	295	1	https://doi.org/10.1016/s0140-6736(15)61137-0	https://doi.org/10.1016/s0140-6736(15)61137-0	PROPN
fnp-5049	295	2	36	36	NUM
fnp-5049	295	3	.	.	PUNCT
fnp-5049	296	1	leppert	leppert	PROPN
fnp-5049	296	2	d	d	PROPN
fnp-5049	296	3	,	,	PUNCT
fnp-5049	296	4	kropshofer	kropshofer	VERB
fnp-5049	296	5	h	h	NOUN
fnp-5049	296	6	,	,	PUNCT
fnp-5049	296	7	häring	häre	VERB
fnp-5049	296	8	da	da	NOUN
fnp-5049	296	9	,	,	PUNCT
fnp-5049	296	10	dahlke	dahlke	PROPN
fnp-5049	296	11	f	f	PROPN
fnp-5049	296	12	,	,	PUNCT
fnp-5049	296	13	patil	patil	PROPN
fnp-5049	296	14	a	a	PROPN
fnp-5049	296	15	,	,	PUNCT
fnp-5049	296	16	meinert	meinert	PROPN
fnp-5049	296	17	r	r	NOUN
fnp-5049	296	18	,	,	PUNCT
fnp-5049	296	19	tomic	tomic	ADJ
fnp-5049	296	20	d	d	PROPN
fnp-5049	296	21	,	,	PUNCT
fnp-5049	296	22	kappos	kappos	PROPN
fnp-5049	296	23	l	l	PROPN
fnp-5049	296	24	,	,	PUNCT
fnp-5049	296	25	kuhle	kuhle	PROPN
fnp-5049	296	26	j	j	PROPN
fnp-5049	296	27	(	(	PUNCT
fnp-5049	296	28	2022	2022	NUM
fnp-5049	296	29	)	)	PUNCT
fnp-5049	296	30	blood	blood	NOUN
fnp-5049	296	31	neurofilament	neurofilament	NOUN
fnp-5049	296	32	light	light	NOUN
fnp-5049	296	33	in	in	ADP
fnp-5049	296	34	progressive	progressive	ADJ
fnp-5049	296	35	multiple	multiple	ADJ
fnp-5049	296	36	sclerosis	sclerosis	NOUN
fnp-5049	296	37	:	:	PUNCT
fnp-5049	296	38	post	post	VERB
fnp-5049	296	39	hoc	hoc	X
fnp-5049	296	40	analysis	analysis	NOUN
fnp-5049	296	41	of	of	ADP
fnp-5049	296	42	2	2	NUM
fnp-5049	296	43	randomized	randomized	ADJ
fnp-5049	296	44	controlled	control	VERB
fnp-5049	296	45	trials	trial	NOUN
fnp-5049	296	46	.	.	PUNCT
fnp-5049	297	1	neurology	neurology	NOUN
fnp-5049	297	2	98	98	NUM
fnp-5049	297	3	:	:	PUNCT
fnp-5049	297	4	e2120	e2120	NOUN
fnp-5049	297	5	-	-	PUNCT
fnp-5049	297	6	e2131	e2131	PROPN
fnp-5049	297	7	.	.	PUNCT
fnp-5049	298	1	https://doi.org/10.1212/wnl.0000000000200258	https://doi.org/10.1212/wnl.0000000000200258	PROPN
fnp-5049	298	2	37	37	NUM
fnp-5049	298	3	.	.	PUNCT
fnp-5049	299	1	leussink	leussink	PROPN
fnp-5049	299	2	vi	vi	PROPN
fnp-5049	299	3	,	,	PUNCT
fnp-5049	299	4	jung	jung	PROPN
fnp-5049	299	5	s	s	PROPN
fnp-5049	299	6	,	,	PUNCT
fnp-5049	299	7	merschdorf	merschdorf	PROPN
fnp-5049	299	8	u	u	PROPN
fnp-5049	299	9	,	,	PUNCT
fnp-5049	299	10	toyka	toyka	PROPN
fnp-5049	299	11	kv	kv	PROPN
fnp-5049	299	12	,	,	PUNCT
fnp-5049	299	13	gold	gold	NOUN
fnp-5049	299	14	r	r	NOUN
fnp-5049	299	15	(	(	PUNCT
fnp-5049	299	16	2001	2001	NUM
fnp-5049	299	17	)	)	PUNCT
fnp-5049	299	18	high	high	ADJ
fnp-5049	299	19	-	-	PUNCT
fnp-5049	299	20	dose	dose	NOUN
fnp-5049	299	21	methylprednisolone	methylprednisolone	NOUN
fnp-5049	299	22	therapy	therapy	NOUN
fnp-5049	299	23	in	in	ADP
fnp-5049	299	24	multiple	multiple	ADJ
fnp-5049	299	25	sclerosis	sclerosis	NOUN
fnp-5049	299	26	induces	induce	VERB
fnp-5049	299	27	apoptosis	apoptosis	NOUN
fnp-5049	299	28	in	in	ADP
fnp-5049	299	29	peripheral	peripheral	ADJ
fnp-5049	299	30	blood	blood	NOUN
fnp-5049	299	31	leukocytes	leukocyte	NOUN
fnp-5049	299	32	.	.	PUNCT
fnp-5049	300	1	archives	archive	NOUN
fnp-5049	300	2	of	of	ADP
fnp-5049	300	3	neurology	neurology	NOUN
fnp-5049	300	4	58	58	NUM
fnp-5049	300	5	:	:	PUNCT
fnp-5049	300	6	91	91	NUM
fnp-5049	300	7	-	-	SYM
fnp-5049	300	8	97	97	NUM
fnp-5049	300	9	.	.	PUNCT
fnp-5049	301	1	https://doi.org/10.1001/archneur.58.1.91	https://doi.org/10.1001/archneur.58.1.91	PROPN
fnp-5049	301	2	38	38	NUM
fnp-5049	301	3	.	.	PUNCT
fnp-5049	302	1	lim	lim	PROPN
fnp-5049	302	2	hy	hy	PROPN
fnp-5049	302	3	,	,	PUNCT
fnp-5049	302	4	müller	müller	PROPN
fnp-5049	302	5	n	n	CCONJ
fnp-5049	302	6	,	,	PUNCT
fnp-5049	302	7	herold	herold	PROPN
fnp-5049	302	8	mj	mj	PROPN
fnp-5049	302	9	,	,	PUNCT
fnp-5049	302	10	van	van	PROPN
fnp-5049	302	11	den	den	PROPN
fnp-5049	302	12	brandt	brandt	PROPN
fnp-5049	302	13	j	j	PROPN
fnp-5049	302	14	,	,	PUNCT
fnp-5049	302	15	reichardt	reichardt	PROPN
fnp-5049	302	16	hm	hm	INTJ
fnp-5049	302	17	(	(	PUNCT
fnp-5049	302	18	2007	2007	NUM
fnp-5049	302	19	)	)	PUNCT
fnp-5049	302	20	glucocorticoids	glucocorticoid	NOUN
fnp-5049	302	21	exert	exert	VERB
fnp-5049	302	22	opposing	opposing	ADJ
fnp-5049	302	23	effects	effect	NOUN
fnp-5049	302	24	on	on	ADP
fnp-5049	302	25	macrophage	macrophage	ADJ
fnp-5049	302	26	function	function	NOUN
fnp-5049	302	27	dependent	dependent	ADJ
fnp-5049	302	28	on	on	ADP
fnp-5049	302	29	their	their	PRON
fnp-5049	302	30	concentration	concentration	NOUN
fnp-5049	302	31	.	.	PUNCT
fnp-5049	303	1	immunology	immunology	NOUN
fnp-5049	303	2	122	122	NUM
fnp-5049	303	3	:	:	PUNCT
fnp-5049	303	4	47	47	NUM
fnp-5049	303	5	-	-	SYM
fnp-5049	303	6	53	53	NUM
fnp-5049	303	7	.	.	PUNCT
fnp-5049	304	1	https://doi.org/10.1111/j.1365-2567.2007.02611.x	https://doi.org/10.1111/j.1365-2567.2007.02611.x	VERB
fnp-5049	304	2	39	39	NUM
fnp-5049	304	3	.	.	PUNCT
fnp-5049	305	1	luchetti	luchetti	PROPN
fnp-5049	305	2	s	s	PROPN
fnp-5049	305	3	,	,	PUNCT
fnp-5049	305	4	fransen	fransen	ADJ
fnp-5049	305	5	nl	nl	PROPN
fnp-5049	305	6	,	,	PUNCT
fnp-5049	305	7	van	van	PROPN
fnp-5049	305	8	eden	eden	PROPN
fnp-5049	305	9	cg	cg	PROPN
fnp-5049	305	10	,	,	PUNCT
fnp-5049	305	11	ramaglia	ramaglia	PROPN
fnp-5049	305	12	v	v	PROPN
fnp-5049	305	13	,	,	PUNCT
fnp-5049	305	14	mason	mason	PROPN
fnp-5049	305	15	m	m	PROPN
fnp-5049	305	16	,	,	PUNCT
fnp-5049	305	17	huitinga	huitinga	VERB
fnp-5049	305	18	i	i	PRON
fnp-5049	305	19	(	(	PUNCT
fnp-5049	305	20	2018	2018	NUM
fnp-5049	305	21	)	)	PUNCT
fnp-5049	305	22	progressive	progressive	ADJ
fnp-5049	305	23	multiple	multiple	ADJ
fnp-5049	305	24	sclerosis	sclerosis	NOUN
fnp-5049	305	25	patients	patient	NOUN
fnp-5049	305	26	show	show	VERB
fnp-5049	305	27	substantial	substantial	ADJ
fnp-5049	305	28	lesion	lesion	NOUN
fnp-5049	305	29	activity	activity	NOUN
fnp-5049	305	30	that	that	PRON
fnp-5049	305	31	correlates	correlate	VERB
fnp-5049	305	32	with	with	ADP
fnp-5049	305	33	clinical	clinical	ADJ
fnp-5049	305	34	disease	disease	NOUN
fnp-5049	305	35	severity	severity	NOUN
fnp-5049	305	36	and	and	CCONJ
fnp-5049	305	37	sex	sex	NOUN
fnp-5049	305	38	:	:	PUNCT
fnp-5049	305	39	a	a	DET
fnp-5049	305	40	retrospective	retrospective	ADJ
fnp-5049	305	41	autopsy	autopsy	ADJ
fnp-5049	305	42	cohort	cohort	NOUN
fnp-5049	305	43	analysis	analysis	NOUN
fnp-5049	305	44	.	.	PUNCT
fnp-5049	306	1	acta	acta	PROPN
fnp-5049	306	2	neuropathol	neuropathol	PROPN
fnp-5049	306	3	135	135	NUM
fnp-5049	306	4	:	:	PUNCT
fnp-5049	306	5	511	511	NUM
fnp-5049	306	6	-	-	SYM
fnp-5049	306	7	528	528	NUM
fnp-5049	306	8	.	.	PUNCT
fnp-5049	307	1	https://doi.org/10.1007/s00401-018-1818-y	https://doi.org/10.1007/s00401-018-1818-y	PROPN
fnp-5049	307	2	40	40	NUM
fnp-5049	307	3	.	.	PUNCT
fnp-5049	308	1	magliozzi	magliozzi	NOUN
fnp-5049	308	2	r	r	NOUN
fnp-5049	308	3	,	,	PUNCT
fnp-5049	308	4	howell	howell	PROPN
fnp-5049	308	5	o	o	NOUN
fnp-5049	308	6	,	,	PUNCT
fnp-5049	308	7	vora	vora	PROPN
fnp-5049	308	8	a	a	X
fnp-5049	308	9	,	,	PUNCT
fnp-5049	308	10	serafini	serafini	ADJ
fnp-5049	308	11	b	b	PROPN
fnp-5049	308	12	,	,	PUNCT
fnp-5049	308	13	nicholas	nicholas	PROPN
fnp-5049	308	14	r	r	PROPN
fnp-5049	308	15	,	,	PUNCT
fnp-5049	308	16	puopolo	puopolo	PROPN
fnp-5049	308	17	m	m	PROPN
fnp-5049	308	18	,	,	PUNCT
fnp-5049	308	19	reynolds	reynolds	PROPN
fnp-5049	308	20	r	r	PROPN
fnp-5049	308	21	,	,	PUNCT
fnp-5049	308	22	aloisi	aloisi	ADJ
fnp-5049	308	23	f	f	X
fnp-5049	308	24	(	(	PUNCT
fnp-5049	308	25	2007	2007	NUM
fnp-5049	308	26	)	)	PUNCT
fnp-5049	308	27	meningeal	meningeal	ADJ
fnp-5049	308	28	b	b	NOUN
fnp-5049	308	29	-	-	PUNCT
fnp-5049	308	30	cell	cell	NOUN
fnp-5049	308	31	follicles	follicle	NOUN
fnp-5049	308	32	in	in	ADP
fnp-5049	308	33	secondary	secondary	ADJ
fnp-5049	308	34	progressive	progressive	ADJ
fnp-5049	308	35	multiple	multiple	ADJ
fnp-5049	308	36	sclerosis	sclerosis	NOUN
fnp-5049	308	37	associate	associate	NOUN
fnp-5049	308	38	with	with	ADP
fnp-5049	308	39	early	early	ADJ
fnp-5049	308	40	onset	onset	NOUN
fnp-5049	308	41	of	of	ADP
fnp-5049	308	42	disease	disease	NOUN
fnp-5049	308	43	and	and	CCONJ
fnp-5049	308	44	severe	severe	ADJ
fnp-5049	308	45	cortical	cortical	ADJ
fnp-5049	308	46	pathology	pathology	NOUN
fnp-5049	308	47	.	.	PUNCT
fnp-5049	309	1	brain	brain	NOUN
fnp-5049	309	2	130	130	NUM
fnp-5049	309	3	:	:	PUNCT
fnp-5049	309	4	1089	1089	NUM
fnp-5049	309	5	-	-	SYM
fnp-5049	309	6	1104	1104	NUM
fnp-5049	309	7	.	.	PUNCT
fnp-5049	310	1	https://doi.org/10.1093/brain/awm038	https://doi.org/10.1093/brain/awm038	PROPN
fnp-5049	310	2	41	41	NUM
fnp-5049	310	3	.	.	PUNCT
fnp-5049	311	1	mahad	mahad	PROPN
fnp-5049	311	2	dh	dh	PROPN
fnp-5049	311	3	,	,	PUNCT
fnp-5049	311	4	trapp	trapp	PROPN
fnp-5049	311	5	bd	bd	PROPN
fnp-5049	311	6	,	,	PUNCT
fnp-5049	311	7	lassmann	lassmann	PROPN
fnp-5049	311	8	h	h	PROPN
fnp-5049	311	9	(	(	PUNCT
fnp-5049	311	10	2015	2015	NUM
fnp-5049	311	11	)	)	PUNCT
fnp-5049	311	12	pathological	pathological	ADJ
fnp-5049	311	13	mechanisms	mechanism	NOUN
fnp-5049	311	14	in	in	ADP
fnp-5049	311	15	progressive	progressive	ADJ
fnp-5049	311	16	multiple	multiple	ADJ
fnp-5049	311	17	sclerosis	sclerosis	NOUN
fnp-5049	311	18	.	.	PUNCT
fnp-5049	312	1	lancet	lancet	PROPN
fnp-5049	312	2	neurol	neurol	PROPN
fnp-5049	312	3	14	14	NUM
fnp-5049	312	4	:	:	SYM
fnp-5049	312	5	183	183	NUM
fnp-5049	312	6	-	-	SYM
fnp-5049	312	7	193	193	NUM
fnp-5049	312	8	.	.	PUNCT
fnp-5049	313	1	https://doi.org/10.1016/s1474-4422(14)70256-x	https://doi.org/10.1016/s1474-4422(14)70256-x	PROPN
fnp-5049	313	2	42	42	NUM
fnp-5049	313	3	.	.	PUNCT
fnp-5049	314	1	martínez	martínez	NOUN
fnp-5049	314	2	-	-	PUNCT
fnp-5049	314	3	cáceres	cácere	VERB
fnp-5049	314	4	em	em	PRON
fnp-5049	314	5	,	,	PUNCT
fnp-5049	314	6	barrau	barrau	PROPN
fnp-5049	314	7	ma	ma	PROPN
fnp-5049	314	8	,	,	PUNCT
fnp-5049	314	9	brieva	brieva	NOUN
fnp-5049	314	10	l	l	PROPN
fnp-5049	314	11	,	,	PUNCT
fnp-5049	314	12	espejo	espejo	PROPN
fnp-5049	314	13	c	c	PROPN
fnp-5049	314	14	,	,	PUNCT
fnp-5049	314	15	barberà	barberà	ADJ
fnp-5049	314	16	n	n	CCONJ
fnp-5049	314	17	,	,	PUNCT
fnp-5049	314	18	montalban	montalban	PROPN
fnp-5049	314	19	x	x	SYM
fnp-5049	314	20	(	(	PUNCT
fnp-5049	314	21	2002	2002	NUM
fnp-5049	314	22	)	)	PUNCT
fnp-5049	314	23	treatment	treatment	NOUN
fnp-5049	314	24	with	with	ADP
fnp-5049	314	25	methylprednisolone	methylprednisolone	NOUN
fnp-5049	314	26	in	in	ADP
fnp-5049	314	27	relapses	relapse	NOUN
fnp-5049	314	28	of	of	ADP
fnp-5049	314	29	multiple	multiple	ADJ
fnp-5049	314	30	sclerosis	sclerosis	NOUN
fnp-5049	314	31	patients	patient	NOUN
fnp-5049	314	32	:	:	PUNCT
fnp-5049	314	33	immunological	immunological	ADJ
fnp-5049	314	34	evidence	evidence	NOUN
fnp-5049	314	35	of	of	ADP
fnp-5049	314	36	immediate	immediate	ADJ
fnp-5049	314	37	and	and	CCONJ
fnp-5049	314	38	short	short	ADJ
fnp-5049	314	39	-	-	PUNCT
fnp-5049	314	40	term	term	NOUN
fnp-5049	314	41	but	but	CCONJ
fnp-5049	314	42	not	not	PART
fnp-5049	314	43	long	long	ADV
fnp-5049	314	44	-	-	PUNCT
fnp-5049	314	45	lasting	last	VERB
fnp-5049	314	46	effects	effect	NOUN
fnp-5049	314	47	.	.	PUNCT
fnp-5049	315	1	clin	clin	PROPN
fnp-5049	315	2	exp	exp	PROPN
fnp-5049	315	3	immunol	immunol	PROPN
fnp-5049	315	4	127	127	NUM
fnp-5049	315	5	:	:	PUNCT
fnp-5049	315	6	165	165	NUM
fnp-5049	315	7	-	-	SYM
fnp-5049	315	8	171	171	NUM
fnp-5049	315	9	.	.	PUNCT
fnp-5049	316	1	https://doi.org/10.1046/j.1365-2249.2002.01725.x	https://doi.org/10.1046/j.1365-2249.2002.01725.x	NOUN
fnp-5049	316	2	43	43	NUM
fnp-5049	316	3	.	.	PUNCT
fnp-5049	317	1	miller	miller	PROPN
fnp-5049	317	2	dh	dh	PROPN
fnp-5049	317	3	,	,	PUNCT
fnp-5049	317	4	thompson	thompson	PROPN
fnp-5049	317	5	aj	aj	PROPN
fnp-5049	317	6	,	,	PUNCT
fnp-5049	317	7	morrissey	morrissey	PROPN
fnp-5049	317	8	sp	sp	PROPN
fnp-5049	317	9	,	,	PUNCT
fnp-5049	317	10	macmanus	macmanus	PROPN
fnp-5049	317	11	dg	dg	PROPN
fnp-5049	317	12	,	,	PUNCT
fnp-5049	317	13	moore	moore	PROPN
fnp-5049	317	14	sg	sg	PROPN
fnp-5049	317	15	,	,	PUNCT
fnp-5049	317	16	kendall	kendall	PROPN
fnp-5049	317	17	be	be	PROPN
fnp-5049	317	18	,	,	PUNCT
fnp-5049	317	19	moseley	moseley	ADJ
fnp-5049	317	20	if	if	SCONJ
fnp-5049	317	21	,	,	PUNCT
fnp-5049	317	22	mcdonald	mcdonald	PROPN
fnp-5049	317	23	wi	wi	PROPN
fnp-5049	317	24	(	(	PUNCT
fnp-5049	317	25	1992	1992	NUM
fnp-5049	317	26	)	)	PUNCT
fnp-5049	317	27	high	high	ADJ
fnp-5049	317	28	dose	dose	NOUN
fnp-5049	317	29	steroids	steroid	NOUN
fnp-5049	317	30	in	in	ADP
fnp-5049	317	31	acute	acute	ADJ
fnp-5049	317	32	relapses	relapse	NOUN
fnp-5049	317	33	of	of	ADP
fnp-5049	317	34	multiple	multiple	ADJ
fnp-5049	317	35	sclerosis	sclerosis	NOUN
fnp-5049	317	36	:	:	PUNCT
fnp-5049	317	37	mri	mri	NOUN
fnp-5049	317	38	evidence	evidence	NOUN
fnp-5049	317	39	for	for	ADP
fnp-5049	317	40	a	a	DET
fnp-5049	317	41	possible	possible	ADJ
fnp-5049	317	42	mechanism	mechanism	NOUN
fnp-5049	317	43	of	of	ADP
fnp-5049	317	44	therapeutic	therapeutic	ADJ
fnp-5049	317	45	effect	effect	NOUN
fnp-5049	317	46	.	.	PUNCT
fnp-5049	318	1	j	j	PROPN
fnp-5049	318	2	neurol	neurol	PROPN
fnp-5049	318	3	neurosurg	neurosurg	PROPN
fnp-5049	318	4	psychiatry	psychiatry	NOUN
fnp-5049	318	5	55	55	NUM
fnp-5049	318	6	:	:	PUNCT
fnp-5049	318	7	450	450	NUM
fnp-5049	318	8	-	-	SYM
fnp-5049	318	9	453	453	NUM
fnp-5049	318	10	.	.	PUNCT
fnp-5049	319	1	https://doi.org/10.1136/jnnp.55.6.450	https://doi.org/10.1136/jnnp.55.6.450	PROPN
fnp-5049	319	2	44	44	NUM
fnp-5049	319	3	.	.	PUNCT
fnp-5049	320	1	milligan	milligan	PROPN
fnp-5049	320	2	nm	nm	PROPN
fnp-5049	320	3	,	,	PUNCT
fnp-5049	320	4	newcombe	newcombe	PROPN
fnp-5049	320	5	r	r	PROPN
fnp-5049	320	6	,	,	PUNCT
fnp-5049	320	7	compston	compston	NOUN
fnp-5049	320	8	da	da	PROPN
fnp-5049	320	9	(	(	PUNCT
fnp-5049	320	10	1987	1987	NUM
fnp-5049	320	11	)	)	PUNCT
fnp-5049	320	12	a	a	DET
fnp-5049	320	13	double	double	ADJ
fnp-5049	320	14	-	-	PUNCT
fnp-5049	320	15	blind	blind	ADJ
fnp-5049	320	16	controlled	control	VERB
fnp-5049	320	17	trial	trial	NOUN
fnp-5049	320	18	of	of	ADP
fnp-5049	320	19	high	high	ADJ
fnp-5049	320	20	dose	dose	NOUN
fnp-5049	320	21	methylprednisolone	methylprednisolone	NOUN
fnp-5049	320	22	in	in	ADP
fnp-5049	320	23	patients	patient	NOUN
fnp-5049	320	24	with	with	ADP
fnp-5049	320	25	multiple	multiple	ADJ
fnp-5049	320	26	sclerosis	sclerosis	NOUN
fnp-5049	320	27	:	:	PUNCT
fnp-5049	320	28	1	1	X
fnp-5049	320	29	.	.	PUNCT
fnp-5049	320	30	clinical	clinical	ADJ
fnp-5049	320	31	effects	effect	NOUN
fnp-5049	320	32	.	.	PUNCT
fnp-5049	321	1	j	j	PROPN
fnp-5049	321	2	neurol	neurol	PROPN
fnp-5049	321	3	neurosurg	neurosurg	PROPN
fnp-5049	321	4	psychiatry	psychiatry	NOUN
fnp-5049	321	5	50	50	NUM
fnp-5049	321	6	:	:	PUNCT
fnp-5049	321	7	511	511	NUM
fnp-5049	321	8	-	-	SYM
fnp-5049	321	9	516	516	NUM
fnp-5049	321	10	.	.	PUNCT
fnp-5049	322	1	https://doi.org/10.1136/jnnp.50.5.511	https://doi.org/10.1136/jnnp.50.5.511	PROPN
fnp-5049	322	2	45	45	NUM
fnp-5049	322	3	.	.	PUNCT
fnp-5049	323	1	ratzer	ratzer	NOUN
fnp-5049	323	2	r	r	NOUN
fnp-5049	323	3	,	,	PUNCT
fnp-5049	323	4	iversen	iversen	NOUN
fnp-5049	323	5	p	p	NOUN
fnp-5049	323	6	,	,	PUNCT
fnp-5049	323	7	börnsen	börnsen	PROPN
fnp-5049	323	8	l	l	PROPN
fnp-5049	323	9	,	,	PUNCT
fnp-5049	323	10	dyrby	dyrby	ADJ
fnp-5049	323	11	tb	tb	NOUN
fnp-5049	323	12	,	,	PUNCT
fnp-5049	323	13	romme	romme	PROPN
fnp-5049	323	14	christensen	christensen	PROPN
fnp-5049	323	15	j	j	PROPN
fnp-5049	323	16	,	,	PUNCT
fnp-5049	323	17	ammitzbøll	ammitzbøll	NOUN
fnp-5049	323	18	c	c	PROPN
fnp-5049	323	19	,	,	PUNCT
fnp-5049	323	20	madsen	madsen	PROPN
fnp-5049	323	21	cg	cg	PROPN
fnp-5049	323	22	,	,	PUNCT
fnp-5049	323	23	garde	garde	PROPN
fnp-5049	323	24	e	e	PROPN
fnp-5049	323	25	,	,	PUNCT
fnp-5049	323	26	lyksborg	lyksborg	NOUN
fnp-5049	323	27	m	m	PROPN
fnp-5049	323	28	,	,	PUNCT
fnp-5049	323	29	andersen	andersen	PROPN
fnp-5049	323	30	b	b	PROPN
fnp-5049	323	31	et	et	PROPN
fnp-5049	323	32	al	al	PROPN
fnp-5049	323	33	(	(	PUNCT
fnp-5049	323	34	2016	2016	NUM
fnp-5049	323	35	)	)	PUNCT
fnp-5049	323	36	monthly	monthly	ADJ
fnp-5049	323	37	oral	oral	ADJ
fnp-5049	323	38	methylprednisolone	methylprednisolone	ADJ
fnp-5049	323	39	pulse	pulse	NOUN
fnp-5049	323	40	treatment	treatment	NOUN
fnp-5049	323	41	in	in	ADP
fnp-5049	323	42	progressive	progressive	ADJ
fnp-5049	323	43	multiple	multiple	ADJ
fnp-5049	323	44	sclerosis	sclerosis	NOUN
fnp-5049	323	45	.	.	PUNCT
fnp-5049	324	1	mult	mult	PROPN
fnp-5049	324	2	scler	scler	PROPN
fnp-5049	324	3	22	22	NUM
fnp-5049	324	4	:	:	PUNCT
fnp-5049	324	5	926	926	NUM
fnp-5049	324	6	-	-	SYM
fnp-5049	324	7	934	934	NUM
fnp-5049	324	8	.	.	PUNCT
fnp-5049	325	1	https://doi.org/10.1177/1352458515605908	https://doi.org/10.1177/1352458515605908	PROPN
fnp-5049	325	2	46	46	NUM
fnp-5049	325	3	.	.	PUNCT
fnp-5049	326	1	ravnborg	ravnborg	PROPN
fnp-5049	326	2	m	m	PROPN
fnp-5049	326	3	,	,	PUNCT
fnp-5049	326	4	sørensen	sørensen	PROPN
fnp-5049	326	5	ps	ps	PROPN
fnp-5049	326	6	,	,	PUNCT
fnp-5049	326	7	andersson	andersson	PROPN
fnp-5049	326	8	m	m	PROPN
fnp-5049	326	9	,	,	PUNCT
fnp-5049	326	10	celius	celius	PROPN
fnp-5049	326	11	eg	eg	PROPN
fnp-5049	326	12	,	,	PUNCT
fnp-5049	326	13	jongen	jongen	PROPN
fnp-5049	326	14	pj	pj	PROPN
fnp-5049	326	15	,	,	PUNCT
fnp-5049	326	16	elovaara	elovaara	PROPN
fnp-5049	326	17	i	i	PROPN
fnp-5049	326	18	,	,	PUNCT
fnp-5049	326	19	bartholomé	bartholomé	NOUN
fnp-5049	326	20	e	e	NOUN
fnp-5049	326	21	,	,	PUNCT
fnp-5049	326	22	constantinescu	constantinescu	PROPN
fnp-5049	326	23	cs	cs	PROPN
fnp-5049	326	24	,	,	PUNCT
fnp-5049	326	25	beer	beer	NOUN
fnp-5049	326	26	k	k	PROPN
fnp-5049	326	27	,	,	PUNCT
fnp-5049	326	28	garde	garde	X
fnp-5049	326	29	e	e	X
fnp-5049	326	30	et	et	PROPN
fnp-5049	326	31	al	al	PROPN
fnp-5049	326	32	(	(	PUNCT
fnp-5049	326	33	2010	2010	NUM
fnp-5049	326	34	)	)	PUNCT
fnp-5049	326	35	methylprednisolone	methylprednisolone	NOUN
fnp-5049	326	36	in	in	ADP
fnp-5049	326	37	combination	combination	NOUN
fnp-5049	326	38	with	with	ADP
fnp-5049	326	39	interferon	interferon	ADJ
fnp-5049	326	40	beta-1a	beta-1a	NOUN
fnp-5049	326	41	for	for	ADP
fnp-5049	326	42	relapsing	relapse	VERB
fnp-5049	326	43	-	-	PUNCT
fnp-5049	326	44	remitting	remit	VERB
fnp-5049	326	45	multiple	multiple	ADJ
fnp-5049	326	46	sclerosis	sclerosis	NOUN
fnp-5049	326	47	(	(	PUNCT
fnp-5049	326	48	mecombin	mecombin	NOUN
fnp-5049	326	49	study	study	NOUN
fnp-5049	326	50	):	):	PUNCT
fnp-5049	326	51	a	a	DET
fnp-5049	326	52	multicentre	multicentre	NOUN
fnp-5049	326	53	,	,	PUNCT
fnp-5049	326	54	double	double	ADJ
fnp-5049	326	55	-	-	PUNCT
fnp-5049	326	56	blind	blind	ADJ
fnp-5049	326	57	,	,	PUNCT
fnp-5049	326	58	randomised	randomise	VERB
fnp-5049	326	59	,	,	PUNCT
fnp-5049	326	60	placebo	placebo	NOUN
fnp-5049	326	61	-	-	PUNCT
fnp-5049	326	62	controlled	control	VERB
fnp-5049	326	63	,	,	PUNCT
fnp-5049	326	64	parallel	parallel	ADJ
fnp-5049	326	65	-	-	PUNCT
fnp-5049	326	66	group	group	NOUN
fnp-5049	326	67	trial	trial	NOUN
fnp-5049	326	68	.	.	PUNCT
fnp-5049	327	1	lancet	lancet	PROPN
fnp-5049	327	2	neurol	neurol	NOUN
fnp-5049	327	3	9	9	NUM
fnp-5049	327	4	:	:	PUNCT
fnp-5049	327	5	672	672	NUM
fnp-5049	327	6	-	-	SYM
fnp-5049	327	7	680	680	NUM
fnp-5049	327	8	.	.	PUNCT
fnp-5049	328	1	https://doi.org/10.1016/s1474-4422(10)70132-0	https://doi.org/10.1016/s1474-4422(10)70132-0	PROPN
fnp-5049	328	2	47	47	NUM
fnp-5049	328	3	.	.	PUNCT
fnp-5049	329	1	salvador	salvador	PROPN
fnp-5049	329	2	e	e	PROPN
fnp-5049	329	3	,	,	PUNCT
fnp-5049	329	4	shityakov	shityakov	PROPN
fnp-5049	329	5	s	s	PROPN
fnp-5049	329	6	,	,	PUNCT
fnp-5049	329	7	förster	förster	NOUN
fnp-5049	329	8	c	c	PROPN
fnp-5049	329	9	(	(	PUNCT
fnp-5049	329	10	2014	2014	NUM
fnp-5049	329	11	)	)	PUNCT
fnp-5049	329	12	glucocorticoids	glucocorticoid	NOUN
fnp-5049	329	13	and	and	CCONJ
fnp-5049	329	14	endothelial	endothelial	ADJ
fnp-5049	329	15	cell	cell	NOUN
fnp-5049	329	16	barrier	barrier	NOUN
fnp-5049	329	17	function	function	NOUN
fnp-5049	329	18	.	.	PUNCT
fnp-5049	330	1	cell	cell	NOUN
fnp-5049	330	2	and	and	CCONJ
fnp-5049	330	3	tissue	tissue	NOUN
fnp-5049	330	4	research	research	NOUN
fnp-5049	330	5	355	355	NUM
fnp-5049	330	6	:	:	PUNCT
fnp-5049	330	7	597	597	NUM
fnp-5049	330	8	-	-	SYM
fnp-5049	330	9	605	605	NUM
fnp-5049	330	10	.	.	PUNCT
fnp-5049	331	1	https://doi.org/10.1007/s00441-013-1762-z	https://doi.org/10.1007/s00441-013-1762-z	NOUN
fnp-5049	331	2	48	48	NUM
fnp-5049	331	3	.	.	PUNCT
fnp-5049	332	1	shahim	shahim	PROPN
fnp-5049	332	2	p	p	PROPN
fnp-5049	332	3	,	,	PUNCT
fnp-5049	332	4	politis	politis	PROPN
fnp-5049	332	5	a	a	X
fnp-5049	332	6	,	,	PUNCT
fnp-5049	332	7	van	van	PROPN
fnp-5049	332	8	der	der	PROPN
fnp-5049	332	9	merwe	merwe	PROPN
fnp-5049	332	10	a	a	PROPN
fnp-5049	332	11	,	,	PUNCT
fnp-5049	332	12	moore	moore	PROPN
fnp-5049	332	13	b	b	PROPN
fnp-5049	332	14	,	,	PUNCT
fnp-5049	332	15	chou	chou	PROPN
fnp-5049	332	16	yy	yy	PROPN
fnp-5049	332	17	,	,	PUNCT
fnp-5049	332	18	pham	pham	PROPN
fnp-5049	332	19	dl	dl	PROPN
fnp-5049	332	20	,	,	PUNCT
fnp-5049	332	21	butman	butman	PROPN
fnp-5049	332	22	ja	ja	PROPN
fnp-5049	332	23	,	,	PUNCT
fnp-5049	332	24	diaz	diaz	PROPN
fnp-5049	332	25	-	-	PUNCT
fnp-5049	332	26	arrastia	arrastia	NOUN
fnp-5049	332	27	r	r	NOUN
fnp-5049	332	28	,	,	PUNCT
fnp-5049	332	29	gill	gill	PROPN
fnp-5049	332	30	jm	jm	PROPN
fnp-5049	332	31	,	,	PUNCT
fnp-5049	332	32	brody	brody	PROPN
fnp-5049	332	33	dl	dl	PROPN
fnp-5049	332	34	et	et	PROPN
fnp-5049	332	35	al	al	PROPN
fnp-5049	332	36	(	(	PUNCT
fnp-5049	332	37	2020	2020	NUM
fnp-5049	332	38	)	)	PUNCT
fnp-5049	332	39	neurofilament	neurofilament	NOUN
fnp-5049	332	40	light	light	NOUN
fnp-5049	332	41	as	as	ADP
fnp-5049	332	42	a	a	DET
fnp-5049	332	43	biomarker	biomarker	NOUN
fnp-5049	332	44	in	in	ADP
fnp-5049	332	45	traumatic	traumatic	ADJ
fnp-5049	332	46	brain	brain	NOUN
fnp-5049	332	47	injury	injury	NOUN
fnp-5049	332	48	.	.	PUNCT
fnp-5049	333	1	neurology	neurology	NOUN
fnp-5049	333	2	95	95	NUM
fnp-5049	333	3	:	:	PUNCT
fnp-5049	333	4	e610	e610	NUM
fnp-5049	333	5	-	-	SYM
fnp-5049	333	6	e622	e622	PROPN
fnp-5049	333	7	.	.	PUNCT
fnp-5049	334	1	https://doi.org/10.1212/wnl.0000000000009983	https://doi.org/10.1212/wnl.0000000000009983	PROPN
fnp-5049	334	2	49	49	NUM
fnp-5049	334	3	.	.	PUNCT
fnp-5049	335	1	smith	smith	PROPN
fnp-5049	335	2	lk	lk	PROPN
fnp-5049	335	3	,	,	PUNCT
fnp-5049	335	4	cidlowski	cidlowski	VERB
fnp-5049	335	5	ja	ja	PROPN
fnp-5049	335	6	(	(	PUNCT
fnp-5049	335	7	2010	2010	NUM
fnp-5049	335	8	)	)	PUNCT
fnp-5049	335	9	glucocorticoid	glucocorticoid	NOUN
fnp-5049	335	10	-	-	PUNCT
fnp-5049	335	11	induced	induce	VERB
fnp-5049	335	12	apoptosis	apoptosis	NOUN
fnp-5049	335	13	of	of	ADP
fnp-5049	335	14	healthy	healthy	ADJ
fnp-5049	335	15	and	and	CCONJ
fnp-5049	335	16	malignant	malignant	ADJ
fnp-5049	335	17	lymphocytes	lymphocyte	NOUN
fnp-5049	335	18	.	.	PUNCT
fnp-5049	336	1	progress	progress	NOUN
fnp-5049	336	2	in	in	ADP
fnp-5049	336	3	brain	brain	NOUN
fnp-5049	336	4	research	research	NOUN
fnp-5049	336	5	182	182	NUM
fnp-5049	336	6	:	:	PUNCT
fnp-5049	336	7	1	1	NUM
fnp-5049	336	8	-	-	SYM
fnp-5049	336	9	30	30	NUM
fnp-5049	336	10	.	.	PUNCT
fnp-5049	337	1	https://doi.org/10.1016/s0079-6123(10)82001-1	https://doi.org/10.1016/s0079-6123(10)82001-1	PROPN
fnp-5049	337	2	50	50	NUM
fnp-5049	337	3	.	.	PUNCT
fnp-5049	338	1	spuler	spuler	PROPN
fnp-5049	338	2	s	s	PROPN
fnp-5049	338	3	,	,	PUNCT
fnp-5049	338	4	yousry	yousry	PROPN
fnp-5049	338	5	t	t	PROPN
fnp-5049	338	6	,	,	PUNCT
fnp-5049	338	7	scheller	scheller	NOUN
fnp-5049	338	8	a	a	NOUN
fnp-5049	338	9	,	,	PUNCT
fnp-5049	338	10	voltz	voltz	NOUN
fnp-5049	338	11	r	r	NOUN
fnp-5049	338	12	,	,	PUNCT
fnp-5049	338	13	holler	holler	NOUN
fnp-5049	338	14	e	e	NOUN
fnp-5049	338	15	,	,	PUNCT
fnp-5049	338	16	hartmann	hartmann	PROPN
fnp-5049	338	17	m	m	PROPN
fnp-5049	338	18	,	,	PUNCT
fnp-5049	338	19	wick	wick	PROPN
fnp-5049	338	20	m	m	PROPN
fnp-5049	338	21	,	,	PUNCT
fnp-5049	338	22	hohlfeld	hohlfeld	ADJ
fnp-5049	338	23	r	r	NOUN
fnp-5049	338	24	(	(	PUNCT
fnp-5049	338	25	1996	1996	NUM
fnp-5049	338	26	)	)	PUNCT
fnp-5049	338	27	multiple	multiple	ADJ
fnp-5049	338	28	sclerosis	sclerosis	NOUN
fnp-5049	338	29	:	:	PUNCT
fnp-5049	338	30	prospective	prospective	ADJ
fnp-5049	338	31	analysis	analysis	NOUN
fnp-5049	338	32	of	of	ADP
fnp-5049	338	33	tnf	tnf	PROPN
fnp-5049	338	34	-	-	PUNCT
fnp-5049	338	35	alpha	alpha	NOUN
fnp-5049	338	36	and	and	CCONJ
fnp-5049	338	37	55	55	NUM
fnp-5049	338	38	kda	kda	NOUN
fnp-5049	338	39	tnf	tnf	PROPN
fnp-5049	338	40	receptor	receptor	NOUN
fnp-5049	338	41	in	in	ADP
fnp-5049	338	42	csf	csf	NOUN
fnp-5049	338	43	and	and	CCONJ
fnp-5049	338	44	serum	serum	VERB
fnp-5049	338	45	in	in	ADP
fnp-5049	338	46	correlation	correlation	NOUN
fnp-5049	338	47	with	with	ADP
fnp-5049	338	48	clinical	clinical	ADJ
fnp-5049	338	49	and	and	CCONJ
fnp-5049	338	50	mri	mri	NOUN
fnp-5049	338	51	activity	activity	NOUN
fnp-5049	338	52	.	.	PUNCT
fnp-5049	339	1	journal	journal	NOUN
fnp-5049	339	2	of	of	ADP
fnp-5049	339	3	neuroimmunology	neuroimmunology	NOUN
fnp-5049	339	4	66	66	NUM
fnp-5049	339	5	:	:	PUNCT
fnp-5049	339	6	57	57	NUM
fnp-5049	339	7	-	-	SYM
fnp-5049	339	8	64	64	NUM
fnp-5049	339	9	51	51	NUM
fnp-5049	339	10	.	.	PUNCT
fnp-5049	340	1	tanaka	tanaka	PROPN
fnp-5049	340	2	j	j	PROPN
fnp-5049	340	3	,	,	PUNCT
fnp-5049	340	4	fujita	fujita	PROPN
fnp-5049	340	5	h	h	PROPN
fnp-5049	340	6	,	,	PUNCT
fnp-5049	340	7	matsuda	matsuda	PROPN
fnp-5049	340	8	s	s	PROPN
fnp-5049	340	9	,	,	PUNCT
fnp-5049	340	10	toku	toku	PROPN
fnp-5049	340	11	k	k	PROPN
fnp-5049	340	12	,	,	PUNCT
fnp-5049	340	13	sakanaka	sakanaka	PROPN
fnp-5049	340	14	m	m	PROPN
fnp-5049	340	15	,	,	PUNCT
fnp-5049	340	16	maeda	maeda	PROPN
fnp-5049	340	17	n	n	PROPN
fnp-5049	340	18	(	(	PUNCT
fnp-5049	340	19	1997	1997	NUM
fnp-5049	340	20	)	)	PUNCT
fnp-5049	340	21	glucocorticoidand	glucocorticoidand	VERB
fnp-5049	340	22	mineralocorticoid	mineralocorticoid	NOUN
fnp-5049	340	23	receptors	receptor	NOUN
fnp-5049	340	24	in	in	ADP
fnp-5049	340	25	microglial	microglial	ADJ
fnp-5049	340	26	cells	cell	NOUN
fnp-5049	340	27	:	:	PUNCT
fnp-5049	340	28	the	the	DET
fnp-5049	340	29	two	two	NUM
fnp-5049	340	30	receptors	receptor	NOUN
fnp-5049	340	31	mediate	mediate	VERB
fnp-5049	340	32	differential	differential	ADJ
fnp-5049	340	33	effects	effect	NOUN
fnp-5049	340	34	of	of	ADP
fnp-5049	340	35	corticosteroids	corticosteroid	NOUN
fnp-5049	340	36	.	.	PUNCT
fnp-5049	341	1	glia	glia	NOUN
fnp-5049	341	2	20	20	NUM
fnp-5049	341	3	:	:	PUNCT
fnp-5049	341	4	23	23	NUM
fnp-5049	341	5	-	-	SYM
fnp-5049	341	6	37	37	NUM
fnp-5049	341	7	52	52	NUM
fnp-5049	341	8	.	.	PUNCT
fnp-5049	342	1	thebault	thebault	NOUN
fnp-5049	342	2	s	s	PART
fnp-5049	342	3	,	,	PUNCT
fnp-5049	342	4	abdoli	abdoli	NOUN
fnp-5049	342	5	m	m	PROPN
fnp-5049	342	6	,	,	PUNCT
fnp-5049	342	7	fereshtehnejad	fereshtehnejad	PROPN
fnp-5049	342	8	sm	sm	PROPN
fnp-5049	342	9	,	,	PUNCT
fnp-5049	342	10	tessier	tessier	PROPN
fnp-5049	342	11	d	d	NOUN
fnp-5049	342	12	,	,	PUNCT
fnp-5049	342	13	tabard	tabard	NOUN
fnp-5049	342	14	-	-	PUNCT
fnp-5049	342	15	cossa	cossa	NOUN
fnp-5049	342	16	v	v	NOUN
fnp-5049	342	17	,	,	PUNCT
fnp-5049	342	18	freedman	freedman	PROPN
fnp-5049	342	19	ms	ms	PROPN
fnp-5049	342	20	(	(	PUNCT
fnp-5049	342	21	2020	2020	NUM
fnp-5049	342	22	)	)	PUNCT
fnp-5049	342	23	serum	serum	NOUN
fnp-5049	342	24	neurofilament	neurofilament	PROPN
fnp-5049	342	25	light	light	NOUN
fnp-5049	342	26	chain	chain	NOUN
fnp-5049	342	27	predicts	predict	NOUN
fnp-5049	342	28	long	long	ADJ
fnp-5049	342	29	term	term	NOUN
fnp-5049	342	30	clinical	clinical	ADJ
fnp-5049	342	31	outcomes	outcome	NOUN
fnp-5049	342	32	in	in	ADP
fnp-5049	342	33	multiple	multiple	ADJ
fnp-5049	342	34	sclerosis	sclerosis	NOUN
fnp-5049	342	35	.	.	PUNCT
fnp-5049	343	1	sci	sci	PROPN
fnp-5049	343	2	rep	rep	PROPN
fnp-5049	343	3	10	10	NUM
fnp-5049	343	4	:	:	SYM
fnp-5049	343	5	11	11	NUM
fnp-5049	343	6	.	.	X
fnp-5049	344	1	https://doi.org/10.1038/s41598-020-67504-6	https://doi.org/10.1038/s41598-020-67504-6	NOUN
fnp-5049	344	2	53	53	NUM
fnp-5049	344	3	.	.	PUNCT
fnp-5049	345	1	thebault	thebault	NOUN
fnp-5049	345	2	s	s	PART
fnp-5049	345	3	,	,	PUNCT
fnp-5049	345	4	d	d	PROPN
fnp-5049	345	5	rt	rt	PROPN
fnp-5049	345	6	,	,	PUNCT
fnp-5049	345	7	lee	lee	PROPN
fnp-5049	345	8	h	h	PROPN
fnp-5049	345	9	,	,	PUNCT
fnp-5049	345	10	bowman	bowman	PROPN
fnp-5049	345	11	m	m	PROPN
fnp-5049	345	12	,	,	PUNCT
fnp-5049	345	13	bar	bar	NOUN
fnp-5049	345	14	-	-	PUNCT
fnp-5049	345	15	or	or	CCONJ
fnp-5049	345	16	a	a	PRON
fnp-5049	345	17	,	,	PUNCT
fnp-5049	345	18	arnold	arnold	PROPN
fnp-5049	345	19	dl	dl	PROPN
fnp-5049	345	20	,	,	PUNCT
fnp-5049	345	21	h	h	PROPN
fnp-5049	345	22	la	la	PROPN
fnp-5049	345	23	,	,	PUNCT
fnp-5049	345	24	tabard	tabard	NOUN
fnp-5049	345	25	-	-	PUNCT
fnp-5049	345	26	cossa	cossa	NOUN
fnp-5049	345	27	v	v	NOUN
fnp-5049	345	28	,	,	PUNCT
fnp-5049	345	29	freedman	freedman	PROPN
fnp-5049	345	30	ms	ms	PROPN
fnp-5049	345	31	(	(	PUNCT
fnp-5049	345	32	2019	2019	NUM
fnp-5049	345	33	)	)	PUNCT
fnp-5049	345	34	high	high	ADJ
fnp-5049	345	35	serum	serum	NOUN
fnp-5049	345	36	neurofilament	neurofilament	PROPN
fnp-5049	345	37	light	light	NOUN
fnp-5049	345	38	chain	chain	NOUN
fnp-5049	345	39	normalizes	normalize	VERB
fnp-5049	345	40	after	after	ADP
fnp-5049	345	41	hematopoietic	hematopoietic	ADJ
fnp-5049	345	42	stem	stem	NOUN
fnp-5049	345	43	cell	cell	NOUN
fnp-5049	345	44	transplantation	transplantation	NOUN
fnp-5049	345	45	for	for	ADP
fnp-5049	345	46	ms	ms	PROPN
fnp-5049	345	47	.	.	PROPN
fnp-5049	345	48	neurol	neurol	PROPN
fnp-5049	345	49	neuroimmunol	neuroimmunol	PROPN
fnp-5049	345	50	neuroinflamm	neuroinflamm	VERB
fnp-5049	345	51	6	6	NUM
fnp-5049	345	52	:	:	PUNCT
fnp-5049	345	53	e598	e598	NUM
fnp-5049	345	54	.	.	PUNCT
fnp-5049	346	1	https://doi.org/10.1212/nxi.0000000000000598	https://doi.org/10.1212/nxi.0000000000000598	PROPN
fnp-5049	346	2	54	54	NUM
fnp-5049	346	3	.	.	PUNCT
fnp-5049	347	1	thompson	thompson	PROPN
fnp-5049	347	2	aj	aj	PROPN
fnp-5049	347	3	,	,	PUNCT
fnp-5049	347	4	banwell	banwell	PROPN
fnp-5049	347	5	bl	bl	PROPN
fnp-5049	347	6	,	,	PUNCT
fnp-5049	347	7	barkhof	barkhof	PROPN
fnp-5049	347	8	f	f	PROPN
fnp-5049	347	9	,	,	PUNCT
fnp-5049	347	10	carroll	carroll	PROPN
fnp-5049	347	11	wm	wm	PROPN
fnp-5049	347	12	,	,	PUNCT
fnp-5049	347	13	coetzee	coetzee	PROPN
fnp-5049	347	14	t	t	PROPN
fnp-5049	347	15	,	,	PUNCT
fnp-5049	347	16	comi	comi	NOUN
fnp-5049	347	17	g	g	NOUN
fnp-5049	347	18	,	,	PUNCT
fnp-5049	347	19	correale	correale	PROPN
fnp-5049	347	20	j	j	PROPN
fnp-5049	347	21	,	,	PUNCT
fnp-5049	347	22	fazekas	fazekas	PROPN
fnp-5049	347	23	f	f	PROPN
fnp-5049	347	24	,	,	PUNCT
fnp-5049	347	25	filippi	filippi	PROPN
fnp-5049	347	26	m	m	PROPN
fnp-5049	347	27	,	,	PUNCT
fnp-5049	347	28	freedman	freedman	PROPN
fnp-5049	347	29	ms	ms	PROPN
fnp-5049	347	30	et	et	PROPN
fnp-5049	347	31	al	al	PROPN
fnp-5049	347	32	(	(	PUNCT
fnp-5049	347	33	2018	2018	NUM
fnp-5049	347	34	)	)	PUNCT
fnp-5049	347	35	diagnosis	diagnosis	NOUN
fnp-5049	347	36	of	of	ADP
fnp-5049	347	37	multiple	multiple	ADJ
fnp-5049	347	38	sclerosis	sclerosis	NOUN
fnp-5049	347	39	:	:	PUNCT
fnp-5049	347	40	2017	2017	NUM
fnp-5049	347	41	revisions	revision	NOUN
fnp-5049	347	42	of	of	ADP
fnp-5049	347	43	the	the	DET
fnp-5049	347	44	mcdonald	mcdonald	PROPN
fnp-5049	347	45	criteria	criterion	NOUN
fnp-5049	347	46	.	.	PUNCT
fnp-5049	348	1	lancet	lancet	PROPN
fnp-5049	348	2	neurol	neurol	PROPN
fnp-5049	348	3	17	17	NUM
fnp-5049	348	4	:	:	PUNCT
fnp-5049	348	5	162	162	NUM
fnp-5049	348	6	-	-	SYM
fnp-5049	348	7	173	173	NUM
fnp-5049	348	8	.	.	PUNCT
fnp-5049	349	1	https://doi.org/10.1016/s1474-4422(17)30470-2	https://doi.org/10.1016/s1474-4422(17)30470-2	PROPN
fnp-5049	349	2	55	55	NUM
fnp-5049	349	3	.	.	PUNCT
fnp-5049	350	1	thouvenot	thouvenot	ADV
fnp-5049	350	2	e	e	X
fnp-5049	350	3	,	,	PUNCT
fnp-5049	350	4	demattei	demattei	PROPN
fnp-5049	350	5	c	c	PROPN
fnp-5049	350	6	,	,	PUNCT
fnp-5049	350	7	uygunoglu	uygunoglu	PROPN
fnp-5049	350	8	u	u	NOUN
fnp-5049	350	9	,	,	PUNCT
fnp-5049	350	10	pittion	pittion	NOUN
fnp-5049	350	11	s	s	PROPN
fnp-5049	350	12	,	,	PUNCT
fnp-5049	350	13	castelnovo	castelnovo	PROPN
fnp-5049	350	14	g	g	PROPN
fnp-5049	350	15	,	,	PUNCT
fnp-5049	350	16	terdonck	terdonck	NOUN
fnp-5049	350	17	ldtd	ldtd	ADJ
fnp-5049	350	18	,	,	PUNCT
fnp-5049	350	19	cohen	cohen	PROPN
fnp-5049	350	20	m	m	PROPN
fnp-5049	350	21	,	,	PUNCT
fnp-5049	350	22	okuda	okuda	PROPN
fnp-5049	350	23	d	d	NOUN
fnp-5049	350	24	,	,	PUNCT
fnp-5049	350	25	kantarci	kantarci	ADJ
fnp-5049	350	26	o	o	NOUN
fnp-5049	350	27	,	,	PUNCT
fnp-5049	350	28	pelletier	pelletier	PROPN
fnp-5049	350	29	d	d	PROPN
fnp-5049	350	30	et	et	PROPN
fnp-5049	350	31	al	al	PROPN
fnp-5049	350	32	(	(	PUNCT
fnp-5049	350	33	2019	2019	NUM
fnp-5049	350	34	)	)	PUNCT
fnp-5049	350	35	neurofilament	neurofilament	NOUN
fnp-5049	350	36	-	-	PUNCT
fnp-5049	350	37	light	light	NOUN
fnp-5049	350	38	chain	chain	NOUN
fnp-5049	350	39	levels	level	NOUN
fnp-5049	350	40	are	be	AUX
fnp-5049	350	41	predictive	predictive	ADJ
fnp-5049	350	42	of	of	ADP
fnp-5049	350	43	on	on	ADP
fnp-5049	350	44	-	-	PUNCT
fnp-5049	350	45	going	go	VERB
fnp-5049	350	46	disease	disease	NOUN
fnp-5049	350	47	activity	activity	NOUN
fnp-5049	350	48	in	in	ADP
fnp-5049	350	49	radiologically	radiologically	ADV
fnp-5049	350	50	isolated	isolate	VERB
fnp-5049	350	51	syndrome	syndrome	NOUN
fnp-5049	350	52	(	(	PUNCT
fnp-5049	350	53	s37.003	s37.003	PROPN
fnp-5049	350	54	)	)	PUNCT
fnp-5049	350	55	.	.	PUNCT
fnp-5049	351	1	92	92	NUM
fnp-5049	351	2	:	:	PUNCT
fnp-5049	351	3	s37.003	s37.003	PROPN
fnp-5049	351	4	56	56	NUM
fnp-5049	351	5	.	.	PUNCT
fnp-5049	352	1	zivadinov	zivadinov	NOUN
fnp-5049	352	2	r	r	NOUN
fnp-5049	352	3	,	,	PUNCT
fnp-5049	352	4	sepcic	sepcic	PROPN
fnp-5049	352	5	j	j	PROPN
fnp-5049	352	6	,	,	PUNCT
fnp-5049	352	7	nasuelli	nasuelli	PROPN
fnp-5049	352	8	d	d	PROPN
fnp-5049	352	9	,	,	PUNCT
fnp-5049	352	10	de	de	PROPN
fnp-5049	352	11	masi	masi	PROPN
fnp-5049	352	12	r	r	PROPN
fnp-5049	352	13	,	,	PUNCT
fnp-5049	352	14	bragadin	bragadin	NOUN
fnp-5049	352	15	lm	lm	SYM
fnp-5049	352	16	,	,	PUNCT
fnp-5049	352	17	tommasi	tommasi	PROPN
fnp-5049	352	18	ma	ma	PROPN
fnp-5049	352	19	,	,	PUNCT
fnp-5049	352	20	zambito	zambito	PROPN
fnp-5049	352	21	-	-	PUNCT
fnp-5049	352	22	marsala	marsala	PROPN
fnp-5049	352	23	s	s	PART
fnp-5049	352	24	,	,	PUNCT
fnp-5049	352	25	moretti	moretti	PROPN
fnp-5049	352	26	r	r	PROPN
fnp-5049	352	27	,	,	PUNCT
fnp-5049	352	28	bratina	bratina	NOUN
fnp-5049	352	29	a	a	NOUN
fnp-5049	352	30	,	,	PUNCT
fnp-5049	352	31	ukmar	ukmar	PROPN
fnp-5049	352	32	m	m	VERB
fnp-5049	352	33	et	et	NOUN
fnp-5049	352	34	al	al	PROPN
fnp-5049	352	35	(	(	PUNCT
fnp-5049	352	36	2001	2001	NUM
fnp-5049	352	37	)	)	PUNCT
fnp-5049	352	38	a	a	DET
fnp-5049	352	39	longitudinal	longitudinal	ADJ
fnp-5049	352	40	study	study	NOUN
fnp-5049	352	41	of	of	ADP
fnp-5049	352	42	brain	brain	NOUN
fnp-5049	352	43	atrophy	atrophy	NOUN
fnp-5049	352	44	and	and	CCONJ
fnp-5049	352	45	cognitive	cognitive	ADJ
fnp-5049	352	46	disturbances	disturbance	NOUN
fnp-5049	352	47	in	in	ADP
fnp-5049	352	48	the	the	DET
fnp-5049	352	49	early	early	ADJ
fnp-5049	352	50	phase	phase	NOUN
fnp-5049	352	51	of	of	ADP
fnp-5049	352	52	relapsing	relapse	VERB
fnp-5049	352	53	-	-	PUNCT
fnp-5049	352	54	remitting	remit	VERB
fnp-5049	352	55	multiple	multiple	ADJ
fnp-5049	352	56	sclerosis	sclerosis	NOUN
fnp-5049	352	57	.	.	PUNCT
fnp-5049	353	1	j	j	PROPN
fnp-5049	353	2	neurol	neurol	PROPN
fnp-5049	353	3	neurosurg	neurosurg	PROPN
fnp-5049	353	4	psychiatry	psychiatry	NOUN
fnp-5049	353	5	70	70	NUM
fnp-5049	353	6	:	:	PUNCT
fnp-5049	353	7	773	773	NUM
fnp-5049	353	8	-	-	SYM
fnp-5049	353	9	780	780	NUM
fnp-5049	353	10	.	.	PUNCT
fnp-5049	354	1	https://doi.org/10.1136/jnnp.70.6.773	https://doi.org/10.1136/jnnp.70.6.773	PROPN
fnp-5049	354	2	57	57	NUM
fnp-5049	354	3	.	.	PUNCT
fnp-5049	355	1	zou	zou	PROPN
fnp-5049	355	2	hj	hj	PROPN
fnp-5049	355	3	,	,	PUNCT
fnp-5049	355	4	guo	guo	PROPN
fnp-5049	355	5	sw	sw	PROPN
fnp-5049	355	6	,	,	PUNCT
fnp-5049	355	7	zhu	zhu	PROPN
fnp-5049	355	8	l	l	NOUN
fnp-5049	355	9	,	,	PUNCT
fnp-5049	355	10	xu	xu	PROPN
fnp-5049	356	1	x	x	PROPN
fnp-5049	356	2	,	,	PUNCT
fnp-5049	356	3	liu	liu	PROPN
fnp-5049	356	4	jb	jb	PROPN
fnp-5049	356	5	(	(	PUNCT
fnp-5049	356	6	2021	2021	NUM
fnp-5049	356	7	)	)	PUNCT
fnp-5049	356	8	methylprednisolone	methylprednisolone	NOUN
fnp-5049	356	9	induces	induce	VERB
fnp-5049	356	10	neuro	neuro	NOUN
fnp-5049	356	11	-	-	PUNCT
fnp-5049	356	12	protective	protective	ADJ
fnp-5049	356	13	effects	effect	NOUN
fnp-5049	356	14	via	via	ADP
fnp-5049	356	15	the	the	DET
fnp-5049	356	16	inhibition	inhibition	NOUN
fnp-5049	356	17	of	of	ADP
fnp-5049	356	18	a1	a1	NOUN
fnp-5049	356	19	astrocyte	astrocyte	NOUN
fnp-5049	356	20	activation	activation	NOUN
fnp-5049	356	21	in	in	ADP
fnp-5049	356	22	traumatic	traumatic	ADJ
fnp-5049	356	23	spinal	spinal	PROPN
fnp-5049	356	24	cord	cord	NOUN
fnp-5049	356	25	injury	injury	NOUN
fnp-5049	356	26	mouse	mouse	NOUN
fnp-5049	356	27	models	model	NOUN
fnp-5049	356	28	.	.	PUNCT
fnp-5049	357	1	front	front	ADJ
fnp-5049	357	2	neurosci	neurosci	NOUN
fnp-5049	357	3	15	15	NUM
fnp-5049	357	4	:	:	PUNCT
fnp-5049	357	5	628917	628917	NUM
fnp-5049	357	6	.	.	PUNCT
fnp-5049	358	1	https://doi.org/10.3389/fnins.2021.628917	https://doi.org/10.3389/fnins.2021.628917	NOUN
fnp-5049	358	2	copyright	copyright	NOUN
fnp-5049	358	3	:	:	PUNCT
fnp-5049	358	4	©	©	PROPN
fnp-5049	358	5	2023	2023	NUM
fnp-5049	358	6	the	the	DET
fnp-5049	358	7	author(s	author(s	NOUN
fnp-5049	358	8	)	)	PUNCT
fnp-5049	358	9	.	.	PUNCT
fnp-5049	359	1	this	this	PRON
fnp-5049	359	2	is	be	AUX
fnp-5049	359	3	an	an	DET
fnp-5049	359	4	open	open	ADJ
fnp-5049	359	5	access	access	NOUN
fnp-5049	359	6	article	article	NOUN
fnp-5049	359	7	distributed	distribute	VERB
fnp-5049	359	8	under	under	ADP
fnp-5049	359	9	the	the	DET
fnp-5049	359	10	terms	term	NOUN
fnp-5049	359	11	of	of	ADP
fnp-5049	359	12	the	the	DET
fnp-5049	359	13	creative	creative	ADJ
fnp-5049	359	14	commons	common	NOUN
fnp-5049	359	15	attribution	attribution	NOUN
fnp-5049	359	16	4.0	4.0	NUM
fnp-5049	359	17	international	international	ADJ
fnp-5049	359	18	license	license	NOUN
fnp-5049	359	19	(	(	PUNCT
fnp-5049	359	20	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
fnp-5049	359	21	)	)	PUNCT
fnp-5049	359	22	,	,	PUNCT
fnp-5049	359	23	which	which	PRON
fnp-5049	359	24	permits	permit	VERB
fnp-5049	359	25	unrestricted	unrestricted	ADJ
fnp-5049	359	26	use	use	NOUN
fnp-5049	359	27	,	,	PUNCT
fnp-5049	359	28	distribution	distribution	NOUN
fnp-5049	359	29	,	,	PUNCT
fnp-5049	359	30	and	and	CCONJ
fnp-5049	359	31	reproduction	reproduction	NOUN
fnp-5049	359	32	in	in	ADP
fnp-5049	359	33	any	any	DET
fnp-5049	359	34	medium	medium	NOUN
fnp-5049	359	35	,	,	PUNCT
fnp-5049	359	36	provided	provide	VERB
fnp-5049	359	37	the	the	DET
fnp-5049	359	38	original	original	ADJ
fnp-5049	359	39	author	author	NOUN
fnp-5049	359	40	and	and	CCONJ
fnp-5049	359	41	source	source	NOUN
fnp-5049	359	42	are	be	AUX
fnp-5049	359	43	credited	credit	VERB
fnp-5049	359	44	,	,	PUNCT
fnp-5049	359	45	a	a	DET
fnp-5049	359	46	link	link	NOUN
fnp-5049	359	47	to	to	ADP
fnp-5049	359	48	the	the	DET
fnp-5049	359	49	creative	creative	ADJ
fnp-5049	359	50	commons	common	NOUN
fnp-5049	359	51	license	license	NOUN
fnp-5049	359	52	is	be	AUX
fnp-5049	359	53	provided	provide	VERB
fnp-5049	359	54	,	,	PUNCT
fnp-5049	359	55	and	and	CCONJ
fnp-5049	359	56	any	any	DET
fnp-5049	359	57	changes	change	NOUN
fnp-5049	359	58	are	be	AUX
fnp-5049	359	59	indicated	indicate	VERB
fnp-5049	359	60	.	.	PUNCT
fnp-5049	360	1	the	the	DET
fnp-5049	360	2	creative	creative	ADJ
fnp-5049	360	3	commons	common	NOUN
fnp-5049	360	4	public	public	ADJ
fnp-5049	360	5	domain	domain	NOUN
fnp-5049	360	6	dedication	dedication	NOUN
fnp-5049	360	7	waiver	waiver	NOUN
fnp-5049	360	8	(	(	PUNCT
fnp-5049	360	9	https://creativecommons.org/publicdomain/zero/1.0/	https://creativecommons.org/publicdomain/zero/1.0/	PROPN
fnp-5049	360	10	)	)	PUNCT
fnp-5049	360	11	applies	apply	VERB
fnp-5049	360	12	to	to	ADP
fnp-5049	360	13	the	the	DET
fnp-5049	360	14	data	datum	NOUN
fnp-5049	360	15	made	make	VERB
fnp-5049	360	16	available	available	ADJ
fnp-5049	360	17	in	in	ADP
fnp-5049	360	18	this	this	DET
fnp-5049	360	19	article	article	NOUN
fnp-5049	360	20	,	,	PUNCT
fnp-5049	360	21	unless	unless	SCONJ
fnp-5049	360	22	otherwise	otherwise	ADV
fnp-5049	360	23	stated	state	VERB
fnp-5049	360	24	.	.	PUNCT